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Summary
Evidence of HCMV infection was assessed in a cohort of 
47 renal allograft recipients followed prospectively for up 
to 1 year post transplantation. Serum was obtained from 
each patient and renal donor immediately pretransplant and 
tested for HCMV-specific antibody by standard or modified 
CFT and by Labsystems and NBL HCMV-IgG ELISA. Patients 
were classified as HCMV-seronegative if the antibody titre 
by CFT was less than 1:2. Whenever possible, a throat 
swab, urine and serum samples were taken from each 
individual immediately pretransplant and every 4 weeks 
thereafter. HCMV was isolated from specimens provided by 
21 renal allograft recipients, 9 with primary HCMV 
infection and 12 with reinfection and/or reactivation. 
HCMV shedding usually continued intermittently throughout 
the first year post transplantation, isolates being 
obtained from multiple urine samples and/or throat swabs 
provided by 16 patients.
In each renal allograft recipient, the HCMV isolation 
data was correlated with the timing of the fourfold or 
greater rise in HCMV CF antibody titre and/or a significant 
increase in HCMV-IgM and IgG measured by Labsystems 
indirect ELISA. There was considerable variation between 
individual patients in the timing and pattern of the 
humoral immune response. On or before the day of first 
HCMV isolation, 12 renal allograft recipients showed a
fourfold or greater rise in HCMV CF antibody titre, 7 were 
positive for HCMV-IgM and 9 had evidence of a significant 
increase in the level of HCMV-IgG. These data show that 
serology alone is of limited value in the detection of 
active HCMV infection post renal transplantation. Taken 
overall, the CFT correlated best with HCMV isolation in 
transplant recipients with primary infection while a 
significant increase in HCMV-IgG correlated best with HCMV 
isolation in patients with reinfection and/or reactivation.
Clinical findings were also correlated with HCMV 
isolation and/or serological data. The small number of 
renal transplant recipients in this study precluded 
statistical analysis. However, ★ were more common
in patients with primary HCMV infection. Furthermore, 
there was a close temporal correlation between the onset of 
symptoms and the HCMV-specific humoral response.
Whenever possible, blood products used to transfuse 
the cohort of renal allograft recipients were also tested 
for HCMV CF antibody and the results correlated with the 
age of the blood donors at the time of donation. Blood 
donors aged between 20 and 29 years provided 61 blood packs 
of which 46 (75.4%) were HCMV-seronegative. There was no 
evidence to suggest that HCMV was transmitted via blood 
products. Four renal allograft recipients of a kidney from 
an HCMV-seronegative donor each received HCMV-seropositive 
blood products but none developed primary HCMV infection 
post-operatively.
The HCMV serostatus was also available for 31 renal
leucopenia, thrombocytopenia, acute rejection, chronic 
rejection, nephrectomy and pyrexial illness
donors who provided kidneys for 37 renal allograft 
recipients. All 8 HCMV-seronegative recipients of a kidney 
from an HCMV-seropositive donor showed evidence of primary 
HCMV infection after the transplant operation. By 
contrast, none of the 9 HCMV-seronegative recipients of a 
kidney from an HCMV-seronegative donor developed HCMV 
infection throughout the period of study. These data 
provide further evidence that the donor kidney is the 
source of HCMV infection in renal transplant recipients.
The ability to detect viral DNA by hybridot assay was 
also investigated. In preliminary experiments using 
partially double stranded M13 probes specific for HSV-1, 
the lower limit of sensitivity was in the ng range. 
Denaturing agarose gel electrophoresis showed radiolabelled 
M13 second strand synthesis to be incomplete.
A BamHI subclone of the Hindlll E fragment (EHBI) of 
HCMV AD169 was cloned in the transcription plasmid pGEM2 
and 32P-labelled cRNA synthesized. Optimal hybridization 
conditions were determined empirically. The sensitivity of 
the RNA-DNA hybridot assay was 8pg of cDNA after 24 hr of 
autoradiography. In reconstruction experiments, 4.3 x 104 
to 3.9 x 105 particles taken from 3 independent stocks of 
HCMV AD169 and added to 7.2 ml of urine were routinely 
detected. Radiolabelled cRNA transcripts also detected 65 
HCMV isolates from urine samples or throat swabs provided 
by 18 renal allograft recipients. The sensitivity of the 
hybridot assay was reduced by urinary DNase. In
reconstruction experiments, 10/xg of either human or E.coli 
DNA added to urine containing HCMV particles or DNA reduced 
the hybrid signal. Radiolabelled cRNA transcripts did not 
hybridize to 10/xg each of human, E.coli and HSV-1 DNA or 
10fig of ribosomal RNA. However, 10 fig of HSV-2 DNA gave a 
hybrid signal equivalent to that obtained with 8pg of 
vector pGHBI DNA. Four hundred and forty five urine 
specimens provided by 47 renal allograft recipients 
throughout the first year post transplantation were tested 
by RNA-DNA hybridization. When the results were correlated 
with HCMV isolation, the sensitivity and specificity of the 
hybridot assay was 25% and 67% respectively.
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INTRODUCTION
1.1. General properties of human cytomegalovirus
1.1.1 History
infected cells
The morphological features of HCMV^/were first reported
many years prior to first isolation of the virus. HCMV 
characteristically produces cell enlargement with 
intranuclear inclusions. Such cells were first noted by 
Jesionek and Kiolemenoglou (1904) and later Ribbert (1904) 
in a variety of tissues from neonates and infants. Earlier 
workers regarded the inclusions as protozoan or syphilitic 
in origin. Subsequently, the similarities between these 
cells and those infected with HSV (Lipschutz, 1921) and VZV 
(Tyzzer, 1906) were recognised and led to the consideration 
of a viral cause.
The recovery of HCMV was first accomplished 
independently in 3 laboratories in the United States. 
Smith (1956) isolated the virus from the salivary gland and 
kidney of 2 moribund infants. Rowe et al.(1956) recovered 
3 HCMV strains from surgically removed adenoid tissue of 
asymptomatic children. The commonly used laboratory
adapted strain of HCMV (AD169) originated from these
studies. Weller et al. (1957) isolated HCMV from liver
biopsy specimens and/or urine samples provided by 3 infants 
with congenital HCMV disease. HCMV was initially called 
"salivary gland virus" or "salivary gland inclusion disease 
virus" (Cole and Kuttner, 1926). Weller et al. (1957)
proposed the term "cytomegaloviruses" which is derived from 
"cytomegalia" originally used by Goodpasture and Talbot
1
(1921) to indicate the significant enlargement and 
alteration of infected cells.
The first evidence that HCMV infection was relatively 
common came from the work of Farber and Wolbach (1932) and 
in 1965 Klemola and Kaariainen described HCMV as one of the 
aetiologic agents of mononucleosis.
1.1.2 Morphology
HCMV is a member of a diverse group of viruses 
belonging to the family herpesviridae (Matthews, 1982) 
which has 3 subgroups designated alphaherpesvirinae, 
betaherpesvirinae and gammaherpesvirinae whose 
characteristics are described in Table 1. HCMV belongs to 
the betaherpesvirinae. Morphologically, HCMV is
indistinguishable from other members of the herpesvirus 
group. The complete virion is 150 to 2 00nm in diameter, 
icosahedral in shape and consists of an inner core, a 
capsid and an envelope (Smith and Rasmussen, 1963; 
Montplaisir et al. . 1972). The inner core is 64nm in
diameter and consists of a linear double stranded DNA 
molecule of approximately 225 ^ b ^  The capsid is H O n m  in 
diameter and has 162 capsomeres. The capsid in turn is 
surrounded by a poorly demarcated area, the tegument. 
Virions are enveloped by 2 discrete membranes, an inner one 
derived from the nuclear membrane and an outer one derived 
from the cytoplasmic membrane of infected cells. When HCMV 
is propagated in cell cultures 2 additional morphological
2
complexed helically with protein to form a core.
Table 1 Classification of herpesviruses according 
to biological properties
Herpesviruses
Properties Alpha-
herpes-
virinae
Beta­
herpes­
virinae
Gamma-
herpes-
virinae
Examples HSV-1 HCMV EBV
Length of 
Cycle Short Long
/Vo ^>«ocf i/c t / v e 
/ ^  v i t ft. a
Cytopathic
Effects
Rapid
Extension
Slow
Progression ---
Latent Nerve Numerous Lymphoid
Infection Ganglia Tissues Tissues
forms are evident. One is an homogenous electron-dense 
material which accumulates in the cytoplasm, especially in 
the Golgi region, of infected cells as viral capsids are 
assembled and enveloped (Ruebner et al. . 1964; McGavran
and Smith, 1965; Craighead et al. . 1972). This dense
material "buds" into cytoplasmic tubules similar to HCMV 
capsids forming circumscribed bodies having a surrounding 
membrane similar to the viral envelope. Viral
nucleocapsids and dense bodies are both enveloped in the 
Golgi region of infected cells during the same period of 
the infectious cycle by mechanisms that are morphologically 
similar (Smith and De Harven, 1973). Nucleocapsids of 
HCMV are also seen budding from the nuclear membrane but 
envelopment of dense bodies by the nuclear membrane has not 
been detected. Dense bodies are of variable size but are 
usually twice the size of enveloped virions. They lack 
both a morphologically identifiable nucleocapsid (Smith and 
De Harven, 1973) and detectable DNA (Sarov and Abady,
1975). However, they contain surface antigenic determinants 
also detectable on the virions of HCMV as demonstrated by 
immune electron microscopy (Craighead et al.. 1972).
Between 23 (Sarov and Abady, 1975) and 35 (Stinski,
1976) structural polypeptides ranging in MWt from 11 to 290 
kd have been described in HCMV virions and dense bodies. 
Purified dense bodies have structural polypeptides with 
relative mobilities and molecular weights similar to the 
structural polypeptides of purified virions. However,in a 
study by Sarov and Abady (1975) dense bodies were noted to
completely lack 1 of the 2 3 polypeptides described in the 
whole virus while 5 others were barely detectable. The 
major polypeptide of dense bodies has a MWt of 67 kd and 
comprises 40% of the total protein complement. Stinski 
(1976) has shown by immunofluorescent studies that HCMV 
dense bodies do not contain host cellular antigens but are
composed solely of protein considered to be specified by
the HCMV genome. The biological significance of dense 
bodies is unknown but they may represent aberrant assembly 
of virion structural protein (Sarov and Abady, 1975) or 
envelope and tegument polypeptides (Fiala et al.. 1976).
In 1983, Irmiere and Gibson described a third type of 
virus particle produced in HCMV-infected cells and which 
they called a non-infectious enveloped particle (NIEP). 
Although similar in appearance to virions, NIEPs are 
distinguished from them principally by their lack of DNA 
and therefore their non-infectivity. The absence of DNA in 
these particles is also thought to account for their 
lighter density and altered core appearance. Furthermore,
the diameter of the NIEP capsid is 10 to 15% smaller than
that of the mature virion. Such NIEPs are produced by all 
HCMV strains examined but have not been observed in HSV or 
Old World monkey CMV-infected cells. NIEPs are generally 
present in lower amounts than virions although HCMV strain 
AD169 overproduces NIEPs by approximately tenfold. 
Compared to virions, NIEPs contain between 10 and 30% less 
of the 74 kd and between 3 0 and 60% less of the 69 kd
4
matrix proteins. However, NIEPs contain a 35 kd protein 
which is not present in virions or dense bodies and which 
represents between 10 and 15% of the total protein mass 
(Irmiere and Gibson, 1983; 1985). This protein is thought 
to be the counterpart of the B-capsid protein of HSV 
(Gibson and Roizman, 1972; 1974) and CMV strain Colburn
(Gibson, 1981b) since they share common properties. 
Therefore, it is proposed that the 3 5 kd protein present in 
NIEPs functions to mediate DNA packaging and/or 
nucleocapsid envelopment and in the normal course of events 
is modified or removed in the intact mature virion.
1.1.3 Genomic structure
HCMV DNA was first isolated by Crawford and Lee (1964) 
and then by Huang et al. (1973). Like all herpesvirus DNA 
it was found to be linear and double stranded. Early 
reports describing HCMV DNA analysed by cosedimentation 
with HSV DNA in sucrose gradients (Huang et al. . 1973) or
by contour measurement (Sarov and Friedman, 1976) indicated 
that the MWt was 100 x 103 or 107 + 2.7 x 103 kd
respectively. Further analysis by electron microscopy 
demonstrated 2 populations of molecules, a major class of 
100 x 103 kd and a minor class of approximately 150 x 103 
kd (Kilpatrick and Huang, 1977). In contrast, other 
workers found that viral DNA molecules of the larger size 
were more abundant as determined by electron microscopy (De 
Marchi et al. . 1978; Geelen et al.. 1978), sedimentation
analysis (De Marchi et a l .. 1978) and reassociation
kinetics (De Marchi et al. . 1978). The generally accepted 
value for the MWt of full length HCMV DNA is 150 x 103 kd.
This population of larger DNA molecules is infectious
(Geelen et al. . 1978) whilst the smaller ones are not
(Kilpatrick and Huang, 1977). Stinski et al. (1979) have
shown that serial high multiplicity passage of HCMV strain 
Towne resulted in the production of defective 
cytomegalovirions which contained DNA with a MWt of 
approximately 100 x 103 kd. Additionally, some viral DNA
molecules had a MWt of 60 x 103 kd. The accumulation of
such smaller DNA molecules packaged into virions was 
associated with a decrease in infectivity but an increase 
in the particle-to-pfu ratio. It is proposed that 
deletions, substitutions and duplications are possible 
mechanisms for the generation of defective CMV DNA. HCMV 
has a buoyant density of 1.716 to 1.717 g/cm3 (Huang et 
al., 1973; Geelen et al.. 1978).
An important feature of herpesvirus genomes is that 
they contain various arrangements of repeat sequences 
(Figure 1) . Demonstration of the existence of repeat 
sequences within the herpesvirus genomes stems from the 
work of Sheldrick and Berthelot (1974) on HSV-1 DNA. They 
performed alkaline denaturation of HSV-1 DNA followed by 
centrifugation through a neutral pH at high ionic strength 
in order to obtain single strands of DNA. Examination of 
such DNA strands by electron microscopy after self­
annealing led to the description of 2 types of folding.
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Figure 1 Genome structures representing five 
herpesvirus groups.
Genomes are drawn to scale. 
Boxed areas represent repetitive 
sequences and single lines indicate 
unique segments. The letters a, b 
and c show the arrangement of 
sequences within the repeats of each 
virus group; sequences arranged in 
inverse orientation relative to a, b 
and c are denoted by a 1, b 1 and c 1 . 
Arrows below boxed areas indicate the 
relative orientations of repeats. 
Tandemly reiterated sequences within 
repeats are shown by vertical lines 
within boxed regions. The number of 
copies of tandemly reiterated 
sequences is represented by 
subscripts (n, m and x) and different 
subscripts within a group indicate 
that copy numbers differ between 
repeats. Segments which invert are 
shown by double-headed arrows above 
unique sequences; unique sequences 
which do not invert are indicated by 
single-headed arrows. The key to 
abbreviations is CCV, channel catfish 
virus; HVS, herpesvirus saimiri; EBV, 
Epstein-Barr virus; PRV, pseudorabies 
virus; HCMV, human cytomegalovirus.
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Form 1 was a single stranded circle closed by a double 
stranded region linking the circle to a single stranded 
zone while Form 2 was two single stranded circles connected 
by a double stranded zone. By measuring the single and 
double stranded regions, the location of the repeat 
sequences was identified (Figure 2). La Femina and Hayward 
(1980) confirmed the presence of such sequences in HCMV DNA 
by electron microscopic examination of self-annealed single 
stranded DNA and by blot hybridization with restriction 
enzyme fragments. They showed that Towne strain HCMV DNA 
contained an internal, inverted duplication of 7.5% of its 
length.
From the above it was inferred that the HCMV genome 
can be divided into 2 regions of unique sequence, a long 
(UL ) and a short (Ug) one representing approximately 
174 kb (82%) and 35 kb (18%) of strain AD169 DNA
respectively (Fleckenstein et al.. 1982). The junction
between the 2 segments is composed of internal repeat (IR) 
sequences designated IR-^  and IRg.
IR sequences are also present but
inverted at both ends of the DNA molecule and are then 
designated terminal repeats (TR). TRL is at the end of UL 
and TRS at the end of Ug . The repeat sequences flanking
UL each approximate 11 kb while those at each end of Us
are about 2 kb.
Kilpatrick and Huang (1977) analyzed HCMV DNA which 
had been partially denatured at a temperature just below 
that leading to total strand separation. Under these
Figure 2 Structure of the HCMV genome
A diagram showing the organization of the 
HCMV genome. Segments of unique DNA 
sequence, the long (UL ) and short (Uo) , 
are each flanked by a set of inverted 
repeats (TRL/ I R L and TR ^ / I R S
respectively). Letters indicate
reiterated sequences. Isomerization at 
the L/S junction results in 4 different 
conformations.
p prototype orientation
Js : inversion of the short region
*L : inversion of the long region
JSL : inversion 
regions.
of the short and long
L S
c a
1.6 23.6 1.6 Megadaltons115
10.610.6
I------- 1-------1 I I l
0 0.2 0.4 0.6 0.8 1.0
Map units
conditions GC-rich regions of the DNA remain double 
stranded while AT-rich regions separate into single 
strands. Four different patterns of these single and 
double stranded zones were observed. The existence of the 
4 isomers of HCMV DNA was confirmed by electron microscopic 
examination of self-annealed single strands (La Femina and 
Hayward, 1980) and by blot hybridization with isolated 
restriction enzyme fragments (De Marchi, 1981; Greenaway et 
al.. 1982; Spector et al.. 1982).
Weston and Barrell (1986) have determined the DNA 
sequence of Ug, IRS/TRS and part of UL of HCMV AD169. 
Thirty eight open reading frames were identified most of 
which were preceded by sequences with homology to TATA 
boxes (Breathnack and Chambon, 1981) and were followed by 
polyadenylation signals. Twenty four of these open reading 
frames fell into 5 homologous families which presumably 
arose by duplication, a process which has not been 
described for HSV or VZV but has been observed in EBV (Baer
are organized in a similar manner, no homologies at the 
nucleic or amino acid level were noted. Hydrophobicity
that approximately half had hydrophobic profiles similar to 
2 types of known membrane proteins, those with hydrophobic 
regions at their N and C termini which could be involved in
highly hydrophobic possible transmembrane regions.
short repeats
et al.. 1984). Although of^ HSV, VZV and HCMV
plots of the predicted protein products of Us indicated
membrane translocation and anchorage and those with several
8
Transcription of Ug is maximal at late (72 hr) times after 
infection (McDonough and Spector, 1983). From the sequence 
data it is difficult to predict the pattern of 
transcription as long range splicing (Bodescot et al. ,
1986) may occur. Since some potential open reading frames 
lack a TATA box it seems likely that splicing is involved 
in some cases.
At the ends of UL and Ug are directly reiterated 
sequences which were demonstrated by Geelen and Westrate 
(1982) who showed that treatment of HCMV DNA with 
exonuclease III resulted in the formation of double 
stranded circular forms. These TR sequences which are 
designated ab in the L component and ca in the S component 
of the HCMV genome are also present in inverted orientation 
at the L/S junction where they are referred to as b'a1 and 
a'c' respectively. The "a" sequence has important functions 
with respect to providing cis signals for 
cleaving/packaging DNA (Stow et a l . , 1983 ; Spaete and
Frenkel, 1985; Spaete and Mocarski, 1985) and inversion of 
the virus genome during replication (Mocarski et al., 1980; 
Smiley et a l . . 1981; Mocarski and Roizman, 1982).
Furthermore, the "a" sequences can undergo amplification 
resulting in several tandem copies which are probably 
responsible for the size heterogeneity of terminal and 
junction fragments described by a number of authors
(Greenaway et al. , 1982; Westrate et al. , 1983) . A short
sequence of DNA homology which Mocarski et u_l_. (1987)
describe as the 'herpes pac homology1 is highly conserved
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amongst a number of herpesviruses (Davison and Wilkie, 
1981; Mocarski and Roizman, 1981; Davison, 1984; Matsuo et 
al., 1984; Albrecht et al.. 1985; Bankier et al. . 1985;
Deiss et al. , 1986) . The distance from this homologous
region to the cleavage site is consistently between 3 0 and 
3 5 bp in 5 human herpesviruses (Davison and Wilkie, 1981; 
Davison, 1984; Van den Berg et al.. 1984; Mocarski et al. . 
1987) . These findings are consistent with the observations 
of Spaete and Mocarski (1985) who showed that the HCMV L/S 
junction could complement HSV-1 packaging signals.
The "a" sequence of HCMV strains AD169 and Towne have 
been investigated (Tamashiro et al.. 1984; Mocarski et al.,
1987) and extensive homology demonstrated. However the "a" 
sequence of Towne strain is not flanked by direct repeats 
as is that of AD169. Unlike HCMV AD169, all genomic 
termini of the Towne strain contain at least 1 "a"
sequence. Furthermore, the degree of heterogeneity is more 
complex in the "a" sequence of HCMV AD169. Tamashiro et 
a l . (1984) demonstrated 3 classes of heterogeneity; Class 
1 = heterogenous fragments of variable size (0.553, 0.95 or 
1.35 kb); Class 2 = tandem duplications of Class 1
fragments; Class 3 = a variable number of 0.2 kb fragments
in tandem. Recently, Takekoshi et sJL* (1987) have
described a new HCMV isolate (strain Tanaka) whose L 
component was composed of 2 subsegments LI and L2. L2 
underwent inversion relative to LI at high frequency to 
produce 8 genome isomers. The sequences flanking L2
10
consisted of inverted repeats unrelated to the "a" sequence.
1.1.4 Replication of HCMV 
(a) Normal growth cycle
CMV is highly species specific and therefore human 
strains will only replicate in cells of human origin. In 
vivo, HCMV can replicate in epithelial (kidney, liver, bile 
ducts, salivary glands, gut epithelium, pancreas) and 
endothelial cells while in vitro HCMV replicates more 
efficiently in fibroblasts than epithelial cells (Knowles, 
1976; Vonka et al.. 1976).
Many light and electron microscopic studies have 
outlined the course of HCMV infection in permissive cells 
(Iwasaki et al. . 1973 ; Smith and De Harven 1973, 1974;
Albrecht et al., 1980) . Within 15 min of inoculation the 
virus attaches to the cells of the monolayer. Enveloped 
and non-enveloped virus capsids are detectable in the 
cytoplasm within minutes of inoculation. The viral capsids 
migrate to the cell nucleus after which enveloped viral 
particles are not detectable for approximately 3 6 to 48 hr, 
a period called the "viral eclipse". Subsequently, 
margination of the cell nucleus together with enlargement 
and rounding of both the nucleus and its cell occur. Novel 
chromatin structural patterns consisting of bipartite and 
oblate ellipsoid structures arranged in an orderly fashion 
along a fibre axis have also been observed (Kierszenbaum 
and Huang, 1978). The first evidence of new viral assembly 
is detected in the form of intranuclear and then
11
<De Marchi (1983a) has reported that cells productively 
infected with HCMV produced an IE protein which stimulated 
host cell functions while an E protein subsequently 
switched off the reaction. One host function which is 
activated in HCMV-infected cells is thymidine kinase and 
HCMV may employ this as a mechanism of increasing 
intracellular thymidine monophosphate concentrations (De 
Marchi, 1983a). Griffiths and Grundy (1987) have 
suggested that the continuous activation of host cellular 
synthesis in cells abortively infected with HCMV may be 
explained since, in such cells, HCMV genome expression may 
not proceed as far as the E protein required to inhibit 
stimulation.
intracytoplasmic viral capsids. Complete virions are first 
observed extracellularly between 72 and 96 hr after 
inoculation (St. Jeor and Rapp, 1973a; Michelson-Fiske et 
al. , 1977) . Between 5 and 8 days after inoculation cell
lysis is observed.
(k) Alteration in host cell functions
HCMV induces the synthesis of cellular DNA in both 
permissive Helu cells and nonpermissive Vero cells (St. 
Jeor et al. , 1974) although the degree of stimulation of
host cell DNA synthesis depends on the physiological state 
of the infected cells (De Marchi and Kaplan, 1977). St. 
Jeor et al. (1974) have also shown that HCMV DNA synthesis
is not required for the stimulation of host cell DNA 
synthesis. Indeed, HCMV which has been subjected to low 
dose UV irradiation shows an enhanced ability to induce 
host cell DNA synthesis (De Marchi and Kaplan, 1977 ; 
Boldough et al.. 1978; De Marchi, 1983a) and defective
virions produce a growth factor which enhances cellular DNA 
synthesis (Gonczol and Plotkin, 1984). However in 
productively infected Helu cells, viral antigens could not 
be detected by immunofluorescence in those cells which had 
been stimulated to synthesize cellular DNA (De Marchi and 
Kaplan, 1976; 1977). These data suggested that the
induction of cellular DNA synthesis delayed or inhibited 
productive HCMV infection.
HCMV also stimulates host cell RNA synthesis in 
permissive and nonpermissive cells (Furukawa et al. , 1975;
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Tanaka et— aT. , 1975) . This induction of RNA synthesis
precedes viral DNA synthesis by approximately 24 hr and the 
RNA species synthesized include ribosomal 28S and 18S, and 
4S transfer RNA. Tanaka et al. (1975) have suggested that
host cell RNA synthesis is induced by a protein or proteins 
which are synthesized during the early stage of HCMV 
infection.
In HCMV-infected cells, protein synthesis is detected 
in 2 peaks, one during the initial 3 6 hr post infection and 
the other in the later stage of infection after the onset 
of viral DNA synthesis. At both stages host cell and viral 
proteins are synthesized simultaneously although host 
proteins account for 70 to 90% and 40 to 50% of the total 
proteins synthesized at early and late times respectively 
(Stinski, 1977).
The induction of host cell enzymes is selective and 
has been shown to be mediated through the regulation of 
transcription (Colberg-Poley and Santomenna, 1988). Poly- 
ADP ribose synthetase activity increases within 1 hr of 
inoculation of cells by HCMV and remains high throughout 
the replication cycle of the virus (Furlini et al. , 1984). 
Between 3 and 6 hr post infection endogenous DNA-dependent 
RNA polymerase activities increase, RNA polymerase I, II 
and III being stimulated 6, 16 and 3 times respectively
(Tanaka et al.. 1975; 1978). At 12 hr post infection
cytosol and mitochondrial thymidine kinase activities 
increase in addition to that of ornithine decarboxylase, 
the first rate-limiting enzyme in the biosynthesis of
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polyamines (Isom, 1979). Synthesis of plasminogen 
activator, a protease involved in the degeneration of 
fibrin, transiently increases prior to viral DNA synthesis 
(Yamanishi and Rapp, 1979). Infection of human fibroblast 
cells by HCMV also leads to the stimulation of host cell 
DNA polymerase as well as the induction of a novel virus- 
specific DNA polymerase (Huang, 1975a; Hirai et al. . 1976; 
Hirai and Watanabe, 1976) . Much of the host cell DNA 
synthesised after HCMV infection is of mitochondrial origin 
(Furukawa et a l . , 1976) . (3-polymerase activity is
unaffected by HCMV infection (Hirai and Watanabe, 1976). 
Weder and Radsak (1983) have also reported an "early" HCMV- 
induced glycopolypeptide found in association with 
chromatin preparations. It is suggested that this host- 
specific molecule may function in DNA replication in 
infected cells.
1.1.5 Replication of HCMV DNA
There have been few reports describing the replication 
of HCMV DNA but the similarity in genome structure between 
HCMV and HSV has tempted authors to propose the replication 
model for HSV which has been described by Jacob et al. 
(1979) . Therefore, it has been suggested that HCMV 
replication occurs by the production of concatemers of 
several viral DNA molecules lined up end to end (La Femina 
and Hayward, 1983). Indeed, Jean et a l . (1978) have 
observed concatemeric DNA molecules in WI-38 fibroblast
14
cells lytically infected with HCMV. The genomic 
localization, sequence and transcription analysis of the 
HCMV DNA polymerase gene has been reported (Heilbronn et 
a l . , 1987; Kouzarides et al.. 1987).
1-1.6 Transcription and translation
Like other herpesviruses, the replicative cycle of CMV 
can be divided into 3 phases, immediate-early (IE), early 
(E) and late (L) (De Marchi, 1981; Wathen et al. . 1981;
Wathen and Stinski, 1982; McDonough and Spector, 1983; Jahn 
et al. . 1984). IE transcripts are made in the absence of 
de novo protein synthesis e.g. in the presence of a 
cycloheximide block (Wathen and Stinski, 1982; Stinski et 
al. , 1983) suggesting that host factors alone suffice for
their expression. Early transcription occurs before the 
onset of viral DNA synthesis as determined by using 
phosphonoacetic acid to specifically block viral DNA 
polymerase (Huang, 1975b). Late transcripts appear after 
viral DNA synthesis.
(a) Immediate-Early
Major IE transcription of HCMV originates from the 
UL region of the viral genome (De Marchi, 1981; Wathen and 
Stinski, 1982; McDonough and Spector, 1983; Stinski et al., 
1983 ; Jahn et a l . , 1984 ; Wilkinson et_ a_l. , 1984) and
predominantly from the Hindlll E region in HCMV strain 
AD169 (McDonough and Spector, 1983; Jahn et— al. , 1984;
Wilkinson et al., 1984). Therefore, although HCMV and HSV
15
are similar in overall genomic structure, these viruses 
show major differences in the map positions of their IE 
genes: While IE transcription of HCMV is limited to a 20 kb 
segment of U^, IE transcripts of HSV originate primarily 
from the inverted repeats of Us and adjacent Ug segments 
(Clements et al. . 1977; Anderson et al. . 1980; Watson et
al., 1981). Figure 3 shows the major transcripts of HCMV
IE RNAs. In strain AD169, the most abundant IE mRNA is a 
1.95 kb transcript transcribed from left to right between 
0.0764 and 0.0865 mu in the prototype orientation. The 
major IE transcripts of HCMV strains Towne and Davis (1.95 
kb and 2.2 kb respectively) map in equivalent regions of 
the genome (De Marchi, 1981; Wathen and Stinski, 1982; De 
Marchi, 1983b; Stinski et al. . 1983). Two other dominant
transcripts are synthesized during the IE phase of viral 
replication in HCMV AD169-infected cells. One (1.7 kb) and 
the other (2.15 kb) are both initiated between 0.08 and 
0.105 mu and in the same orientation as IE 1.9 kb RNA. 
Stinski et a l . (1983) also identified an IE
transcriptionally active region (IE-2) immediately 
downstream of the major IE gene (IE-1) of HCMV Towne strain 
but the RNA produced differed in both size and orientation 
from the transcripts observed with strain AD169.
A second transcriptionally active area of HCMV AD169 
has been identified between 0.593 and 0.619 mu (Wilkinson 
et al. . 1984) and minor transcripts for the Towne and Davis 
strains have also been described as originating from 
equivalent regions of the viral genome (Wathen et al. ,
16
Figure 3 Location of IE transcription on the
HCMV genome
A summary showing size, map location 
and, in some cases, orientation of 
IE transcripts. The region of the 
genome omitted from this map, 
between BamHI P and BamHI A, shows 
no significant hybridization with 
cytomegalovirus poly (A) +-RNA.
(From Wilkinson et a l .. 1984)
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1981; De Marchi, 1983b). Sequence and transcriptional 
analysis of this region has identified 3 abundant RNAs of 
1.65, 1.7 and 3.4 kb (Kouzarides et al. . 1988). The
putative translation product of the 3.4 kb transcript has 
features normally associated with membrane bound 
glycoprotein, potentially the first example within the 
herpesvirus group of such a protein to be transcribed at IE 
times. There also appears to be transcription from the 
repeat regions bordering UL of strain AD169 (Wilkinson et 
al. , 1984; McDonough et al. . 1985). Wilkinson et al.
(1984) have also shown that transcription occurs from the 
U s region of HCMV AD169 and Weston (1988) detected 4 
extremely abundant differentially spliced IE transcripts 
originating from this region of the virus genome. Five 
other RNA species transcribed at IE times from the long 
repeated DNA sequences of strain Towne (Wathen and Stinski,
1982) have not been detected in cells infected with either 
the Davis (De Marchi, 1983b) or AD169 (Wilkinson et al . ,
1984) strains of HCMV.
In vitro translation of mRNA selected by hybridization 
to the most abundantly transcribed region of HCMV shows it 
to code for a polypeptide with a MWt ranging from 72 to 75 
kd depending on the strain (Cameron and Preston, 1981; 
Gibson, 1981a) and differences in post translation 
modification (Michelson et a l . , 1979; Gibson, 1981a;
Stinski et al.. 1983). However, the major IE polypeptides 
of strains AD169, Towne and Davis do cross react
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immunologically (Goldstein et al. f 1982). The major IE 
polypeptide is found in cells within 1 hr of infection 
(Stinski, 1978; Blanton and Tevethia, 1981; Stinski et al.,
1983) . It is a phosphorylated protein (Gibson, 1981a) which 
accumulates primarily in the nucleus (Tanaka et al. , 1979) 
and is chromatin associated (Stenberg et al. . 1984). Both 
the phosphoprotein and its mRNA reach maximal levels 
between 0 and 5 hr post infection and decrease to virtually 
undetectable levels later in infection (Stinski, 1978; 
Stenberg and Stinski, 1985). The observation that IE 
proteins of CMV increase chromatin transcriptional activity 
and alterations in chromatin confirmation within 1 hr of 
infection (Gibson, 1981a) suggest that the major IE protein 
may well be a regulatory protein. Munch et al. (1988) have 
shown that the MCMV IE-1 protein (pp89) is not able to bind 
DNA directly but pp89-DNA interaction can be mediated by 
histones. IE-1 and IE-2 proteins independently function as 
trans-activating factors for E gene viral transcription 
(Hermiston et al.. 1987; Tevethia et al., 1987).
Jahn et a l . (1984) have identified a 5 kb IE
transcript which is distinguished from other IE transcripts 
by expression during the IE and L phases of virus 
replication. Furthermore, this RNA represents an 
unprecedented case of a large non—coding transcript present 
in cells that are lytically infected by an animal virus 
(Plachter et a l . , 1988). De Marchi (1983b) has also
described a 4.8 kb IE RNA transcript confined to the nuclei
of infected cells and which is transcribed from IE to L
18
times after infection. A 2.7 kb RNA transcript has been 
identified by Wilkinson et al. (1984) at both IE and E
times after HCMV AD169 infection of MRC-5 cells but it is 
not clear whether there was a low level read through of the 
cycloheximide inhibition resulting in limited early 
transcription. The IE-2 region of Towne strain HCMV is 
known to code for a 2.7 kb RNA species which was noted to 
be most abundant at L times after infection (Stenberg et 
al. , 1985). These data suggest that some IE transcripts
are exempt from the general rule of temporal transcription 
regulation in herpesvirus replication.
The major IE gene of HCMV strains ADI69 and Towne have 
been sequenced (Stenberg et a l .. 1984 ; Akrigg et a l . .
1985). Both genes encode for a spliced RNA molecule 
containing 4 exon sequences and which is 173 6 nucleotides 
and 1341 nucleotides in strains AD169 and Towne 
respectively. Both mRNA species have 1 open reading frame 
which begins within the second exon and extends for 491 
amino acids. The predicted MWt of the polypeptide is 64 
kd which is between 8 and 11 kd less than that estimated by 
denaturing polyacrylamide gel electrophoresis. This 
discrepancy is accounted for by the high density of proline 
residues sit the amino terminal which impart a ^—pleated 
structure and which may be responsible for anomalous 
migration of the protein during gel electrophoresis.
In HCMV strains AD169 and Towne a promoter-regulatory 
region has been identified as extending 509 and 465
19
nucleotides respectively beyond the transcriptional start 
site (Thomsen et al., 1984; Akrigg et al.. 1985). Deletion 
studies within this region have indicated that CAAT and
TATA boxes (Cordon et al. , 1980) within 68 bp of the mRNA 
5' terminus are required for a minimum level of 
transcription (Stinski and Roehr, 1985). Although the HCMV 
IE promoter is a strong promoter (Sinclair,1987), sequences 
upstream of the CAAT box function to enhance downstream
expression of the HCMV IE gene.___Indeed, Boshart et_al.
(1985) have identified a strong transcription enhancer 
upstream of the transcription initiation site of the major 
IE gene of HCMV AD169 between nucleotides -524 and -118 
relative to the cap site. This regulatory region has a
series of repeat sequences referred to as the 16-, 18- and
19- nucleotide repeats which are each reiterated 4 times. 
The 18 bp repeats have some homology to the enhancer core 
sequence found in many enhancer elements, including SV40 
(Laimins et al.. 1982; Weiher et al. . 1983). In addition, 
there is a 21-nucleotide sequence which is repeated twice 
(Thomsen et al.. 1984). A direct correlation has been 
established between the 18- and 19- nucleotide repeats and 
the level of downstream expression but the 16-nucleotide 
sequence has been shown to be unnecessary for the
enhancement of downstream transcription (Stinski and Roehr,
1985). It has been suggested that the 19-nucleotide repeat 
sequences may interact to form a cruciform structure, this 
secondary conformation facilitating an entry site for some 
component(s) of the transcriptional machinery (Thomsen et
—  • ' i^84) • Indeed, 5 constitutive DNase I hypersensitive
sites have been identified at nucleotides -525, -425, -375, 
-275 and -175 relative to the cap site of the major IE RNA 
of HCMV strain AD169 (Nelson and Groudine, 198 6). Such 
DNase I-hypersensitive sites have also been found in 
enhancer elements of eukaryotic genes (Parslow and Granner, 
1982) and other viruses (Cremisi, 1981; Schubach and 
Groudine, 1984) controlling active transcription and are
thought to represent structural changes in the chromatin 
due to complexing with regulatory proteins. Furthermore, 
Hennighausen and Fleckenstein (1986) have identified 4 high 
affinity nuclear factor 1 (NF1) binding sites in the
promoter-regulatory region of HCMV strain Towne between 
nucleotides -780 and -610 and another in the first intron 
at nucleotide +350 with respect to the transcription 
initiation site of IE-1 RNA. NF1 is a sequence-specific
DNA-binding protein which is required for the in vitro 
replication of adenovirus DNA (Nagata et al. , 1982; 1983).
The NF1 binding sites in the major IE gene of HCMV strain 
Towne coincide with regions known to be sensitive to DNase 
in the active gene. However, no NF1 binding sites have been 
observed in the DNase I-hypersensitive transcription 
enhancer of the major IE gene (Hennighausen and 
Fleckenstein, 1986). NF1 binding sites surrounding the 
major IE promoter of both SCMV strain Colburn and HCMV
Towne have been reported by Stinski and Roehr (1985) 
who also demonstrated virus-specific transactivation of the 
IE-1 promoter-regulatory region in the Towne strain of HCMV.
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The major IE protein is also known to regulate its own
expression (Stenberg and Stinski, 1985).
(b) Earlv
The E period of HCMV transcription begins at 8 hr and
ends at 27 hr after the onset of HCMV infection. This
period extends from the onset of virus coded protein
synthesis to the start of virus DNA replication.
McDonough et a l . (1985) have identified a single
transcription unit in IR^/TR^ which is active at E times in
cells infected with HCMV AD169. Hutchinson et al . (1986)
have described the size, temporal expression, gene
organization and direction of transcription of the 3 major 
transcripts from HCMV IRL . These 3 transcripts in order of 
their relative abundance are 2.7, 1.2 and 2.0 kb. The
genomic sequences encoding the 2.7 kb E transcripts are 
unspliced and approximately 2.4 kb in size with the
corresponding message containing a polyadenylated tail of
approximately 300 bp (Greenaway and Wilkinson, 1987). A
similar transcript has also been detected in cells during 
the E phase of infection with HCMV strain Towne (Wathen and
Stinski, 1982).
The 2.7 kb E gene promoter upstream of the
transcription initiation site lacks the numerous direct and 
inverted repeat sequences which are present in the 
corresponding region of the HCMV major IE gene (Akrigg et 
a l . , 1985). However 2 sets of imperfect direct repeats,
one 9 bases and another 12 bases, each repeated twice have
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been observed. Twenty seven nucleotides upstream of the 
transcription initiation site is a consensus sequence for a 
TATA box. The best open reading frame correlated with the
2.7 kb E gene encodes a predicted polypeptide of 170 amino 
acids which has not yet been identified in infected cell 
extracts. However, the rapid and efficient synthesis of the
2.7 kb transcript during productive infection indicates 
that it encodes an important viral function.
Hutchinson and Tocci (1986) have investigated a 1.2 kb 
RNA transcript which is synthesized during E and L times 
after HCMV infection (McDonough et a l . , 1985) . This
transcript maps between 0.792 and 0.797 mu in the long 
inverted repeat of the HCMV strain Eisenhardt genome. A
single large ORF consisting of 254 amino acid codons has
been identified within the 1.2 kb mRNA, translation of
which would result in the synthesis of a highly basic 3 0 kd 
protein. No function yet has been attributed to this 
protein although the amino acid composition is similar to 
that of the HCMV 67 kd L protein which is part of the virus 
tegument (Davis and Huang, 1985) . This 67 kd protein has 
protein kinase activity and binds to DNA. The 3 0 kd
protein may also be a DNA binding protein which would 
correlate with the temporal expression of the 1.2 kb mRNA 
which is first detected prior to DNA synthesis and whose 
sxprsssion increases at L times after infection when the 
number of virus genomes is also increasing (Hutchinson et 
al 1986) . A viral protein has not yet been related to
the 2.0 kb E RNA.
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The functional role of most proteins synthesized during 
the E period of HCMV transcription remains to be 
elucidated. Some of them play a role in the induction of 
host cell macromolecular synthesis (Furukawa et a l . . 1973; 
1975? 1976; St. Jeor et al.. 1974; Tanaka et a l . , 1975?
Garnett, 1979) and the development of cpe (Furukawa et al . . 
1975; Albrecht et al., 1983). Viral DNA polymerase and a 
virus-induced protein kinase also make their appearance 
during this period (Huang, 1975a? Hirai et a l . . 1976?
Miller and Rapp, 1976; Nishiyama et al.. 1983; Michelson et 
al., 1984). One E protein (ICP 22) described by Mocarski 
et al . (1988) is released from cells as a soluble protein
and is highly immunogenic in both humans and mice.
(c) Late
Late transcription occurs after viral DNA synthesis. 
At this time more than 90% of the genome is transcribed 
into stable RNAs which become associated with polyribosomes 
in various proportions (Chua et a l . , 1981? De Marchi,
1983b) . The proteins coded for by L mRNA are structural 
proteins and at least 35 have been described (Sarov and 
Abady, 1975; Fiala et al. , 1976? Kim et al. , 1976? Stinski, 
1976? 1977? 1978? Gupta et al., 1977). Nowak et al . (1984)
localized the regions coding for 2 L proteins on the AD169 
genome: A 71 kd protein (0.3 to 0.32 mu) and an abundant 65 
kd polypeptide. Pande et al. (1984) located the gene 
coding for a 64 kd structural protein to a 0.5 — 0.51 mu 
fragment of Towne strain DNA, corresponding to the same
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region as that described by Nowak et al. (1984) . A DNA
binding protein (ICP 36) has also been mapped to a single 
gene at 0.225 to 0.243 mu on the HCMV strain Towne genome
(Mocarski et al. , 1985) . Expression of many HCMV
transcripts is regulated by post transcriptional mechanisms 
(Wathen and Stinski, 1982; De Marchi, 1983b; Geballe et 
al. , 1986). Even though the HCMV genome is extensively
transcribed at E times after infection only a few of these 
transcripts are present on the polyribosomes or in the 
cytoplasm while at L times after infection transcripts from 
all regions of the genome are present on the polysomes or 
in the cytoplasm. Goins and Stinski (1986) have shown the 
expression of an HCMV L gene to be post transcriptionally 
regulated by a 3 1-end-processing event involving either the 
selection of an upstream cleavage and polyadenylation site 
or the removal of a region of the primary transcript by 
alternative splicing.
1.1.7 Inter-strain variation
(a) Genomic
Physical maps of HCMV strain AD169 (Westrate et al.,
1980; Fleckenstein et al. , 1982; Greenaway et aT. , 1982;
Oram et al. . 1982; Spector et al., 1982), Towne (La Femina 
and Hayward, 1980) and Davis (De Marchi, 1981) have been 
constructed after digestion with several different 
endonucleases. Physical maps for the digestion products of 
Hindlll, BamHI, EcoRI, PstI, Bglll and Xbal of HCMV AD169 
are given in Figure 4.
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Figure 4 Map of the HCMV genome
Restriction endonuclease cleavage map of 
HCMV DNA strain AD169 for the enzymes 
Hindlll, BamHI, PstI, Bglll and Xbal. 
The prototype orientation is shown. 
Repeated sequences are indicated by ■ ■ ■  
A dotted line shows the position 
of the junction between the long and 
short internally repeated sequences.
(Adapted from Greenaway et al. . 1982) .
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Kilpatrick et— al. (1976) compared the restriction 
enzyme profile of 11 strains of HCMV obtained after 
digestion with 2 enzymes and found that, although some 
bands co-migrated, no isolates had identical patterns 
unless they were epidemiologically related. It is not 
possible based on co-migration alone to decide whether 
sequences are homologous or whether co-migrating fragments 
are located in the same map positions. The same is also 
true for fragments which do not co-migrate. However, 
colinearity of HCMV genomes has now been confirmed (La 
Femina and Hayward, 1980; Westrate et al.. 1983; Colimon et 
al.. 1985).
Restriction endonuclease analysis of various HCMV 
isolates can yield information on the epidemiology of the 
virus. Huang et al. (1980) were the first to use this
technique to study transmission of HCMV from infected 
mothers to their offspring. Other such studies have 
included the sexual transmission of HCMV (Handsfield et 
al. , 1985), the reinfection and/or reactivation of HCMV
after renal (Chou, 1986) and bone marrow (Drew et a l ., 
1985) transplantation. The same technique has also 
demonstrated multiple infections in patients with AIDS 
(Drew et a l . , 1984 ; Spector et a l . , 1984a). HCMV
restriction profiles remain stable during in vitro
passaging (Doerr et al. , 1979; Huang et— al., 1980) although 
some profile modifications have been observed (Furukawa, 
1984) . Profiles of HCMV DNA isolated repeatedly in vivo
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over long periods of time are uniform (Huang et a l . . 1976; 
Winston et al.r 1985).
Kinetics of DNA-DNA reassociation in liquid medium 
have demonstrated that HCMVs share at least 80% homology 
(Kilpatrick et al., 1976). Pritchett (1980) has shown HCMV 
strains Towne and AD169 to share about 90% sequence 
homology. Most of the genetic variability and 
heterogeneity between CMV isolates exists within the repeat 
sequences (La Femina and Hayward, 1980; Westrate et al. .
1983) . The HCMV genome shares less than 5% nucleic acid 
homology with the DNAs of HSV-1, HSV-2, EBV, SCMV and MCMV 
(Huang and Pagano, 1974) . Peden et al. (1982) and Ruger et 
a l . (1984) have shown that AD169 DNA has sequence
homologies to cellular DNA.
(b) Antigenic
Antigenic variation between HCMV strains has been 
studied by neutralization (Weller et al. . 1960; Zablotney
et a l . . 1978), complement fixation (Huang et al., 1976),
immunodiffusion (Sweet et aJL. , 1985) and
immunoprecipitation (Gibson, 1981a; 1983). In 1960, Weller 
et al . proposed the classification of HCMV into 3 serotypes 
but more recent studies have not supported this view (Waner 
and Weller, 1978; Zablotney et al., 1978). The use of 
anti-HCMV monoclonal antibodies has also failed to permit a
serotypic classification of the virus (Pereira et al. ,
1982b; Rasmussen et al., 1984b).
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1.2 Latency
1.2.1 Definition
There are at least 3 mechanisms of viral persistence 
in the host. One is progressive infection characterized by 
tissue injury and organ dysfunction e.g. subacute 
sclerosing panencephalitis caused by measles virus (Horta- 
Barbosa et al. , 1969) . Some viruses e.g. HCMV may produce 
a cytolytic infection which is chronic and subclinical in 
which organ function is preserved (Ho, 1979). Finally, 
some viruses may persist in a "silent" state which is 
referred to as latency. Latent infection differs from 
acute or persistent infection by the absence of infectious 
virus but the continued presence of at least 1 other viral 
attribute (Hudson, 1979). Such a definition, however, 
depends on the sensitivity and specificity of the test used 
to define latency. Fluctuations in HCMV CF antibody titre 
in seropositive individuals has been interpreted as 
evidence for dynamic interaction between the host and 
latent virus (Waner et al., 1973).
During the past decade considerable effort has gone 
into defining experimentally the sites and mechanisms of 
latency for 2 herpesviruses, HSV and EBV. Stevens and Cook 
(1971) and Stevens et al. (1972) have demonstrated latent 
HSV in the spinal and trigeminal ganglia of mice and 
rabbits infected experimentally. These findings have 
been confirmed in humans (Bastian et— al • , 1972,
Baringer and Swoveland, 1973; Baringer, 1974).
It has been shown that EBV, which causes
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infectious mononucleosis (Evans et al. . 1968) and is a
factor in the aetiology of Burkitt's lymphoma in humans 
(Zur Hausen et a l . . 1970 ; Nonoyama et a l . . 1973),
establishes latent infection in B lymphocytes (Pattengale 
et— al.. , 1974). EBV persists both by intracellular
formation of a closed circular extrachromosomal plasmid and 
by linear integration of viral nucleic acid sequences into 
the DNA of host cells (Adams and Lindahl, 1975; Kaschka- 
Dierich et al. , 1977). Following primary infection it is 
believed that HCMV remains latent in host cells. The 
evidence for this is described in Section 1.2.2.
1.2.2 Evidence for HCMV latency
The evidence that HCMV establishes latent infection is 
largely circumstantial. There is a high incidence (over 
80%) and lifelong persistence of antibody to HCMV in the 
absence of detectable virus shedding within the general 
population (Weller, 1971). Numazaki et al. (1970) showed
that there was a progressive increase in the rate of HCMV 
infection of the uterine cervix throughout the gestational 
period. All women had pre-existing serum antibody to HCMV 
and, since no woman seroconverted, it was concluded that 
cervical HCMV infection resulted from reactivation of 
latent virus. Patients with rheumatological disorders who 
receive immunosuppressive drugs are also known to 
reactivate HCMV from a latent state (Dowling et al., 1976).
Two decades ago Finnish physicians were the first to
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document HCMV infections in transfusion recipients (Kaariainen 
et a l ., 1966 ) and HCMV viraemia has been demonstrated by
cultivating leucocytes of previously healthy adults, 
children with congenital infection, patients with 
heterophil-negative mononucleosis, post perfusion syndrome 
and a number of immunosuppressive conditions (Diosi et al. , 
1969; Lang and Hanshaw, 1969; Armstrong et al. . 1971; Fiala 
et_al. , 1973; Rinaldo et al. . 1977). The virus resides in 
the blood leucocytes in a latent form because it cannot be 
recovered by cultivation of leucocytes from asymptomatic 
seropositive healthy donors. However, such cells are 
capable of transmitting HCMV (Klemola et a l . . 1969a;
Mirkovic et a l . . 1971; Kane et a l . . 1975). Indeed,
approaches to the prevention of primary HCMV infection have 
included the exclusive use of blood products from 
seronegative donors in neonates (Yeager et al. , 1981) and
recipients of cardiac (Preiksaitis et al., 1983) and bone
marrow (Hersman et al., 1982) transplants. Fresh or stored 
blood or granulocyte transfusions can transmit the 
infection (Prince et al. . 1971; Winston et al. , 1980) . The 
risk of transmission of HCMV by blood products is estimated 
at 2.7% per unit transfused (Armstrong et al., 1976; Singh 
et a l . , 1988a) , the risk increasing with the number of
units (Prince et al., 1971) and the volume (Meyers et— al.,
1983) of blood received. The quantity of blood required to 
transmit HCMV is unknown although 50 to 99 ml was 
sufficient to infect 3 of 18 neonates in a study by Yeager
et a l . (1981).
30
HCMV has been increasingly recognized as a cause of 
frequent and potentially serious infection in recipients of 
organ grafts. Abundant epidemiologic data indicate that 
HCMV can be transmitted from donors of transplanted organs 
to their recipients even though the donor has no evidence 
of HCMV-related disease and culture of the donated organ 
reveals no infectious virus. Specifically, when an organ 
from an HCMV-seropositive donor is transplanted into a 
seronegative recipient that recipient has a 70 to 80% risk 
of acquiring HCMV infection (Glenn, 1981) . This has been 
confirmed for recipients of renal (Rubin et a l . . 1985;
Smiley et al. , 1985; Weir et al. . 1987), cardiac (Chou,
1987; Chou and Norman, 1988; Wreghitt et al. . 1988) and
hepatic (Rakela et al. . 1987; De Hemptinne et al. , 1988;
Singh et al. . 1988a) grafts. Supportive data include the
correlation between the incubation period of HCMV and the 
time interval from transplantation (the postulated 
inoculation) to the onset of clinical evidence of 
infection. Restriction endonuclease analysis of HCMV DNA 
from recipients of transplants from a given individual have 
indirectly established transmission of HCMV via renal 
(Wertheim et al., 1983; Chou, 1986) and heart (Chou, 1987) 
donors. Indeed, infection by HCMV strains from donors has 
also been demonstrated by restriction endonuclease cleavage 
patterns of virus isolated from HCMV-seropositive renal 
allograft recipients (Chou, 1986; Grundy et al., 1987).
Not all HCMV-seropositive donors transmit the virus even to 
seronegative recipients (Warrell et— al., 1980; Marker et
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a l . , 1981; Walker et al., 1982). Chou and Norman (1988)
have shown that only approximately 60% of HCMV-seropositive 
renal donors actually transmit the infection. This could 
be related to differences in immune function in the 
recipients or to differences in the content or biological 
properties of latent HCMV in seropositive donors. Using in 
situ hybridization, Schrier et al. (1985) found that some 
subjects had a higher content of hybridizable nucleic acid 
than others perhaps reflecting variation in the amount of 
latent virus in different persons. HCMV-seronegative 
recipients of an organ from donors known to be seronegative 
for HCMV rarely develop HCMV infection (Betts et al.. 1975; 
Ho et a l . , 1975) , nosocomial spread of the virus being
uncommon in the context of organ transplantation (Meyers,
1984) .
Although bone marrow latently infected with HCMV can 
transmit the virus (Meyers et al.. 1986), the bone marrow 
donor is not an obviously important source of HCMV since 
donor serology does not predict the risk of developing HCMV 
infection after the transplant operation (Meyers et— al., 
1980; 1983; Hersman et a l . , 1982). Indeed, HCMV-
seropositive bone marrow recipients develop HCMV infections 
nearly 3 times as freguently as seronegative ones (Miller 
et a l . . 1986). However, the acquisition of HCMV from
multiple blood products may mask the contribution of the 
bone marrow donor (Bowden et al., 1985).
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1.2.3 Attempts to demonstrate latent HCMV
The cell type in which HCMV persists or remains latent 
is unknown. There is evidence that lymphocytes may play a 
role in HCMV infection since individuals with HCMV
mononucleosis have atypical lymphocytes and in vitro tests 
reveal depression of lymphocyte functions (Rinaldo et al., 
1977; 1980; Carney and Hirsch, 1981). Other authors (Fiala 
et a l . , 1977 ; Howell et a l . . 1979) have implicated
granulocytes as a possible site of HCMV latency. In 1969, 
Diosi et al . reported the recovery of HCMV from cultures of 
leucocytes provided by 2 of 21 healthy HCMV-seropositive 
blood donors. However, in further large scale
investigations involving 1500 blood donors HCMV was never 
recovered from leucocyte cultures (Mirkovic et al. . 1971;
Perham et a l . . 1971; Kane et a l . . 1975; Bayer and
Tegtmeier, 1976). Furthermore, attempts to cultivate HCMV 
in vitro in primary polymorphonuclear or mononuclear cells 
have failed to show appreciable virus replication (Rinaldo 
et a l .. 1978; Einhorn and Ost, 1984) nor has it been 
possible to demonstrate HCMV replication in 
undifferentiated primary human bone marrow cells (Reiser et
al. , 1986) . Skin fibroblasts (Williams et aJL. , 1980) ,
epithelial (Pagano, 1975) and prostatic cells (Rapp et al.,
1975) are also possible sites of HCMV latency.
Although there is epidemiologic evidence implicating 
the transplanted kidney as a source of HCMV infection, 
cultures of donor kidney specimens have been, with 1 
exception, uniformly negative (Pien et al. , 1973; Betts et
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al., 1975; Nankervis, 1976; Howard et al.. 1977; Naraqi et 
al. , 1978). The exception, the study by Orsi et al.
(1978), reported the isolation of HCMV from the kidney in 8 
of 10 renal donors. There is ample evidence that HCMV 
infects the kidney. HCMV-specific antigen (Payne et al. . 
1974) and characteristic inclusion bodies (Rifkind et al. . 
1967) have been identified in glomerular and tubular 
epithelial cells (Figure 5) . HCMV has been isolated from 
allograft kidneys at biopsy or autopsy (Craighead et al., 
1967; Spencer, 1974 ; Naraqi et a l . . 1977). Recently,
Heieren et a l . (1988) have shown HCMV to replicate
efficiently in human kidney mesangial cells. The 
consistent inability to demonstrate latent HCMV in renal 
allografts by explantation could be explained by the tissue 
obtained not being representative of the entire organ or 
the explant procedure not being suitable for the 
demonstration of latent HCMV. Furthermore, the renal 
parenchyma may be an uncommon locus of latent infection.
Past attempts to define the site of HCMV latency have 
been hampered by several factors including the cryptic 
nature of the infection and the difficulty in detecting low 
levels of virus in a small percentage of cells. In recent 
years sensitive molecular techniques have been employed. 
Therefore, Pagano (1975) has been able to detect HCMV DNA 
in leucocytes of bone marrow transplant recipients at 
levels of 2.5 to 19 genome copies per cell. Lymphocytes 
bearing the OKT4 and OKT8 markers have been shown to
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Figure M a n i f e s t a t i o n  of HCMV infection in the
kidney
A section taken through a kidney showing
A; Normal tubular epithelium
B: Giant mononuclear tubular cells with
characteristic cytomegalic inclusion 
bodies.
Stain: Haematoxylin and Eosin 
Magnification: x 350
The photograph was very kindly provided 
by my colleague Dr David Millan, 
Pathology Department, Western Infirmary, 
Glasgow.
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hybridize specifically to a portion of the HCMV genome 
which is heavily transcribed during the IE period of 
infection (Schrier et— al., 1985). HCMV-specific sequences 
have also been identified in a number of locations in the 
kidney, including cells of the glomerulus and tubular 
epithelium (Myerson et al.. 1984). Less than 1 genome 
equivalent per cell of HCMV has been demonstrated in 2 
lymphoblastoid cell lines (Huang et al. . 1978).
1.2.4 Experimental animal models of latent CMV infection
Many animal species e.g. mice, guinea pigs, rats, pigs 
and monkeys are naturally infected with their own strains 
of CMV (Weller, 1971) but the murine model of CMV latency 
has been studied in greatest detail (Olding et al. . 1976;
Brautigam et al. . 1979; Hudson, 1979; Hudson et a l . . 1979;
Cheung et a l . , 1980). Several variables are apparent
including the age of the mice at the time of initial 
infection, the genetic strain of the mice used, the route 
of infection and whether live or attenuated virus was 
inoculated. However, Jordan et al. (1982) have shown that 
these factors do not directly affect the development of 
MCMV latency.
Intraperitoneal inoculation of MCMV results in the 
virus being harboured in a latent phase within peritoneal 
macrophages (Brautigam et__al., 1979). Expression of latent 
MCMV required activation of the macrophages which contained 
5 to 7 viral genome copies per 100 cells. Latent MCMV may 
persist in other tissues, nucleic acid hybridization having
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detected 4.5 and 0.2 genome equivalents per cell of MCMV 
DNA in cultures of salivary and prostate gland cells 
respectively (Cheung et al. , 1980). Other reports have
indicated that MCMV can be reactivated from latently 
infected spleen cells (Mayo et al.. 1977; 1978).
Hamilton and Seaworth (1985) have demonstrated the 
transmission of latent MCMV in a murine kidney tissue 
transplantation model. MCMV has also been reported to grow 
in primary and SV40-transformed kidney cells (Hudson, 
1979) . Hamilton and Seaworth (1985) have also shown that 
the transplanted kidney is a more efficient vector of MCMV 
transmission than transfused blood and that major 
histocompatibility complex matching and treatment with 
immunosuppressive drugs favour the reactivation of latent 
virus from within the renal allograft. Another study by 
Klotman et al. (1985) has shown that in mice latently
infected with 1 strain of MCMV and transplanted with a 
kidney harbouring latent MCMV of another strain, 
reactivation of the endogenous recipient strain of MCMV was 
the source of active infection in 10 of 12 cases but at no 
time were exogenous and endogenous strains reactivated 
simultaneously. The donor kidney as the source of latent 
MCMV in the uninfected recipient was also confirmed. 
Porter et al. (1985) have shown that MCMV reactivated from
renal tissue by explantation has the same restriction 
enzyme profile as the original infecting strain. 
Experimental mouse models of cardiac transplantation (Rubin
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et— al.. , 1984) and rat models of renal and cardiac 
transplantation (Bruning et al.. 1985; 1988) have been
described and confirmed the ability of latent CMV to be 
transferred to and reactivated in the allograft recipient.
Although animal models have revealed interesting 
information concerning the reactivation of latent CMV, 
there are a number of problems including the ability to 
differentiate when acute or chronic infection ends and 
latency begins. The small number of animals involved, the 
relatively brief time intervals used to suggest latency and 
the lack of firm evidence of latent infection are other 
areas of difficulty.
1.2.5 In vitro models of CMV latency
A number of in vitro latency systems have been 
developed. These eliminate the complexities of animal 
studies and provide a simple reproducible method to examine 
HCMV latency.
HCMV infection of permissive human diploid fibroblast 
cells results in the sequentially ordered expression of the 
virus genome, the generation of progeny virus and 
eventually cell death. To examine the establishment and 
maintenance of persistent and latent HCMV infections in 
vitro it is therefore essential to limit the expression of 
the virus genome. Various approaches have included the use 
of inhibitors of virus replication e.g. cytosine 
arabinoside (Gonczol and Vaczi, 1973), phosphonoformic acid 
(Gadler and Wahren, 1983) and human leucocyte IFN plus ACV
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(Bucher et— al. , 1983). Other approaches have included the 
use of cells nonpermissive for HCMV replication (Fioretti 
/ 1973) and defective HCMV populations obtained by
serial passage at high multiplicity (Stinski et al .. 1979). 
Mocarski and Stinski (1979) established persistent HCMV 
infections in human fibroblasts by high multiplicity 
infection and long term tissue culture. Cockley and Rapp 
(1986) have reported the establishment of an in vitro model 
in which the HCMV genome can be maintained for an extended 
period in a latent form by limiting the expression of the 
virus genome by a combination of iFN-a and ACV followed by 
incubation at 37°C. Inhibitor removal and temperature shift 
to 40.5°C resulted in a reduction in the retained HCMV 
sequences detected by blot hybridization to 0.5 copies of 
HCMV per haploid cell genome equivalent. Recently, Tanaka 
et a l . (1988) have described the use of indomethacin and
tetracaine, prostaglandin synthesis inhibitors, to 
establish a latently infected human thyroid papillary 
carcinoma cell line (TPC-1) . Such in vitro latency models 
are likely to provide significant results with respect to 
the understanding of gene expression in nonpermissive cell 
lines.
1.2.6 Viral genome
Very little is known about the state of the viral 
genome during latency. Gadler and Wahren (1983) have 
provided evidence that HCMV DNA integrates into or is 
associated with a subset of cell DNA relatively rich in A-T
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content. These authors suggest that viral genomes persist 
in the cells either as a continuous sequence or in a 
fragmented form. Cockley and Rapp (198 6) have shown that 
only a few unique HCMV genome fragments were detected when 
virus was incubated at 40.5°C after removal of IFN-a and 
A C V . The physical state of the HCMV genome may influence 
the period of reappearance of infectious virus since Tanaka
et al. (1987) have shown that reactivation of latent HCMV
in vitro requires a much longer period of time than that 
required for the multiplication of superinfected HCMV.
1.2.7 Cellular factors
Tanaka et al. (1987) have suggested that the blockage
of HCMV replication in the TPC-1 cell line during the 
latent period occurs early in the HCMV replication cycle 
since IE antigens were synthesized while an appreciable 
amount of DNA polymerase was not induced. This block may 
be a cellular function(s) which can be sensitive to 
temperature (Tanaka et al. . 1987), prostaglandin synthesis 
inhibitors (Tanaka et al. , 1988), UV irradiation (Furukawa 
et a l . . 1975) and iododeoxyuridine (St. Jeor and Rapp,
1973b). A host cell factor(s) may be required to regulate 
the viral genome for complete early gene expression or to 
provide crucial protein(s) for the initiation of viral DNA 
replication. There have been several reports on the 
influence of the cell cycle on virus production, yields of 
HCMV (Furukawa, 1979 ; Falcieri et— a T . , 1982) and MCMV
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(Kramvis and Garnett, 1987) being higher in cells 
challenged during the S and G-2 phases. A cellular 
differentiation step is also essential for replication of 
HCMV in human embryonal carcinoma cells (Gonczol et a l .,
1984) and human bone marrow cells (Reiser et al. . 1986).
Boom et— al. (1988) have provided evidence that both the 
expression and activation of the IE enhancer-promoter occur 
in the absence of viral gene products thereby implying an 
important role for cellular functions in maintenance of the 
latent state and in the reactivation process. It is 
recognized that chromatin organization plays an essential 
role in the maintenance and establishment of the 
transcriptional state of cellular genes (Reeves, 1984 ; 
Weintraub, 1985). To maintain the repressed state of a 
gene throughout cell division its repressed conformation 
must remain intact throughout replication of the gene. 
This may be mediated by DNA methylation. However, Boom et 
a l . (1987) have shown that the HCMV IE enhancer is
refractory to DNA methylation de novo and have speculated 
that this may provide a molecular basis for the potential 
of HCMV to become activated even after a long latent 
period.
1.2.8 Reactivation of latent virus
CMV reactivates in response to a number of stimuli. 
Explantation techniques may lead to the reactivation of 
latent virus by removing cells from normal immunological 
constraints or by changing the cellular replication cycle
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resulting in the production of substances vital for 
reactivation. Support for the latter theory comes from 
Dutko and Oldstone (1981) who showed that cellular 
differentiation promoted virus reactivation. In a murine 
model of cardiac transplantation the trauma of surgery and 
anaesthesia was itself capable of reactivating MCMV to 
produce subclinical primary infection (Rubin et al., 1984) .
Allogeneic stimuli also promote the reactivation of 
latent CMV. In vivo. such stimuli include skin grafting 
(Wu et a l . , 1975), spleen cell transfer (Mayo et al. . 1978) 
and solid organ and bone marrow transplantation (Craighead, 
1969? Rinaldo et al. . 1976; Gadler et al. . 1982). It has 
also been postulated that donor leucocytes present in blood 
transfusions allogeneically stimulate recipient leucocytes 
thereby reactivating HCMV (Lang, 1972) . In vitro 
allogeneic stimuli which have promoted the reactivation of 
latent HCMV include co-cultivation of histoincompatible 
cells (Olding et al. , 1975).
Immunosuppressive therapy, which has no in vitro 
effect, reactivates HCMV from a latent state in vivo. In 
humans such drugs have included cyclophosphamide and 
azathioprine (Dowling et al., 1976) while mouse models have 
used antithymocytic serum (Gardner et— al.. , 1974) ,
anti lymphocyte serum and cortisone (Jordan et— al. , 1977;
Shanley et al. , 1979) and azathioprine or cyclophosphamide 
(Mayo et a l . , 1978). The transient immunosuppressive
effect of blood transfusions may itself suffice to
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reactivate the recipients' endogenous virus. Recent 
indirect evidence suggests that reactivation accounts for 
most post transfusion HCMV infections in seropositive 
adults (Adler et— al. , 1985). Transfusion, especially of
multiple units of blood, leads to various immunological 
aberrations including production of cytotoxic antibodies to 
lymphocytes (Mohankumar et al. , 1981) , depressed NK cell 
function (Gascon et__al., 1984), abnormal immunoglobulin
levels (Balias et al. , 1980) and decreased in vitro T cell 
responses to foreign antigens (Munn et al. , 1981).
1.3 Organ Transplantation
Despite the technical and immunologic advances in 
recent years, infection remains a major barrier to success 
in organ transplantation. More than 80% of renal allograft 
recipients experience at least 1 episode of infection 
within the first year after the transplant operation and 
infection remains the major cause of death at all stages 
po s t —operatively (Rubin and Tolkoff-Rubin, 1988). A
summary of these infections is shown in Figure 6.
The 5 major herpesviruses (CMV, EBV, HSV-1, HSV-2 and 
VZV) share 2 characteristics which explain their clinical 
impact in organ transplant patients: latency and the
ability to reactivate as discussed in Section 1.2: cell
association and the evasion of neutralizing antibody.
This
chapter discusses HCMV, the most important infectious agent
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Figure 6 Infections after renal transplantation
The figure shows the timetable for the 
occurrence of the most frequent
infections in renal allograft recipients.
(Modified from Rubin et a l ., 1981).
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affecting transplant recipients.
1.3.1 Incidence of HCMV infentinn
HCMV is a ubiquitous agent. Studies indicate that the 
majority of people in the world experience HCMV infection 
during their lifetime (Krech, 1973). The prevalence of
HCMV rises with increasing age (Rowe et al. . 1956) and poor 
socioeconomic conditions (Lang et al. . 1977b). At birth,
only 0.5 to 2.5% of neonates have HCMV infection as
demonstrated by virus shedding (Larke et a l . , 1980) .
However at the end of the first year of life, 8 to 60% of 
infants in the Western world excrete HCMV (Leinikki et a l . , 
1972). The rate of infection in young adults is
approximately 1% per year (Naraqi, 1984) . HCMV infections 
are more common in certain populations including pregnant 
women (Gold and Nankervis, 1976) and immunocompromised 
hosts (Ho, 1977). Autopsy and clinical studies indicate 
that 90% of patients with AIDS develop active HCMV
infection during their illness (Reichert et al., 1983).
There are many reports in the literature that examine 
HCMV in the context of renal transplantation and these are 
reviewed by Ho (1977) , Glenn (1981) and Ho (1982) . In 
these studies up to 60% of seronegative and 90% of 
seropositive allograft recipients showed evidence of active 
HCMV infection post-operatively. Using the Mantel-Haenszel 
test controlling for the site of the study (Fleiss, 1973), 
Hamilton (1982) has estimated the relative risk of 
acquiring a secondary HCMV infection to be between 15 and
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16 times greater than it is for a primary infection.
After bone marrow transplantation, between 4 0 and 60% 
of patients show evidence of active HCMV infection (Neiman 
et— al. / 1977; Winston et al. . 1979; Meyers et al. . 1980).
Wreghitt et— ad. (1988) have reported that 45% of heart 
transplant recipients experience HCMV infection post- 
operatively while in a similar study by Dummer et al . 
(1985) the incidence was 85%. Fifty nine per cent (Singh 
et a l . f 1988a) to 77% (Dummer et al. . 1983) of adult and
30% of paediatric (Breinig et al.. 1987) liver transplant 
recipients have evidence of active HCMV infection post 
transplantation.
1.3.2 HCMV-related disease
In renal allograft recipients, the incidence of 
clinically apparent HCMV infection ranges from 13 to 38%, 
most of the symptomatic infections occurring in the first 
few months after the onset of immunosuppressive therapy
(Naraqi, 1984).
Pyrexia is the most common feature observed in 
immunosuppressed patients with symptomatic HCMV infection. 
This varies in severity and is usually prolonged. Illness 
most commonly presents with signs of the mononucleosis 
syndrome (Klemola and Kaariainen, 1965; Klemola et— ad., 
1967; 1969b; 1970). Some combination of the following, can
also be observed: hepatomegaly, splenomegaly, myalgia and
arthralgia (Fiala et al. , 1975; Betts et— aJL. , 1977, Marker
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et a l ., 1981).
After the mononucleosis syndrome, interstitial 
pneumonia is the most frequent manifestation of HCMV 
infection in immunosuppressed patients. It may accompany 
the mononucleosis syndrome or appear separately. In a 
study by Hill et a l . (1964), 47% of renal allograft 
recipients whose deaths were complicated by pneumonia 
showed evidence of pulmonary HCMV infection at post mortem. 
Between 10 and 50% of bone marrow recipients experience 
HCMV-associated interstitial pneumonitis of which 60 to 80% 
prove fatal (Neiman et al. . 1973). HCMV pneumonia has
also been observed in 44% of cardiac (Stinson et a l . , 1971) 
and 30% of hepatic (Fulginiti et al.. 1968) transplant
recipients. The pneumonia has a variable course and may 
resolve spontaneously or advance to marked respiratory 
depression and death.
Clinically apparent hepatitis has been observed in 7 
to 16% of renal transplant recipients (Aldrete et al. , 
1975; Luby et al. . 1974; Anuras et al. , 1977; Ware et al. , 
1979) . While hepatitis is common it is not usually severe, 
even in patients who receive other organ transplants (Ten 
Napel et al. , 1984). The causes of hepatic dysfunction
after liver transplantation include rejection, ischaemia, 
vascular thrombosis, bile duct complications, haemolysis 
and hepatitis (Starzl et al. , 1982; Esquivel et_al., 1985). 
Recently, Bronsther et al. (1988) have shown that HCMV 
hepatitis in liver transplant recipients is a definite 
clinical entity with specific signs and symptoms,
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serological and culture findings and pathological features. 
A number of authors have reported the onset of chronic 
hepatic dysfunction during an episode of febrile illness 
caused by HCMV (Luby et al. . 1974; Ware et al. . 1975; 1979; 
Rubin et a l ., 1977). However, it remains debateable whether 
HCMV is the sole aetiologic agent of this condition. 
Indeed, the cause of hepatitis in immunosuppressed patients 
is often unclear.
Until recently, involvement of the gastrointestinal 
tract with HCMV has been reported infrequently. Most of 
the recognized cases have occurred in the colon where the 
virus is associated with caecal ulceration (Wolfe and 
Cherry, 1973 ; Sutherland et a l . . 1979 ; Foucar et a l . .
1981) . More recently, the biliary tree has been shown to 
be a site of HCMV replication (Galloway, 1984) . HCMV 
infection of the gastrointestinal tract has been reported 
in renal (Franzin et al.. 1981; Cohen et al., 1985; Kodama
et a l . . 1985) and bone marrow (Strayer et a l . , 1981)
transplant recipients. The risk of gastrointestinal HCMV 
infection is 26.5 times greater in patients studied after 
rather than before liver transplantation (Alexander et al., 
1988) . Most infections are of little clinical significance 
but in some cases they are associated with morbidity and
increased mortality (Chatterjee et al., 1978; Schooley et
al., 1983).
HCMV infection in immunosuppressed patients is 
associated with chorioretinitis in 4-s of cases (Fiala et
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al.. , 1975) . HCMV retinitis is usually indicative of
disseminated infection and prolonged viraemia may be a 
factor in the pathogenesis (Pollard et a l . , 1980) .
Cessation of immunosuppressive agents may halt progress of 
the lesions (Egbert et al.r 1980).
HCMV infection also predisposes to a number of 
opportunistic infections the major ones being other viruses 
of the herpes group and papovaviruses, bacteria e.g. L. 
monocytogenes, N. asteroides and Legionella; fungi e.g. 
Candida and aspergillus; protozoans e.g. P. carinii, S. 
stercoralis and T. gondii. Rubin and Tolkoff-Rubin (1988) 
have recently reviewed this subject.
1.3.3 HCMV and renal allograft rejection
A controversial relationship exists between active 
HCMV infection and renal transplant dysfunction. Kidney 
allograft rejection temporally associated with active HCMV 
infection has been reported by some workers (Rubin et al ., 
1977; Fryd et al. , 1980; Tilg et al. . 1987) while others
(Bia et al.. 1985; Poliak et al.. 1987) have failed to 
confirm this finding. Hamilton (1982) has assessed the 
available data from 8 transplant centres and shown that 
renal allograft recipients infected with HCMV have a 
statistically higher rate of rejection than those patients 
who remain uninfected. Such data do not prove that HCMV 
infection provokes or causes allograft rejection, although 
Mourad et al. (1984) have shown that renal dysfunction 
abates with the resolution of infection. While Betts et
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al.. (1977) have demonstrated HCMV infection followed by 
graft rejection, others (Lopez et al.f 1974 ; Braun et a l . ,
1976) have documented rejection followed by seroconversion 
and virus isolation.
It has been proposed that HCMV itself incites tissue 
injury. Interstitial nephritis has been described in 
neonates (Platt et al.. 1985) and in a renal allograft 
recipient (Cameron et a l . . 1982) with HCMV infection.
Glomerular microthrombi in the absence of an interstitial 
infiltrate have been observed during symptomatic HCMV 
infection after renal transplantation (Bia et al. , 1985) .
A distinctive diffuse glomerulopathy has been recognized in 
renal allograft recipients with clinically apparent HCMV 
infection and viraemia (Richardson et al. , 1981). Immune
complexes observed in the circulation of renal allograft 
recipients with primary HCMV infection (Baldwin et a l . ,
1982) may deposit in the kidney and impair its function 
(Ozawa and Stewart, 1979).
Enhancement of alloreactivity by concomitant HCMV 
infection may also be involved in graft rejection. After 
successful transplantation the MHC antigens of the kidney 
parenchymal cells are no longer detectable but reappear 
during rejection (Hayry et al. , 1981; Hall et— ad., 1984) .
HCMV infection is invariably associated with upregulation 
of Class II MHC antigens accompanied by evidence of graft 
rejection (Von Willebrand et al.,1986). Re-expression of 
MHC antigens may be induced by IFN- in response to virus
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infection (Pober et al., 1983; Van Es et al.. 1984). HCMV 
could also induce graft rejection by immunologic 
recognition of expressed viral IE products in infected 
kidney cells. The IE-2 gene of HCMV codes for an amino 
acid sequence also present on the external surface of the 
HLA-DR (3 chain (Fujinami et al. . 1988) . The sequences are 
sufficiently similar such that an immune response generated 
against the virus is also observed to react with "self"
HLA-DR. The sharing of a microbial epitope with a host
"self" epitope from 2 dissimilar proteins has been termed 
molecular mimicry (Fujinami et al.. 1983; Fujinami and
Oldstone, 1985) and is sufficiently common that almost 4% 
of the monoclonal antibodies against viruses also react 
with host "self” determinants (Srinivasappa et al. , 1986).
The available data does not favour reactivation of 
latent HCMV by alloimmune responses (Miller et al. . 1986;
Tilg et a l . . 1987). Indeed, it rather suggests
excessive immunosuppression as the main predisposing factor
for HCMV infection and is supported by the close
correlation between the severity of infection and the 
intensity of the immunosuppressive regime (Fiala et al ., 
1975? Glenn, 1981; Rubin et al. , 1985). This is discussed 
in more detail in Section 1.3.4.
1.3.4 Risk factors for HCMV infection and disease
Immunosuppressive therapy and its impact on HCMV- 
related disease has been reported in detail. The 
importance of immunosuppressive agents is shown by the
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following observations: HCMV infection is seen in almost 
all patients who are treated with cytotoxic agents 
regardless of the underlying condition (Duvall et al . ,
1966; Dowling et al., 1976; Glenn, 1981); renal allograft
recipients who do not receive these drugs do not have a 
high incidence of HCMV infection (Kanich and Craighead, 
1966); there is a close temporal relationship between 
immunosuppressive therapy and the onset of HCMV infection 
(Fiala et a l . , 1975); there is a direct correlation
between the degree of immunosuppression and the morbidity 
of infection (Pass et a l . . 1980). Rubin (1981) has
suggested that the net state of immunosuppression is 
important and if excessive can increase the risk for HCMV 
infection. Indeed, Preiksaitis et al. (1983) have shown
that heart transplant recipients receiving high doses of 
antithymocyte globulin (ATG), azathioprine and prednisolone 
experienced more severe HCMV infections than those given 
low doses.
High doses of corticosteroids (e.g. prednisolone) have 
been implicated in increasing the incidence of HCMV 
infections in patients who have received a renal allograft 
(Velasco et a l .. 1984). The use of antilymphocytic 
preparations is well recognized as having a deleterious 
influence on both the incidence and severity of HCMV 
infections even when the dosage of coadminstered 
immunosuppressive therapy is reduced. Indeed, cytoreductive 
therapy is known to promote HCMV reactivation (Dowling et
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al. , 1976; Pass et al., 1980; Chou and Norman, 1985) and
Tolkoff-Rubin and Rubin (1986) have concluded that adding 
agents such as ATG is more important in potentiating HCMV 
disease than is the basic immunosuppressive therapy. 
Immunosuppressive regimens containing ATG have been 
associated with a higher frequency of symptomatic HCMV 
infection in renal transplant patients (Cheeseman et al. ,
1979; Pass et al. , 1980; Canadian Multicentre Transplant
Study Group, 1983; Nunan and Banatvala, 1984; Bia et al. .
1985) . The incidence of HCMV pneumonia in renal allograft 
recipients has also been related to the use of ATG 
(Peterson et a l . , 1983). OKT3, a murine monoclonal
antibody directed against lymphocytes, has been shown to 
increase the risk of disseminated disease in patients with 
HCMV infection after liver transplantation (Singh et al., 
1988b).
Mild primary HCMV infections in renal allograft 
recipients receiving CsA have been reported (Morris et a l .,
1983) . A lower incidence of HCMV-related disease has been 
observed in patients receiving CsA than azathioprine 
perhaps because of the less frequent use of pulse doses of 
corticosteroids or ATG (Henry et al. , 1985; Najarian et
al., 1985). However, Bia et al. (1985) have suggested that
CsA may lower the risk of HCMV disease independent of its 
ability to reduce the need for aggressive antilymphocyte 
therapy. In other studies the incidence of HCMV-related 
disease in transplant recipients receiving either CsA or 
azathioprine was equivalent (Dummer et—al., 1983, Harris et
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a l ., 1984; Arnfred et al., 1987). Takahashi et al. 1987b) 
have suggested that the incidence of viral infections in 
renal transplant patients immunosuppressed with CsA shows a 
relative increase secondary to a reduction in the frequency 
of bacterial infections. Although CsA improves graft 
survival in comparison with other immunosuppressive agents, 
renal function is often impaired (Opelz, 1988).
In a study by Weir et al. (1987) the major risk for
development of HCMV disease was not related to excessive 
doses of immunotherapy but was due to whether or not an 
HCMV-seronegative recipient received a kidney from an HCMV- 
seropositive donor. HCMV-seronegative patients who receive 
transplants from HCMV-seropositive donors represent the 
group of renal transplant recipients that is at highest 
risk for HCMV-related disease (Ho et al. , 1975) . The same
has been confirmed in the context of cardiac (Wreghitt et 
a l .. 1988) and liver (Singh et al. . 1988a) transplantation. 
When an HCMV-seropositive patient receives a kidney from an 
HCMV-seronegative or seropositive donor the incidence of 
HCMV disease is similar but the latter group have more 
complications (Smiley et al., 1985). Ringden et al. (1987)
have reported a higher incidence of pneumonitis in 
recipients of bone marrow from HCMV—seropositive donors 
while others (Grob et al.. 1987) have failed to confirm 
this finding.
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The type of transplant operation is an important 
determinant of HCMV infection. In patients receiving 
identical prophylactic immunotherapy there is a lower 
incidence of HCMV infection after renal or pancreatic 
transplantation than after cardiac or hepatic 
transplantation (Tilg et al. f 1987). Several studies have 
shown that the most severe form of primary HCMV disease 
arises when infection is acquired from the donated organ 
(Ho, 1977; Dummer et a l . . 1985) than blood products
(Wreghitt et a l . . 1988). Heart and lung transplant
recipients are more likely to experience severe or fatal 
HCMV infections than those receiving a heart transplant 
alone (Wreghitt et al. . 1988) presumably because of the
increased dose of virus which may be acquired from 2 
organs. Among the known risk factors for HCMV 
pneumonia in allogeneic bone marrow recipients are age, 
radiation dose, dose rate and graft-versus-host disease 
(Meyers et al. . 1986; Weiner et al. . 1986). Fewer
recipients of HLA identical kidneys develop HCMV infection 
compared to recipients of mismatched kidneys (Poliak et 
al. , 1987). Roenhorst et al. (1985) have reported that
recipients of cadaver kidney grafts who are positive for 
HLA-DRw6 show a significantly increased incidence of HCMV 
infection and associated clinical symptoms. Pirson et al. 
(1985) have confirmed an association between HLA-DRw6 and 
HCMV disease but not infection in renal allograft 
recipients.
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1.3.5 Prophylaxis
(a) Protective m a t c h i n g
Rubin et— al^ . (1979) proposed the concept of 
"protective matching" of donor-recipient pairs to prevent 
HCMV disease in recipients of solid organ transplants. 
Therefore, some transplant centres attempt to match HCMV- 
seropositive donors with HCMV-seropositive recipients 
while HCMV-seronegative patients receive organs from HCMV- 
seronegative donors (May et al. . 1978; Burleson et al. .
1984) . However, not all HCMV-seropositive donors transmit 
the virus post transplantation (Chou and Norman, 1988) . 
Furthermore, HCMV-seropositive recipients of a kidney from 
an HCMV-seropositive donor have an overall risk of HCMV 
disease approximately double that had they received a 
kidney from an HCMV-seronegative donor (Smiley et al. ,
1985) . Therefore, it would be an unfair disadvantage to 
HCMV-seropositive patients to only give them kidneys from 
HCMV-seropositive donors especially in the setting of an 
inadequate supply of suitable donors.
Several studies have shown that transfusion- 
associated primary HCMV infection can be prevented if 
HCMV-seronegative patients are given blood products only 
from HCMV-seronegative donors (Winston et al. , 1980; Adler
et a l . . 1984; Bowden et al., 1986; MacKinnon et al. ,
1988). Other approaches to the prevention of primary HCMV 
infection have included the use of leucocyte depleted 
(Lang et a l . , 1977a; Verdonck et— aJL. , 1985) , washed
(Williams et al • ,. 1984) and frozen deglycerolized
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(Tolkoff Rubin et al., 1978; Brady et al. . 1984) red blood 
cells.
(b) Passive immunotherapy
In bone marrow transplant recipients there is some 
evidence that intramuscular [IM] (Meyers et al. . 1983) and 
intravenous [IV] (Condie and O'Reilly, 1984; Winston et 
al. , 1984) HCMV hyperimmune globulin, IV HCMV hyperimmune
plasma (Winston et al., 1982) and unselected IV
immunoglobulin (Winston et al., 1987) may prevent HCMV
disease. The same has also been confirmed in the context 
of renal transplantation (Snydman et a l . . 1984 ; 1987 ;
1988). However, some workers (Bowden et al... 1986) have 
failed to show any benefit of passive immunotherapy in 
reducing the incidence or severity of HCMV infection post 
transplantation. Indeed, the apparent beneficial effect of 
immunoglobulin is surprising since severe HCMV-related 
disease can occur in the presence of high titres of 
endogenous specific antibody. While passive immune 
prophylaxis has the advantage of being targeted at high 
risk patients, blood products may serve as a vehicle for 
transmitting other infectious agents (Weiland et a l . , 
1986).
(c) Vaccination
In 1976, Plotkin et al. developed a live attenuated 
vaccine using a virus strain (Towne—125) that was isolated 
from a child with congenital HCMV infection. Studies in 
HCMV-seronegative renal transplant candidates found the
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virus to be immunogenic but did not prevent HCMV shedding 
or become latent in the host in a form that could be 
reactivated following immunosuppression (Lang, 1980; 
Osborn, 1981) . The vaccine has been associated with a 
lower :severity of HCMV disease after renal transplantation
(Starr et a_l. , 1981; Plotkin et a l . , 1984) but there
continues to be concern about the safety and efficacy of 
herpesvirus vaccines in general as well as the oncogenic 
potential of Towne-125 in particular (Parks and Rapp, 1975; 
Betts, 1979).
1.3.6 Treatment
(a) Interferon
Although human IFN has been shown to inhibit HCMV 
replication in vitro (Postic and Dowling, 1977; Rasmussen 
et a l . , 1984a) , it was of little clinical efficacy when
used to treat bone marrow recipients with HCMV infection 
(Meyers et al. . 1982; Wade et al.. 1983).
Recent advances in protein engineering have allowed 
highly purified IFN to be produced. Prophylaxis with 
leucocyte-derived IFN-a has been shown to prevent severe 
HCMV infection in renal transplant patients (Cheeseman et 
a l . . 1979; Hirsch et a l .. 1983). However in 1 study,
recombinant IFN_a was associated with steroid resistant 
acute vascular rejection (Kramer et__al. , 1984). The in
vitro antiviral effect of IFN-jS (Nakamura et al.. , 1988) and
IFN- ^  (Yamamoto et al. . 1987) have been reported. IFN-
/3 has also been useful in the treatment of renal allograft
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recipients with HCMV pneumonitis (Takahashi et al., 1987a).
(b) Antiviral drugs
Adenine arabinoside [vidarabine] has been used to 
treat HCMV infection with little or no effect (Ch'ien et 
al . , 1974; Meyers et al. . 1982). In clinical trials, ACV
used alone or in combination with other antivirals has 
failed to resolve severe HCMV infections (Wade et a l . ,
1983; Shepp et a l ., 1984). Although ACV is not
therapeutically useful against HCMV the drug does exert a 
significant prophylactic effect on HCMV shedding and 
pneumonia (Meyers et al.. 1988). Ganciclovir (DHPG) is a 
new antiviral which, like ACV, is a cogener of 
deoxyguanosine (Field et al. . 1983) but is a more efficient 
substrate for HCMV-induced d e o x y p y r i m i d i n e  kinase than 
other guanosine analogues (Dolin, 1985). The drug shows 
excellent activity against HCMV in vitro (Mar et al. . 1983; 
Tyms et al., 1984) . Ganciclovir is effective in reducing 
HCMV shedding (Shepp et al., 1985; Creasy et al., 1986; 
Erice et al. . 1987) and has been successful in treating
HCMV pneumonitis (De Hemptinne et al., 1988; Shabtai et 
al. , 1988), retinitis (Jacobson et al., 1988), colitis
(Collaborative DHPG Treatment Study Group, 1986) and 
hepatitis (Harbison et al.. 1988). Ganciclovir has no 
effect on latent virus and immunosuppressed patients may 
resume HCMV shedding after cessation of therapy 
(Collaborative DHPG Treatment Study Group, 1986). The main 
adverse side effect of ganciclovir is reversible
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neutropenia. Since the drug is excreted primarily 
unchanged in the urine, dosage adjustment is required in 
the event of renal insufficiency. In a murine model, a 
combination of ganciclovir and immune globulin was found to 
be more effective in controlling HCMV infection than either 
modality alone (Wilson et a l . . 1987). Some authors
(Schmidt et al. , 1988) have shown a synergistic effect of 
HCMV immune globulin with ganciclovir in the treatment of 
HCMV pneumonitis after bone marrow transplantation while 
others (Aulitzky et al., 1988) have failed to confirm this 
finding.
1.4 Immunology of HCMV infection
HCMV affects humoral and cell-mediated immune 
responses in previously healthy as well as 
immunocompromised hosts. In this chapter the role of each 
arm of the immune response during HCMV infection will be 
described although interplay between cellular and humoral 
immune mechanisms may be more important than either 
modality alone.
1.4.1 Cell-mediated immunity
(a) Cvtotoxic T cells 
Cytotoxic T cells (CTL) are non-adherent cells that
possess receptors for SRBCs (Quinnan et al., 1981) but not
for Fc of IgG (Quinnan et al., 1982; Rook and Quinnan, 
1983) . In humans, CTL possess surface antigens which are 
usually 0KT3 and 0KT8 positive (Reinherz et al. , 1979).
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Maturation of CTL precursors into effector cells is 
dependent on lymphokines including IL-1 (Oppenheim et al. ,
1982) , IL-2 (Farrar et al. , 1982) and IFN- ^  (Reddehase et 
al.. , 1982). CTL are typically antigen-specific and are
also restricted in activity by antigens of the MHC 
(Zinkernagel and Welsh, 197 6). Three different patterns of 
specific CTL responses generated against HCMV-infected 
allogeneic target cells have been described; those 
restricted by Class 1 HLA-A and/or B loci, Class II HLA-DR 
or self restricted to lysis of autologous targets (Lindsley 
et a l .. 1986).
In both transplant recipients and healthy volunteers, 
the HCMV-specific cytotoxic response occurs early in 
infection, either prior to or coincident with clinical 
features of HCMV infection or shedding and persists until 
clinical manifestations have resolved (Quinnan et a l . , 
1984a; 1984b). Although lymphocyte proliferation in
response to HCMV antigen in vitro correlates poorly with 
the development or outcome of HCMV infection in bone marrow 
recipients (Meyers et al..1980) , extensive studies have 
demonstrated that the development of HCMV-specific CTL 
responses in vivo correlates closely with recovery (Rook et 
al. , 1984). CTL responses also correlate negatively with
graft rejection (Rook et al., 1984).
Mice develop CTL responses that are similar to those 
seen in humans and are restricted by the MHC Class I 
antigens, H-2D and K (Quinnan and Manischewitz, 1979) .
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Nude mice, deficient in T cell responses, are extremely 
susceptible to MCMV infection (Starr and Allison, 1977). 
Ho (1980) has shown that adoptive transfer of MCMV-specific 
CTL protects mice of the same, but not different, H—2 type 
from fatal MCMV disease.
A subset of T lymphocytes carrying the OKT8 marker 
(T8+) contains cells with cytotoxic/suppressor function 
whilst the 0KT4 positive T cell subset (T4+ ) contains 
lymphocytes with helper as well as cytotoxic activity 
(Reinherz et al. . 1980; Thomas et al. , 1980; 1981; Morimoto 
et a l . , 1981) . Lymphocytes of the T8+ subset have been
implicated in recovery from HCMV (Quinnan et_al., 1982) and 
MCMV (Reddehase et al. . 1987) infection and exert their
antiviral effect in vivo by direct cytolysis of CMV- 
infected cells (Zinkernagel et a l . . 1986) or via
lymphokines (Lehmann-Grube et al., 1985) . Infection by
HCMV results in an inverted T4+/T8+ ratio due to an 
increase in T8+ cells and a decrease in T4+ cells. This 
has been confirmed in previously healthy individuals 
(Carney et a l . , 1981) and recipients of bone marrow
(Persson et al. . 1987) and renal (Schooley et a l . , 1983)
transplants. A reduction in the T4+/T8+ ratio has also 
been observed in mice infected with MCMV (Doody et al. ,
1986). The majority of the expanded T8+ population also 
express HLA-DR (la) antigens suggesting a state of 
activation (Winchester and Kunkel, 1979). In— vitro, the 
T8+ Ia+ subset is hyporesponsive to mitogens and 
alloantigens but retains suppressor activity. In
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convalescence, the T4+/T8+ ratio usually reverts to normal 
and T8+ cells regain full functional activities. However 
in some allograft recipients, a prolonged T cell subset 
inversion has been noted and linked to persistent HCMV
infection (Rubin et al. f 1981a; O'Toole et al.. 1986). A 
reduction in the T4+/T8+ ratio due to herpesvirus infection 
in renal transplant patients has also been correlated with 
a risk of opportunistic superinfection (Schooley et al., 
1983). Some authors (Rinaldo et al. . 1983; Dummer et al. . 
1984; Stadtler et al. . 1985) have reported that allograft
recipients receiving CsA rarely show inversion of the 
T4+/T8+ ratio while others (Metselaar et al. . 1986; Dafoe
et a l . , 1987) have failed to confirm this finding. The
pyrimidinone compound, bropirimine, when administered to 
MCMV-infected mice was able to restore the T4+/T8+ ratio 
(Brideau and Nicholas, 1987) .
Although antigens expressed during the E (Rodgers et 
al. , 1987) and L (Forman et al. , 1985) phases of MCMV
replication are recognized by CTL, non-structural IE 
proteins serve as the dominant target antigens for the 
cellular immune system (Reddehase and Koszinowski, 1984). 
Borysiewics et al. (1983) have also demonstrated HCMV-
specific CTL precursors in the peripheral blood of healthy 
seropositive individuals which recognize antigens expressed 
in HCMV-infected cells as early as 6 hr post infection. L 
cells transfected with the IE-1 gene of MCMV are lysed by 
IE-specific CTL (Koszinowski et al. , 1987), the dominant
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antigen being the IE-1 polypeptide pp89 (Volkmer et al.,
1987) . The recognition of non-structural CMV proteins by 
CTL is not without precedent. Murine CTL can recognise the 
non-structural large T antigen in SV40-transformed murine 
cells (Campbell et al. f 1983) and the non-structural NS1 
protein of influenza virus is also a target for CTL
(Benninck et al., 1987). The mechanism by which proteins
that lack signal sequences for transport to the plasma 
membrane and that do not possess transmembrane domains are 
presented as antigens for CTL is unclear. There is recent 
evidence for intracellular protein degradation and membrane 
presentation of peptides in association with Class I gene 
products (Maryanski et al. . 1986; Townsend et al. . 1986).
Why IE antigens dominate the CTL response to CMV is also 
unclear since during infection of permissive cells IE gene 
transcription is transient. However, the infection of 
permissive embryo fibroblasts in vitro may not necessarily 
reflect the duration of IE gene expression in other cell 
types. Some nonpermissive cell lines infected in vitro 
overproduce the major HCMV IE protein (Jeang et a l . , 1982)
and in vivo-infected lymphocytes from seropositive 
individuals have been found to selectively express HCMV IE 
gene products (Schrier et al., 1985).
(b) Natural killer cells
Natural killer (NK) cells are lymphocytes of the type 
referred to previously as null cells (Herberman and Holden,
1978) . They are distinguished from T cells in that they do 
not form rosettes with SRBCs at 29°C and they lack or have
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very low density of T cell surface antigens. NK cells lack 
surface immunoglobulin differentiating them from B cells 
and, unlike macrophages, they do not bind to nylon wool 
columns. NK cells have characteristic cell surface markers 
including HNK1 [Leu 7] (Abo et al. f 1982) and receptors for 
the Fc portion of IgG (Perussia et al. . 1984). Subsets of 
HNK1 lymphocytes have also been distinguished on the basis 
of phenotypic, morphologic and functional criteria (Lanier
 a l . , 1983; Abo et a l . . 1984). NK cells mediate
spontaneous killing of virus-infected and tumour cells 
without showing conventional immunological specificity or 
memory and without necessarily sharing HLA antigens with 
the target cell (Trinchieri and Perussia, 1984). Their 
action can be augmented by IFN-a and IFN-/? (Bandyopadhyay 
et a l . . 1987) although in one study long term
administration of IFN-a to renal transplant recipients 
resulted in decreased NK activity (Kelly et al., 1984) .
Sayers et al. (1986) reported that IFN- y  is a relatively
poor stimulator of NK activity against tumour cells while 
others (Weigent et al. . 1983) have shown I F N - ^  to enhance 
NK activity against murine fibroblasts to the same extent 
as 50-fold higher concentrations of IFN-a or IFN-/3. IL-2 
also augments NK activity against non-infected and HCMV— 
infected fibroblasts (Bandyopadhyay et— al.. , 1987) but
whether this is (Ortaldo et al., 1984) or is not (Ito et 
al. , 1986) dependent on the induction of I F N - ^  remains
controversial. NK activity is suppressed by drugs such as
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CsA (Introna et al., 1981) or azathioprine and prednisolone 
(Dupont et— ad. , 1984) . HLA-DR+ accessory cells also
contribute to NK activity by mechanisms other than the 
secretion of extracellular IFN (Bandyopadhyay et a l . ,
1986).
The resistance of various strains of mice to the early 
lethal effect of MCMV infection correlates with the 
magnitude of the NK cell response (Bancroft et al. . 1981;
Ohashi et al. , 1988) . Bukowski et al. (1984) have shown
that treatment of mice with antibody to asialo GM1, which 
selectively depletes NK cell activity in vivo, results in 
an MCMV infection which is more severe. Suckling mice are 
protected from lethal MCMV infection by adoptive transfer 
of NK cells from adult mice (Bukowski et al. , 1985) . NK
cells have been shown to be among the first immune cells to 
reappear after marrow transplantation (Livnat et a l . , 
1980), usually within the first few months (Dokhelar et 
al. , 1981). Studies in bone marrow transplant recipients
have also found increased NK activity associated with 
improved survival from HCMV infection (Bowden et al., 1987) 
while others have failed to confirm this finding (Forman et 
a l ., 1986). Healthy HCMV-seropositive individuals have
persistently raised levels of NK cells in the peripheral 
blood perhaps reflecting some control in viral 
dissemination (Gratama et al., 1987) . Indeed, a fall in NK 
activity has been correlated with overwhelming HCMV 
infection post transplantation (Dokhelar et— al. , 1981) .
However during HCMV infection of experimentally infected
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healthy volunteers, NK activity followed the CTL response 
(Quinnan et— a_l., 1984b) and therefore the importance of NK 
cells in the containment of HCMV infection remains to be 
determined.
(c ) Antibody-dependent cell-mediated cytotoxicity
The effector cells that mediate antibody-dependent 
cell-mediated cytotoxicity (ADCC) include all leucocytes 
that possess receptors for the Fc portion of IgG. In human 
and murine CMV infections, the effector cells that have 
been found to mediate this effect are similar or identical 
to NK cells (Quinnan and Manischewitz, 1979; Kirmani et
a l ., 1981). Monocytes and neutrophils may also mediate ADCC 
(Kohl et al.. 1977; Oleski et al., 1977). Certain classes 
of antibodies are more active than others in ADCC probably 
because they are more cytophilic and bind to Fc receptors 
more avidly (Okafor et al. . 1974). Like NK cells, ADCC
requires direct contact between effector and target cell. 
ADCC is antigen-specific by virtue of the fact that the 
effector cells are armed with specific antibodies but the 
antigens recognized by CMV-specific ADCC are unknown.
(d) Delaved-type hypersensitivity
In contrast to the current state of understanding of 
the roles of cytotoxic effector cells in defence against 
HCMV infections, very little is known about delayed-type 
hypersensitivity (DTH) responses in this respect. However, 
the effector cells mediating DTH and T cell cytotoxicity 
are distinct and are subject to different immunoregulatory
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controls (Nash and Ashford, 1982). The only currently 
available method that may be useful for measuring DTH 
responses to HCMV is by skin test reactivity. This 
response has been manifest in HCMV-seronegative recipients 
of the Towne strain vaccine who developed a local reaction 
at the injection site approximately 10 days after 
vaccination but not in HCMV-seropositive vaccinees in whom 
the DTH response may have been actively suppressed (Quinnan 
et a l .. 1984b).
1.4.2 Humoral immunity
With the description of T cell-specific antiviral 
function and the correlation of cytotoxic T cell activity 
with recovery after HCMV infection, the role of antibody 
has taken a position of secondary importance in resistance 
to HCMV. HCMV viraemia and disease occur in the presence 
of high titres of neutralizing antibody (Fiala et al . , 
1973) . Indeed, renal allograft recipients with primary 
HCMV infection often show a slow rise in virus-specific 
neutralizing antibody levels (Craighead, 1969; Pass et a l . .
1983) . HCMV infection may occur in a second offspring of 
mothers with a previous congenitally infected child, 
indicating that maternal antibody does not prevent 
transplacental transmission of HCMV (Embil et al. , 1970;
Stagno et a l . . 1973). Furthermore, there is a higher 
incidence of HCMV infection in organ allograft recipients 
who are HCMV-seropositive immediately pretransplant than in 
those who are not (Section 1.3.1).
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Some protective role for humoral antibody in HCMV 
infection is suggested by several observations.
Congenitally infected infants born to HCMV-immune mothers 
have a lower incidence of brain damage and HCMV disease 
than those born to non-immune mothers (Stagno et a l . , 
1982). Although HCMV-seropositive organ transplant 
recipients are not protected against HCMV infection they 
are protected from HCMV-related disease as indicated by the 
fact that the majority of infections in these patients are 
asymptomatic (Ho, 1977). Furthermore, there is an 
association between fatal HCMV infection and an impaired 
specific antibody response in recipients of renal (Simmons 
et a l . . 1974), cardiac (Rasmussen et al. . 1982) and bone
marrow (Neiman et al. . 1977) transplantations. However, it 
is not clear whether the failure to produce specific 
antibody is the cause or the result of overwhelming HCMV 
infection. Furthermore, these data do not prove that
antibody is the beneficial component of the immune 
response. Indeed, the local humoral immune response in 
transplant recipients with HCMV pneumonitis is not specific 
to the infecting agent (Milburn et al.. 1988). Cytotoxic T 
cells may be protective and the ability to mount this 
response may correlate with the ability to mount a humoral 
immune response.
Antibody production against HCMV is relatively intact 
in patients receiving immunosuppressive therapy (Rytel and 
Balay, 1976; Rasmussen et al. . 1982) and the detection of
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specific antibodies in the different immunoglobulin classes 
has been described (Van Loon et al.. 1985; Nielsen et al. . 
1986; 1987; 1988). These are discussed in more detail
below but their primary function, like all immunoglobulins, 
is the recognition and binding of specific antigenic 
determinants followed by secondary effects which may 
include enhanced phagocytosis, ADCC, or target cell lysis 
following complement activation.
(a) HCMV-IcrM
IgM, a pentamer with 5 disulphide-linked subunits, 
has a sedimentation coefficient of 19S whereas the 
individual subunits each have a sedimentation coefficient 
of 7S [low molecular weight IgM] (Metzger, 1970; McDougal 
et al.. 1975). In acute viral infections, virus-specific
IgM antibody is found in the 19S fraction of human serum 
but 7S IgM antibody has also been noted in patients 
infected with HCMV (O'Neill et a l .. 1988b). The
significance of this 7S HCMV-IgM antibody remains to be 
clarified.
Virus-specific IgM antibody in patients serum is 
usually transient and its presence normally suggests a 
recent or current infection. Studies of previously healthy 
individuals have shown HCMV-IgM to persist for up to 3 and 
5 months in patients with HCMV mononucleosis (Rasmussen et 
al., 1982) and in asymptomatic pregnant women (Griffiths et 
al., 1982a). However in immunosuppressed organ transplant 
recipients, HCMV-specific IgM antibody may persist for up 
to 2 years (Nagington, 1971; Kangro et a l . . 1982 ;
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Sutherland and Briggs, 198 3). Studies of pregnant women 
have also shown that IgM antibody to HCMV generally 
signifies recent primary infection whereas those women with 
HCMV reinfection and/or reactivation seldom have this 
antibody (Stagno et a_l. , 1985) . However in organ
transplant recipients, HCMV-specific IgM is observed in 
some individuals with non-primary HCMV infections (Pass et 
al. , 1983) although Wreghitt et al. (1986a) consider high
concentrations of HCMV-IgM in the sera of allograft 
recipients to be diagnostic of primary infection. There is 
conflicting evidence as to whether high levels of HCMV-IgM 
in HCMV-seropositive recipients of kidneys from HCMV- 
seropositive donors represents reinfection by donor virus 
(Betts and Schmidt, 1981; Chou et al.. 1987). However, the 
presence of HCMV-IgM on the day of transplantation is an 
index of greater susceptibility to severe recurrent 
infections at a later date (Tardy et al.. 1987).
Complement-fixing IgM (CF-IgM) has been reported for 
only few viruses including rotavirus (Abe and Inouye,
1979), HSV (Tokumaru, 1966) and HCMV (Booth et al. . 1980).
HCMV CF-IgM possesses cytolytic activity and is directed 
against cell surface antigens (Booth and Mohammed, 1988). 
However, this antibody is detected in only a small 
proportion of individuals possessing HCMV-IgM and its 
usefulness in passive immunotherapy remains to be 
established.
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(b) HCMV-IqG
Human immunoglobulin IgG consists of 4 subclasses 
designated IgGl, IgG2, IgG3 and IgG4 (Grey and Kunkel, 
1964; Kunkel et a l . . 1966). The subclass percentile
distribution is usually IgGl, 66%; IgG2, 23%; IgG3, 7%;
IgG4, 4% (Yount et al.. 1970).
In HCMV infection, as well as in other viral 
infections, the IgG antibody response appears to be 
restricted (Beck, 1981; Morell et al. . 1983). IgGl and
IgG3 are produced in primary infection and IgGl is the main 
responding subclass in patients with reactivation of HCMV. 
IgG4 specific for HCMV occurs in approximately 30% of 
individuals with primary infection (Linde et al. . 1983).
The relative importance of the various subclasses of IgG in 
recovery from HCMV infection is still not well understood. 
Recent findings indicate that IgG3 is the first subclass to 
appear after HCMV infection and shows a higher ratio of IgG 
concentration to antibody titre than the other subclasses 
as determined by neutralization and haemagglutination 
inhibition (HAI) assays (Linde et al.. 1983). Furthermore, 
bone marrow transplant recipients with severe HCMV disease 
show a concomitant disappearance of virus-specific IgGl 
and/or IgG3 (Wahren et a l ., 1984) perhaps reflecting
consumption by antigen or cessation of production leading 
to more severe illness. The biological roles of IgGl and 
IgG3 are not clear (Spiegelberg, 1974; Winkelhake, 1978) 
but both appear to have neutralizing capacity (Wahren et 
al., 1984). However, human complement factor Clq binds to
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the IgG subclasses in the following order IgG3 > IgGl > 
IgG2 > IgG4 (Schumaker et a l . . 1976) and recently
Middeldorp et al. (198 6) have reported the presence of
cytolytic HCMV-specific CF-IgG in transplant recipients.
It is well appreciated that IgG antibodies can persist 
in the serum for many years after viral infections, usually 
being associated with lifelong immunity (Mims, 1982).
(c) HCMV-IaA
Several authors have reported on the occurrence of 
virus-specific serum antibodies of IgA class in HCMV 
infections. These can be detected as early as 3 days after 
the onset of symptoms in 8 of 9 patients with primary HCMV 
infection (Levy and Sarov, 1980) and in 7 of 8 renal 
allograft recipients with reinfection and/or reactivation 
(Sarov et al.. 1982). There is considerable individual
variation in the duration and magnitude of the HCMV-IgA 
response (Strand and Hoddevik, 1984). Consequently the 
results of HCMV-IgA detection may be difficult to 
interpret. Several authors consider HCMV-IgA as a 
transient antibody indicative of recent infection or 
reactivation since serum HCMV-IgA persists longer than 
specific IgM but declines before specific IgG (Levy and 
Sarov, 1980). Recently, Morris et al. (1985) have found
HCMV-IgA to persist for several years after initial 
infection perhaps reflecting antigenic boosting by virus 
reinfection and/or reactivation. Russel et al. (1981) have
suggested that serum IgA transports foreign antigens from
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the bloodstream into the bile. However, further work is 
required to determine whether HCMV-specific IgA antibodies 
in the serum are involved in protecting the host from 
infection.
(d) Immunogenic proteins
The most direct approach to determining which HCMV 
proteins elicit the formation of antibodies in man is to 
use human sera to probe infected cell and virion proteins. 
This has been done using both immunoprecipitation 
(Rasmussen et al. . 1988) and immunoblotting (Shimokawa et
al. , 1987) analysis.
At least 3 to 4 polypeptides (MWt: 30, 69 to 70, 72 to 
76 and 78 to 80 kd) made before viral DNA synthesis can be 
precipitated from HCMV-infected cell extracts, 
predominantly by sera from acutely infected individuals 
(Blanton and Tevethia, 1981). Immunogenic infected cell 
proteins made after HCMV DNA synthesis have a MWt ranging 
from 25-30 to 183 kd (Zaia et al.. 1986).
With 1 exception (Anders et al. , 1986), immunogenic
proteins of purified virions have been studied exclusively 
by immunoblotting (Landini et al. , 1986). The number of
polypeptides recognized and the intensity of reaction have 
been found to correlate closely with serum IgG titres. 
While IgG reactivity is broad, IgM preferentially binds to 
a few polypeptides of MWt 34 to 38, 64 to 66 and 150 to 155 
kd (Landini et al., 1985).
Of all the polypeptides recognized by human sera, the 
one of 150 to 155 kd [the phosphorylated matrix protein]
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appears to be the most immunogenic (Jahn et al.. 1987) and
response to this polypeptide persists for years after 
convalescence when antibody to the other HCMV polypeptides 
has disappeared (Landini et a l ., 1985). Another
polypeptide of MWt 82 kd may play a role in inducing a 
protective immune response since renal transplant 
recipients with antibody to this protein at the time of 
operation have a lower incidence of HCMV reactivation 
(Landini et al.. 1986). In the majority of HCMV infections 
there is an intense antibody response to the 64 to 66 kd 
polypeptides (Zaia et al. . 1986) which probably correspond 
to the lower matrix protein described by Gibson (1983) and 
which may be the principal component of the CF antigen (Kim 
et al.. 1977). Some immunogenic proteins e.g. the matrix 
and major capsid proteins are internal structural proteins 
and are unlikely to be expressed on the viral envelope or 
the membrane of infected cells. Therefore, the role that 
antibodies to these proteins might have in the host defence 
against HCMV is unclear.
Another approach to the study of immunogenic proteins 
has been to identify those which induce neutralizing 
antibodies. Characterization of HCMV proteins which 
compose neutralization epitopes on virions has been done 
almost exclusively by use of murine monoclonal antibodies 
(Masuho et al., 1987). HCMV polypeptides identified in
this way include a complex of 2 major co- 
immunoprecipitating polypeptides pp55/13 0 of 55 and 13 0 kd 
with a broad band centred at 92 kd (Rasmussen et al. ,
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1985). The second polypeptide (pp86) detected by virus 
neutralizing monoclonal antibody is 86 kd (Rasmussen et 
a l . . 1984b). pp86 and pp55/130 are immunologically
unrelated (Rasmussen et al.. 1988).
For lack of an animal model of HCMV, the effective 
role of these complexes in inducing neutralizing antibody 
has been assessed by administering purified proteins (Clark 
et a l .. 1984), protein complexes (Gonczol et al.. 1986b) or 
genetically engineered HCMV-protein-vaccinia virus (Cranage 
et a l ., 1986) to animals and testing for neutralizing
antibody induction.
The mechanism(s) of neutralization of HCMV has been
studied by Rundell and Betts (1980; 1981; 1982) but our
knowledge remains scant.
1.4.3 Interferon
IFN was first described in 1957 by Isaacs and 
Lindenmann. It is now known that there are numerous
species of IFN. They are classified into 3 types of 
functionally related proteins designated a, p a n d ^  largely 
on the basis of their antigenic specificities.
IFN-a is produced mainly by lymphocytes and has over a 
dozen isolectric forms (Stewart et al. , 1977) . IFN-/3 is a 
glycoprotein of 22 kd (Heine et a l . , 1980) and is
synthesized by fibroblasts in response to virus infection. 
IFN-0/is a glycoprotein composed of dimers of 20 and 25 kd 
subunits (Yip et a l . . 1982) and is produced by T
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lymphocytes following non-specific stimulation by mitogens 
in vitro or by sensitized lymphocytes stimulated with 
specific antigen in vitro or in vivo (Epstein, 1979).
The mechanism by which IFNs inhibit herpesviruses are 
poorly understood. NK cells do not appear to be required 
for the antiviral effect of prophylactically administered 
IFN in a mouse model of CMV infection (Bukowski et al. ,
1987) . IFN may activate another arm of the host immune 
response e.g. macrophages (Schultz et a l .. 1977).
Alternatively, IFN may directly inhibit virus replication. 
Indeed, Stinski et al. (1982) have clearly shown IFN-a and
to inhibit translation of IE HCMV mRNA.
1.4.4 HCMV-induced immunosuppression
HCMV can also cause immunosuppression e.g. depressed 
in vitro lymphocyte proliferative responses (Carney et al., 
1983; Roenhorst et al. . 1988) and NK activity (Schrier et
al. , 1986) . Monocytes may also be infected by HCMV and
their phagocytic activity reduced (Kapasi and Rice, 1986). 
In other experiments, it has been shown that HCMV can 
suppress not only T cell proliferation to HCMV but also to 
HSV and mitogens (Sing and Garnett, 1984). Low passage 
HCMV isolates are more efficient suppressors than 
laboratory adapted strains (Schrier and Oldstone, 198 6).
The mechanism(s) by which HCMV induces 
immunosuppression is unknown. However, the demonstration 
that the monocyte is integral to in vitro immunosuppression 
(Kapasi and Rice, 1986) complements the observation that
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only a small percentage of lymphocytes can be shown to 
express HCMV gene products (Rice et al. . 1984; Schrier et
al. , 1985) . Monocytes infected with HCMV in vitro are no
longer able to produce IL-1 activity (Rogers et al . ,
1985) . IL-1 is required as a second signal for T cell
activation during antigen presentation. Loss of IL-1 
activity is now known to be due to release of an inhibitor 
of IL-1 from HCMV-infected monocytes (Rogers et al., 1985).
1.4.5 Immunological aberrations
A variety of immunologic abnormalities has been 
observed in association with HCMV infection. These include 
circulating immune complexes, cold agglutinins, rheumatoid 
factor (RF), cryoglobulin and monoclonal gammapathy of IgA, 
IgM and IgG types (Kantor et al. . 1970; Vodopick et a l . .
1974; Stagno et al. . 1977). HCMV can also act as a
polyclonal B cell activator (Hutt-Fletcher et al.. 1983).
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1.5 Diagnosis of HCMV infection
The diagnosis of HCMV infection cannot be made 
clinically but requires laboratory confirmation. Many 
methods are or have been used and these are discussed in 
detail below.
1.5.1 Histology
For many years the diagnosis of HCMV infection was 
made by identifying the characteristic inclusion bodies in 
histologic sections of autopsy tissues (Smith and Vellios, 
1950; Wong and Warner, 1962). More recently,
identification of inclusion bodies in tissues obtained by 
biopsy has been used for making the diagnosis in living 
patients (Risdon and Turner, 1980). Although histology is 
a relatively reliable technique its sensitivity is 2 to 6 
times less than that of virus isolation (Naraqi, 1984) . 
The specificity of histology for diagnosis of HCMV is high 
but the intranuclear inclusions can occasionally be 
confused with those of other herpesviruses or adenovirus 
(Schumann et al., 1977).
1.5.2 Cytology
Inclusion-bearing cells may be found in urine, saliva, 
milk, cervical secretion and touch preparations of HCMV- 
infected tissues. Exfoliative cytology for the detection 
of HCMV-infected cells in the urinary sediment was used in 
1952 and for the first time made it possible to diagnose
HCMV infection in living patients (Fetterman, 1952). While
what proved to be
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the specificity of this method is similar to histology the 
sensitivity is poor in comparison to virus isolation (Morse 
and Coleman, 1974). The diagnostic yield can be improved 
by cytocentrifugation (Schumann et al.. 1977). Recently,
cytologic examination of alveolar lavage fluid has proved 
useful in identifying bone marrow transplant recipients 
with HCMV pneumonitis (Cordonnier et al.. 1987).
1.5.3 Electron microscopy
Detection of virus particles in the urine by electron 
microscopy has been found useful for the rapid diagnosis of 
HCMV infection in neonates with congenital infection 
(Stagno et al. , 1980) . Such patients have a high titre of 
cell-free virus in the urine. While this method takes only 
a few hours and so could provide a same-day diagnostic 
service it is of limited usefulness in the diagnosis of 
HCMV infection in renal allograft recipients for two 
reasons: the titre of HCMV found in clinical samples from
adults is generally lower than that found in infants 
(Griffiths, 1987); all 6 human herpesviruses which 
frequently infect immunosuppressed patients are 
morphologically indistinguishable (Stagno et al . , 1981).
Whether the application of specific reagents such as 
monoclonal antibodies to basic electron microscopy 
techniques proves useful remains to be determined (Doane 
and Anderson, 1977).
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1.5.4 Viral culture
(a) Collection of specimens
Samples should be collected under sterile conditions 
and be transported to the laboratory with minimum delay in 
order to avoid loss in infectivity (Stagno et al., 1981).
If storage is required samples should be kept at 4°C but 
under no circumstances should they be frozen. Freezing of 
the specimen results in loss of HCMV infectivity (Alford 
and Britt, 1985). HCMV has been isolated from urine, 
saliva, throat swabs, circulating leucocytes, cervical 
secretions, semen, breast milk and tears. Human foreskin 
and embryonic lung fibroblasts are commercially available 
and are the only cells that support HCMV replication in 
vitro.
(b) Detection of HCMV
Virus isolation in conventional tissue culture is the 
most sensitive method for laboratory diagnosis of active 
HCMV infections (Goldstein et a l . . 1982 ? Sullivan and
Hanshaw, 1982). Although this method is sensitive it is 
hampered by the fact that HCMV grows slowly in cell culture 
and a considerable period may elapse, often up to 5 weeks, 
before the typical cpe becomes apparent (Reynolds et al. ,
1979) . Centrifugation of the inoculum on to the cell 
monolayer enhances the infectivity of HCMV (Hudson et al. , 
1976) . The mechanism is unclear but is time dependent, 
cells and virus having to be centrifuged during the 
inoculation phase (Hudson, 1988). Ho (1982) has suggested 
that centrifugal enhancement of HCMV infectivity relates to
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an inherent property of the virus while others (Gleaves et 
al. , 1985; Shuster et al.. 1985) explain the phenomenon on 
the basis of increased HCMV adsorption. Recently, Agha et 
al. (1988) have proposed that centrifugation overcomes the 
tendency of negatively charged HCMV particles to be 
repelled by negatively charged cell membranes.
1.5.5 Tissue immunofluorescence
(a) Cell culture
The rapidity of detection of HCMV-infected culture 
cells can be significantly increased by using 
immunofluorescence (Stirk and Griffiths, 1987) and 
peroxidase-antiperoxidase (Swenson and Kaplan, 1985) 
staining to identify HCMV-specific proteins. Monoclonal 
antibodies have been produced that detect IE (Schuster et 
al. . 1985) and L (Sutherland et al. . 1987) antigens after
16 hr and 24 to 72 hr post infection respectively. 
Compared with HCMV isolation, detection of early antigen 
fluorescent foci (DEAFF) is reported to have a sensitivity 
of 75 to 100% with a specificity of about 95% (Gleaves et 
al. . 1984; Alpert et al. . 1985; Gleaves et al. . 1985;
Swenson and Kaplan, 1985; Stirk and Griffiths, 1987).
Centrifugation of the inoculum on to indicator cell 
monolayers has been shown to increase the sensitivity of 
FAT by 40% (Gleaves et al. , 1985) . Sonication of urine
samples prior to inoculation and testing by FAT increases 
both the number of fluorescent foci and intensity of
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fluorescence of HCMV-infected fibroblasts and decreases 
non-specific background signal (Agha et al., 1988). The
mechanism is unknown but may involve the freeing of virus 
particles from their /32m coat (McKeating et al. , 1986) .
The sensitivity of FAT is not increased by pretreatment of 
cell monolayers with dimethyl sulphoxide or dexamethasone 
which have been shown to enhance HCMV replication in vitro 
(Tanaka et al.. 1984; Espy et al.. 1988).
FAT can be performed in most clinical laboratories and 
requires minimal technician time and expertise. The 
reduction in time required by FAT to detect HCMV isolates 
has significantly reduced the problems associated with 
specimen contamination and toxicity in cell culture (Howell 
et al. , 1986). However, false negative FAT results may
occasionally arise particularly with respect to those
specimens containing low titres of HCMV (Stirk and
Griffiths, 1987). Furthermore, there is evidence that some
strains of HCMV encode proteins not recognized by FAT (Chou 
and Scott, 1988) but this problem has been resolved by 
Griffiths et al. (1984) who used a mixture of 7 monoclonal
antibodies each directed at a different HCMV protein. 
Recently, Agha et al. (1988) have shown FAT on inoculated
tissue cultures using convalescent human serum to be as 
sensitive as conventional tube cell culture for the
detection of HCMV in clinical specimens.
(b) Clinical specimens
Monoclonal antibodies against HCMV can also be used to 
stain cells obtained directly from the infected patient
81
(Volpi et al. . 1983 ; Cordonnier et al. . 1987). Although
this procedure has the advantage of providing results 
within a few hours, it is relatively insensitive since it 
detects only a quarter of bronchoalveolar lavage fluids 
known to contain HCMV by FAT and/or conventional cell 
culture (Stirk and Griffiths, 1988). However, direct 
detection of HCMV antigen in peripheral blood leucocytes by 
monoclonal antibodies has proved to be as specific as and 
more sensitive than current virus isolation techniques (Van 
der Bij et al.. 1988).
1.5.6 Enzvme immunoassay for the detection of HCMV antigens
Since the titres of HCMV within urine specimens are 
relatively high (Stagno et a l . . 1975), several
investigators have attempted to detect the virus by 
ELISA using monoclonal antibodies. While such assays have 
given good results with laboratory passaged strains of 
HCMV, results of poor specificity and sensitivity were 
obtained when clinical specimens were processed (Yolken and 
Stopa, 1980; Yolken, 1982).
Recently, McKeating et al. (1986; 1987) have shown
that j02m coats HCMV in body fluids and inhibits the binding 
of HCMV-specific antibody. Nevertheless, Naqvi and Blair
(1986) have been able to detect HCMV antigen by ELISA in 
84.47% of clinical samples which yielded the virus in 
tissue culture.
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1.5.7 Serology
A number of serological assays relating to the 
detection of virus-specific antibodies have been described 
(Grist et a l . . 1979). This section discusses the
advantages and disadvantages of some of these methods.
(a) Complement fixation test
The CFT for HCMV-specific antibody as described in 
Section 3.16.2 was the first widely used serological assay 
for HCMV (Bradstreet and Taylor, 1962). However, the 
procedure is time consuming and requires considerable 
expertise to perform. Shorter incubation times have been 
used but with noticeably inferior sensitivity (Hunt et al., 
1984) . There are many variables in the test and the end 
point depends on subjective evaluation. The preparation of 
potent high-titre CF antigen by alkaline glycine buffer
extraction and ultrasonication of infected cells is 
important for reliable results in the CFT (Booth et al. , 
1982). Screening at a 1:8 dilution may miss some low
positive sera whereas screening at less than 1:8 may give
rise to anticomplementary activity (McHugh et al., 1985).
Some antibodies do not fix complement and would therefore 
remain undetected by CFT (Roitt, 1985). Recently, Faix
(1985) has shown that antigenic heterogeneity among HCMV 
strains can result in misclassification of up to 6% of sera 
as negative for HCMV CF antibody if only a single strain of 
virus is used as the antigen. However, in a study by Adler 
and McVoy (1986) the continued use of the AD169 strain of
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HCMV as a reference antigen in serological assays is 
supported.
(b) Indirect haeiaaaalutination test
The IHA test is the simplest of the various techniques 
and offers the advantages of IgM sensitivity, rapid 
turnaround times and lack of interference by 
anticomplementary activity (Faix, 1985). A high incidence 
of non-specific agglutination can be reduced by the use of 
glutaraldehyde-fixed human type 0 erythrocytes and careful 
attention to determining the optimal tannic acid 
concentration for each cell batch (Yeager, 1979). Some 
authors have found IHA to be superior to many other 
commercially available test methods (Phipps et al. . 1983;
Chung et al., 1984).
(c) Neutralization assays
In the humoral immune response to viruses, the 
development of neutralization antibodies provides the best 
information about the state of protection of the 
individual. However, neutralization tests for HCMV have 
not been popular because the virus is slow-growing and it 
is not easy to obtain in a high-titred cell-free form. 
Methods such as the plaque-reduction neutralization test 
(Waner et al. , 1976) require a 14 day incubation of the
plates while microneutralization tests are readable only 
after 7 to 10 days (Stalder and Ehrensberger, 1980;
Rasmussen et al. . 1984b). Gonczol et al. (1986a) have now
described a simple and reliable microneutralization test 
that is readable in 24 or 48 hr.
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Neutralizing antibodies to HCMV usually appear 
considerably later than antibodies detectable by other 
techniques (Spencer and Andersen, 1972; Stalder and 
Ehrensberger, 1980). While the delayed appearance of
neutralizing antibodies may be of little benefit in the 
serologic diagnosis of acute HCMV infection, the rapid and 
reliable demonstration of neutralizing antibodies may be 
important in vaccination studies.
(d) Radioimmunoassay
RIA, a method of detecting antigen-antibody reactions 
by means of a radiolabelled anti-antibody, is a very 
specific and sensitive serological method (Knez et al., 
1976; Jankowski et al.. 1980). However, the preliminary
work necessary to establish an RIA is considerable since 
commercial kits are generally unavailable. The specialized 
equipment and designated radioisotope facilities required 
may not be available in all laboratories. RIA is labour 
intensive and therefore unsuitable as a screening 
procedure. Furthermore, RIA requires the use of reagents 
that have a short shelf life. To efficiently detect low 
levels of specific IgM antibodies by RIA the radiolabel 
must be fresh. For instance, to detect HCMV-IgM antibodies 
in cord and adult sera the radiolabelled antibody must be 
used within 72 hr and 3 to 4 weeks respectively (Griffiths 
et al.. 1982a; 1982b).
(e) Enzvme linked immunosorbent assay
Enzyme immunoassay procedures, first reported in 1971,
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initially used to quantitate antigen and subsequently 
antibody (Ingvall and Perlmann, 1971). ELISA is now firmly 
established as an alternative to RIA. Instead of using 
radioactive isotopes, ELISA uses enzymes such as horse 
radish peroxidase and alkaline phosphatase, for the 
labelling of antibodies. Each enzyme is detected by its 
ability to produce an easily recognisable change, quickly 
and reliably, in a substrate solution. Most tests employ a 
substrate that develops a strong colouration but there are 
also substrates which liberate a fluorescent product 
(Shalev et a l ., 1980), undergo an increase in temperature
(Mattiasson et a l . . 1977) or generate a burst of
chemiluminescent energy (Hornsleth et al.. 1988).
While ELISA and RIA techniques are of equal 
sensitivity and specificity when testing adult sera (Booth 
et al. . 1982? Kangro et al. . 1984) the former method does 
have a number of advantages. These include the stability 
of the enzyme label and the fact that special facilities 
are not required for the safe handling and disposal of 
enzyme-labelled reagents. However some ELISA substrates, 
such as 0-phenylene diamine, are mutagenic (Voogd et al. .
1980). ELISA has an objective quantitative end point but 
there are problems in handling large numbers of sera 
because of the need to control the substrate reaction.
(f) Latex agglutination
Passive latex agglutination is a simple and rapid 
method for routine detection of antibody to viral antigens 
and was first described by Singer and Plotz (1956) for the
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detection of RF. The assay is based on the fact that latex 
particles, when coated with a ligand such as an antigen, 
form stable colloids. The particles remain in suspension 
when stored but aggregate when mixed with antibody specific 
to the antigen.
Latex agglutination is a simple technique requiring 
little specialized equipment. Reagents are stable and have 
a relatively long shelf life. Furthermore, the test is 
rapid since up to 50 sera can be screened within 2 0 min 
(Puckett and Davis, 1987) . Some centres now use the latex 
agglutination test for the detection of HCMV antibody in 
potential organ donors and recipients (Wreghitt, 1988).
1.5.8 Measurement of HCMV-IcrM
The potential usefulness of virus-specific IgM class 
antibodies as a marker of congenital and recently acquired 
HCMV infections has long been recognized (Weller, 1971). 
Hence considerable effort has gone into developing a 
reliable test for HCMV-specific IgM antibodies. Numerous 
indirect immunoassays utilizing a solid-phase antigen and 
labelled anti-human IgM indicator antibody have been 
described including FAT (Hekker et a l .. 1979), ELISA
(Buimovici-Klein et al. . 1983) and RIA (Torfason et al. .
1981) . More recently, antibody-capture assays using 
enzyme-labelled HCMV antigen (Van Loon et al. , 1981) or
radiolabelled anti-HCMV antibody [MACRIA] (Sutherland and 
Briggs, 1983) have been developed.
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RIA is a specific and sensitive method for the 
detection of IgM antibodies to HCMV (Griffiths and Kangro,
1984). ELISA and RIA are of comparable specificity and 
sensitivity (Demmler et al. , 1986). Both assays are more
specific than FAT (Griffiths et al., 1982a).
Monitoring of IgM does not usually discriminate 
between specific and non-specific IgM activities. Some 
sera contain IgM that attaches non-specifically to the 
solid phase antigen of the ELISA (Krishna et al., 198 0). A 
further complication is that the majority of sera 
containing HCMV-specific IgM react with the control antigen 
(Booth, 1983) . Studies on HCMV have shown that much of 
this non-specific reactivity is due to IgM that attaches to 
host-cell cytoplasmic antigens. Its effect can be 
minimised through the use of viral and control antigens 
prepared from isolated nuclei (Sundqvist and Wahren, 1981) 
although this does not eliminate the problem of false- 
positive reactions in sera containing anti-nuclear IgM 
(Schmitz et al.. 1977).
A further complication in all indirect tests for HCMV- 
IgM is that of false-positive reactions in sera containing 
RF of the IgM class (IgM-RF) together with virus-specific 
IgG (Kangro, 1980; Salonen et a l . . 1980). IgM-RF
recognizes the Fc portion of IgG bound to antigen; the 
attached IgM-RF is then detected by the anti-IgM conjugate. 
Some 3% of unselected sera have been shown to possess IgM- 
RF (Roggendorf et al. , 1981). To eliminate non-specific
IgM activities several methods for removing anti-IgG IgM
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from sera have been proposed. These methods include 
binding of IgG by protein A (Jankowski et al .. 1979), serum 
fractionation (Robertson et al. . 1977) and absorption of
IgM-RF with IgG-coated latex beads or with heat-aggregated 
human IgG (Shirodira et al. . 1973). Recently, Joassin and
Reginster (1986) have shown anti-human IgG hyperimmune 
serum to be the most efficient method of removing non­
specific HCMV-IgM activities. While MACRIA is much less 
susceptible to reactions involving IgM-RF, it has been 
shown that spurious results can occur with sera containing 
heterophile antibody (Morgan-Capner et al.. 1983).
1.5.9 Measurement of HCMV-IaG
A variety of serological methods are currently 
available including FAT (Betts et a l . . 1976), IHA
(Bernstein and Stewart, 1971), CFT (Waner et al. . 1973),
ELISA (Cheung et a l ., 1981) and latex agglutination
(Beckwith et a l ., 1985). Recently, antibody capture
(Nielsen et al. , 1986) and competitive (Wreghitt et al. ,
1986b) ELISAs have been described.
ELISA and RIA are comparable in sensitivity and some 
10 to 100 times more sensitive than CFT and IHA (Booth et 
al., 1982). While ELISA and RIA provide higher antibody
titres than CFT they do not detect substantially more 
seropositive individuals. Some authors have found IHA to 
be as sensitive as CFT (Bernstein and Stewart, 1971; Cremer 
et al. . 1978) whereas others (Booth et al. . 1982) have
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reported IHA titres to be lower and false negative results 
higher compared to those obtained by CFT. This may be 
related to HCMV antigenic heterogeneity described by Faix 
(1985) and discussed in Section 1.5.7(a). Latex 
agglutination is slightly less sensitive than CFT (Puckett 
and Davis, 1987) , IHA (Shekarchi et al. , 1988) and RIA
(Barbara et al. . 1987). While there is good correlation
between CFT and IgG antibody capture ELISA (Nielsen et al., 
1986), the competitive ELISA of Wreghitt et al. (1986b) is
5 times more sensitive than CFT and twice as sensitive as 
indirect ELISA.
The sensitivity of indirect tests for anti-viral IgG 
is reduced in the presence of IgM-RF. The latter binds 
non-specifically to the Fc portion of IgG molecules after 
they have attached to the antigen on the solid phase and 
hinders the attachment of the anti-IgG conjugate (Salonen 
et al .. 1980).
1.5.10 Novel serological assays
Serological methods that rely on changes in total 
HCMV-specific antibody levels may be ineffective, 
particularly in patients whose humoral response is absent 
or weak. Using immunoblotting techniques, Ashley et al.
(1987) and Mirolo et al. (1987) have demonstrated that
total antibody levels may remain constant although titres 
to specific HCMV polypeptides may change during infection. 
Landini et al. (1986) have identified 2 polypeptides that
are consistently and preferentially reactive with HCMV-IgM.
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Humoral responses to E and L antigens are useful in
differentiating renal allograft recipients with primary 
HCMV infection from those with reinfection and/or 
reactivation (O'Neill et a l . . 1988a). Use of new
technology rather than traditional methods may be requisite 
if HCMV infections are to be evaluated serologically.
1.5.11 Other diagnostic approaches
There is a clear demand for markers which facilitate 
detection of HCMV and simplify measurements of virus 
activity in renal transplant recipients. Serum
deoxythymidine kinase activity has been used in this 
respect (Larson et al., 1986). However, this enzyme is
also induced by other herpesviruses (Gronowitz et al.,
1984).
£2m / a protein with a MWt of 11.8 kd, is the small
invariant chain of human leucocyte antigen (Peterson et
al., 1974). Neopterin [7,8-dihydroneopterin triphosphate] 
is synthesized by macrophages upon stimulation by factors 
derived from activated T cells (Huber and Troppmair, 1985). 
Recently, Backmann et al. (1988) have found monitoring of
serum and neopterin levels to be helpful in the early
diagnosis of HCMV infections.
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1.6 Detection of DNA in clinical specimens
Standard methods for the diagnosis of HCMV depend on 
either isolating the virus by conventional cell culture or 
detecting a rise in antibody titre. The slow appearance of 
cpe in cell culture has limited the usefulness of this 
method for diagnostic purposes (Richman et al. . 1984).
Furthermore, tissue culture methods are sometimes 
impossible due to microbially contaminated specimens or to 
inactivated non-infectious virus (Schuster et al. , 1986).
In addition, serological diagnosis in immunosuppressed 
patients is hampered by the long lag period until an immune 
response occurs or by a complete lack of response (Augustin 
et al.. 1987).
The speed of diagnosis is becoming more important as 
the prospect of specific antiviral chemotherapy becomes a 
reality. This chapter discusses the detection of viral DNA 
in clinical specimens by nucleic acid hybridization and the 
polymerase chain reaction (PCR).
1.6.1 Theoretical background of nucleic acid hybridization
Molecular hybridization is based on the tendency of 
nucleic acids to form double stranded hydrogen-bonded 
complexes if strands of complementary sequences are 
incubated under appropriate salt and temperature 
conditions. The hydrogen bonds between two complementary 
strands of nucleic acids can be reversibly separated. This 
can be achieved at neutral pH and low ionic strength by the
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application of heat or, in the case of DNA, by treatment 
with alkali. The temperature at which double stranded DNA 
or RNA is converted into single strands is defined as the 
melting temperature (Tm ) and is strongly dependent on base 
composition (Marmur and Doty, 1962), the monovalent cation 
concentration (Schildkraut and Lifson, 1965) and the 
concentration of denaturing agents such as formamide, which 
are often used to reduce the temperature of hybridization 
(McConaughy et al. . 1969). For DNA-DNA
Tm = 81.5 + 16.6 log(Na+ ) + 0.41(%GC) - 0.7(% formamide)
-1.4 (% mismatch)
(Howley et al., 1979).
Reassociation is the joining together by typical base 
pairing of two fully-separated complementary sequences. 
Once reassociation has commenced, zippering describes the 
formation of successive base pairs. Techniques for 
measurement of reassociation include the use of 
hydroxyapatite (Britten et al. . 1974), the single strand- 
specific nuclease [SI] (Smith et al., 1975) and optical 
methods (Young and Anderson, 1985). The rate at which 
complementary strands of nucleic acid form stable base- 
paired duplexes is dependent on a number of factors. From 
the results of Hutton and Wetmur (1973) it has been well 
established that the rate of both DNA reannealing and RNA- 
DNA hybridization is proportional to the square root of the 
length of the shorter strand. The base composition of 
nucleic acids has little effect on the rate of DNA-DNA 
annealing (Wetmur and Davidson, 1968) or RNA-DNA
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hybridization (Bishop, 1972). The effect of ionic strength 
on DNA reannealing was first studied by Wetmur and Davidson 
(1968) who showed the rate to be strongly dependent on 
sodium ion concentration at least up to 3.2M. At 
concentrations up to 0. 2M the rate has been shown to be 
proportional to the cube of the ionic strength (Studier, 
1969). The effect of ionic strength on the rate of RNA-DNA 
hybridization has not been studied in detail but Nygaard 
and Hall (1964) have demonstrated a 5- to 6-fold increase 
in the rate of hybridization of phage T2 RNA to T2 DNA by 
increasing the ionic strength from 0.2 to 1.5M NaCl.
In considering the effect of viscosity on the rate of 
hybridization it is important to distinguish between 
microscopic and macroscopic viscosity. Microscopic 
viscosity refers to the micro-environment around the DNA 
bases. The macroscopic viscosity is dependent on the 
presence of polymers (including DNA) which will have no 
effect on the micro-environment. Thrower and Peacocke 
(1968) and Subirana and Doty (1966) have reported a 
decrease in DNA renaturation rates after the microscopic 
viscosity had been increased with sucrose. Chang et al. 
(1974) have investigated the effect of macroscopic 
viscosity on DNA renaturation and shown a 5.7% Ficoll 
solution to increase the rate of phage T4 DNA reannealing 
by 50%.
The optimal temperatures for nucleic > acid 
reassociation in aqueous salt solutions lie in the range 60
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to 75°C. However, extended incubation at such temperatures 
can lead to a considerable amount of thermal strand 
scission. It may be desirable to reduce the hybridization 
temperature whilst maintaining the stringency of the 
nucleic acid interaction. This can be achieved by 
introducing formamide whose effect on the reassociation 
rate of DNA has been studied by Hutton (1977). Increasing 
the formamide concentration decreases the optimal DNA 
renaturation rate by 1.1% per 1% of formamide. 
Schmeckpeper and Smith (1972) found that the presence of 
50% formamide reduced the rate of RNA-DNA hybridization by 
a factor of 0.25 compared with the reaction rate in an 
aqueous solution at a similar stringency. Furthermore, the 
stability of RNA-DNA hybrids is greater in 50% formamide 
than that of DNA duplexes of similar base composition 
(Bishop, 1972).
The dependence of DNA reassociation rate on incubation 
temperature was first studied by Marmur and Doty (1961). 
They observed that as the temperature was reduced from Tm , 
the rate of DNA reassociation increased until a maximum was 
reached at about 25°C below Tm . Further reductions in 
temperature reduced the reaction rate. A similar 
dependence for RNA-DNA hybridization has been shown with 
both reactants free in solution (Bishop, 1972) and with DNA 
bound to nitrocellulose filters (Birnstiel et al. . 1972).
However, in contrast to DNA reassociation, the maximum rate 
of RNA-DNA hybridization is obtained at about 10 to 15°C 
below the Tm of the hybrids.
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1.6.2 Hybridization procedures
(a) Filter hybridization
Single stranded DNA or RNA can be immobilized on 
nitrocellulose paper under appropriate conditions without 
losing the ability to form stable duplexes (Gillespie and 
Spiegelman, 1965; Thomas, 1980). Nitrocellulose filters 
bind DNA and RNA very efficiently (80jug/cm2 ) but are 
fragile. Nylon filters are more pliable than
nitrocellulose and can be used indefinitely without 
disintegrating (Anderson and Young, 1985). Although 
nitrocellulose and nylon filters immobilise nucleic acid, 
binding by conventional procedures is non-covalent. 
Therefore, hybrids may dissociate from the filter (Haas et 
al., 1972). New techniques have been developed for binding 
of nucleic acid to membranes by UV light induction (Church 
and Gilbert, 1984). All filters require the nucleic acid 
to be denatured for binding but there is no immobilisation 
procedure uniformly applicable to all types of filter. 
Nitrocellulose filters require high ionic strength for 
binding of both DNA and RNA (Nagamine et al., 1980).
Hybridization of radioactively-labelled nucleic acids 
to filter-bound DNA is a three-stage procedure. The filter 
is first prehybridized in a solution containing 
heterologous single stranded nucleic acid, SDS and 
Denhardt's solution (Denhardt, 1966). The purpose of this 
step is to saturate binding sites on the filter that would 
otherwise lead to an unacceptable background. The filter
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is then incubated in the same solution containing the 
radioactively-labelled probe for sufficient time to allow 
hybridization to take place. Even under optimal conditions 
no more than 80% of a single sequence probe appears in 
hybrids (Flavell et al. . 1974). In practice, for double
stranded DNA probes, there is no need to continue 
hybridization for longer than is necessary to allow the 
probe in solution to achieve 1-3 times CQt 1/2, the value 
required for 50% reassociation and is a product of the 
concentration of nucleotides (mol. litre-1) and the time in 
seconds. To determine the number of hours needed to 
achieve CQt 1/2 for renaturation of any other probe the 
appropriate values can be substituted in the equation
n = 1 x y x 2. x z
x 5 10 where
n = number of hours '
x = weight of the probe added in /ig
y = length of the probe in kb
z = volume of the reaction in ml. (Anderson and Young,
1985)
After hybridization the filters are washed under 
conditions of temperature and salt concentration such that 
only specific hybrids are stable. The location of the
hybrid molecules is then determined by autoradiography. 
Nonisotopic nucleic acid probes are described in Section 
1.6.4b.
Several developments seek to improve the sensitivity 
of filter hybridization and bring it to the point where it
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may be a realistic diagnostic method. One such approach is 
sandwich hybridization (Wolf et al. , 1986). In the first
step, hybridization takes place between the denatured 
nucleic acid on a filter and unlabelled M13 containing a 
complementary DNA insert. In the second hybridization, the 
replicative form of M13 without an insert but radiolabelled 
with P is used. Thus a network of DNA strands forms 
above the first hybrid increasing the sensitivity of the 
hybridot assay to less than pg quantities of viral DNA.
(b) In situ hybridization
This methodology allows the detection and localization 
of nucleic acid sequences within cell and tissue 
preparations. For example, in situ hybridization can be 
used to map sequences of interest in condensed chromosomes 
(Harper et a l ., 1986), provide analysis of the tissue
distribution of transcripts (Singer and Ward, 1982) and 
enable identification of the site of gene expression 
(Pardue, 1985). One of the major difficulties with in situ 
hybridization has proved to be the fixation and 
pretreatment of the cells to maintain their integrity yet 
allow access of the probe. The size of the probe is 
important in this context with small probes, about 70 bp, 
giving optimal hybridization efficiency (Moench et al.,
1985). Pretreatment of slides with poly-L- or D-lysine 
(Aksamit et al. , 1985) or by silanation (Tourtellotte et
al. , 1987) may be helpful in keeping the specimens intact 
during the hybridization procedure.
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1.6.3 Nucleic acid probes
(a) Nick-translated
The most frequently used methods for uniformly 
labelling hybridization probes are nick-translation, random 
priming and in vitro transcription using phage polymerases. 
These are discussed in more detail below.
The process of "nick-translation" utilises DNase I to 
create single strand nicks in double stranded DNA. The 5 1- 
3' exonuclease and 5 1- 3 1 polymerase actions of E.coli DNA 
polymerase I are then used to remove stretches of single 
stranded DNA starting at the nicks and replace them with 
new strands made by the incorporation of labelled 
deoxyribonucleotides (Rigby et al.. 1977). As a result,
each nick moves along the DNA strand being repaired in a 5'
- 3' direction (nick-translation). Spector et al. (1984b)
have used such nick-translated DNA probes to detect HCMV in 
clinical specimens. Advantages and disadvantages of nick- 
translation are listed in Table 2.
(b) Primer extension
In common with nick-translation, primer extension 
methods utilize the ability of DNA polymerases to 
synthesize a new DNA strand complementary to a template 
strand, starting at a free 3'-hydroxyl. In this case, the 
latter is provided by a short oligonucleotide primer 
annealed to the template. The various approaches are 
described below.
1. Random primers used with Klenow polymerase
Hexanucleotides of random sequence, either derived
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Table 2 Advantages and disadvantages o f nick— 
* translation.
Advantages
1. Allows control over a 
variety of parameters, for 
example, probe size, yield, 
specific activity, substrate 
concentration and reaction 
time.
2. Subcloning is not required.
3. Medium (10® to 109 cpm//ig) 
and high (>10 cpm//xg) specific 
activity probes can be 
produced.
4. Good utilization of label 
(60 to 70% incorporation).
5. DNA probes allow standard 
hybridization temperatures to 
be used.
6. Large amount of probe 
produced in standard protocols 
(~l/zg), and so a single 
labelling reaction usually 
produces sufficient probe for 
several hybridizations.
7. Ideal for generating 
microgram quantities of 
biotinylated probe.
8. Labels circular and linear 
DNA.
9. Short reaction times 
possible (60 to 90 min).
10. Leads to very uniform 
labelling.
11. A variety of radiolabels 
( H, S and P) can be used.
12. More than one labelled 
nucleotide can be used 
simultaneously, for example [a-
P]dCTP and [a-32P] dATP.
Particularly suitable for 
purified DNA available in 
relatively large amounts, (for 
example, a plasmid preparation 
for which the presence of 
vector sequence in
hybridization is unimportant).
Disadvantages
1. Unpredictable results with 
impure DNA substrates
(particularly DNA in agarose).
2. Uniform labelling method - 
not limited to insert sequence.
3. Large amount of substrate 
(~l/ig) usually required.
4. Temperature and time of 
reaction require careful 
control to avoid strand 
displacement and excision of 
incorporated label.
5. Requires control of two 
enzyme activities.
6. DNA-DNA hybrids have lower 
stability than DNA-RNA and RNA- 
RNA hybrids.
7. Probe denaturation required.
8. Probe not strand-specific. 
Strand reannealing of probes 
may occur.
9. Will not label single 
stranded DNA.
from DNase I digestion of calf thymus DNA or produced by 
oligonucleotide synthesis, have been used to prepare 
labelled copies of both DNA and RNA. Feinberg and 
Vogelstein (1983) first described this approach for the 
labelling of DNA fragments to high specific activity. 
Advantages and disadvantages of random primer labelling 
with Klenow polymerase are given in Table 3.
2. Unique primers used with Klenow polymerase
High specific activity hybridization probes can be 
generated using the M13 universal probe primer (Hu and 
Messing, 1982) . The DNA which is to be used as probe is 
first cloned into one of the bacteriophage M13 vectors. On 
first infecting bacteria, 100 to 2 00 copies of the double 
stranded replicative form of M13 are synthesized but 
thereafter the synthesis of DNA is asymmetric, only one 
cDNA strand ( + ) being produced. This is packaged into 
phage particles which are then released from the host 
continuously without lysing it, thus making subsequent 
purification very simple. Viral inserts are placed in the 
intergenic M13 sequence which does not affect viral 
replication and inserts up to 1000 nucleotides are stable 
on replication of the bacteriophage.
The 13-base sequence of the M13 universal probe primer 
(5 'GAAATTGTTATCC3 ') is complementary to the 5' side of the 
multiple cloning site (MCS) of the family of M13 vectors 
and is used to initiate synthesis of the (-) strand from 
the (+) strand template by the Klenow fragment of E.coli
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Table 3 * Advantages and disadvantages of random 
primer labelling
Advantages
1. High specific activity 
probes (>lCrcpm/jLig) .
2. Efficient utilization of 
label (70 to 80%).
3. Flexible reaction temperature 
and time (up to overnight).
4. Can label small amounts of 
DNA.
5. Labels single stranded DNA 
(and double stranded after 
denaturation).
6. Labels impure DNA 
efficiently (minilysate or DNA 
in agarose).
7. Several labelled nucleotides 
can be used simultaneously.
8. Subcloning is not required.
9. DNA probes allow standard 
hybridization temperatures to 
be used.
10. Leads to uniform labelling.
11. Incorporated label not 
excised during reaction.
12. Reaction parameters can be 
controlled (for example, input 
label, primer concentration) to 
influence probe size, yield, 
etc.
Ideal for probe sequence 
available in small amounts, in 
impure form (for example, gel- 
purified insert).
Disadvantages
1. Quantity of probe produced 
(~70ng); generally sufficient 
for a single hybridization only
2. Relatively inefficient with 
circular DNA substrates.
3. Uniform labelling method - 
not limited to insert sequence.
4. DNA-DNA hybrids have lower 
stability than DNA-RNA and RNA- 
RNA hybrids.
5. Denaturation of input DNA 
required.
6. Probe denaturation required.
7. Probe not strand-specific. 
Strand reannealing of probes 
may occur.
DNA polymerase I (Jacobsen et al., 1974). Synthesis of the 
complementary strand, which can be labelled by 
incorporation of an [a- *P] deoxynbonucleotide, does not 
proceed to completion so that the inserted probe sequence 
remains single stranded. Synthesis of the probe is shown 
diagrammatically in Figure 7.
One example of an M13 recombinant probe being used 
diagnostically is for rhinovirus detection in nasal 
secretions (Al-Nakib et al. , 1986). An indirect sandwich
hybridization based on M13 probes is described above (Wolf 
et al., 1986).
3. Unique primers used with reverse transcriptase
Unique primers have been used most frequently in 
conjunction with reverse transcriptase in two ways. The 
first is in the technique of primer extension mapping by 
which a labelled primer is annealed to an RNA molecule and 
is then extended in order to map the 5' -end of the RNA 
(Williams and Mason, 1985). The second major approach is 
more strictly a method of probe production. By annealing 
an oligo-dT primer to the 3' poly (A) tail of an mRNA 
molecule, it is possible to synthesize a labelled cDNA in 
the presence of reverse transcriptase and appropriate 
nucleotides (Arrand, 1985).
(c) Synthetic oligonucleotide probes
With advances in the technology of synthesizing DNA it 
has become possible to prepare oligonucleotides of defined 
sequence at reasonable cost. The success of such an 
approach depends on the availability and correctness of
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Figure 7 M13 partially double stranded DNA probes
A schematic representation of M13 second 
strand synthesis.
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sequencing data but has the considerable advantage of 
eliminating the need for purification and cloning of viral 
nucleic acids. In addition, absolutely defined sequences, 
specific for or shared by members of a virus group, can be 
easily selected. The use of a synthetic oligonucleotide 
probe in hepatitis B virus (HBV) diagnosis has been 
described recently (Lin et al., 1987). The sensitivity of 
hybridization was comparable to that using cloned HBV DNA 
probes but the time period of hybridization was shortened 
from 16 to 2 hr.
(d) Methods based on RNA polymerase
RNA polymerases catalyze the synthesis of RNA from 
ribonucleoside triphosphates (rNTPs) using a DNA template. 
Historically two main approaches to the production of RNA 
probes have been adopted. The first involved the use of 
E.coli RNA polymerase. This enzyme when used in vitro 
shows very little template and promoter specificity and 
therefore produces transcripts which have been initiated 
and terminated more or less at random. The RNA polymerases 
from a number of bacteriophages including salmonella phage 
SP6 and coliphages T3, T5, T7 possess a high degree of
specificity for their own promoters in vitro (Butler and 
Chamberlin, 1982; Davanloo et al.. 1984).
A number of SP6 and T7 cloning and transcription 
systems are now available (Green et al. . 1983). These
generally consist of a pBR3 22 plasmid into which has been 
inserted the appropriate RNA polymerase gene and its
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promoter. A few bases away from the promoter is a MCS into 
which a selected fragment of the DNA required as a 
hybridization probe can be subcloned. Transcription in the 
presence of [a- *P] rNTP and RNA polymerase proceeds from 
the promoter through the probe sequence giving rise to an 
RNA transcript of high specific activity. This is outlined 
schematically in Figure 8. Up to 10/xg of RNA probe may be 
synthesized from Ifiq of template DNA (Melton et al. . 1984).
RNA probes have been reported to show higher 
sensitivity than nick-translated probes in both Northern 
blots (Melton et al.. 1984) and in situ hybridization (Cox 
et a l . , 1984) . This is most probably due to the inability 
of the probe to reanneal during hybridization and the 
greater stability of RNA-RNA and RNA-DNA hybrids compared 
to DNA-DNA hybrids. A further advantage of RNA probes is 
that non-specifically bound probe can be removed by 
treatment with RNase A which is very specific for single 
stranded RNA (Melton et al., 1984). Other advantages and
disadvantages of phage polymerase methods are listed in 
Table 4.
1.6.4 Labelling of nucleic acid probes
There are 2 important parameters which largely 
determine the choice of label) resolution and sensitivity. 
Different applications may require a different balance 
between these parameters. Other considerations include 
safe handling of radioisotopes and probe stability. The 
choice of label is discussed below.
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Figure 8 The SP6 polymerase system
labelled RNA transcripts
rNTPs ribonucleoside triphosphates
MCS multiple cloning site
0 SP6 polymerase
direction of transcription
SP6 promoter
mcs
SP6 vector probe DNA cloned in SP6 
vector next to promoter
linearise
linear template
SP6 polymerase + rNTPs
system generating 
multiple transcripts
Table 4 ’ Advantages and disadvantages of phacre 
polymerase methods
(a) Radioactive
Traditionally, filter hybridizations have been carried 
out with radioactively-labelled probes. Indeed, nick- 
translation with the incorporation of one or more <*-32p- 
labelled deoxynucleoside triphosphates into double stranded 
DNA is often used. As 32P has a half-life of only 14 days, 
isotopes of longer half-life have been assessed. 125i with 
a half-life of 60 days may be introduced catalytically into 
cytosine residues but this alters the Tm of the 
hybridization reaction and has rarely been used in a 
diagnostic context (Norval and Bingham, 1987). 35S (half-
life 87 d a ys), as the a-35S thiotriphosphate of the 
nucleotides, has been incorporated into probes by nick- 
translation. Such probes have been used in the detection 
of viruses by both filter (Chowdhury et al. , 1986) and in
situ (Gendelman et al. , 1985) hybridization. 3H-labelled
probes have been used only for in situ hybridization but 
exposure times are often in excess of several weeks 
(Pardue, 1985). Such a lengthy procedure is likely to be 
of little interest in routine diagnosis.
(b) Non-radioactive
Biotin is a small, water-soluble vitamin which is 
becoming increasingly popular in the labelling of nucleic 
acids (Leary et al.. 1983). Detection of biotinylated
probes after hybridization is generally via avidin, a 
glycoprotein of MWt 68 kd which has 4 binding sites and 
extremely high affinity for biotin. Visualization of
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Advantages
1. Transcription limited to 
insert.
2. Efficient utilization of 
label (80%).
3. High specific activity 
probes (>10 cpm//xg) .
4. Short reaction time (60 
min) .
5. No requirement for probe 
denaturation leading to 
improved background on 
nitrocellulose,
6. Probe can be specific for 
either DNA strand.
7. Template removal possible*
8. Variety of labels (32P, S, 
H, biotin) can be used.
Ideal for multiple use probes; 
avoids contamination with 
vector sequences.
Disadvantages
1. Subcloning required.
2. Restriction digestion to 
completion required.
3. RNA probe must be stored 
correctly to avoid RNase 
activity.
4. Narrow temperature optima 
for hybridization for many RNA 
probes.
5. Difficult to control probe 
size without limiting
transcription.
6. Large amount of template 
required (1 to 2/xg) .
7. Small amount of probe 
produced (~300ng).
8. Premature termination may 
occur.
9. Template removal may be 
required.
10. Performance depends on 
labelling nucleotide.
11. Only a single labelling 
nucleotide can be used 
efficiently (except for 3H, 
where concentration is not 
limiting).
(a) Radioactive
Traditionally, filter hybridizations have been carried 
out with radioactively-labelled probes. Indeed, nick- 
translation with the incorporation of one or more <xl32p -  
labelled deoxynucleoside triphosphates into double stranded 
DNA is often used. As J*P has a half-life of only 14 days, 
isotopes of longer half-life have been assessed. 125i with 
a half-life of 60 days may be introduced catalytically into 
cytosine residues but this alters the Tm of the 
hybridization reaction and has rarely been used in a 
diagnostic context (Norval and Bingham, 1987). 35S (half-
life 87 days) , as the a-35S thiotriphosphate of the 
nucleotides, has been incorporated into probes by nick- 
translation. Such probes have been used in the detection 
of viruses by both filter (Chowdhury et al. , 1986) and in
situ (Gendelman et al. , 1985) hybridization. 3H-labelled
probes have been used only for in situ hybridization but 
exposure times are often in excess of several weeks 
(Pardue, 1985). Such a lengthy procedure is likely to be 
of little interest in routine diagnosis.
(b) Non-radioactive
Biotin is a small, water-soluble vitamin which is 
becoming increasingly popular in the labelling of nucleic 
acids (Leary et al.. 1983). Detection of biotinylated
probes after hybridization is generally via avidin, a 
glycoprotein of MWt 68 kd which has 4 binding sites and 
extremely high affinity for biotin. Visualization of
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biotin-avidin complexes is usually via conjugates of avidin 
or anti-avidin antibodies with enzymes, fluorescent groups 
or heavy metals. In practice, streptavidin, an avidin-like 
protein isolated from the bacterium Streptomyces avidinii, 
is often used in place of avidin. Its main advantage is a 
near neutral isoelectric point which leads to a reduction 
in non-specific binding to DNA thereby minimizing 
background signal. Presently many studies employ a 
streptavidin-biotinylated complex containing peroxidase 
(Przepiorka and Myerson, 1986) or alkaline phosphatase 
(Rotbart et al ., 1988).
There are several advantages of using biotinylated 
probes. For example, non-toxic materials are employed and 
there are no problems of inconveniently short half-lives of 
the label. Detection of hybrids is much faster than for 
radioactive probes, visualization of hybrids being complete 
betweem 2 and 4 hr after washing. The major disadvantage 
of biotin, and of other non-radioactive labels, is low 
sensitivity in comparison to radioactive labels. Most 
studies report a sensitivity approximately 5- to 10- fold 
less than equivalents32?-label led probes (McKeating et al.,
1985).
The labelling methods described so far have primarily 
utilized enzymatic reactions to incorporate nucleotides 
labelled with radioisotopes or non-radioactive reporter 
molecules e.g. biotin. In the remainder of this section 
several examples of direct labelling methods which do not 
use enzymes to incorporate label are outlined briefly. The
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aim of such techniques is to attach the label covalently to 
the nucleic acid probe.
For use in non-radioactive labelling, a photoactivable 
analogue of biotin has been used fcr rapid preparation of 
DNA and RNA hybridization probes (Forster et al., 1985).
Upon brief irradiation with visible light, stable linkages 
are formed with both single and double stranded nucleic 
acids. Another class of photochemical reagents for 
investigation of nucleic acid structure and function are 
the psoralens. These primarily react with pyrimidine bases 
and can be detected by enzymatic methods (Sheldon et al. ,
1986).
Peroxidase and alkaline phosphatase have been directly 
crosslinked to DNA thereby obviating the requirement for a 
reporter group such as biotin (Jablonski et al., 1986).
For example, horseradish peroxidase can be crosslinked to 
polyethyleneimine with p-benzoquinone and the resulting 
conjugates covalently linked to DNA using glutaraldehyde 
(Renz and Kurz, 1984). Other chemical methods include 
modification of nucleic acids by acetylaminofluorene (Tchen 
et al.. 1984) and 5 1-end-labelling of oligodeoxynucleotides 
with biotin through an aminoalkylphosphoramide linker arm 
(Kempe et al., 1985).
Whilst direct labelling may offer more convenience in 
preparation of probes than enzymatic methods, there is 
little published data on their application and 
sensitivities.
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1.6.5 Clinical application of hybridization probes
Several situations may be envisaged where nucleic acid 
hybridization might provide valuable information not 
obtainable by other methods:-
1. Where no infectious virions are present in the 
clinical sample because of inactivation during specimen 
collection or transport to the laboratory. The virus may 
only be found as defective particles or in immune complexes 
or indeed, only as viral nucleic acid in an integrated or 
non-integrated form.
2. Where there is contamination of the sample with 
other microbes.
3. Where there is no in vitro culture system available 
or the isolation is particularly slow.
4. Where no specific antigenic reagents are available.
5. Where it is necessary to identify a specific cell 
type, containing virus or viral nucleic acid, within a 
tissue.
The development of specific, cloned subgenomic 
fragments of DNA provides new reagents for the detection of 
HCMV in clinical specimens (Fleckenstein et al. . 1982).
Several hybridot assays providing results within 24 hr of 
specimen collection have been established. °^-32P-labelled 
nick-translated DNA probes have been shown to detect 
between 500fg (Augustin et al. , 1987) and lOOpg (Churchill
et al. , 1987) of HCMV DNA with a sensitivity of 83% and a
specificity of 92% compared with virus isolation (Schuster
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et al., 1986). Furthermore, there is a strong correlation 
between the titre of HCMV in the clinical specimen and the 
intensity of the hybrid signal (Chou and Merigan, 1983). 
In vitro synthesized <*-32P-labelled RNA transcripts specific 
for HCMV have also been used to detect the virus in urine 
specimens but the sensitivity of the hybridot assay was 
equivalent to that when using nick-translated DNA probes 
(Schuster et al.. 1986). Recently an oligo-primed ^32P-
labelled DNA probe specific for HCMV has been described and 
shown to have a sensitivity of 86.7% compared with 
conventional virus isolation (Agha et a l .. 1988).
Nonisotopic HCMV-specific probes have also been assessed. 
A DNA probe labelled with peroxidase was reported to have a 
sensitivity of 80pg (Schuster et a l . , 1986) while,
hybridization using biotin-labelled probes can detect a 
minimum of 30pg of HCMV DNA or 3 log10 TCID50 of HCMV in 
urine samples (Buffone et al.. 1986; Lurain et al.. 1986).
While several groups have reported promising results 
concerning the detection of HCMV DNA in urine samples there 
are several problems inherent in the methodology. In 
addition to the relatively fastidious procedures necessary 
for the preparation of a specific hybridization probe, 
sample preparation is also laborious, requiring 
ultracentrifugation to obtain maximum sensitivity. The use 
of insert-containing plasmids rather than isolated inserts 
as hybridization probes may yield false-positive results 
owing to the presence of homologous bacterial DNA sequences
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in the clinical specimens (Ambinder et al., 1986) . Another 
matter of concern is the presence of DNA sequences in the 
HCMV genome which are complementary to those of human 
cellular DNA (Ruger et al. . 1984). Finally, HCMV DNA
cannot be detected in all urine specimens yielding the 
virus in tissue culture (Spector et al., 1984b).
The detection of HCMV by in situ hybridization in dram 
vial cell culture (Sorbello et al.. 1988), peripheral blood 
mononuclear cells (Stockl et al. , 1988) and formalin fixed 
paraffin wax embedded specimens (Naoumov et al. . 1988) has 
also been assessed. Although good sensitivity has been 
reported with biotinylated DNA probes, hybridized DNA 
complexes were not detected up to 4 days after early 
nuclear antigens were identified by FAT (Scott et al. , 
1988; Gleaves et al. . 1989). This delay is likely to be
related to the sequential events of the HCMV replicative 
cycle in which early proteins are synthesized before viral 
DNA replication.
1.6.6 Polymerase chain reaction
Advances in nucleic acid technology during the past 
few years have yielded practical probe-based assays for 
diagnosing infectious and genetic diseases. Although the 
assays are sensitive, cells, tissues, or body fluids often 
need to be cultured to increase the number of available 
cells or microorganisms to readily detectable levels.
A novel technique, PCR, has recently been developed 
for in vitro amplification of DNA or RNA (Saiki et al. ,
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1988). The principle of the PCR is straightforward, 
requiring a three-step cycling process: (1) denaturation of
double stranded DNA (2) annealing of primers and (3) primer 
extension. A cycle typically takes between 3 and 5 min and 
is repeated 20 to 40 times (Mullis and Faloona, 1987). 
After 30 cycles, a single copy of DNA can be amplified by a 
factor of 106 (Schochetman et al., 1988).
PCR has been used in the detection of HCMV in urine
(Demmler et al., 1988) and peripheral blood (Shibata et
al. , 1988) . Using no more than 10/xl of specimen, the
amplification reaction could be performed within 48 hr and 
provided a sensitivity and specificity of 93% and 100%
respectively compared with virus isolation.
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MATERIALS
2.1 Tissue culture cells
The following cells were used during the project
Flow 2002, a semicontinuous cell line established from 
human embryo lung fibroblasts, was purchased from Flow 
Laboratories Limited, Rickmansworth, England.
BHK21/C13, a continuous cell line established from
baby hamster kidney cells by MacPherson and Stoker (1962) 
and maintained in the Institute of Virology.
Vero, a continuous cell line derived from the kidney 
of an African green monkey, was provided by the Cytology 
Laboratory, Institute of Virology.
2.2 Tissue culture media
Flow 2002, BHK21/C13 and Vero cells were grown in the 
Glasgow modification of Eagles medium (Busby et al. . 1964) 
supplemented with lOOU/ml penicillin, 100/ug/ml streptomycin 
and 0.002% (w/v) phenol red.
Foetal calf serum was purchased from Gibco BRL,
Paisley, Scotland.
Calf serum and pooled human serum were prepared in the 
Institute of Virology.
The following composite solutions were used:- 
EFX = Eagles medium containing X% (v/v) foetal calf serum
ECX = Eagles medium containing X% (v/v) calf serum
ECl-Pi = Eagles medium containing 1% (v/v) calf serum but 
lacking orthophosphate.
EHu4 = Eagles medium containing 4% (v/v) pooled human
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serum
PBS = Phosphate buffered saline contained 17 0mM NaCl,
34mM KC1, ImM Na2HP04 , 2mM KH2P04 
in distilled water pH 7.2.
PBS Ca = PBS containing 10% (v/v) calf serum
PBS F = PBS containing 10% (v/v) foetal calf serum.
Trypsin was prepared as a 0.25% solution supplemented 
with 0.0015% (w/v) phenol red.
Agar overlay medium for HCMV titrations was prepared 
at 45°C to a final concentration of 0.3% (w/v) Seakem LE
agarose, 1 x Eagles medium without phenol red and 
supplemented with 2.6% (v/v) foetal calf serum.
2.3 Viruses
The following viruses were used during the project 
HCMV AD169 (Rowe et al. , 1956) was provided by the
Diagnostic Laboratory, Western Infirmary, Glasgow.
HCMV strain Davis (Weller et al. , 1957) was supplied
by the Virus Reference Laboratory, Public Health Laboratory 
Service, Colindale, U.K.
HSV-1 strain 17 syn+ (HSV-1 17 syn+ ) (Brown et al. , 
1973) was provided by the Institute of Virology.
HSV-2 strain HG52 (HSV-2 HG52) (Timbury, 1971) was 
supplied by the Institute of Virology.
VZV was provided by the Regional Virus Laboratory, 
Ruchill Hospital, Glasgow.
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2.4 Bacterial strains
Two strains of E.coli were employed:-
JM101 [ (lac; pro), sup E, thi” , F'tra D36, pro AB, 
lac I^, Z M15] (Messing et al.. 1981), the host strain for 
maintenance of M13 bacteriophage, was a gift from Dr D. 
McGeoch, Institute of Virology.
DH5 [F“ , end Al, hsd R17 (r”^, m"1”^ ) , sup E 44, thi-1, 
” , rec Al, gyr A96, re 1A1] (Hanahan, 1983), purchased from 
Gibco BRL, Paisley, Scotland, was used as the host in all 
recombinant plasmid experiments.
2.5 Bacteriophage
The vector used for the production of partially double 
stranded DNA probes was derived from M13mp8. The clone, 
JR139, was a gift from Dr D. McGeoch, Institute of Virology 
and contained part of HSV-1 gene UL 8j.
2.6 Plasmid vectors
Two vectors were used during the project:- 
The Hindlll E/BamHI (EHBI) subclone in pAT153 was made 
available by Dr J.D. Oram, PHLS Centre for Applied 
Microbiology and Research, Porton Down, England.
p G E M 2 , a transcription plasmid based on the SP6 
polymerase system (Melton et al.. 1984), was purchased from 
Promega, Wisconsin, U.S.A. This plasmid contains promoters 
for both SP6 and T7 polymerase.
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2.7 Bacterial culture media
2.7.1 JM101
JM101 were propagated in 2YT broth which was 1.6%
(w/v) bactopeptone, 1% (w/v) yeast extract and 0.5% (w/v) 
NaCl in distilled water sterilized by autoclaving.
Top agarose for plating bacteriophage consisted of LB 
(1% [w/v] bacto-tryptone, 0.5% [w/v] yeast extract and
170mM NaCl with the pH adjusted to 7.5) supplemented with 
0.7% (w/v) agarose (type 1, low EEO) prior to autoclaving.
2.7.2 DH5
DH5 were propagated in LB. Solid media for the growth
of colonies were prepared from LB to which was added 1.5%
(w/v) bacto-agar. All media were sterilized by autoclaving 
and then supplemented with ampicillin to a final
concentration of 50/xg/ml.
2.8 Standard buffer solutions
Denhardt's solution: 0.02% (w/v) Ficoll, 0.02% (w/v),
polyvinylpyrollidone, 0.02% (w/v) BSA.
Dye Ficoll: 150mM Na2HP04 , lOmM EDTA, 180mM Tris-HCl
(pH 7.8), 10% (w/v) Ficoll, 0.05% (w/v) bromophenol blue.
RSB: lOmM KC1, 1.5mM MgCl2 , lOmM Tris-HCl (pH 7.5). 
SSC: 150mM NaCl, 15mM Tri-sodium citrate (pH 7.0).
STE: ImM EDTA (pH 8.0), lOOmM NaCl, lOmM Tris-HCl
(pH 8.0).
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TBE electrophoresis buffer: 89mM Tris-borate, 89mM
boric acid, 2mM EDTA.
TBE electroelution buffer: 10.8g Tris-HCl, 2.35g
boric acid and 0.37g EDTA in 1 litre of 
water.
TE: lmM EDTA, lOmM Tris-HCl.
2.9 Chemicals
M13 hybridization probe primer was purchased from 
Biolabs, Beverly, MA, U.S.A.
Ammonium persulphate and TEMED were obtained from 
Biorad Laboratories Ltd., Richmond, CA, U.S.A.
Bactotryptone and yeast extract were supplied by Difco 
Laboratories, Detroit, Michigan, U.S.A.
Formamide was purchased from Fluka Chemie AG, CH-9470, 
Buchs.
Seakem LE agarose was obtained from FMC Corporation, 
Marine Colloids Division, Rockland, U.S.A.
Biotinylated dATP, a 0.16 to 1.77 kb RNA ladder 
and restriction enzyme (React) buffers were supplied by 
Gibco BRL, Paisley, Scotland.
Caesium chloride and dimethyl sulphoxide were 
purchased from Koch-Light Laboratories Ltd., Colinbrook, 
Bucks., U.K.
BSA, deoxyribonucleotides, Ficoll (average MWt
^p / a  c  e  a  £  a  2-
400000), E. coli DNA, human J j D N A ,  ribonucleotides and 
Sephadex G50 were obtained from Pharmacia Ltd., Central 
Milton Keynes, Bucks, U.K.
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Agarose (type 1, low EEO), bacteriophage lambda DNA, 
bromcresol green, bromophenol blue, diethylpyrocarbonate, 
DTT, ethidium bromide, IPTG, NP40, salmon sperm DNA, triton 
X-100, xylene cyanol and X-Gal were provided by Sigma 
Chemical Company Ltd., Poole, Dorset, U.K.
Ampicillin was purchased from Vestric Ltd., Glasgow. 
All other chemicals were obtained from BDH Chemical 
Company Ltd., Poole, Dorset, U.K. and were of analytical or 
reagent grade.
2.10 Radiochemicals
All radiochemicals were purchased from Amersham 
International pic, Bucks, U.K. at the following 
specificities 
5 1- [a-32P] dATP )
5'-[a-32P] dGTP ) 3000Ci(111 TBq)/mmol 10 mCi(370MBq)/ml 
5'-[a-32P] dCTP )
5'-[y -32p] ATP 5000Ci(185 TBq)/mmol lOmCi(370MBq)/ml
5 1- [a-32P] UTP 800Ci(29.6 TBq)/mmol 20mCi(740 MBq)/ml
32P orthophosphate was carrier free.
2.11 Enzvmes
All restriction enzymes, E.coli polymerase I, CIAP, 
polynucleotide kinase, T4 DNA ligase and Klenow polymerase 
were purchased from Gibco BRL, Paisley, Scotland.
T7 polymerase and proteinase K were obtained from 
Boehringer Mannheim, GmbH, West Germany.
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RNasin and RQ1 DNase were supplied by Promega, 
Wisconsin, U.S.A.
DNase (bovine pancreas), lysozyme, RNAse A and RNase 
T1 were purchased from Sigma Chemical Company Ltd., Poole, 
Dorset, U.K.
2.12 Complement fixation test reagents
HCMV, HSV (Types 1 and 2) and VZV glycine-extracted 
freeze-dried CF antigens were purchased from Institute 
Virion Limited Diagnostic Laboratories, Zurich, 
Switzerland.
Freeze-dried standard antisera were obtained from the 
Public Health Laboratory Service, Colindale, U.K.
Complement, a freeze-dried preparation of preserved 
guinea pig serum, and haemolysin were supplied by Wellcome 
Reagents Ltd., Beckenham, U.K.
SRBCs in Alsevers solution were purchased from Gibco 
BRL, Paisley, Scotland.
CFT diluent tablets were obtained from Oxoid Ltd. ,
U.K.
2.13 Enzvme linked immunosorbent assays
The following ELISA systems were used during the 
project:-
HCMV-specific IgM and IgG purchased from Labsystems 
Oy, Pulttitie 8, 00880 Helsinki, Finland.
HCMV-specific IgG obtained from Northumbria 
Biologicals Ltd., Cramlington, U.K.
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Rubazyme-M, an ELISA for the detection of IgM antibody 
to rubella virus in serum, was supplied by Abbott 
Laboratories, Diagnostic Division, Chicago, U.S.A.
2.14 Other serological assays
Rapitex assays for the detection of RF in serum were 
purchased from Behring Diagnostics, Hounslow, U.K.
Infectious mononucleosis absorption assays for the 
detection of heterophile antibodies were obtained from 
Mercia Diagnostics Ltd., Surrey, U.K.
2.15 Miscellaneous materials
An RIA for the quantitative measurement of i-n
urine was provided by Abbott Laboratories, Diagnostic 
Division, Chicago, U.S.A.
Amersham Hyperfilm MP was purchased from Amersham 
International pic, Bucks., U.K.
Dupont Cronex Lighting Plus intensifying screens were 
obtained from Dupont, Connecticut, U.S.A.
Hybridization bags and a 96-well dot blot manifold 
were supplied by Gibco BRL, Paisley, Scotland.
X-Omat S film was provided by Kodak, Herts, U.K.
Cidex was purchased from Lever Industrial, Cheshire,
U.K.
Millex 0.45/Lun filters were obtained from Millipore 
U.K. Ltd., Middlesex, U.K.
Ecoscint was supplied by National Diagnostics, New 
Jersey, U.S.A.
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Gene Screen Plus TM hybridization transfer membranes 
were provided by New England Nuclear, Dupont U.K. Ltd., NEN 
Products Division, Herts, U.K.
Microtitre plates with 96 U-shaped wells, 50mm 
diameter petri dishes, linbro wells and 25cm2 and 800ml 
plastic tissue culture flasks were purchased from Inter Med 
(Nunc) A/S Nunc, Kamstrupvej 90, Kamstrup, DK-4000, 
Roskilde, Denmark.
Nitrocellulose membrane filters (0.45jum pore) were 
obtained from Schleicher and Schuell, D3 354, Dassel, West 
Germany.
2.5cm diameter circles of Whatman No.l chromatography 
paper were supplied by Whatman Ltd., Maidstone, U.K.
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METHODS
3.1 Tissue Culture
Flow 2002 cells were cultured in 800ml plastic flasks 
seeded at 2.5 x 107 cells in 100ml of EF10. 50mm diameter 
plastic petri dishes were seeded at a density of 5 x 105 
cells per dish in 4ml of EF10 and Linbro wells at a density 
of 5 x 104 cells in 1ml of EF10.
BHK21/C13 cells were cultured in 80oz roller bottles 
seeded at 5 x 107 cells in 200ml of EC10. 50mm diameter 
petri dishes were seeded at a density of 2.0 x 106 cells 
per dish in 4ml of EC10 and Linbro wells at a density of 
1.0 x 106 cells in 1ml of EC10.
Vero cells were cultured in 800ml plastic flasks 
seeded at 1.0 x 107 cells in 100ml of EF10 and subcultured 
in Linbro wells at a density of 5.0 x 104 in 1ml of EF10.
Cells were grown in an atmosphere of 5% C02 in air at
37°C.
All cells were harvested by washing twice with 
trypsin, incubating at 37°C for a few minutes and 
resuspending at the required concentration in the 
appropriate medium.
Routine checks for mycoplasma contamination were 
performed by the Cytology Laboratory, Institute of 
Virology.
Sterility checks were routinely performed by plating 
on to blood agar and incubating at 37°C.
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3.2 Virus stocks
3.2.1 HCMV AD169
After removal of the growth medium, subconfluent Flow 
2002 cells in an 80oz roller bottle were infected at a moi 
of 0.01 pfu per cell. The virus was absorbed for 1 hr at 
37°C and the cells then overlaid with 50ml of E F 5 . 
Approximately 10 days later, when the cpe was complete, the 
cells were washed once with trypsin, harvested into 50ml of 
lx Eagles medium and spun at 2 000 rpm for 10 min in an MSE 
Coolspin centrifuge. The virus preparation was resuspended 
in 5ml of EF10 containing 10% (v/v) dimethyl sulphoxide and 
stored in sterile vials at -70°C. Before use, the HCMV 
stock was sonicated in a Cole Palmer ultrasonic cleaning 
bath until the solution became clear. Routine sterility 
checks were performed using blood agar plates. Particle 
counts were performed by Mr J. Aitken, Electron Microscopy 
Laboratory, Institute of Virology.
3.2.2 HSV
Ten 80oz bottles containing subconfluent monolayers of 
BHK21/C13 cells were infected with HSV at a moi of 1:300 
pfu per cell. Virus was added in 40ml of EC5 per burler 
and incubated at 37°C for approximately 4 to 7 days when 
the cpe was near confluent. Cells were harvested by 
shaking them into suspension and the contents removed to 
250ml glass MSE bottles which were centrifuged at 2000 rpm 
for 10 min. The pellet was resuspended in 5ml of 
supernatant, aliquoted and sonicated as described above.
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Virus stock was frozen at -7 0°C until required. Particle 
counts were performed by Mr J. Aitken, Electron Microscopy 
Laboratory, Institute of Virology.
3.3 Isolation of virus from urine samples and throat
swabs
Samples were transported to the laboratory and 
inoculated with minimum delay on to semi-confluent 
monolayers of Flow 2002 cells in 25cm2 tissue culture 
bottles. Monolayers were overlaid with 5ml of maintenance 
medium (EF5) and incubated for a minimum of 8 weeks at 3 7°C 
in an atmosphere of 5% C02 in air. Cultures were usually 
examined at weekly intervals for the development of a cpe 
and then overlaid with fresh maintenance medium. In some 
bottles the characteristic morphological changes of HCMV 
were evident. Isolates were subcultured when the cpe was 
near confluent and identified as HCMV by their ability to 
grow on Flow 2002 cells but not on Vero cells or on 
BHK21/C13 cells. Isolates were also confirmed as HCMV by 
RNA-DNA hybridization (Section 4.4.12). All HSV isolates 
were confirmed by FAT performed by the staff of the 
Diagnostic Laboratory, Western Infirmary, Glasgow.
3.4 Virus titration
3.4.1 HCMV
The plaque assay of Wentworth and French (1970) was 
employed. Serial tenfold dilutions of HCMV were made in 
PBS containing 2% (v/v) foetal calf serum. 100/zl inocula
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were added to confluent monolayers of Flow 2002 cells in 
50mm plastic petri dishes. After 60 min absorption at 
37°C, 5ml of overlay agar medium were added to each plate 
and the monolayers incubated in a humidified atmosphere of 
5% C02 in air at a temperature of 3 7°C. Seven days later a 
further 5ml of agar overlay medium were added and the 
incubation continued for 7 more days. Monolayers were then 
fixed by adding 5ml of Cidex to each plate for a minimum 
period of 4 hr. Then the agar overlays were discarded and 
the monolayers stained with Giemsa for 10 min at room 
temperature. Plaques were counted using a dissecting 
microscope.
3.4.2 HSV
Serial tenfold dilutions of HSV stock were made in PBS 
Ca and lOOpl inocula added to confluent monolayers of 
BHK21/C13 cells. The virus was absorbed for 45 min at 37°C 
after which time 4ml of EHu4 were added. Incubation
proceeded for a period of 2 days at 37°C in an humidified 
atmosphere of 5% C02 in air. Monolayers were then stained 
with Giemsa and plaques counted as described above.
3.5 In vivo labelling of HSV DNA
The method of Lonsdale (1979) was employed.
Confluent BHK21/C13 cells were harvested in ECl-Pi and 
seeded in Linbro wells at a density of 1 x 106 cells in 1ml 
of ECl-Pi. After overnight incubation at 37°C, the cell 
monolayers were almost confluent and were then infected
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with HSV at a moi of 10 pfu per cell. Incubation was 
continued for 1 hr at 37°C after which time the medium was 
replaced by 0.5ml of ECl-Pi containing 50/xCi of 32P 
orthophosphate (carrier free). The infected cells were 
reincubated at 31°C for 24 to 48 hr.
Cells were harvested by the addition of 0.5ml of 5% 
(w/v) SDS to each well and mixed with an equal volume of 
phenol saturated with RSB. The phases were separated by 
centrifugation at 2000 rpm for 10 min at 4°C. The 
supernatant was mixed with 2 volumes of ethanol and the DNA 
precipitated by centrifugation at 2000 rpm for 10 min at 
15°C. After the pellet was air dried, it was resuspended 
in 200/xl of sterile distilled water containing 25/xg and 5U 
of boiled RNase A and RNase T1 respectively and incubated 
at 37°C for a minimum period of 2 hr. Thereafter, 10/xl 
aliquots were spotted on to 2.5cm diameter discs of Whatman 
No.l paper. Unbound counts were removed by 3 washes each 
of 5 min duration in 5% (w/v) TCA at 4°C. The discs were 
then washed in ethanol, air dried and counted for 32P in 
Ecoscint in order to equalize counts before restriction 
enzyme analysis.
3.6 DNA extraction
3.6.1 HSV
The procedure was based on that of Wilkie (1973).
Confluent monolayers of BHK21/C13 cells in 80oz roller 
bottles were infected as described above. After 3 days of 
incubation at 31°C, infected cells were detached by
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agitation and pelleted by centrifugation at 2 000 rpm for 10 
min at 4°C. The supernatant containing cell released virus 
was saved while the cell pellet was resuspended in 5ml of 
RSB containing 0.5% (w/v) NP40 and held on ice for 10 min
to allow lysis of cell membranes and release of nuclei. 
After centrifugation at 2 000 rpm for 10 min at 4°C, the 
cytoplasmic supernatant was saved and the pellet 
resuspended in RSB/NP4 0. The nuclei were re-extracted and 
the second cytoplasmic supernatant retained. Virus was 
pelleted by centrifugation of the combined supernatants at 
12000 rpm for 2 hr at 4°C in a Sorvall GSA rotor.
The virus pellet was resuspended in 8ml of RSB, 
sonicated in a Cole Palmer ultrasonic cleaning bath and 
lysed by the addition of SDS to a final concentration of 
0.5% (w/v) . The pellet was twice extracted with an equal 
volume of phenol equilibrated with TE and then an equal 
volume of chloroform/isoamyl alcohol 24/1 (v/v). The upper 
aqueous phase was dialysed overnight at 4°C against 0.1 x 
SSC and the DNA recovered by ethanol precipitation (3 
volumes of ethanol and a tenth volume of 3M NaAc) at -2 0°C 
overnight.
HSV DNA was purified by isopycnic banding on caesium 
chloride gradients. Solid caesium chloride was added to 
the DNA solution to give a refractive index of 1.393. 
Centrifugation was for 24 hr at 40000 rpm in a Sorvall 
TV8 6 5B vertical rotor at 20°C. The gradients were 
fractionated by piercing the bottom of the tubes and
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collecting 15 drop fractions. 5/Ltl samples of each fraction 
were assayed by electrophoresis on a 1% (w/v) agarose mini 
gel containing 0.5/xg/ml ethidium bromide and nucleic acids 
visualised under short wave UV radiation (254nm). 
Fractions containing HSV DNA were combined, dialysed 
overnight at 4°C against 0.1 x SSC and stored at -2 0°C.
3.6.2 Human cellular DNA
Confluent monolayers of Flow 2 002 cells grown in an 
80oz roller bottle were washed 3 times with 10ml of 1 x 
SSC: 2% (w/v) SDS and 5M sodium perchlorate added to a
final concentration of 1M. The preparation was extracted 
twice with TE saturated phenol and once with 
chloroform/isoamyl alcohol 24/1 (v/v). After
centrifugation at 2000 rpm for 10 min at 4°C, the upper 
aqueous layer was made 0. 3M sodium acetate and the DNA 
precipitated in 3 volumes of ethanol at -2 0°C overnight. 
The DNA was pelleted at 2000 rpm for 10 min at 15°C, dried 
in a vacuum chamber and incubated at 37°C in sterile 
distilled water containing boiled RNase A and proteinase K 
to a final concentration of 25/xg/ml and 20/ig/ml 
respectively. Thereafter, the DNA was phenol extracted as 
described above and finally dialysed against 0.1 x SSC at 
4°C. Stock DNA solutions were stored in aliquots at -2 0°C.
3.7 Estimation of DNA concentration
The concentration of DNA was estimated by agarose gel 
electrophoresis in mini gels. Samples of DNA were 
electrophoresed with known standard concentrations of X DNA
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on 1.0% (w/v) agarose gels in TBE electrophoresis buffer
containing 0.5Mg/ml ethidium bromide. The DNA was 
visualized by UV illumination at 254nm and the 
concentration determined by visual comparison of the sample 
fluorescence with that of the standards.
A more accurate estimate of the DNA concentration was 
obtained by optical density (O.D.) measurement at 2 60nm in 
quartz microcuvettes in a Perkin Elmer double beam RH 
spectrophotometer. The concentration was calculated 
assuming that 1 O.D. unit is equal to 40/xg/ml of single
stranded DNA. The purity of the DNA could be assessed by 
calculating the ratio between readings at 260nm and 280nm 
(O.D. 260/0.D. 280) . For pure preparations of DNA this
ratio is 1:8.
3.8 Gel electrophoresis
3.8.1 Aaarose gel electrophoresis
Horizontal agarose gels (260mm x 160mm) ranging in 
concentration from 0.5 to 1.2% (w/v) in 1 x TBE
electrophoresis buffer were used. The agarose was 
dissolved by boiling in a microwave oven, cooled to 50°C
and 0.5jitg/ml ethidium bromide added before pouring. TBE
electrophoresis buffer containing O.S^iq/ml ethidium bromide 
was routinely used. DNA samples with added 0.2 volumes of 
Dye-Ficoll were subjected to electrophoresis at 2V/cm for 
16 hr at room temperature. Gels were photographed under 
short or long wavelength UV light using Polaroid 665 or 667
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film. Gels for autoradiography were dried on to glass
plates in an oven at 8 0°C.
3.8.2 Alkaline agarose gel electrophoresis
0.7% (w/v) agarose in 50mM NaCl, ImM EDTA was
dissolved by boiling in a microwave oven and cooled to 50°C 
before pouring. Horizontal gels were routinely used. 
Samples of DNA to be analysed were ethanol precipitated and 
redissolved in 20jLtl of alkaline loading buffer (50mM NaOH,
ImM EDTA, 2.5% [w/v] Ficoll, 0.025% [w/v] bromcresol
g r e e n ) . Electrophoresis was carried out in a buffer
consisting of 3 0mM NaOH, 2mM EDTA at 2V/cm for 16 hr at 
4°C. Prior to autoradiography the gel was soaked in 70%
(w/v) TCA at room temperature for 30 min and thereafter
placed in a gel drier.
3.8.3 Denaturing polyacrylamide gel for RNA electro­
phoresis
Vertical urea polyacrylamide gels measuring 2 65mm x 
165mm x 0.35mm were prepared. Polyacrylamide at a 
concentration of 3.5% (w/v) was made 1.0 x for TBE and 8M 
for urea from stock solutions of 9.5M urea and 38% (w/v)
acrylamide, 2% (w/v) N,N'-methylene bis-acrylamide in 7 x 
TBE electrophoresis buffer. To a final volume of 3 0ml were 
added 300/xl of freshly prepared 10% (w/v) ammonium
persulphate and 20^1 TEMED to initiate polymerization. The 
gel was cast and allowed to set. 2/xl of samples were mixed 
with lOjLtl of loading buffer (10M urea, ImM Na2EDTA, 17% 
[v/v] glycerol, 0.6% [w/v] bromophenol blue, 0.6% [w/v]
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xylene cyanol) , boiled for 5 min, quenched in ice and 
loaded. Gels were electrophoresed at 40W in 1 x TBE 
electrophoresis buffer until the bromophenol blue dye 
reached the bottom of the gel. Radioactive species were 
detected by autoradiography.
3.9 Restriction enzyme digestion of DNA
All restriction enzyme digests were performed at 37°C 
for a minimum of 3 hr in the appropriate REact buffer. 1U 
of the restriction enzyme was used per 1/ig of DNA to be 
cleaved. Reactions were terminated by the addition of 1/6 
volume of Dye-Ficoll and the products of digestion 
separated by gel electrophoresis.
3.10 3 1-end-labelling of \ DNA
DNA was digested with the restriction enzyme Aval 
using the procedure described in Section 3.9. ljLtl each of 
5'-[a-32P] dGTP and 5'-[a-32P] dCTP were added and the 
volume adjusted to 29/il with water. 1/xl (10U) of Klenow 
polymerase was added and the mixture incubated at room 
temperature for 15 min. Unincorporated radionucleotides 
were removed by G50 Sephadex chromatography while the 
radiolabelled DNA was ethanol precipitated and redissolved 
in 100/xl of sterile distilled water.
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3.11 5 1-end-labelling of the Gibco BRL 0. 16-1.77 3cb RNA
ladder
3.11.1 Dephosphorvlation
A reaction mixture consisting of 40^g RNA, 1.38U CIAP, 
20/xl 10 x CIAP buffer (500mM Tris-HCl [pH 9.0], lOmM MgCl2 , 
ImM ZnCl2 , lOmM spermidine) was made up to 200/il with DEPC 
treated water (50/xl of DEPC mixed with 20ml of sterile 
distilled water which is then autoclaved). After 
incubation at 37°C for 30 min, 160/xl water, 40/xl 10 x STE 
and 20/xl 10% (w/v) SDS were added, the solution mixed and 
then heated at 68°C for 15 min. The solution was extracted 
once with water saturated phenol, twice with phenol/ 
chloroform 1/1 (v/v) , twice with chloroform and 3 times
with water saturated ether. Traces of ether were removed 
by heating at 50°C for 10 min. RNA was precipitated by the 
addition of a tenth volume of 3M sodium acetate (pH 5.5) 
and 2.5 volumes of ethanol. After overnight incubation at 
-20°C, the RNA was pelleted and resuspended in 40/il of DEPC 
treated water. Finally, the RNA was quantitated by reading 
the absorbance at A260 as described in Section 3.7.
3.11.2 Labelling with polynucleotide kinase
A reaction mixture containing 10/ig CIAP treated RNA 
ladder, 10/xl (500mM Tris-HCl [pH 7.5], lOOmM MgCl2 , 50mM
DTT, ImM spermidine and ImM Na2EDTA), 30U polynucleotide
kinase and 100/iCi [ ^  - 32P] ATP was prepared. The volume 
was adjusted to 50/xl with DEPC treated water and incubated 
at 37°C for 3 0 min. The reaction was stopped by the
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addition of 2/il 500mM Na2EDTA (pH 7.5) and then extracted, 
once with phenol/chloroform 1/1 (v/v) and once with
chloroform. Unincorporated nucleotides were separated by 
G50 Sephadex chromatography in buffer containing ImM EDTA, 
50mM NaCl, lOmM Tris-HCl, (pH 7.5). Radiolabelled RNA was 
ethanol precipitated and resuspended in lOOjul of DEPC 
treated water as described in Section 3.11.1.
3.12 M13
3.12.1 Transfection
The method was essentially that of Cohen et a l . 
(1972). E.coli JM101 grown to an O.D. of 0.3 at 630nm was 
pelleted by centrifugation at 8000 rpm for 5 min at 4°C in 
a Sorvall SS34 rotor. The cells were resuspended in a half 
volume of 50mM CaCl2 and left on ice for 20 min. 
Centrifugation was repeated as before and the cells 
resuspended in a tenth volume of 50mM CaCl2 . 200/xl of
cells were added to lOO/xl CaCl2 and ljtxg of M13 recombinant 
DNA (l/xg/50/il) . The suspension was kept on ice for 45 min 
followed by incubation at 42°C for 15 min. Thereafter, it 
was added to 4ml of top agar at 42°C containing 25jul of 
lOOmM IPTG and 25jLil of 2% (w/v) X-Gal in dimethylformamide. 
The mixture was poured directly on to 90mm diameter LB agar 
plates and incubated overnight at 37°C.
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3.12.2 Growth and purification of recombinant M13 clones
Four drops of an overnight culture of JM101 were added 
to 100ml of 2YT broth which was then dispensed in 1.5ml 
aliquots. One white recombinant M13 colony was added to 
each aliquot and incubated for 6 hr at 37°C in a shaking 
incubator. The broth was transferred to 1.5ml Eppendorf 
tubes and the cells pelleted by centrifugation at 13 000 rpm 
for 10 min at 15°C. 800^1 of supernatant were removed to a
fresh Eppendorf tube and bacteriophage precipitated by the 
addition of 200/xl of 20% (w/v) PEG 6000 in 2. 5M NaCl at 4°C 
overnight. Bacteriophage was pelleted by centrifugation at 
13000 rpm for 10 min at 15°C, resuspended in lOOpl of TE 
and the DNA extracted once with 50^1 TE saturated phenol. 
After ethanol precipitation, M13 DNA was dissolved in 50/xl 
of sterile distilled water and stored at -20°C.
3.13 Construction of riboprobe p GHBI
3.13.1 Growth and purification of vector p EHBI DNA
The method is based on the alkaline lysis method of 
Birboim and Doly (1979).
10ml of LB containing 50/xg/ml ampicillin were 
inoculated with 20/xl of vector pEHBI seed stock and 
incubated overnight at 37°C in an orbital shaker. The 
following morning, this suspension was added to 3 00ml of LB 
containing 50jLig/ml ampicillin and reincubated overnight as 
described above. Bacteria were pelleted by centrifugation 
at 8000 rpm for 5 min at 4°C, washed with 200ml of STE and 
centrifuged as before. The bacterial pellet was
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resuspended in 5ml of Solution 1 (0.5% [w/v] lysozyme in
50mM glucose, 25mM Tris-HCl [pH 8.0], lOmM EDTA) and left 
at room temperature for 10 min. 10ml of freshly prepared 
Solution 2 (200mM NaOH, 1% [w/v] SDS) were added, the
suspension carefully mixed and left on ice for 10 min until 
white strands of an SDS/protein/nucleic acid complex were 
visible. After centrifugation at 15000 rpm for 30 min at 
4°C in a Sorvall SS34 rotor, the bacterial pellet was twice 
extracted with RSB saturated phenol and once with 
chloroform/isoamyl alcohol 24/1 (v/v). Nucleic acid was
ethanol precipitated, vacuum dried and resuspended in 8.5ml 
of sterile distilled water. Plasmid DNA was purified by 
centrifugation to equilibrium in caesium chloride - 
ethidium bromide gradients. Caesium chloride and ethidium 
bromide at a final concentration of lg/ml and 500/ig/ml 
respectively were added to the solution of DNA. 
Centrifugation proceeded at 40000 rpm for 3 0 hr at 2 0°C in 
a Sorvall Ti65 rotor. The supercoiled plasmid DNA was 
visualized by fluorescence in long wave UV and aspirated by 
syringe. After the ethidium bromide had been removed by 
multiple extractions with water saturated butan-2-ol, the 
DNA was dialysed overnight at 4°C against 0.1 x SSC, 
ethanol precipitated and redissolved in sterile distilled 
water to a final concentration of lmg/ml.
3.13.2 Recovery of HCMV-soecific sequences
Cloned HCMV DNA sequences were removed from pEHBI by
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double digestion with the restriction enzymes Hindlll and 
EcoRI. Fragments were separated on a 0.6% (w/v) horizontal 
agarose gel containing 50^g/ml ethidium bromide and 
visualized by long wave UV illumination. The relevant DNA 
band was identified, cut from the gel and placed in the 
"sample well" of an electroelution chamber. After 
electrophoresis in TBE electroelution buffer at 2 00V for 3 
hr, the insert DNA was removed from the "collection well", 
ethanol precipitated and resuspended in sterile distilled 
water at a concentration of l^g//il.
3.13.3 Cloning of riboorobe p GHBI
Insert DNA was prepared as described in Section 
3.13.2.
Vector pGEM2 DNA was digested with the restriction 
enzymes EcoRI and Hindlll, extracted once with TE saturated 
phenol, precipitated with an equal volume of isopropanol, 
air dried and resuspended in sterile distilled water at a 
concentration of Ifiq/iil.
Reactions were performed in 20mM Tris-HCl (pH 7.6), 
lOmM MgCl2 , lOmM DTT, 0.6mM ATP in a final volume of 1 0 / j l I. 
Ligation of insert and vector DNA was achieved by 
incubating an approximate tenfold molar excess of insert 
DNA with 20ng of vector DNA. 1U of T4 DNA ligase was added 
and the preparation incubated overnight at room 
temperature.
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3.13.4 Transformation of DH5 cells
The ligation reaction was diluted fivefold with 
sterile distilled water. 1/ul of the diluted DNA 
(approximately 5ng) was added to 2 0/il of chilled DH5 cells 
and kept on ice for 3 0 min after which the cells were 
incubated at 42°C for 40s and again placed on ice. 80jil of 
S.O.C. (2% [w/v] bactotryptone, 0.5% [w/v] yeast extract,
lOmM NaCl, 2.5mM KC1, lOmM MgCl2 , lOmM MgSO^, 2 0mM glucose) 
were added and the preparation incubated for 1 hr at 37°C 
in an orbital incubator. Cells were streaked on 90mm LB 
agar plates containing 50/zg/ml ampicillin and incubated 
overnight at 37°C.
3.13.5 Identification of recombinant clones
Single colonies were taken on a toothpick, inoculated 
into 5ml of LB containing 50/xg/ml ampicillin and shaken 
overnight at 37°C in an orbital shaker. 1.5ml of the 
suspension was then centrifuged at 13000 rpm for 1 min at 
21°C and the bacterial pellet resuspended in 350^1 Stets 
buffer (8% [w/v] sucrose, 0.5% [v/v] Triton X-100, 50mM
EDTA [pH 8.0], lOmM Tris-HCl [pH 8.0]) to which were added 
25 /xl of a freshly prepared solution of lOmg/ml lysozyme. 
The suspension was vortexed, boiled for 40s and immediately 
centrifuged at 13 000 rpm for 10 min at 21°C. The pellet 
was discarded. To the supernatant were added an equal 
volume of isopropanol and a tenth volume of 3M sodium 
acetate. After overnight storage at -20°C DNA, was 
concentrated by centrifugation at 13 000 rpm for 10 min at
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21°C, vacuum dried and resuspended in 50/xl of sterile 
distilled water.
Recombinant clones were identified by agarose gel 
electrophoresis of DNA fragments generated by restriction 
enzyme digestion. One of these clones (pGHBI) was grown 
and purified as described in Section 3.13.1.
3.14 Synthesis of hybridization probes
3.14.1 Radiolabelled M13 DNA
In a standard reaction, a 100 molar excess of M13 
hybridization probe primer was added to 50ng of M13 single 
strand template DNA in a lOjtil volume of 50mM NaCl, lOmM 
Tris-HCl [pH 7.5], lOmM DTT, lOmM MgCl2 . The solution was 
vortexed for 5s, boiled for 3 min and incubated for 3 0 min 
at 21°C. 33pmol of 5'-[a-32P] dATP were dried under vacuum 
and resuspended in the reaction mix. To this were added 
5/il of a dNTP solution (150/iM dTTP, 150juM dGTP, 150/iM dCTP) 
and 6U of Klenow polymerase. The reaction mix was made up 
to 20/zl with sterile distilled water and then incubated for 
6 hr at 15°C. Incorporation of the radiolabelled 
nucleotide was monitored at hourly intervals by TCA 
precipitation: 1 / j l I of the reaction mix was diluted in 1ml
of sterile distilled water and 10/xl spotted on to duplicate 
2.5cm discs of Whatman No.l paper. One disc was washed in 
3 changes of 5% (w/v) TCA, rinsed in ethanol and air dried. 
Washed and unwashed discs were counted for P m  a liquid 
scintillation counter and the percentage incorporation
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calculated. Unincorporated radionucleotide was removed by 
passing the reaction mix through a 10ml Sephadex G50 column 
equilibrated with 0.1 x SSC. Radiolabelled DNA was 
collected, ethanol precipitated, vacuum dried and 
resuspended in 8ml of hybridization solution (Section 
3.15.3). Probes with efficiencies of 1 to 5 x 108 cpm/jug 
DNA were usually obtained. Sizing of the radiolabelled M13 
second strand was by alkaline agarose gel electrophoresis.
3.14.2 Biotin-labelled and unlabelled DNA
Second strand synthesis from the single strand M13 DNA 
template was also achieved using unlabelled d A T P , 
biotinylated dATP and a 50:50 mixture of these. Reaction 
conditions were as described in Section 3.14.1 with the 
exception that 0.5)ug of M13 DNA and 350pmol of dATP were 
used. This higher concentration of M13 DNA allowed direct 
visualization of the synthesized DNA products by short wave 
UV illumination after 0.6% (w/v) agarose gel
electrophoresis.
3.14.3 Riboorobe pGHBI
10/ig of plasmid pGHBI DNA was linearized by digestion 
with the restriction enzyme EcoRI, extracted once with TE 
saturated phenol, ethanol precipitated, vacuum dried and 
resuspended in sterile distilled water at a concentration 
of 1/xg/Ml •
ljLtg of the linearized DNA template was added to 4/xl of 
Gibco BRL 5 x T7 reaction buffer (200mM Tris-HCl [pH 8.0],
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40mM MgCl2 , lOmM spermidine-HCl, 125mM NaCl) and
supplemented with lOmM DTT, ljLil RNasin (2U/jnl) , 500/iM each
of ATP, GTP, CTP and 12.5/xM each of 5 1 - [a-32P] -labelled and 
unlabelled UTP. Finally 22U of T7 RNA polymerase were 
added. The reaction mix was made up to a final volume of 
20/xl with DEPC treated water and incubated for a minimum 
period of 1 hr. Following RNA synthesis, the DNA template 
was removed by the addition of 1U of RQ1 DNase and 
incubation for 10 min at 37°C. The solution was made up to 
200/il by the addition of 2 x PK buffer (lOOmM Tris-HCl [pH 
8.0], 20mM EDTA, 20mM NaCl, 0.4% [w/v] SDS) and extracted
with TE saturated phenol. Unincorporated radionucleotide 
was removed after passage through a 10ml column of Sephadex 
G50 equilibrated with lOmM Tris-HCl [pH 7.5], 50mM NaCl and 
ImM EDTA [pH 8.0]. Radiolabelled RNA was pooled, ethanol 
precipitated and resuspended in 8ml of the hybridization 
solution. Incorporation of the radionucleotide was 
monitored by TCA precipitation. Usually 5 x 107 to 5 x 108 
cpm/ml of hybridization solution were obtained. 
Radiolabelled RNA transcripts were subjected to 
urea/acrylamide gel electrophoresis and their size 
estimated by reference to 32P-labelled RNA MWt markers.
3.14.4 Nick-translated human DNA
Human DNA probes were labelled internally as described 
by Rigby et al. (1977).
1/xg of DNA was nick-translated in a final volume of
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50>LX 1 containing 50mM Tris-HCl [pH 7.2], 5mM MgCl2 , ImM DTT, 
0.03% (w/v) BSA, 0.05mM dATP, 0.05mM dTTP, 0.7/xM each of
5'-[a-32P] dGTP and 5'-[a-32P] dCTP. DNase was added to a 
final concentration of O.Oljxg/ml and the solution vortexed. 
5U of E.coli DNA polymerase I were added and the reaction 
incubated for 1 hr at 15°C.
Incorporation of radiolabelled nucleotides was 
monitored by TCA precipitation and scintillation counting. 
Unincorporated radionucleotides were removed from the 
reaction mix by passage through a 10ml Sephadex G50 column 
equilibrated with 0.1 x SSC. The radiolabelled DNA probe 
was ethanol precipitated and resuspended in 200(il of 
sterile distilled water. Before use, the probe was 
denatured by boiling, quenched on ice and resuspended in 
8ml of hybridization solution. Probes with specific 
activities of at least 108 cpm/jLig were used for dot blot 
hybridization.
3.15 Hybridization
3.15.1 Specimen preparation
10ml of urine were centrifuged at 3000 rpm for 15 min 
at 4°C and the pellet discarded. The supernatant was 
transferred to a fresh tube and centrifuged at 10000 rpm 
for 90 min at 4°C. The supernatant was discarded. To the 
pellet were added 400jiil of lysis solution (3% [w/v]
Sarkosyl, 75mM Tris-HCl, 25mM EDTA) . 100/il of proteinase K
(5mg/ml) were then added and the suspension incubated for 1 
hr at 37°C. DNA was extracted once with an equal volume of
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TE saturated phenol, ethanol precipitated and resuspended 
in 50/il of sterile distilled water.
3.15.2 Denaturation of the target DNA
DNA in a volume of 50/xl was denatured by the addition 
of an equal volume of 800mM NaOH and incubated for 10 min 
at 21°C. After neutralization with 2 volumes of 2M sodium 
acetate, the DNA was bound to nitrocellulose paper 
presoaked in 2M sodium acetate using a dot blot manifold. 
The paper was air dried and baked at 80°C for 2 hr.
Prehybridization and hybridization were carried out in 
sealed hybridization bags submerged in a water filled 
plastic box placed in a shaking water bath at the 
appropriate temperature.
3.15.3 Prehvbridization and hybridization conditions
(a) M13 probes
Blots were prehybridized in a solution of 50% (v/v)
formamide, 5 x SSC, 5 x Denhardt's buffer, 50mM NaP04 [pH 
6.8], 0.1% (w/v) SDS and lOOjug/ml sonicated denatured
salmon sperm DNA for 2 to 16 hr at a temperature of 42°C. 
80111 of prehybridization solution per cirr’ of nitrocellulose 
paper was used.
The hybridization solution in which the radiolabelled 
probe was suspended was essentially the same as the 
prehybridization solution with the exceptions that the 
final concentration of NaP04 (pH 6.8) and SDS were 2 0mM and
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0.2% (w/v) respectively. Hybridization proceeded for 16 hr 
at 42°C/ 50/xl of hybridization solution being used per cm2 
of nitrocellulose paper.
(b) Riboorobe p GHBI
The prehybridization and hybridization solutions both 
consisted of 50% (v/v) formamide, 6 x SSC, 5 x Denhardt's
buffer, 0.1% (w/v) SDS and 200/xg/ml sonicated denatured
salmon sperm DNA. The volumes used were as described for 
the M13 system. Conditions of hybridization were varied 
with respect to temperature (4 0°C, 50°C, 60°C) and time
period (14 hr, 38 hr, 62 hr) in order to find the optimum. 
Standard hybridization conditions are defined as 14 hr at 
50°C.
(c) Nick-translated human DNA
The compositions and volumes of the prehybridization 
and hybridization solutions were as described for riboprobe 
pGHBI. Prehybridization was performed for 2 to 16 hr at 
50°C while hybridization was for 38 hr at 60°C.
3.15.4 Washing
Each blot was washed for 30 min in 2 changes of 1 x 
SSC, 0.1% (w/v) SDS in a volume of 1 litre at room
temperature on a shaking platform. This was followed by 2 
further washes, each of 30 min duration, in a 1 litre 
solution of 0.1 x SSC, 0.1% (w/v) SDS at a temperature of 
60°C. Finally each blot was air dried.
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3.15.5 Detection of hybrids
Dried blots were autoradiographed by exposure at -70°C 
to Kodak X-Omat S film sandwiched between 2 Dupont 
phosphotungstate intensifying screens. In 1 experiment 
Amersham Hyperfilm MP was assessed.
In the RNA-DNA hybridot assay urine specimens were 
regarded as negative for HCMV-DNA if no hybrid signal was 
observed. Urines were reported as positive for HCMV DNA if 
there was a hybrid signal not present in any of the 
negative controls with the exception of HSV-2 DNA. In some 
hybridot assays uninfected control urine showed a hybrid 
signal equivalent to that observed in some of the clinical 
specimens. These latter samples were recorded as equivocal 
for HCMV DNA.
3.16 Complement Fixation Test
VB was used as the diluent throughout and was prepared 
by dissolving 1 CFT diluent tablet in 100ml of distilled 
water. VB containing 0.1% (w/v) BSA (VBA) was used to
stabilize complement when testing in the absence of other 
proteins such as antigen or antibody.
A fresh suspension of SRBCs in Alsevers solution was 
obtained weekly and washed in VB until the supernatant was 
clear. For volumetric standardization, an aliquot of the 
SRBC suspension was placed in a haematocrit tube and 
centrifuged at 3 000 rpm for 10 min at 21°C in an MSE 
benchtop centrifuge. The SRBC suspension was made up to a
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concentration of 4% (v/v) in VB.
A freeze-dried preparation of complement (preserved 
guinea pig serum) was reconstituted with 1ml of distilled 
water while dilution of this stock solution with 7 volumes 
of distilled water gave the equivalent of a 1:10 solution 
of guinea pig serum in isotonic saline. Further dilutions 
to the desired working strength were made in VB.
Freeze-dried glycine-extracted CF antigen was 
reconstituted with 1ml of distilled water and VB added to 
attain final dilutions of 1:8, 1:16 and 1:32 for HCMV, VZV 
and HSV respectively. Antigens were prepared immediately 
before use and stored on ice. Control antigens extracted 
from uninfected cell cultures were similarly prepared.
Freeze-dried standard antisera were reconstituted with 
lml of distilled water and made up to the recommended 
working dilution with VB.
The test was routinely performed in 96-well 
microtitre plates with U-shaped wells.
3.16.1 Standardization of complement and haemolvtic serum
The haemolytic titre of each new batch of complement 
was determined by "chessboard" titration against each new 
batch of lysin.
Serial 1:5 dilutions of complement from 1:60 to 1:288 
in VB were prepared. 75/nl of VBA were added to each of the 
haemolytic serum control wells and 50/xl to the remaining 
wells. 25/xl of each complement dilution was added to the 
appropriate well and the microtitre plate incubated
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overnight at 4°C. Doubling dilutions of haemolysin from 
1:50 to 1:800 in VB were prepared. VB acted as a negative 
control for haemolysin. To each dilution of haemolysin was 
added an equal volume of 4% (v/v) washed SRBCs which were 
then sensitized for 30 min at 37°C. Thereafter, plates were 
warmed for 3 0 min at 37°C and 25fil of the sensitized SRBCs 
were added to the appropriate wells. The plates were 
incubated for 40 min at 37°C, cells being gently 
resuspended at 15 min, 30 min and 40 min using a 
microshaker. SRBCs were allowed to settle at 4°C for a few 
hours and the plates read. The OSD of haemolytic serum is 
the dilution giving most lysis with the highest dilution of 
complement. Since 50% haemolysis is a more sensitive and 
reproducible index of the haemolytic activity of complement 
than 100%, 1U of complement (HD50) is the dilution giving 
50% lysis with the OSD of haemolysin. In the CFT proper 
complement is used at 4HD5Q.
3.16.2 CFT proper
Sera from each patient were tested in parallel at 2 
starting dilutions; 1:2 and 1:8. All sera were diluted in 
VB.
Prior to use an aliquot of serum was removed from the 
original sample and incubated for 30 min at 56°C to remove 
endogenous complement.
25/xl of VB were placed in every test well. 25jLil of 
neat serum and 25jiil of serum diluted 1:4 in VB were placed
144
in adjacent wells and diluted from 1:2 to 1:256 and 1:8 to 
1:1024 respectively using a hand microdiluter. 25^1 of
complement 4HD50 were added to each test well followed by 
25/xl of viral antigen at the appropriate dilution. Plates 
were wrapped in foil and incubated overnight at 4°C. The 
following morning a 4% (v/v) solution of SRBCs were
sensitized by mixing with an equal volume of haemolysin and 
incubation for a minimum period of 3 0 min at 37°C (a final 
mixture of 2% [v/v] cells with OSD of haemolysin) .
Microtitre plates were warmed for 30 min at 37°C and 25/il 
of the sensitized SRBCs added to each test well. The 
plates were reincubated for 40 min at 37°C, cells being 
gently resuspended at 15 min, 30 min and 40 min using a 
microshaker. After storage for a few hours at 4°C, the 
plates were read. The highest dilution of serum in which 
lysis of SRBCs was limited to 0-25% was taken as its titre.
Controls comprised (i) anticomplementary activity: 
serum 1:2 and 1:8 with no antigen tested against 4 and 2 
HD50 complement (ii) complement (with 2 volumes of VBA 
replacing antigen and antiserum) HD50U of 4, 2, 1, 0.5 and 
0 (cell control) (iii) specific reagent controls: standard 
positive antiserum titrated from 4 times titre (4T) to 1/4 
titre (T/4) against the dilution of antigen used in the 
test? controls of specific antigen (no antiserum) plus 4 
and 2 H D 5 q complement and a control of the standard 
antiserum at the lowest dilution (4T) without antigen plus 
4 and 2HD50 complement.
Sera with anticomplementary activity were treated by
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the addition of 1 volume of freshly reconstituted 
complement (preserved guinea pig serum) at working dilution 
to 4 volumes of test serum. This was followed by 
incubation overnight at 4°C and then for 3 0 min at 37°C to 
inactivate residual complement. Sera were diluted 1:8 in 
VB prior to testing.
Sera were regarded as negative for virus-specific CF 
antibody if the titre was less than 1:2 in the modified 
CFT.
3.17 Enzyme linked immunosorbent assays
3.17.1 Labsvstems HCMV-soecific IaM and IoG
Assays of HCMV-specific IgM and IgG were performed 
strictly in accord with the manufacturers1 protocol. Serum 
specimens were diluted 1:200 in Labsystems diluent buffer 
and 100/nl dispensed into 2 microtitre wells coated with 
inactivated AD169 grown in human foreskin fibroblasts and 1 
well of uninfected foreskin fibroblasts. Following 
incubation for 90 min (IgG) or 120 min (IgM) at 37°C the 
wells were washed 3 times with 200/xl of a 1:500 solution 
of Tween 20 in distilled water. Swine antihuman IgG or IgM 
coupled to alkaline phosphatase was diluted 1:49 in 
Labsystems conjugate diluent buffer (lOmM PBS, 0.1% [w/v] 
sodium azide) and 100/xl added to each well. After 
incubation for 2 hr at 37°C followed by another 3 rounds of 
washing, 100/lxI of pNNP (2mg/ml in 1.01M DEA, 0.505mM 
MgCl2 , 0.1% [w/v] sodium azide) were added to each well.
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The reaction continued for 3 0 min at 37°C and was stopped
by the addition of 100/xl of 1M NaOH. The absorbance
readings at 410nM and 450nm were recorded. In all
experiments an HCMV positive and negative control sera were
included. The ELISA value for each serum was calculated
using the formula
(Ass - Arbc) - (Asc - Arbc)
EIU = (Acs - Arbs) - (Acc - Arbc) x 100
where
EIU = enzyme immuno unit
Ass = average absorbance of the sample in 2 sensitized 
wells
Arbs = average absorbance of the reagent blank in 2 
sensitized wells
Asc = absorbance of the sample in the control well
Arbc = absorbance of the reagent blank in the control well
Acs = average absorbance of the positive control serum in 
2 sensitized wells
Acc = absorbance of the positive control serum in the 
negative control well.
An ELISA IgM value of ^ 40 EIU was regarded as
positive and a value of < 20 EIU as negative. Similarly,
an ELISA IgG value of ^ 20 EIU was regarded as positive and
a value of < 10 EIU as negative. Levels intermediate to the
clear positive and negative zones were categorised as
equivocal. These values are those recommended by the
manufacturer for the interpretation of results obtained.
3.17.2 NBL HCMV-specific IgG
Each test serum was diluted 1:50 in NBL sample diluent
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buffer and lOO/xl added to 1 well coated with HCMV antigen 
and to 1 uncoated well. After incubation for 30 min at 
21°C in a moist atmosphere, the wells were rinsed 4 times 
with NBL washing solution (saline/Tween 20) . lOQfil of a 
solution of swine antihuman IgG coupled to horseradish 
peroxidase and diluted in NBL conjugate diluent fluid were 
added to each well. Following incubation for 60 min at room 
temperature in a moist atmosphere, the wash cycle was 
repeated. 100/Ltl of the chromogenic substrate (3,3', 5,5'
tetramethylbenzidine in citrate/acetate solution) were 
added to each well and the incubation continued for 3 0 min
at room temperature. The reaction was stopped by adding
100/xl of 5M H2S04 and the absorbance reading at 450nM 
recorded. ELISA values were calculated using the formula
Ac = Ap - An
Ac = corrected absorbance
Ap = absorbance of the sample in the antigen coated 
well
An = absorbance of the sample in the uncoated well.
In all experiments 3 control sera (high titre
positive? low titre positive? negative) were included.
Sera were regarded as positive for HCMV-IgG if the Ac 
was greater than that produced by the low positive standard 
serum. Those sera with an Ac between 90 and 100% of that 
produced by the low positive serum control were regarded as 
equivocal for HCMV-IgG. Sera classified as negative for 
HCMV-IgG had an Ac of between 0 and 90% of that produced 
by the low positive standard serum.
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3.17.3 Abbott rubella IgM
Each test serum was diluted 1:10 in Specimen Dilution 
Buffer and 2 0/il placed in 2 wells of the ELISA containing 
200/il of Specimen Incubation Buffer. Following incubation 
for 60 min at 45°C, a rubella virus coated bead was added 
to one of the wells while the other received an uncoated 
bead. Incubation continued for 90 min at 45°C. Each bead 
was then washed with 4 to 6ml of deionized water and 
reincubated for 90 min at 45°C in the presence of 2 00/il of 
antihuman IgM conjugated with horseradish peroxidase. The 
beads were again washed as described above and transferred 
to an Abbott reaction tube containing 300/il of OPD 
substrate solution. After incubation for 3 0 min at 15°C, 
the reaction was stopped by the addition of 2ml of 1M H2S04 
and the absorbance at 492nm recorded. ELISA values were 
calculated using the formula
Ac = Ap - An 
where Ac = corrected absorbance
Ap = absorbance of the sample in the presence of
the rubella virus coated bead
An = absorbance of the sample in the presence of
the uncoated bead.
In all experiments 5 control sera (1 high positive; 3 
low positive; 1 negative) were included.
Sera were regarded as positive for rubella-IgM if the 
Ac was greater than that of the average Ac of the 3 low 
positive controls. Those sera with an Ac of between 90 
and 100% of the average Ac of the 3 low positive controls
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were regarded as equivocal for rubella-IgM. Sera 
classified as negative for rubella-IgM had an Ac of between 
0 and 90% of the average Ac of the 3 low positive standard 
sera.
3.18 Other serological assays
3.18.1 Mercia Diagnostics infectious mononucleosis 
absorption test
25/41 of each positive control or test serum were added 
to a white glass slide and mixed with 25/41 of guinea pig 
antigen. The slides were allowed to stand at room 
temperature for 30s after which time 25/41 of horse cell 
suspension were added. At 1 min slides were examined for 
the presence of distinct agglutination. In a second 
experiment performed in parallel, guinea pig antigen was 
replaced by an equal volume of ox cell antigen. Sera were 
regarded as positive for heterophile antibodies if there 
was agglutination of horse cells in the presence of guinea 
pig but not ox cell antigen.
3.18.2 Behring Rapitex RF assay
Each test serum was diluted 1:6 with 0.9% (w/v) NaCl. 
40/41 of this dilution and 40/41 of each positive and 
negative control serum were placed in separate zones of a 
test plate. 40/41 of latex-RF reagent were then added to 
each zone and the suspension mixed. Marked agglutination 
indicated the presence of RF. An example is shown in 
Figure 9.
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Figure 9 RF latex-slide agglutination test
The figure shows the results of a typical 
latex-slide agglutination test for the 
presence of RF in serum samples. To each 
of wells 1-6 were added 40/xl of 
polystyrene particles coated with humanT 
globulin. These were mixed with 4 0/xl of 
positive RF control serum (well 1) , 40/xl 
of negative RF control serum (well 2) and 
40/xl of a 1:6 dilution of each test serum 
(wells 3-6) . Marked agglutination 
indicates the presence of RF.
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3.19 Abbott /?2 microalobulin RIA
1 0 0 /xl of each urine specimen were placed in the 
respective well of a reaction tray containing 2 0 0 ^ 1 of ^ 2in 
125j Reagent solution. One anti- / ^ 111 monoclonal antibody 
coated bead was introduced into each well which was then 
incubated for 1 hr at 15°C while rotating at 2 00 rpm. 
Beads were then washed twice with 4 to 6ml of deionized 
water and immediately transferred to an assay tube. The 
radioactivity in each tube was counted for 1 min in a gamma 
scintillation counter. In each experiment 6 standards (0, 
50, 150, 400, 1000 and 4000/xg/litre) and 2 known controls
were tested in duplicate. Two assay tubes containing only 
200/xl of /32m 125I Reagent solution served as the "total 
counts" tubes. At the end of the experiment the average 
cpm of background was subtracted from the average cpm of 
each standard, control and total (T) count to get the net 
cpm. For each standard and unknown the percentage of 1 2 5 I- 
labelled bound (B) to the bead (B/T%) was calculated
using the formula
B/T% = net com of each standard or unknown 
net total counts
The concentration of p 2m the unknown samples was
estimated by reference to a curve of B/T% v standard
concentrations of /32m.
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3.20 Renal allograft recipients
3.20.1 Study group
From March 1985 to December 1985 52 patients received 
kidney transplants at the Western Infirmary, Glasgow. Five 
patients who suffered acute rejection underwent nephrectomy 
within 4 weeks of the transplant operation and were 
therefore omitted from the investigation. The final study 
group comprised 47 patients with a mean age of 38 years 
(range 19 to 61) . Twenty eight patients were male and 19 
female. Forty patients were recipients of a first kidney 
transplant while 7 received their second. Four patients 
were recipients of a kidney from a live related donor while 
the remaining 43 kidneys were of cadaver origin. Each 
renal allograft recipient is identified by a letter(s) 
which remained invariable throughout the project.
3.20.2 Immunosuppressive therapy
All patients received a combination of prenisolone and 
CsA throughout the period of the study. The prednisolone 
dose was 20mg per day for the first 3 months then reduced 
to 15mg per day for 3 months followed by 12.5mg per day for 
6 months. The CsA dose was 15mg/kg/day for the first few 
days after the transplant operation with a reduction to 
around 5 mg/kg/day by 3 months, 4mg/kg/day by 6 months and 
2 to 3mg/kg/day by 1 year post transplantation. The CsA 
dose was adjusted on the basis of whole blood levels 
measured by RIA. In some patients CsA was replaced by
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azathioprine.
3.20.3 Specimens
A throat swab, urine and serum samples were obtained 
from every patient immediately prior to the transplant 
operation and subsequently at intervals of 3 to 4 weeks 
whenever possible. Sera from any 1 renal allograft 
recipient were always tested in parallel within a single 
batch of a serological assay. A serum specimen taken from 
the renal donor immediately prior to nephrectomy was 
provided by the donating hospital subject to availability. 
Plasma was separated from an aliquot of blood withdrawn 
from each transfusion pack, the contents of which had been 
infused into a renal allograft recipient participating in 
this project. Information regarding the age of the blood 
donors and date of donation was provided in confidence by 
Dr R. Crawford, Consultant, West of Scotland Blood 
Transfusion Service.
3.20.4 Clinical details
Clinical manifestations in each patient were reported 
by Dr J.D. Briggs, Consultant Physician who at the time of 
reporting was unaware of the results of HCMV isolation or 
the HCMV-specific humoral response. The following clinical 
parameters were identified.
leucopenia: a decrease in the total number of white cells 
below 4.0 x 109/litre
thrombocytopenia: a diminution in the total number of blood 
platelets below 100 x 1 0 9/litre
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abnormal liver function tests (SGOT level > 35U/litre;
SGPT level > 50U/litre; serum > 50U/litre; serum
bilirubin > 18/mol/litre)
pyrexia: a temperature of > 38°C for more than 24 hr. 
acute rejection: a 10 to 15% rise in the level of serum
creatinine which occured within 3 months of the transplant 
operation or which occured at a later date and resolved. 
chronic rejection: a 10 to 15% rise in level of serum
creatinine which did not resolve. 
nephrectomy: removal of the transplanted kidney.
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RESULTS
4. 1 Dot blot hybridization using M13 partially double
stranded probes
The use of M13 partially double stranded hybridization 
probes of high specific activity has been described and 
applied to the selection of M13 clones complementary to the 
probe from within an M13 shotgun sequence bank (Hu and 
Messing, 1982). Before using M13 probes for the detection 
of viral DNA in clinical samples it was necessary to 
investigate thoroughly the sensitivity and specificity of 
the M13 hybridization system. HSV-1 17 syn+ DNA and M13 
clones containing HSV-1 17 syn+ sequences were used for 
this purpose because of the ease of availability of the 
latter from within the Institute of Virology.
4.1.1 Sensitivity
HSV-1 DNA (l/xg/2 0)Ltl) was diluted 1:2 from 500ng to 
3.9ng and 1:10 from 50ng to 5pg in distilled water, 
denatured and bound to a nitrocellulose filter. Both sets 
of dilutions were simultaneously probed with radiolabelled 
partially double stranded JR139, an M13 clone containing 
sequences from gene UL8 of HSV-1. Only 15.6ng and 5ng 
respectively of HSV-1 DNA could be detected after 20 hr 
exposure of the nitrocellulose paper to X-ray film (Figure 
10A) . Exposure for 96 hr increased those signals already 
obtained after 2 0 hr of autoradiography and improved the 
lower limit of detection from 15.6ng to 3.9ng (Figure 10B). 
Since other authors have been able to detect pg quantities 
of complementary HCMV DNA using nick-translated (Spector et
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Figure 10 Detection of HSV-1 DNA bv the M13
probe JR139 after 20 hr (A) and 96 hr 
of autoradiography
Lane 1: Serial 1:2 dilutions of HSV-1 
DNA from 500ng to 3.9ng.
Lane 2: Serial 1:10 dilutions of HSV- 
1 DNA from 50ng to 5pg.
The probe is 50ng of oi-3 2 p-labelled 
partially double stranded JR139 DNA 
at a specific activity of 1.19 x 109 
cpm/jixg.
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al . . 1984b) and RNA (Schuster et al. . 1986) probes, it was
decided to try and improve the sensitivity of the M13 
hybridization assay.
The integrity of M13 probes depends on the binding of 
the newly synthesized radiolabelled DNA to the 
complementary single stranded M13 template. Therefore, it 
was considered ill advised to attempt to improve the 
sensitivity of the hybridot assay by increasing the 
hybridization temperature and risk denaturing the probe. 
High background signals (Figure 10B) prohibited the use of 
less stringent washing procedures while increasing the 
probe concentration to lOOng/ml of hybridization solution 
failed to improve on the lower limit of detection. 
Attempts to increase the sensitivity of the M13 
hybridization assay were therefore focused, on improving 
the specific activity of the M13 probe.
4.2 M13 reaction conditions
This section describes a number of experiments in 
which the conditions used to radiolabel the M13 
hybridization probe were examined in an attempt to improve 
the specific activity.
4.2.1 Variation between batches of r a - 3 2 P l  dATP
In preliminary experiments the incorporation of [a- 
3 2 P] dATP was seen to vary between batches of the 
radioactive nucleotide. Two standard M13 reactions were
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prepared in parallel and incubated at 37°C. Constituents 
were identical with the exception that each reaction mix 
contained [a-3 2 P] dATP from a different batch. One 
experiment showed the percentage incorporation of the 
radionucleotide to be 52% at 3 0 min and by 4 hr 64% of [a-
'i p , ,
J*P] dATP had been incorporated into the second strand of 
the M13 probe. In the parallel experiment using [a-3 2 P] 
dATP from another batch, the incorporation of the 
radionucleotide at the same time points was 17 and 32% 
respectively. Both experiments were repeated and similar
results obtained (Figure 11).
It was concluded that an inhibitor of M13 second strand
3 7synthesis was present m  some batches of [a- P] dATP.
4.2.2 Reaction temperature
Two standard M13 reactions were prepared in parallel 
and incubated at 15 or 37°C. In both experiments 
incorporation of [a-3 2 P] dATP was monitored at 30 min 
intervals for 3 or 4 hr. The results are presented in 
Figure 12. The rate of incorporation of the
radionucleotide was higher during the first 90 min of 
incubation at 37°C but thereafter it reached a plateau. At 
15°C, incorporation of [a-3 2 P] dATP continued beyond 2 hr 
and was still rising after 4 hr of incubation at which time 
80% of the radiolabelled nucleotide had been incorporated 
in contrast to 64% after 4 hr of incubation at 37°C. 
Subsequent experiments showed that incorporation of [a-3 2 P] 
dATP did not plateau until after 5 hr of incubation at 
15°C. Therefore, in all future experiments the M13 reaction
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3 2Figure 11 Time course of incorporation of ra- PI 
during M13 second strand synthesis; 
Variation between batches of the
radionucleotide.
The graph shows the percentage 
incorporation of [a-3 2 P] dATP plotted at 
30 min intervals in 2 standard M13 
reactions prepared in parallel but with 
different batches of the radionucleotide 
□ and A . The results of a 
duplicate experiment are also shown 
( ■ and ▲ respectively) . Lines are
drawn through the average of 2 values at 
each time point.
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Figure 12 Time course of incorporation of fa- *P1 
during M13 second strand synthesis at 
15°C and 37°C.
The graph shows the percentage
incorporation of [a-3 2 P] dATP plotted at 
30 min intervals in 2 standard M13 
reactions prepared in parallel and 
incubated at 15 C ( A ) or 37°C ( □) . The 
results of a duplicate experiment are 
also shown ( a and ■ respectively) . 
Lines are drawn through the average of 2 
values at each time point with the 
exception of 3.5 and 4 hr when the 
results from only 1 set of experiments 
( A and □ ) were available.
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mixture was incubated at 15°C for a minimum period of 6 hr.
4.2.3 Concentration of Klenow polymerase
An investigation was made into the number of units of 
Klenow polymerase required to give the most incorporation 
of [a-3 2 P] dATP. Two standard M13 reactions were prepared 
in parallel, all constituents being identical except for 
the number of units of Klenow polymerase. In one reaction 
containing 1U of the enzyme (lU//xl) the percentage 
incorporation of [a-3 2 P] dATP at each hour was an average 
of 39% (range 3 0.1 to 50.5) lower than that observed in a 
parallel reaction to which 6U of the enzyme (6U//xl) had 
been added. The experiment was repeated in parallel and 
similar results obtained (Figure 13) . When the M13 mix 
contained 12U of Klenow polymerase [6U//1I], the percentage 
incorporation of [a-3 2 P] dATP at each hour during the first 
6 hr of the reaction was an average of 5.5% (range 2.5 to 
8.2) higher than in a parallel experiment containing 6U of 
the enzyme.
Further attempts to increase the specific activity of 
the M13 hybridization probe were directed at the addition 
of fresh Klenow polymerase during second strand synthesis. 
Two standard M13 reactions were prepared in parallel. 
After 2 and 4 hr of incubation, 6U of Klenow polymerase 
[6U//zl] were added to one while 1/zl of Klenow dilution 
buffer was added to the other. Monitoring of both 
reactions showed the percentage incorporation of [a-3 2 P] 
dATP at each hour to be higher in the former experiment by 
an average of 7.1% (range 2.6 to 12.2), the difference
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Figure 13 Time course of incorporation of fa- PI 
dATP during M13 second strand synthesis
in the presence of 1 and 6 units of 
Klenow polymerase
The graph shows the percentage 
incorporation of [a-3 2 P] dATP plotted at 
1 hr intervals in 2 standard M13 
reactions containing 1U ( A ) or 6U ( □ ) 
of Klenow polymerase. The results of a 
duplicate experiment are also shown 
( ▲ and ■ respectively) . Lines are
drawn through the average of 2 values at 
each time point.
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increasing with longer incubation times. The addition of 
fresh Klenow polymerase did not result in a sharp increase 
in the amount of incorporated radionucleotide (Figure 14).
4.2.4 Concentration of r a - 3 2 Pl dATP
Higher specific activity M13 hybridization probes were 
made by increasing the quantity of the radionucleotide 
available for incorporation. Three standard M13 reactions 
were prepared in parallel. Constituents were identical 
with the exception that each reaction contained either 3 3 
or 66 or 132pmol of [a-3 2 P] dATP taken from the same batch. 
The results of parallel experiments performed on 2 
occasions are shown in Figure 15. When 3 3pmol of the 
radionucleotide were included in the reaction mix, an 
average of 73% or 24pmol had been incorporated after 6 hr 
of incubation. When 66 or 132pmol of [a-3 2P] dATP were 
made available for M13 second strand synthesis the average 
incorporation was 64% and 31% or 42.2pmol and 41.2pmol 
respectively.
4.2.5 Denaturing agarose gel electrophoresis of radio­
labelled M13 reaction products
When preparing M13 probes it is essential for cloned 
viral DNA to remain single stranded and therefore capable 
of hybridizing to complementary nucleic acid. Limited M13 
second strand synthesis is achieved by restricting the 
concentration of a nucleotide to an amount which will
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3 OTime course of incorporation of fa- PI 
ATP during M13 second strand synthesis: 
Interval addition of Klenow polymerase
The graph shows the percentage 
incorporation of [a-3 2 P] dATP plotted at 
1 hr intervals in 2 standard M13 
reactions prepared in parallel. The 
arrows at 2 and 4 hr represent the 
addition of 6U of Klenow polymerase 
[6u//xl] ( □ ) or l/il of Klenow dilution
buffer ( A ) . The results of a duplicate 
experiment are also shown ( ■ and
▲ respectively). Lines are drawn 
through the average of 2 values at each 
time point with the exception of 6 hr 
when the results of only 1 set of 
experiments ( □ and a ) were available.
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9 9Figure 15 Time course of incorporation of fa- *P1 
dATP during M13 second strand synthesis: 
Increasing amounts of radionucleotide
The graph shows the percentage 
incorporation of [a-3 2 P] dATP plotted at 
1 hr intervals in 3 standard M13 
reactions prepared in parallel but 
containing either 3 3pmol ( □ ), 6 6 pmol 
( A ) or 132 pmol (O) of the 
radionucleotide. The results of a 
duplicate experiment are also shown ( ■ , 
▲ and • respectively). Lines are 
drawn through the average of 2 values at 
each time point.
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permit DNA to be synthesized around the M13 template 
without extending into cloned HSV-specific sequences. For 
50ng of M13 DNA (140pmol of nucleotides) this is calculated 
to be 35pmol of [a-3 2 P] dATP.
The length of the newly synthesized radiolabelled M13 
strands can be determined by electrophoresis under 
denaturing conditions. After autoradiography only the 
radioactive species but not the unlabelled M13 template is 
detected and its MWt can be estimated by reference to an 
appropriate radiolabelled DNA marker. The denaturing 
system employed here was agarose gel electrophoresis in a 
sodium hydroxide buffer. A 32P end-labelled Aval digest of A 
DNA served as the MWt marker. Figure 16A shows the 
radiolabelled species obtained at hourly intervals in a 
standard M13 reaction during which the percentage 
incorporation of [a-3 2 P] dATP was also monitored (Figure 
16B) . While sufficient [a-3 2P] dATP had been added to the 
reaction to ensure DNA synthesis around the 7000 bp M13 
template, second strand synthesis did not exceed a few 
hundred bp after 8 hr of incubation at which time 87.1% of 
the radionucleotide had been incorporated. Increasing the 
amount of [a-3 2 P] dATP in the M13 reaction to 6 6pmol with 
90.7% incorporation produced similar results. The 
experiment was repeated on numerous occasions and 
reproducible results obtained.
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Figure 16A Sodium hydroxide agarose gel
electrophoresis of radiolabelled M13 
hybridization probes
An autoradiograph showing the ->4L'P- 
labelled products of a standard M13 
reaction after overnight
electrophoresis in a sodium 
hydroxide 0 .6 % (w/v) agarose gel.
The radiolabelled DNA obtained at 
hourly intervals during the first 8 
hr of M13 synthesis is shown in 
Lanes 1-8 respectively. Percentage 
incorporation of [a-3 2 P] dATP at 
equivalent times is given in Figure 
16B. Lane 9 is a 32P end-labelled 
Aval digest of X DNA.
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Figure 16B Time course of incorporation of r a - 3 2 P l  
dATP during a standard M13 reaction
The graph shows the percentage 
incorporation of [a-3 2 P] dATP plotted at 
1 hr intervals during the first 8 hr of a 
standard M13 reaction. The radiolabelled 
M13 DNA products of this reaction are 
described in Figure 16A.
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4.2.6 Non~denaturina acrarose gel electrophoresis of radio­
labelled M13 reaction products 
In further experiments 2 standard M13 reactions were 
prepared in parallel. Constituents were identical with the 
exception of one reaction which contained 16.5pmol of the 
radionucleotide and 16.5pmol of unlabelled dATP. The 
latter experiment was designed to reduce the specific 
activity of the probe by 50% and possibly increase the 
stability of the M13 hybrids. After electrophoresis, 
synthesized radiolabelled M13 DNA not bound to the template 
would be detected in the same location on the same 
concentration of agarose gel under both denaturing and non­
denaturing conditions. In contrast, if the newly 
synthesized DNA of a few hundred bp had remained attached 
to the M13 template then the radiolabelled species would 
appear to be of higher molecular weight. The results are 
shown in Figure 17. Both experiments showed the 
radiolabelled DNA extending from 6000 to 14000 bp but a 
smear of radioactivity corresponding to a few hundred bp 
was not observed. Therefore, it was concluded that the 
newly synthesized Ml 3 DNA had remained annealed to the 
template.
4.2.7 Use of unlabelled dATP
Second strand synthesis of M13 DNA was further 
investigated by replacing [a-3 2 P] dATP with unlabelled 
dATP. Since it would be difficult to detect a 50ng smear
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Non-denaturing acrarose gel electro­
phoresis of radiolabelled M13 hybridiz­
ation probes
Two standard M13 reactions were prepared 
in parallel, all constituents being 
identical with the exception that 3 3pmol 
of [a-3 2 P] dATP were added to one (Lane 
2) while the other received 16.5pmol of 
[a-3 2 P] dATP plus 16.5pmol of unlabelled 
dATP (Lane 3). After 8 hr of incubation, 
radiolabelled M13 DNA was purified from 
unincorporated [a-3 2P] dATP and subjected 
to electrophoresis in a non-denaturing 
0.6% (w/v) agarose gel. The
autoradiograph of this gel is shown here. 
Lane 1 is a 32P end-labelled Aval digest 
of X DNA.
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Lanes 
1 2
 •
of DNA in an agarose gel by UV illumination, 500ng of the
M13 template was used. All constituents of the reaction
were increased proportionately with the exception that 12U 
of Klenow polymerase [6U//1I] were added. The addition of 
more enzyme would have increased the final concentration of 
glycerol in which the enzyme is stored beyond 1 0 % of the 
reaction volume and risked inhibiting DNA synthesis.
At the start of the experiment most of the M13
template was in a supercoiled form which had an apparent 
MWt of about 2000 bp (Figure 18). After 1 hr of incubation 
there was a smear of DNA whose MWt ranged from 
approximately 2000 to 3000 bp but by 6 hr this had 
increased to between 3000 and 14000 bp. When compared with 
the results of Figure 17, Lanes 2 and 3, the results
suggest that the partially double stranded DNA products of 
a standard M13 reaction are of similar size regardless of 
whether radiolabelled or unlabelled dATP is used as the 
substrate. Attempts to repeat the experiment in a sodium 
hydroxide agarose gel were unsuccessful.
4.2.8 Use of biotinvlated dATP
Compared to radiolabelled nucleic acid probes, 
biotinylated ones have the advantages of being less 
hazardous, having a long shelf life and hybrids can be 
detected within a few hours since there are no long periods 
of autoradiography (Arrand, 1985). To investigate the 
possibility of preparing biotinylated probes, triplicate 
M13 reactions were prepared in parallel as described in
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Figure 18 Non-denaturing agarose gel electrophor­
esis of unlabelled M13 hybridization
probes
Three reaction mixes, each containing 
500ng of single strand M13 DNA, were 
prepared in parallel. Assimilation of 
standard M13 reaction conditions was 
achieved by a proportionate increase in 
the concentration of all reagents with 
the exception that 12U of Klenow 
polymerase were used in each experiment. 
dATP was unlabelled. Reactions were, 
stopped after 0, 1 or 6 hr of incubation 
and subjected to electrophoresis in a 
non-denaturing 0.6% (w/v) agarose gel
(Lanes 4, 2 and 1 respectively) . Lane 3 
is an Aval digest of A DNA.
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Section 4.2.7 and the products analysed by non-denaturing
agarose gel electrophoresis. The results are shown in
Figure 19. When dATP was unlabelled, the partially double
stranded M13 DNA had a MWt ranging from approximately 3000 
nucleot ides
to 14000 /j-*1113 confirming the result of Figure 18, Lane
1. When unlabelled dATP was replaced by biotinylated dATP,
nucleotides
a DNA smear of around 2000 was noted at a position
equivalent to the single strand M13
template. The latter result suggests that the biotinylated 
nucleotide had not been incorporated in sufficient quantity 
to permit synthesis of high MWt products.
In summary, the results of this section show the lower 
limit of detection of HSV DNA by radiolabelled M13 
hybridization probes to be in the ng range. Although it 
was possible to improve the specific activity of the probes
by changing reaction conditions, second strand M13
nucleotides
synthesis was limited to a few hundred . The remainder
nucleotides
of the 7000 Ml3 template was therefore single stranded
and capable of hybridizing to complementary nucleic acid 
other than HSV-specific sequences. Finally, there was 
evidence that biotinylated dATP was poorly incorporated 
during M13 second strand synthesis. Taken together, the 
results suggest that the M13 hybridot assay would be 
impractical as a diagnostic test. Therefore, it was 
decided to concentrate on the riboprobe hybridization 
system described in the next section.
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Figure 19 Non-denaturing agarose gel electrophor­
esis of biotin-labelled M13 hybridiz­
ation probes
Three reaction mixes, each containing 
500ng of single strand M13 DNA, were 
prepared in parallel. Assimilation of 
standard M13 reaction conditions was 
achieved by a proportionate increase in 
the concentration of all reagents with 
the exception that 12U of Klenow 
polymerase were used in each experiment. 
The products of each reaction were 
subjected to overnight electrophoresis in 
a non-denaturing 0.6% (w/v) agarose gel. 
One reaction was not allowed to proceed 
and was therefore the single strand M13 
template control (Lane 4) . Two other 
experiments containing an equal 
concentration of either unlabelled (Lane 
3) or biotin-label led (Lane 1) dATP were 
stopped after 8 hr of incubation. Lane 2 
is an Aval digest of X DNA.
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4*3 ftlbeerebe eS-Hif
An increase in hybridization efficiency cam hm 
achieved by using single strand RNA probes which are a M e  
to detect fg quantities of cDNA (Church and Gilbert* 1m*), 
Such probes are best prepared by using an in vitro 
transcription system in which radiolabelled ©RNA specific 
for probe sequences is synthesized (Melton et ai. * ISM) * 
This section will describe an HCMV-specific RNA probe and 
its ability to detect cDNA in a hybridot assay*
4.3.1 Construction
Plasmid pEHBI (a BamHJ subclone of the Hindlll I 
region of HCMV ADI69 in vector pAT153) was provided by Br 
J.D. Oram. Figure 20 shows a Hindlll cleavage map ©f AB 
169 and identifies the BamHJ subclone (HBI) used in these 
experiments. This subclone was chosen because it was known 
not to cross-hybridize to human DNA (Ruger et al. t 1114) » 
HCMV-specific sequences were purified and recloned in the 
transcription plasmid pGEM2 (Figure 21) , The new plasmid 
construct was named pGHBl and is shown diagrammatieally in 
Figure 22.
4.3.2 TLimtearizatiom
Prior to rha transcription, vector pGHil was digested 
with an appropriate restriction enzyme to linearize the 
plasmid at a site within the cloned HCMV DMA, distal t© the
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Figure 2 0 Location of the BamHI subclone of HCMV 
AD169 used in the construction of 
riboprobe p GHBI
Diagrammatic representation of the 
HCMV genome showing the Hindlll cleavage 
sites and the BamHI subclone from which 
cRNA probes were transcribed.
Open boxes represent the terminal 
and internal repeat sequences which 
bound the long (L) and short (S) unique 
components of the genome.
Adapted from Oram et al. (1982).
CO
Figure 21 Construction of riboprobe pGHBI
Vector pEHBI (a BamHI subclone of the 
Hindlll E fragment of HCMV AD169 cloned in 
plasmid pAT153) was simultaneously 
digested with restriction enzymes Hindlll 
and BamHI to separate vector DNA (3 657 bp) 
from HCMV-specific sequences (6100 bp). 
The latter were purified and recloned in 
vector pGEM2 to create the riboprobe 
p G H B I . Double digestion of this new 
construct with restriction enzymes Hindlll 
and BamHI released vector pGEM2 DNA (2900 
bp) from the cloned HCMV DNA fragment.
Restriction enzyme fragments were 
separated by overnight electrophoresis in 
a non-denaturing 0.6% (w/v) agarose gel.
Lane 1 : 0.5/xg of uncut riboprobe pGHBI
Lane 2 : 1.0/xg of riboprobe pGHBI after
double digestion with
restriction enzymes Hindlll and 
BamHI.
Lane 3 : 0.5(ig of the purified HCMV DNA
fragment HBI
Lane 4 : Aval digest of X DNA
Lane 5 : 0.5iig of vector pEHBI after
double digestion with restrict­
ion enzymes Hindlll and BamHI.
Lane 6 0.5/xg of uncut vector pEHBI.
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T7 promoter but proximal to plasmid-specific sequences. 
This prevents the T7 RNA polymerase transcribing plasmid 
DNA and therefore only RNA complementary to cloned DNA is 
synthesized. In all experiments riboprobe pGHBI was 
linearized by the restriction enzyme EcoRI. The products 
of digestion are shown in Figure 23 and are depicted 
diagrammatically in Figure 22.
4.3.3 Transcription Products
Linearization of riboprobe pGHBI with the restriction 
enzyme EcoRI followed by transcription in the presence of 
T7 RNA polymerase should give rise to cRNA transcripts with 
a MWt of 1400 bp (Figure 22) . Confirmation of this was 
sought by subjecting radiolabelled transcripts to urea- 
acrylamide gel electrophoresis in parallel with RNA of 
known MWt. The results are shown in Figure 24. Although 
cRNA with a MWt of 1400 bp was observed, a number of other 
radiolabelled transcripts of lower MWt were also noted.
4.3.4 Labelling
In 4 experiments performed on separate occasions the 
percentage incorporation of [a- ^P] UTP was monitored at 10 
min intervals during the first hour of RNA transcription. 
The constituents of each reaction were obtained from the 
same stock solutions with the exception that different 
batches of radionucleotide were used. Figure 25 shows 
considerable variation in the percentage incorporation of 
[a-32P] UTP at the same time point within each reaction.
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Figure 22 Schematic representation of riboprobe 
pGHBI
A figure showing the construction of 
riboprobe pGHBI and the predicted DNA 
fragments after digestion with the 
restriction enzyme EcoRI. Transcription 
in the presence of T7 RNA polymerase 
should give rise to cRNA with a MWt of 
1400 bp.
EcoRI 
I__
^700bp
cRNA transcripts
| I^OQbp t 2900bp p G E M 2  DNA
EcoRI EcoRI T7 p r omoter
EcoRI
diges t i o n
^700pb lAOO b p
 ►«
EcoRI Bam HI 
i 1
EcoRI Hin d l l l  T ^ r o m o t e r
 1------- 1---JBL-a^va
Cloned HCMV DNA
\ \\ \ pGHBI
\ \
SP6 
promo t e r
\ ' / 
EcoRI BamHI Hindlll
\ -----
T7
promoter
pGE M - 2
Transcription
plasmid
(2900bp)
Figure 23 Linearization of riboprobe p GHBI bv the
restriction enzyme EcoRI
1/xg of riboprobe pGHBI was cleaved by the 
restriction enzyme EcoRI and the DNA 
fragments separated by electrophoresis in 
a non-denaturing 0.6% (w/v) agarose gel
(Lane 1) . An Aval digest of A DNA 
provided the MWt markers (Lane 2).
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Figure 24 Radiolabelled transcription products of
riboprobe pGHBI
An autoradiograph of a 3.5% (w/v)
polyacrylamide 8. 3M urea gel showing the 
radiolabelled cRNA transcripts produced 
after linearization of riboprobe pGHBI by 
the restriction enzyme EcoRI followed by 
transcription in the presence of T7 RNA 
polymerase (Lane 2) . A P end-labelled 
0.16 to 1.77 kb RNA ladder provided the 
MWt markers (Lane 1).
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Figure 25 Time course of incorporation of fa-
3 2 p m T p  during RNA transcr iptionT
Variation between batches of the radio-
nucleotide
Riboprobe pGHBI was linearized with the 
restriction enzyme EcoRI and transcribed 
in the presence of T7 RNA polymerase. 
This graph shows the percentage 
incorporation of [a-32P] UTP plotted at
10 min intervals during the first hour of
RNA transcription. The constituents of 
each reaction were identical with the 
exception that [a-32P] UTP was from a
different batch (0, □ , a  and *
respectively).
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This in turn would produce probes of differing specific 
activities.
4.4 RNA-DNA dot blot hybridization
The radiolabelled RNA transcripts described above were 
used for the detection of complementary vector pEHBI DNA or 
pGHBI DNA by dot blot hybridization. The specificity of 
the assay was assessed and attempts made to improve the 
lower limit of detection. Unless stated otherwise standard 
conditions of prehybridization, hybridization and washing 
were employed.
4.4.1 Sensitivity
After 1 hr of autoradiography 800pg of vector pGHBI 
DNA was routinely detected although in some experiments a 
faint hybrid signal was noted at 80pg. Similarly, after 24 
hr of autoradiography the lower limit of detection of cDNA 
varied between 80pg and 8pg. Typical autoradiographs are 
shown in Figure 26.
4.4.2 Hybridization temperature
Three replicate nitrocellulose filters each containing 
serial 1:10 dilutions of vector pGHBI DNA from 800ng to 
80fg were hybridized at a temperature of 40°C or 50°C or 
60°C (Figure 27A). Although the lower limit of detection 
of vector pGHBI DNA was 80pg in each experiment, the hybrid 
signal observed at each dilution of the target DNA
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Sensitivity of the RNA-DNA hvbridot assay
The figure shows 2
autoradiographs, one taken after 1 
hr and the other after 24 hr 
exposure of a nitrocellulose filter 
containing serial 1:10 dilutions of 
vector pGHBI DNA from 8/ig to 800fg. 
The filter was hybridized with 
radio label led cRNA input counts 
totalling 9.8 x 107 cpm. Standard 
prehybridization, hybridization and 
washing procedures were employed. 
Asterisks show the positions of 
hybrid signals noted in the original 
autoradiographs but which are not 
obvious in this photograph.
Hours o f autoradiography
241
• SMS• 8 0 0  ng
• 8 0  ng
• 8 ng
8 0 0  pg
* 80 pg
8 p g
800  fg
Vector
pGHBI
DNA
RNA-DNA hybridization: Effect of the
hybridization temperature
The figure shows the
autoradiograph obtained after 24 hr 
exposure of 3 replicate
nitrocellulose filters each 
containing serial 1:10 dilutions of 
vector pGHBI DNA from 800ng to 80fg. 
One cRNA probe
/ 8 WaS synthesized and 10 cpm
simultaneously added to each filter
which was subsequently hybridized at
either 40°C or 50°C or 60°C.
Asterisks show the positions of
hybrid signals noted in the original
autoradiograph but which are not
obvious in this photograph. Dots
were also counted for in a
liquid scintillation counter and the
results are shown in Figure 27B.
input counts totalling
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increased with increasing hybridization temperature. The 
experiment was repeated and similar results obtained.
Dots were also counted for 32P in a liquid 
scintillation counter and the results of the aforementioned 
experiments are shown in Figure 27B. At each dilution of 
vector pGHBI DNA from 800ng to 8 00pg the hybrid signal 
increased as the hybridization temperature was raised from 
40 to 60°C. With increasing dilution of the target DNA 
from 80pg to 80fg the cpm of 32P detected on the 
nitrocellulose filters were noted to vary independently of 
the hybridization temperature.
Hybridization at 70°C was unsuccessful on 3 occasions 
because the nitrocellulose paper became fragile and 
difficult to manipulate. A nylon filter (Gene Screen 
Plus) , which is more durable, was hybridized at 70°C but 
the background signal was unacceptably high. Therefore, a 
decision was made to use nitrocellulose filters at a 
hybridization temperature of 60°C in all subsequent 
hybridot assays.
4.4.3 Time period of hybridization
The optimum time period of hybridization was 
determined empirically. Duplicate nitrocellulose filters, 
each containing serial 1:10 dilutions of vector pEHBI DNA 
from 1/jig to lOOfg, were hybridized at 60°C for either 14 or 
62 hr. Other experimental conditions remained standard. 
Autoradiographs obtained after 63 hr exposure of the 
nitrocellulose filters are shown in Figure 28A. The hybrid
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Figure 27B RNA-DNA hybridization: Effect of the
hybridization temperature
After autoradiography, dots were cut 
from the nitrocellulose filters 
described in Figure 27A and counted for 
3 P in a liquid scintillation counter. 
The cpm of P detected at each dilution 
of vector pGHBI DNA are shown after 
filter hybridization at either 40°C (O) 
or 50°C ( A ) or 60°C (□) . The results 
of duplicate experiments are also shown 
( • , a and ■ respectively) .
Lines are drawn through the average of 2 
counts at each DNA dilution with the 
exception of 80pg at 50°C and 8ng at 
60°C where the results from only 1 
experiment are available ( a  and □ 
respectively).
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Figure 28A RNA-DNA hybridization: Variation
with the duration of hybridization
The figure shows the
autoradiograph obtained after 63 hr 
exposure of 2 duplicate
nitrocellulose filters each 
containing serial 1:10 dilutions of 
vector pEHBI DNA from 1/xg to lOOfg. 
One cRNA probe
I 7 WaSsynthesized and jL 4 x 10 cpm
simultaneously added to each filter
which was subsequently hybridized at
60°C for either 14 hr or 62 hr.
Asterisks show the positions of
hybrid signals noted in the original
autoradiograph but which are not
obvious in this photograph. Dots
were also counted for 32P in a
liquid scintillation counter and the
results are shown in Figure 28B.
input counts totalling
Du
ra
tio
n 
of 
hy
br
id
iz
at
io
n 
(h
r)
0) 0) 0) 0) 0) 0) 0) 0) 
3. C C C Q. Q. Q. **-
i— O O  i-OO i- O
Or- O i- O
VNQ taHBd JOJO0A
signal observed at each dilution of the target DNA was 
higher when hybridization was performed for 14 than 62 hr. 
Furthermore, the lower limit of detection of cDNA was lOpg 
after 14 hr of hybridization but was lOOpg when 
hybridization was allowed to proceed for 62 hr. The 
experiment was repeated and similar results obtained.
Dots were also counted for 32P in a liquid 
scintillation counter and the results of the aforementioned 
experiments are shown in Figure 28B. The hybrid signals 
detected at lOng and lng of vector pEHBI DNA were higher 
after 14 hr of hybridization than after 62 hr. At other 
dilutions of the target DNA the cpm of 32P detected on each 
nitrocellulose filter were similar irrespective of the 
number of hours that the hybridization reaction had been 
allowed to proceed.
In another experiment, duplicate nitrocellulose 
filters each containing serial 1 : 1 0 dilutions of vector 
pGHBI DNA from 800ng to 80fg were hybridized at 60°C for 
either 14 or 38 hr. The autoradiographs obtained after 24 
hr exposure of the nitrocellulose filters are shown in 
Figure 28C. Although the lower limit of detection of cDNA 
was 8pg in both experiments, the hybrid signal observed at 
each dilution of the target DNA was marginally improved 
when hybridization was performed for 14 than 38 hr. These 
experiments were not repeated. The sensitivity of the 
hybridot assay was not evaluated at hybridization periods 
of less than 14 hr but it was decided that it would be
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Figure 2 8B RNA-DNA hybridization: Variation with
the duration of hybridization
After autoradiography, dots were cut 
from the nitrocellulose filters 
described in Figure 28A and counted for 
22P in a liquid scintillation counter. 
The cpm of P detected at each dilution 
of vector pEHBI DNA are shown after 
filter hybridization at 60°C for 14 hr 
( □ ) and 62 hr ( A ) . The experiment
was repeated with a cRNA probe at a 
specific activity of 1.76 x 107 cpm ( ■ 
and ▲ respectively). Lines are drawn 
through the average of 2 counts at each 
DNA dilution with the exception of lOOfg 
after 14 hr of hybridization when the 
result from only 1 experiment ( □ ) is 
available.
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Figure 28C RNA-DNA hybridization: Variation
with the duration of hybridization
The figure shows the 
autoradiograph obtained after 24 hr 
exposure of duplicate nitrocellulose 
filters each containing serial 1 : 1 0  
dilutions of vector pGHBI DNA from 
800ng to 80fg. One cRNA probe
was synthesized and jLlO® cpm 
simultaneously added to each filter 
which was subsequently hybridized at 
60°C for either 14 hr or 38 hr. 
Asterisks show the positions of 
hybrid signals noted in the original 
autoradiograph but which are not 
obvious in this photograph.
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convenient if all subsequent hybridization reactions were 
allowed to proceed overnight (approximately 14 hr).
4.4.4 Washing temperature
Attempts to improve the sensitivity of the hybridot 
assay were now focused on lowering the stringency of the 
washing procedure (Figure 29). The hybrid signals observed 
at equivalent dilutions of the target DNA were similar 
regardless of whether the filter was washed at 40 or 65°C. 
In both experiments the non-specific background signal was 
negligible and no evidence of hybridization to lOjug of 
either E.coli or human DNA could be found. The hybridot 
assay was repeated using serial 1 : 1 0 dilutions of vector 
pGHBI DNA and confirmation of the results obtained. In all 
subsequent experiments the nitrocellulose filters were 
washed in 0.1 x SSC, 0.1% (w/v) SDS at a temperature of 
65°C.
4.4.5 Amersham film (MP1
Further attempts to increase the sensitivity of the 
hybridot assay were centred on the use of an alternative 
autoradiography film (Hyperfilm MP, Amersham) which the 
manufacturers claimed to be more sensitive. Two 
nitrocellulose filters, each containing serial 1 : 1 0  
dilutions of vector pEHBI DNA from 1/xg to lOOfg, were 
prepared in parallel. One cRNA probe
added to both filters which were then hybridized in
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Figure 29 RNA-DNA hybridization: Variation in
the washing temperature
A nitrocellulose filter 
containing 2 sets of serial 1 : 1 0  
dilutions of vector pEHBI DNA from 
ljtig to lOOfg was prepared. Ten 
micrograms each of E.coli and human 
DNA served as negative controls. 
The filter was hybridized at 60°C 
for 14 hr with a cRNA probe input 
counts totalling- of 6.9 x 1 0 7 cpm 
and then washed twice for 3 0 min in 
1 x SSC, 0.1% (w/v) SDS at 21°C.
The nitrocellulose filter was then 
halved, each half containing 1 set 
of the DNA dilutions described above 
together with both negative 
controls. Both halves of the filter 
were washed twice for 3 0 min in 0.1 
x SSC, 0.1% (w/v) SDS, one at a
temperature of 40°C, the other at 
65°C. An autoradiograph obtained 
after 24 hr exposure of each half of 
the nitrocellulose filter is shown 
opposite. Asterisks show the 
positions of hybrid signals noted in 
the original autoradiograph but 
which are not obvious in this 
photograph. Arrows E and H indicate 
the positions of lOjug each of E.coli 
and human DNA respectively.
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parallel at 60°C. All other experimental conditions 
remained standard with the exception that the 
nitrocellulose filters were exposed for 24 hr to either 
Kodak autoradiography film or Amersham hyperfilm MP. The 
hybrid signals obtained at equivalent dilutions of the 
target DNA were similar irrespective of which 
autoradiography film had been used. Kodak film was chosen 
for use in all subsequent hybridot assays because it was 
less expensive.
4.4.6 Detection of human DNA
In the experiment of Section 4.4.4, hybridization 
between the radiolabelled RNA transcripts and 10/xg each of 
E.coli and human DNA was not observed. Although this may 
be attributed to assay conditions of high stringency it is 
also possible that the E.coli and human DNA had not bound 
to the nitrocellulose paper and were therefore unavailable 
for hybridization. Therefore, a nitrocellulose filter 
containing 10/xg of human DNA was hybridized with 
radiolabelled nick-translated human DNA under experimental 
conditions identical to those of the RNA-DNA hybridot 
assay. Serial 1:10 dilutions of vector pGHBI DNA served as 
negative controls. The autoradiograph obtained after 72 hr 
exposure of the filter is shown in Figure 30. Human DNA 
was detected but no hybrid signal could be observed at any 
dilution of the plasmid DNA. Therefore, it was concluded 
that in the experiment of Section 4.4.4 human DNA had bound
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Figure 3 0 Detection of human DNA
The figure shows an 
autoradiograph obtained after 72 hr 
exposure of a nitrocellulose filter 
which contained lOjug of human DNA 
and serial 1 : 1 0 dilutions of vector 
pGHBI DNA from 800ng to 80fg. The 
filter was hybridized with 
labelled nick-translated human DNA 
in conditions identical to those of 
the RNA-DNA hybridot assay.
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to the nitrocellulose filter but assay conditions were 
stringent enough to prevent cross-hybridization to the RNA 
probe. Furthermore, the inability of the human DNA probe 
to hybridize to vector pGHBI sequences confirms the lack of 
homology between human DNA and the BamHI subclone (EHBI) of 
the Hindlll E fragment of HCMV AD169 (Ruger et al.. 1984).
4.4.7 Availability of the cRNA probe
Because the target DNA could be loaded on to any one 
of the 96 wells of the dot blot manifold over an area of
p .
135cm it was necessary to determine if there was equal 
availability of the cRNA probe at every position on the 
nitrocellulose filter. At equivalent dilutions of the 
target DNA an equal hybrid signal was observed irrespective 
of the position on the filter (Figure 31). The experiment 
was repeated and similar results obtained. Therefore, it 
was concluded that there was equal availability of the cRNA 
probe over the entire area of the nitrocellulose filter.
4.4.8 Reconstruction experiments
Prior to screening all post transplantation urine 
samples for HCMV by dot blot hybridization, reconstruction 
experiments were performed to assess the sensitivity and 
specificity of the hybridot assay when using whole virus 
preparations. The results obtained after 10 days of 
autoradiography are shown in Figure 3 2 and are summarized 
in Table 5.
Radiolabelled cRNA transcripts were able to detect DNA
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RNA-DNA hybridization: Availability
of the cRNA probe
Three sets of serial 1:10 
dilutions of vector pGHBI DNA from 
8 /xg to 80fg were prepared in 
parallel and bound to a 
nitrocellulose filter. One set of 
dilutions was placed in the middle 
of the filter while the other 2 were 
located at either end. The filter 
was hybridized with a cRNA probe 
input counts totalling 1.45 x 108 
cpm. An autoradiograph obtained 
after 1 hr exposure of the filter is 
shown here. Asterisks show the 
positions of hybrid signals noted in 
the original autoradiograph but 
which are not obvious in this 
photograph.
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Figure 32 RNA-DNA hybridization: The results
of a typical reconstruction experiment
One hundred microlitres of each 
virus stock was made up to 8ml and 
serially diluted 1 : 1 0 in urine obtained 
from a patient known to be seronegative 
for HCMV. The DNA was extracted and 
bound to a nitrocellulose filter which 
was then hybridized with a cRNA probe 
input counts totalling 9 . 5 x 10 cpm. 
An autoradiograph obtained after 10 days 
exposure of the filter is shown here. 
The location of each positive and 
negative control is given below.
1A to IF: Serial 1:10 dilutions of HCMV 
AD169 (stock V 6 ) from ^ 9 x 10 to ^ 9 x 
10 particles/7.2 ml.
2A to 2F: Serial 1:10 dilutions of HSV-1 
from 1 . 1  x 1 0 8 to 1 . 1  x 1 0 3 
particles/7.2 ml.
3A to 3F: Serial 1:10 dilutions of HCMV 
ADI69 (stock V7) from 1.8 x 108 to 1.8 x 
10 particles/7.2 ml.
4A to 4F: Serial 1:10 dilutions of HSV-2 
from 1.8 x 10 to 1.8 x 10 
particles/7.2 ml.
5A to 5F: Serial 1:10 dilutions of HCMV 
AD169 (stock V 8 ) from 4.3 x 108 to 4.3 x 
103 particles/7.2 ml.
6A to 6 F: Serial 1:10 dilutions of
uninfected Helu cells from 1.8 x I06 to 
1.8 x 101 cells/7.2 ml.
12A to 12H: Serial 1:10 dilutions of
vector pGHBI DNA from 800ng to 80fg.
Other controls included:-
1/xg of HSV-1 DNA (8A, 8 B)
1/Ltg of HSV-2 DNA (10A, 10B)
10/xg of E.coli DNA (8 D, 10D)
10/xg of human DNA (8F, 10F)
10/ig of ribosomal RNA (8H, 10H)
Asterisks show the positions of hybrid 
signals noted in the original 
autoradiograph but which are not obvious 
in this photograph.
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Table 5 Virus stocks
A table showing the titre and particle 
counts of all virus stocks used to 
simulate infected urine samples in 
reconstruction experiments. Also shown 
are estimates of the number of viral 
particles detected by the RNA-DNA 
hybridot assay after 10 days of 
autoradiography.
N.A. = not available
N.D. = not detected
* = after 24 hr of autoradiography
Particle counts were performed by Mr J. 
Aitken, Electron Microscopy Laboratory, 
Institute of Virology.
Virus pfu/ml
particles
/ml
Number of 
HCMV 
particle 
equivalents 
of DNA 
detected by 
hybridot assay 
(particles/7.2 ml)
HCMV
(stock V5)
2 x 105 4.4 x 109 3.9 x 105*
HCMV 1 
(stock V6)
.3 x 102 ^ 108 $9 x 102
HCMV
(stock V7)
1 x 105 2 x 109 1.8 x 105
HCMV
(stock V8)
5 x 104 4.8 x 109 4.3 x 104
HSV-1 5 x 107 1.2 x 109 N.D.
HSV-2 8 x 107 2.0 x 1010 N.D.
VZV N.A. 1.4 x 109 N.D.
extracted from all 3 stocks of HCMV AD169. In 2 of these 
stocks (V7 and V8) the sensitivity of the hybridot assay 
was similar with 1.8 x 105 and 4.3 x 104 viral particles/
7.2 ml of urine respectively being detected. In HCMV stock 
V6 no viral particles were detected by electron microscopy 
and must therefore have been at a concentration of 108/ml 
or less. Consequently, the lower limit of detection by dot 
blot hybridization could not have been greater than 9 x 102 
viral particles/7.2 ml of urine. No hybrid signal was 
detected in similar reconstruction experiments using HSV-1 
and HSV-2 although background noise was noted in positions 
2B, 2E and 4D. DNA extracted from uninfected Flow 2002 
cells was never detected by the hybridot assay. In a 
separate reconstruction experiment, 100/zl of a stock of VZV 
did not hybridize to the cRNA transcripts on 3 occasions of 
testing (Figure 33).
The ability of the cRNA probe to detect non-infectious 
HCMV particles was also established. In 2 stocks of HCMV 
ADI69 (V8 and V6) the number of viral particles detected by 
the hybridot assay was 1 and 2 logs1Q respectively greater than 
the number of pfus. This suggests the presence of non- 
infectious viral particles which contained a DNA core that 
provided a target for the radiolabelled cRNA transcripts.
The cRNA probe did not hybridize to 10/xg of ribosomal 
RNA or lOjLtg each of E.coli and human DNA. One microgram of 
HSV-1 DNA also remained undetectable although 1/Ltg of HSV-2 
DNA hybridized to the radiolabelled RNA transcripts to give
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Figure 3 3 RNA-DNA hybridization: VZV reconstruction
experiment
One hundred microlitres of a stock of VZV 
was made up to 7.2ml in urine. The DNA was 
extracted and then loaded on to a 
nitrocellulose filter which was hybridized 
with a cRNA probe input counts totalling 
3.57 x 108/cpm. An a utor adlograph 
obtained after 10 days exposure of the 
nitrocellulose filter is shown here. The 
location of all positive and negative 
controls is given below.
1A: 80pg of vector pGHBI DNA
IB to 1G: Serial 1:10 dilutions of HCMV
AD169 (stock V8) from 4.32 x 108 to 4.32 x 
103 particles/7.2 ml of urine.
1H: 8pg of vector pGHBI DNA
2A: uninfected urine
2B: lOjLtg of human DNA
2C: 10/xg of E.coli DNA
2D: VZV reconstruction experiment (1.43 
x 108 particles in 7.2ml of urine)
2E: 10/ig of HSV-2 DNA
2F to 2H: urine samples from a 
allograft recipient.
renal
Asterisks show the positions of hybrid 
signals noted in the original 
autoradiograph but which are not obvious 
in this photograph.
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a signal equivalent to that observed with 8pg of vector 
pGHBI DNA.
In a separate experiment (Figure 34), the RNA 
transcripts were shown to hybridize to vector pGEM2 DNA, 
lOng of the latter giving a hybrid signal equivalent to 
that observed with 8pg of vector pGHBI DNA.
4.4.9 Precipitation of HCMV from the urine bv PEG 6000
An attempt was made to improve the sensitivity of the 
hybridot assay by adding PEG 6000 to HCMV-infected urine in 
reconstruction experiments. At equivalent dilutions of 
HCMV AD169 (stock V5) , the hybrid signals observed were 
similar irrespective of whether PEG 6000 had been added to 
the urine (Figure 35) . Furthermore, the addition of PEG 
6000 did not improve the lower limit of detection of HCMV 
with 3.9 x 105 particles/7.2 ml of urine being detected in 
reconstruction experiments prepared both in the presence 
and absence of PEG 6000.
4.4.10 Urinary DNase
The presence of DNase in urine samples may digest any 
viral DNA available for binding to the nitrocellulose 
filter and therefore decrease the sensitivity of the 
hybridot assay. Therefore, reconstruction experiments were 
prepared and the results of a representative hybridot assay 
are shown in Figure 3 6A.
In the absence of an incubation step, the hybrid 
signals observed were marginally improved when equivalent
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Figure 34 RNA-DNA hybridization: Detection of vector
PGEM2 DNA
DNA from vectors pGHBI and pGEM2 
was serially diluted 1:10 from 800ng to 
80fg and from l^g to lpg respectively. 
The DNA was loaded on to a 
nitrocellulose filter which was 
hybridized with a cRNA probe input 
counts totalling 2.8 x 108 cpm. An
autoradiograph obtained after 24 hr 
exposure of the filter is shown here. 
Asterisks show the position of hybrid 
signals noted in the original 
autoradiograph but which are not obvious 
in this photograph.
100 ng
10 ng
LLI
$ l  100 pg
10 pg
. 8 0 0  ng
80 ng
8 0 0  pg
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Figure 3 5 RNA-DNA hybridization: PEG 6000
precipitation of HCMV from the urine
HCMV ADI 69 (stock V5) was 
serially diluted 1:10 from 3.96 x 
10 to 3.96 x 102 particles /7.2 
ml of urine. 0.2 volumes of 40%
(w/v) PEG 6000 were added and the 
virus precipitated (Lane 3) . A 
duplicate set of dilutions without 
PEG 6000 was prepared in parallel 
(Lane 2) . DNA was extracted and 
loaded on to a nitrocellulose 
filter which was hybridized with a 
cRNA probe input counts totalling 
108 cpm. An autoradiograph 
obtained after 24 hr exposure of 
the filter is shown here. Serial 
1:10 dilutions of vector pGHBI DNA 
from 8/ig to 800fg provided a. set 
of reference standards (Lane 1). 
Asterisks show the positions of 
hybrid signals noted in the 
original autoradiograph but which 
are not obvious in this 
photograph.
+ shows the positions of non-specific 
background signals.
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RNA-DNA hybridization: Urinary DNase
activity
Serial 1:10 dilutions of vector 
pGHBI DNA from 8/xg to 800fg were 
prepared in urine and incubated
overnight at 21°C. The DNA was then 
denatured and loaded on to a 
nitrocellulose filter (Lane 1) . 
Controls included replicate dilutions of 
vector pGHBI DNA in urine (Lane 2) or 
sterile distilled water (Lane 3) but 
without a prior incubation step. The
filter was hybridized with a
radiolabelled cRNA probe and subjected 
to autoradiography for 1 hr. Asterisks 
show the positions of hybrid signals 
noted in the original autoradiograph but 
which are not obvious in this
photograph. Dots were also counted for 
^2P in a liquid scintillation counter 
and the results are shown in Figure 3 6B.
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dilutions of the target DNA were prepared in sterile water 
than in urine but the lower limit of detection of cDNA was 
the same in both experiments. However, when vector pGHBI 
DNA was diluted in urine and incubated overnight at 21°C 
the hybrid signal at each dilution was reduced compared to 
the respective controls and the sensitivity of the hybridot 
assay was decreased by 1 log1Q.
Dots were also counted for 32P in a liquid 
scintillation counter and the results of this and a 
duplicate experiment are shown in Figure 36B. When 
dilutions of vector pGHBI DNA from 800ng to 800pg were 
incubated overnight in urine, the hybrid signals detected 
were less than those observed for equivalent dilutions 
prepared in sterile water or in urine without a prior 
incubation step. For all other dilutions of vector pGHBI 
DNA, the cpm of 32P detected on the nitrocellulose filter 
were similar at equivalent dilutions of the target DNA 
irrespective of the experimental conditions.
One hundred microlitres of HCMV AD169 (stock V8) was 
made up to 8ml and serially diluted 1:10 in urine. After 
overnight incubation at 37°C, DNA was extracted, denatured 
and loaded on to a nitrocellulose filter. A duplicate set 
of dilutions prepared in the absence of an incubation step 
served as the control. Preincubation of the virus reduced 
the lower limit of detection by hybridot assay from 4.8 x 
105 to 4.8 x 107 particles/7.2 ml of urine (Figure 37A) . 
This experiment was not repeated.
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Figure 36B RNA-DNA hybridization: Urinary DNase
activity
After autoradiography, dots were cut 
from the nitrocellulose filter described 
in Figure 36A and counted for 32P in a 
liquid scintillation counter. The graph 
opposite shows the cpm of 32P detected 
after dilution of the target DNA in 
urine followed by overnight incubation 
at 21°C (o) or after dilution in sterile 
distilled water ( □) or urine without a 
prior incubation step ( A ). The results 
of duplicate experiments are also shown 
( • , ■ and A respectively) .
Lines are drawn through the average of 2 
counts at each DNA dilution.
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Figure 37A RNA-DNA hybridization: Addition of
human and E.coli DNA to HCMV DNA
Serial 1:10 dilutions of vector pGHBI DNA 
from 800ng to 80fg.
1A to 1H: DNA dilutions alone
3A to 3H: DNA dilutions to each of which 
were added 10/xg of E.coli DNA
5A to 5H: DNA dilutions to each of which
were added 10/xg of human DNA
Serial 1:10 dilutions of HCMV AD169 
(stock V8) from 4.8 x 108 to 4.8 x 103 
particles/7.2 ml of urine. The DNA was 
then extracted and loaded as follows:
7A to 7F: DNA dilutions alone
8A to 8F: DNA dilutions to each of which 
were added 10/xg of E.coli DNA
9A to 9F: DNA dilutions to each of which
were added 10/xg of human DNA
10A to 10F: Serial 1:10 dilutions of HCMV 
ADI69 (stock V8) from 4.8 x 108 to 4.8 x 
103 particles/7.2 ml of urine and 
incubated overnight at 37°C prior to DNA 
extraction.
The following controls were included:-
7.2ml of normal urine: 4A, 4B
7.2ml of normal urine incubated
overnight at 37°C: 10G
10/xg of HSV-1 17 syn+ DNA: 4C
10/xg of HSV-2 HG52 DNA: 4D
10/xg of human DNA: 6A, 6B
10/xg of E.coli DNA: 6C, 6D
10/xg of ribosomal RNA: 6E, 6F
100/xl of a stock of uninfected Helu
cells: 6G, 6H
100/xl of a stock of HSV-1 17 syn+ :7G,7H 
100/xl of a stock of HSV-2 HG52: 8G, 8H 
1/xg of HSV-1 17 syn+ DNA: 9G 
1/xg of HSV-2 HG52 DNA: 9H
Autoradiography was for 3 days.
Asterisks show the positions of hybrid 
signals noted in the original 
autoradiograph but which are not obvious 
in this photograph.
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4.4.11 Addition of human and E.coli DNA to HCMV DNA in
reconstruction experiments 
Human or E.coli DNA extracted from urine specimens may 
bind to the nitrocellulose filter and decrease the area 
available for the binding of virus-specific DNA. This in 
turn would reduce the sensitivity of the hybridot assay. 
To investigate this possibility reconstruction experiments 
were performed and the results of a typical hybridot assay 
are shown in Figure 37A. Although the lower limit of 
detection of HCMV DNA was not diminished by the addition of 
human or E.coli DNA, the hybrid signals observed at 
equivalent dilutions of the target DNA increased in their 
absence. The addition of human DNA was more effective in 
reducing the hybrid signal than E.coli DNA.
Dots were also counted for 32P and the results of this 
and a duplicate experiment are shown in Figure 37B. At 
equivalent dilutions of HCMV DNA ranging from 800ng to 80 
pg, the hybrid signals detected were higher in the absence 
of human and E.coli DNA while the addition of human DNA 
reduced the hybrid signals below those observed after the 
addition of E.coli DNA. Between 8pg and 80fg of vector 
pGHBI DNA the hybrid signals varied independently of the 
experimental conditions.
4.4.12 Detection of HCMV isolates
An investigation was made into the ability of the 
radiolabelled cRNA probe to detect HCMV isolates other than 
strain AD169. Therefore, lOOjul were removed from stocks of
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RNA-DNA hybridization: Addition of human 
and E.coli DNA to HCMV DNA
After autoradiography, dots were cut 
from the nitrocellulose filter 
described in Figure 37A (Lanes 1A to 1H; 
3A to 3H; 5A to 5H) and counted for 32P 
in a liquid scintillation counter. The 
graph opposite shows the cpm of P 
detected at each dilution of vector 
pGHBI DNA after the addition of 10/xg of 
E.coli DNA ( A ) , 10/xg of human DNA (o)
or no other DNA ( □ ) . The results of 
duplicate experiments are also shown 
( A , • and ■ respectively) . Lines
are drawn through the average of 2 
counts at each DNA dilution.
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65 HCMV isolates cultured from urine samples or throat 
swabs provided by 18 renal allograft recipients (9 with 
primary HCMV infection and 9 with reinfection and/or 
reactivation). Each aliquot was added to 7.9ml of urine 
and the DNA extracted. Positive controls included 100/xl of 
stocks of HCMV strains AD169 and Davis while negative 
controls were equivalent volumes of stocks of HSV-1 17 syn+ 
and HSV-2 HG52 together with 10/xg each of human, HSV-1 17 
syn+ and HSV-2 HG52 DNA.
All HCMV isolates were positive in the hybridot assay 
while the negative controls remained undetectable.
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4.5 Isolation of HCMV
4.5.1 Specimens submitted for tissue culture
From March 1985 to December 1985, 490 urine samples
and 449 throat swabs were collected from 47 renal 
transplant recipients. Two hundred and nine (42.6%) of the 
urines and 193 (43%) of the throat swabs were obtained from 
22 patients who were seronegative for HCMV immediately 
prior to the transplant operation. Twenty five renal 
allograft recipients who were HCMV-seropositive prior to 
transplantation provided 281 (57.4%) and 256 (57%) of the
urines and throat swabs respectively.
Twenty two (4.5%) of the 490 urine samples originally 
submitted for tissue culture had to be reinoculated on to a 
newly prepared monolayer of Flow 2 002 cells. At the first 
attempt at virus isolation 4 cultures became contaminated 
by bacteria and 2 by fungi. A further 16 urine samples 
from 14 patients caused an unexplained cpe within 3 to 23 
days of incubation at 37°C. Only 1 (0.2%) of all throat
swabs had to be reinoculated and this was on account of an 
unexplained cpe which was recorded after 19 days of 
incubation at 37°C. No attempt was made to identify which 
virus, if any, with the exception of HCMV and HSV, was 
responsible for destruction of the cell monolayer on these 
occasions. When aliquots of these 22 specimens which had 
been stored at -70°C were reinoculated on to fresh 
monolayers no cpe was evident.
HSV was isolated from 6 urines and 13 throat swabs 
(Section 4.9). It was considered unlikely that HCMV could
Plaques obtained in tissue culture -from a throat swab of 
patient (c) at 14 weeks post transplantation were lost 
as a result of bacterial contamination and could only be 
identified as HCMV on the basis of tissue culture 
morphology.
also be isolated from these 19 specimens because HSV has a 
quicker replication cycle which results in destruction of 
the cell monolayer within a' few days of incubation at 37°C.
4.5.2 HCMV isolates
Ninety three viral isolates (83 from urine and 10 from 
throat swabs) were initially identified as HCMV on the 
basis of plaque morphology. Of these, 69 (64 from urine
and 5 from throat swabs) grew well enough to allow 
subculturing and positive identification. A further 2 
isolates (1 from urine and 1 from a throat swab) were lost 
as a result of bacterial contamination of the cell 
monolayer. Attempts to reisolate these 2 viruses from the 
original specimens which.had been stored at -70°C proved to 
be unsuccessful.
The remaining 22 plaques (18 from urine and 4 from
throat swabs) progressed slowly and could only be 
identified as HCMV by morphology in the original cell 
monolayer (Figures 39A and B) . Ten of these cpes were
observed after culture of the urine taken from 7 patients 
(b,c,d,e,g,h,i) with primary HCMV infection while a further 
8 were obtained from the urine of 6 individuals
(l,n,o,t,u,w) with reinfection aiid/or reactivation. The
remaining 4 plaques not positively identified as HCMV were 
cultured from throat swabs provided by 3 patients (d,f,i) 
each with primary HCMV infection. ★
Of the 9 individuals (a,b,c,d,e,f,g,h,i) with primary
2
HCMV infection from whom the virus was isolated only 1 (d) 
consistently shed HCMV which was identified solely on the 
basis of plaque morphology. In contrast, of the 40 plaques
cultured from the urine of patients (a) , (b) , (c) , (e) ,
(f) / (9) / (h) and (i) only 7 (17.5%) were not positively
identified as HCMV, 1 each from patients (b) , (e) , (g) ,
(h) , (i) and 2 from patient (c) . All 6 isolates cultured
from the urine of patient (f) and both viruses isolated 
from the throat of patient (c) could be subcultured and 
identified as HCMV. Six plaques were obtained in tissue
culture from throat swabs of patients (a) , (c) , (f) , (i)
(c)z (f) and (i) 
but 3 , one each from patients
progress sufficiently to allow positive identification.
Of the 39 plaques obtained after culturing the urine 
of 12 patients (l,m,n,o,p,q,r,s,t,u,v,w) with reinfection 
and/or reactivation, 8 could not be successfully 
subcultured. These 8 cpes originated from the urine of 6 
individuals, one from each of patients (1), (n), (t) , (u) , 
and (z) and 2 from each of patients (o) and (w) . One of
the 3 plaques cultured from the urine of patient (n) and 2
of the 3 cpes originating from the urine of patients (o) 
and (w) could not be successfully subcultured. Four
plaques were isolated from the urine of patient (u) but 1 
did not grow well enough to permit positive identification. 
Throughout the period of study, only 1 urine sample 
provided by each of patients (1) and (t) yielded a cpe in
culture and both were classified as HCMV by plaque
morphology. Four patients (m,p,r,v) consistently shed HCMV
y  failed to
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which could be subcultured and positively identified.
Plaques were first noted after an average of 2 6 days 
in culture [range 7 to 54] (Figure 38A) . Of those 22 
plaques not positively identified as HCMV, 7 were first 
noted within 12 to 26 days of incubation while the 
remaining 15 were initially observed after 29 to 53 days in 
culture. Four of the 6 isolates cultured from throat swabs 
were first detected in tissue culture after an incubation 
period of 31 to 41 days while the remaining 2 viruses 
showed a cpe after 14 and 25 days of culture respectively. 
Multiple HCMV isolates obtained from any one individual 
also differed in the time taken to produce plaques in 
vitro. For example, of the first 5 isolates cultured from 
the urine of patient (f) , a cpe was initially observed 
after 26, 7,8, 3 0 and 9 days of incubation respectively.
No correlation was observed between the isolation of 
virus which could not be positively identified and the time 
after transplantation when the corresponding throat swab or 
urine sample was taken (Figure 38B). For example, of the 8 
plaques originating from the urine of patient (h), the only 
one which failed to subculture was isolated from a sample 
taken at 33 weeks post transplantation. In contrast, 2 
cpes not positively identified as HCMV originated from 2 
independent urine samples provided by patient (c) at 4 and 
5 weeks respectively after renal transplantation. Five 
subsequent urines taken from this patient at regular 
intervals up to 28 weeks after the transplant operation
4
Figure 38A Timing of HCMV plague formation
The figure shows the number of days 
taken for a cpe to be observed in 
each of 87 cultures at 37°C. 
Viruses which were subcultured and 
positively identified as HCMV are 
denoted by □ or 0 when isolated 
from a urine sample or throat swab 
respectively. Plaques which were 
classified as HCMV on the basis of 
morphology in the original cell 
monolayer are indicated by ■ 
Specimens are grouped according to 
numerical accession order.
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Figure 38B Timing of HCMV plaque formation
The figure shows the correlation 
between the number of days in culture at 
37°C after which cpe was first observed 
and the weeks post transplantation when 
the original specimen was submitted.
The following symbols are used:-
□ : A urine yielding a virus positively
identified as HCMV
A : A throat swab yielding a virus
positively identified as HCMV
■ : A urine or throat swab which
yielded a cpe classified as HCMV only on
the basis of plaque morphology in the
original cell monolayer.
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yielded virus which was subcultured and positively 
identified as HCMV.
4.5.3 Timing of HCMV shedding post renal transplantation
(a) Primary infection
Forty four (40.7%) of 108 urine samples and 8 (7.8%)
of 102 throat swabs provided by 11 patients with primary 
infection yielded HCMV in tissue culture (Figure 39A).
The earliest detection of HCMV shedding was in a urine 
taken from patient (c) at 4 weeks post transplantation. By 
14 weeks after the transplant operation HCMV had been 
isolated from the urine of 8 renal allograft recipients 
(b,c,d,e,f,g,h,i) . Patients (c) , (d) , (e) , (g) , (h) , (i)
shed HCMV intermittently while virus was consistently 
isolated from all urine samples provided by patients (b) 
and (f) on or after the seventh and fifth week respectively 
post transplantation. Only 2 urine samples were ever 
obtained from patient (a) who developed acute tubular 
necrosis and anuria immediately post transplantation. 
Similarly acute rejection of the renal allograft prevented 
patient (j) from providing urine samples beyond the seventh 
week after the transplant operation.
Throat swabs obtained from 5 patients (a,c,d,f,i) 
between 6 and 12 weeks post transplantation yielded HCMV in 
tissue culture. HCMV could not be isolated from any of the 
20 throat swabs taken beyond the nineteenth week after the 
transplant operation though 16 of the 2 6 urine samples 
obtained during the same period yielded the virus in tissue
5
Figure 39A HCMV shedding post renal transplant­
ation: Primary infection
The figure shows urine 
samples ( — ^—  ) and throat
swabs ( — ) provided by 10
renal allograft recipients (a to 
j) who had evidence of primary 
HCMV infection post
transplantation. Urine samples 
and throat swabs which yielded 
HCMV in tissue culture are denoted 
by — ■—  and — B—  
respectively. Asterisks indicate 
those cpes which were identified 
as HCMV only on the basis of 
plaque morphology in the original 
cell monolayer. One patient (k) 
who had serological evidence of 
primary HCMV infection at 59 weeks 
post transplantation is omitted 
from the diagram.
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culture. The onset of HCMV isolation from the throat was 
coincident with (i) or followed (c,d,f) but in no case 
preceded excretion of the virus in the urine.
(b) Reinfection and/or reactivation
HCMV was isolated from 12 of the 2 0 patients in this 
group (Figure 39B). Virus was first detected in a urine 
provided by patient (w) 2 weeks after the transplant
operation. By 14 weeks, HCMV had been isolated from the 
urine of 9 other individuals (m,n,o,p,q,r,t,u,v) while HCMV 
shedding by patient (1) was first noted in a urine sample 
taken at 18 weeks post transplantation. Ten patients 
(l,m,n,o,p,q,t,u,v,w) shed HCMV intermittently while there 
was consistent isolation of virus from urine specimens 
provided by patient (r) between 4 and 27 weeks after the 
transplant operation. No urinary isolates were obtained 
from patient (s) but HCMV was detected in a throat swab 
taken at 11 weeks post transplantation. HCMV was only 
isolated from the throat of patient (s) on a single 
occasion n  weeks after the transplant operation. HCMV was 
never cultured from any specimen provided by 9 other 
individuals who had serological evidence of reinfection 
and/or reactivation.
HCMV-seropositive patients who receive their kidney 
from a seronegative donor usually shed endogenous HCMV 
which has reactivated from a latent state post-operatively. 
However, HCMV-seropositive renal allograft recipients of 
kidneys from HCMV-seropositive donors are also at risk of
6
Figure 39B HCMV shedding post transplantation: 
Reinfection and/or reactivation
The figure shows urine
samples ( — 1=1—  ) and throat
swabs ( — n—  ) provided by 12
renal allograft recipients (1 to 
w) with reinfection and/or 
reactivation of HCMV and from whom 
virus was isolated. Urine samples
and throat swabs which yielded 
HCMV in tissue culture are denoted 
by — ■—  and — a—  
respectively. Asterisks indicate 
those cpes identified as HCMV only 
on the basis of plaque morphology in 
the original cell monolayer.
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reinfection with another strain of HCMV from within the 
transplanted kidney (Chou, 1986). In this project the 
frequency and pattern of virus shedding by each HCMV- 
seropositive allograft recipient independent of
the HCMV serostatus of the renal donor. Five (l,m,s,t,u) 
of the 12 patients from whom HCMV was isolated each 
received their kidney from donors known to be seropositive 
for HCMV while 4 (n,p,r,v) were each transplanted with a
kidney from an HCMV- seronegative donor. Similarly, 4 renal 
donors who were seropositive for HCMV and 3 who were 
seronegative provided kidneys for 7 renal allograft 
recipients with serological evidence of post 
transplantation HCMV infection but from whom virus was 
never isolated. No sera were available from those 
individuals who donated kidneys for 4 other renal 
transplant recipients including patients (o),(q) and (w).
4.5.4 Urinary 6 2 microglobulin levels
Between 10 and 17 weeks post transplantation HCMV was 
isolated from 16 of the 21 urine samples provided by 8 
patients (b,c ,d ,e ,f ,g ,h ,i) with primary HCMV infection 
(Figure 39A ) . During the same period 46 urine samples were 
obtained from 2 0 transplant recipients with evidence of 
reinfection and/or reactivation but HCMV was isolated from 
only 14 (32.5%) urines provided by 7 patients
(m,n,p,q,r,u,v) (Figure 39B). An investigation was made 
into the possibility that low levels of urinary >02lri maY 
have accounted for the inability to isolate HCMV from the
7
urine of some patients who showed a fourfold or greater 
rise in HCMV-specific CF antibody after renal 
transplantation. It was not possible to measure ^ 2m levels 
in all urine samples from all renal allograft recipients. 
Therefore, /?2m was estimated in only 1 urine sample 
obtained from each of 4 0 patients (Figure 4 0A) . The £ 2m 
level in each urine was estimated by reference to a 
standard curve drawn from the results obtained when using 
known standard controls (Figure 4OB). Each urine sample 
was tested only once but the results of known amounts of 
/?2m analysed in duplicate confirm that there was good 
intra-assay reproducibility.
In each group of patients with primary, secondary or 
no HCMV infection, levels ranged from 7 x 101/ig/litre to
greater than or equal to 4 x 10 jizg/1 itre. Only 3 urines in 
each of the 3 groups of patients had a /32m level which was 
below the limit of normal (1.6 x 102/xg/litre) . Of the 8 
patients with primary HCMV infection, virus could be 
isolated from 7 urine samples in which /32m was measured and 
found to range from 7 x 10 /zg/litre to greater than or equal 
to 4 x 103/xg/litre. HCMV was not isolated from the urine 
of patient (d) at 12 weeks post transplantation when the 
urinary /?2m level was 8 x 101/zg/litre. Of those patients 
with reinfection and/or reactivation of HCMV, virus could 
not be isolated from 13 of the 16 urine samples in which 
was measured though only 2, one each from patients (m) 
and (ss) at 17 and 10 weeks respectively post
8
Figure 40A Urinary # 2 microglobulin levels post
renal transplantation
The figure shows the level in each
of 4 0 urine samples obtained between 10 
and 17 weeks post transplantation. One 
urine was provided by each of 8 renal 
allograft recipients (b,c,d,e,f,g,h,i) 
with primary HCMV infection, 16
(l,m,n,o,p,r,s,t,w/x,y,z,qq/ss,tt,uu) 
with reinfection and/or reactivation and 
16 (aa,bb,cc,dd,ee,ff,gg,hh,ii,j j ,kk,11, 
mm,nn,oo,pp) with no evidence of active 
HCMV infection.
The following symbols are used:-
• - virus isolated from this specimen
▲ - virus not isolated from this 
specimen but other urine samples 
obtained from the same patient did 
yield HCMV in tissue culture
O - virus not isolated from this 
specimen or any other urine 
samples provided by the same 
patient.
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Figure 40B B2 microglobulin calibration curve
Six known concentrations of /?2m 
ranging from 0 to 4 x 10 /xg/litre of 
urine were tested by RIA. The standard 
curve was obtained by plotting the /?2m 
concentration of each standard against 
B/T%, the percentage of the total (T)
^  I-labelled /32m bound (B) to beads 
coated withanti— /32m antibody. The 
results of duplicate experiments ( o  and 
• ) performed in parallel are shown and 
lines are drawn through the average 2 
values at each concentration of /?2m.
The (32m concentration in each clinical 
urine specimen was determined from the 
curve.
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transplantation, had a /32m level below the limit of normal. 
However, HCMV was isolated from the urine of patient (n) at 
13 weeks post transplantation when the level of /32m was 7 x 
lO-^ /xg/ litre.
In conclusion therefore, it was not possible to 
explain on the basis of low urinary /?2m levels the 
inability to isolate HCMV from the urine of all patients 
with serological evidence of recent infection.
4.5.5 Correlation between virus isolation and the results 
of dot blot hybridization
The results of a typical RNA-DNA hybridot assay are 
shown in Figure 41. Of the 490 urine samples submitted for 
tissue culture, 445 (91%) were analysed by dot blot
hybridization. Twenty (25%) of the 80 urine samples which 
yielded HCMV in tissue culture were positive by dot blot 
hybridization, 16 (20%) equivocal and 44 (55%) clearly
negative. HCMV could not be isolated from 365 urine 
samples of which 244 (67%) were negative by dot blot
hybridization, 52 (14%) equivocal and 69 (19%) clearly
positive. Indeed, of the 94 urine samples obtained from 10 
patients who remained seronegative for HCMV throughout the 
period of study, 66 (70%) were negative by dot blot
hybridization but 11 (12%) were equivocal and 17 (18%)
clearly positive. HCMV could not be isolated from 79 
samples provided by 8 patients who had serological evidence 
of reinfection and/or reactivation of HCMV. Of these, 52 
(66%) were negative, 9 (11%) equivocal and 18 (23%)
9
Figure 41 A typical RNA-DNA hvbridot assay
IB to IF: Serial 1:10 dilutions of HCMV
AD169 (stock V8) from 4.8 x 108 to
4-8 x 104 particles/7.2ml of
urine.
12A to 12E: Serial 1:10 dilutions of
vector pGHBI DNA from 800pg to 80fg
Additional controls include
7.2ml of normal urine : 2A, 6D, 11G
10/xg of human DNA : 2B, 5C, 12F
10/xg of E.coli DNA : 2C, 5D, 12G
10/xg of ribosomal RNA : 2D, 5E, 12H
10/xg of HSV-2 DNA : 2E, 6C, 11A
80pg of vector pGHBI DNA: 1A
8pg of vector pGHBI DNA: 1H
800fg of vector pGHBI DNA: 6E
All other positions are occupied by 
clinical specimens.
Autoradiography was for 10 days.
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positive by dot blot hybridization.
HSV was isolated from 6 urine specimens provided by 3 
renal transplant recipients. Five of these urines obtained 
from 2 patients were negative for HCMV by dot blot 
hybridization. Not enough urine was available from the 
third patient to permit analysis by hybridot assay.
Eighty five urine samples provided by 8 renal 
allograft recipients (b,c,d,e,f,g,h,i) with primary HCMV 
infection were tested for HCMV-specific sequences by RNA- 
DNA hybridization (Figure 42A). HCMV was isolated from 43 
of these specimens, 13 (30%) of which were positive for
HCMV by hybridot assay while 9 (21%) were equivocal and 21 
(49%) were negative. HCMV could not be isolated from 42 
other samples of which 6 (14%) were positive, 6 (14%)
equivocal and 3 0 (72%) negative by RNA-DNA hybridization.
There was good correlation between the results of virus 
isolation and those of the hybridot assay in patient (h) 
but not in patients (b) , (c) , (d) , (e) , (f), (g) and (i)
who collectively provided 2 6 urine samples in which HCMV 
was positively identified by isolation and subculture. Of 
these, 3 were positive, 6 equivocal and 17 negative by dot 
blot hybridization. A urine obtained from patient (c) at 1 
week after the transplant operation was the first post 
transplantation urine specimen to be recorded as positive 
for HCMV by RNA-DNA hybridization although no virus was 
isolated. Four weeks later 2 other renal allograft 
recipients (e and g) each provided a urine sample from 
which HCMV could not be cultured but which were regarded as
10
Figure 42A Correlation between detection of HCMV in
urine samples bv tissue culture and RNA~ 
DNA hybridization: Primary HCMV infection
The figure shows those urine 
samples provided by 8 renal allograft 
recipients (b,c,d,e,f,g,h,i) with 
primary HCMV infection. Specimens which 
yielded HCMV in tissue culture are 
differentiated from those which did not 
by the symbols — ■—  and — n—
respectively. Asterisks indicate those 
cpes which were identified as HCMV only 
on the basis of plaque morphology in the 
original cell monolayer. Whenever 
possible each urine was tested for HCMV 
DNA by dot blot hybridization using the 
^ P - l a b e l l e d  cRNA probe described in 
Sections 4.3 and 4.4. The results of 
this assay ( — ^—  negative; — ^—
equivocal; — ^—  positive) were
correlated with those of HCMV isolation.
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positive for the virus by hybridot assay. In patients (b), 
(d) and (i) , the first urine to be classified as positive 
for HCMV by dot blot hybridization was taken at 13, 47 and 
19 weeks respectively post transplantation. No urine 
provided by patient (f) was ever positive for HCMV by RNA- 
DNA hybridization although 2 of the 5 specimens which 
yielded the virus in tissue culture were equivocal. A 
urine obtained from patient (h) immediately pretransplant 
appeared positive for HCMV in the hybridot assay while a 
specimen taken 4 weeks later was negative. In patients 
(b) , (d) and (i) , the onset of HCMV isolation preceded the
first detection of the virus by RNA-DNA hybridization by 6, 
41 and 10 weeks respectively, while in patients (c) , (e)
and (g) a positive result in the hybridot assay was 
recorded between 3 and 9 weeks prior to the onset of HCMV 
isolation.
Also tested for HCMV by hybridot assay were 117 urine 
specimens obtained from 12 renal allograft recipients (1, 
m,n,o,p,q,r,s,t,u,v,w) with reinfection and/or reactivation 
of HCMV who shed the virus post-operatively (Figure 42B) . 
HCMV was isolated and positively identified in 29 of these 
urines of which 6 (21%) were positive, 7 (24%) equivocal
and 16 (55%) negative by RNA-DNA hybridization. Eight
other urinary isolates were identified as HCMV on the basis 
of plaque morphology in the original cell monolayer. When 
the respective urine samples were tested in the hybridot 
assay only 1, that provided by patient (t) at 3 weeks post
11
Figure 42B Correlation between detection of HCMV in 
urine samples bv tissue culture and RNA- 
DNA hybridization: Reinfection and/or 
reactivation
The figure shows those urine samples 
provided by 12 renal allograft recipients 
(l,m,n,o,p,q,r,s,t,u,v,w) with reinfection 
and/or reactivation of HCMV who shed the 
virus post-operatively. Urinary isolates 
were obtained from all patients with the 
exception of (s) from whom HCMV was 
isolated in a throat swab taken at 11 
weeks after the transplant operation. 
Urine specimens which yielded HCMV in 
tissue culture are differentiated from 
those which did not by the symbols — ■—  
and — 1=1—  respectively. Asterisks 
indicate those cpes which were identified 
as HCMV only on the basis of plaque 
morphology in the original cell monolayer. 
Whenever possible, all specimens were 
tested for HCMV DNA by dot blot 
hybridization using the 32P-labelled cRNA 
probe described in Sections 4.3 and 4.4. 
The results of this assay ( —
negative; — ^—  equivocal; — g—  
positive) are correlated with those of 
HCMV isolation.
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transplantation, was positive. Of the 80 urine samples 
which did not yield HCMV in tissue culture, 12 (15%) were
positive by dot blot hybridization while 15 (19%) were
equivocal and 53 (66%) negative. RNA-DNA hybridization 
could not positively detect HCMV-specific sequences in any 
urine obtained from patients (1), (o) , (r) and (w)
throughout the post transplant period although 16 HCMV 
isolates were identified in tissue culture. Furthermore, in 
these 4 renal allograft recipients virus was isolated from 
only 2 of 8 other urine specimens which were equivocal for 
HCMV by dot blot hybridization. Patients (m) , (q) and (u)
provided 1 urine sample at 6, 4 and 11 weeks respectively 
post transplantation each of which was positive for HCMV in 
the hybridot assay but none yielded the virus in tissue 
culture. In patients (n), (p), (q), (t) and (v), the first
post transplantation urine specimen to be classified as 
positive for HCMV by RNA-DNA hybridization was taken at 13, 
5, 4, 1 and 5 weeks respectively after the transplant
operation but virus was isolated from only 2 specimens, 1 
from each of patients (n) and (v) . The onset of HCMV 
isolation in patients (m) and (n) preceded a positive 
reaction in the hybridot assay by 1 week while patients 
(P) t (<3) / (t) and (u ) first showed evidence of a positive 
reaction by dot hybridization in urine samples taken 
between 2 and 10 weeks prior to first isolation of HCMV. 
In patient (v) , the onset of HCMV isolation from the urine 
at 5 weeks post transplantation coincided with the first 
positive result in the hybridot assay. No urinary isolates
12
were obtained from patient (s) who shed HCMV in the throat 
at 11 weeks after the transplant operation and who remained 
equivocal for HCMV by RNA-DNA hybridization in 5 urine 
specimens provided between 5 and 15 weeks post-operatively.
4.6 HCMV-specific CF antibody titres
4.6.1 Specificitv
Prior to the measurement of the HCMV CF antibody titre 
in all serum samples, an investigation was made into the 
possibility of cross reaction between HCMV CF antigen and 
HSV or VZV antigens. Therefore, a number of sera were 
simultaneously tested for CF antibody to HCMV, HSV and VZV, 
but no cross reaction was noted (Figure 43).
4.6.2 Timing of the fourfold or greater rise in HCMV CF
antibody titre post renal transplantation
Ten (a,b,c,d,e,f,g,h,i,j) of the 11 renal allograft 
recipients with primary HCMV infection showed a fourfold or 
greater rise in the HCMV CF antibody titre between 3 and 14 
weeks post transplantation while 1 patient (k) had a 
eightfold rise in the HCMV CF antibody titre between 40 and 
59 weeks after the transplant operation (Figure 44).
Of the 18 patients with reinfection and/or 
reactivation of HCMV who had a fourfold or greater rise in 
the HCMV CF antibody titre, virus was isolated from 10 
(l,m,n,o,p,q,r,s,t,u). No significant difference was noted 
between shedders and non-shedders of HCMV in the timing of
13
Figure 43 Correlation between the HCMV, HSV and 
VZV CF antibody titres
Figure A shows the correlation between 
the HCMV and HSV CF antibody titres in 
75 sera, 1 each of which was provided by 
28 renal donors and 47 renal allograft 
recipients immediately pretransplant. 
Seventy three of these sera were also 
assayed for VZV CF antibody and the 
titres are correlated with those of HCMV , 
in Figure B. All tests were performed 
in parallel using identical reagents 
with the exception of the respective CF 
antigens.
Spearman rank correlation
Figure A 0.293 (p > 0.01)
Figure B 0.139 (p > 0.01)
Spearman rank correlations were kindly 
provided by Dr G.D. Murray, Medical 
Statistics Unit, Western Infirmary, 
Glasgow.
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Figure 44 Timing of the fourfold or greater rise in 
HCMV CF antibody titre after renal 
transplantation
The figure shows the timing of the 
fourfold or greater rise in HCMV CF 
antibody titre in 11 patients (a to k) 
with primary infection and 18 (l,m,n,o,p, 
q,r,s,t,u,x,y,z,qq,rr,ss,t t ,uu) with 
reinfection and/or reactivation of HCMV 
after renal transplantation. Each bar 
identifies the time interval between 
consecutive serum samples the last of 
which showed the fourfold or greater rise 
in HCMV CF antibody titre. ■ and □ 
differentiate patients from whom virus 
was isolated and not isolated 
respectively.
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this rise in CF antibody titre post renal transplantation.
In 17 renal allograft recipients with reinfection and/or 
reactivation of HCMV (m,n,o,p,q,r,s,t,u,x,y,z, aa, bb, cc, 
dd, ee) , the fourfold or greater rise in HCMV CF antibody 
titre was recorded up to 16 weeks after the transplant 
operation and in 1 individual (1) between 18 and 2 5 weeks 
post transplantation.
4.6.3 Changing levels of HCMV CF antibody post renal 
transplantation 
Figure 45 shows the post transplantation HCMV CF 
antibody titres in each of 10 patients 
(a,b,c,d,e,f,g,h,i,j ) with primary infection. The rise in 
HCMV CF antibody titres was very abrupt, 1 patient showing 
an increase in titre from less than 1:2 to greater than or 
equal to 1:1024 over a 2 week period. However, once the CF 
antibody titre had reached a plateau it was maintained with 
minimal fluctuation for at least between 35 and 53 weeks 
after the transplant operation in the 9 patients 
(b,c,d,e,f,g,h,i,j) with primary HCMV infection whose CF 
antibody levels were regularly monitored for this period of 
time.
4.7 Post transplantation levels of HCMV-IgG measured bv 
Labsvstems ELISA
4.7.1 Reproducibility
To assess inter-assay variation in the measurement of 
HCMV-specific IgG, 191 serum samples were each subjected to
14
Figure 45 Post transplantation HCMV CF antibody
titres in patients with primary infection
The figure shows the post 
transplantation HCMV CF antibody titres in 
each of 10 renal allograft recipients (a 
to j) with primary HCMV infection. 
Patient (k) who showed an eightfold 
increase in HCMV CF antibody at 59 weeks 
post transplantation is omitted from the 
diagram.
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testing in 2 batches of the Labsystems ELISA. The results 
are shown in Figure 46.
On reanalysis of 79 sera initially classified as 
negative for HCMV-IgG, 1 serum was found to be positive 
while 18 sera each had an HCMV-IgG antibody level in the 
equivocal zone. The remaining 60 sera were confirmed to be 
negative for HCMV-IgG. When 109 sera which were regarded as 
positive for HCMV-IgG were retested, the HCMV serostatus 
was confirmed in 104 while the other 5 sera were each found 
to have an HCMV-IgG level in the equivocal zone. 
Confirmation of the antibody level was obtained in each of 
the 3 sera initially classified as equivocal for HCMV-IgG.
Taken overall, the average variation in the ELISA 
value of the 191 sera was 13.2 EIU (range 0 to 62.0). Of 
the 80 sera in which HCMV-IgG was negative or equivocal, 
the ELISA value varied by an average of 5.96 EIU (range 0 
to 16.7). The average variation in the ELISA value of 111 
sera classified as positive for HCMV-IgG was 18.4 EIU 
(range 0.1 to 62.0).
15
Figure 46 Reproducibility of HCMV-IaG levels 
measured bv Labsystems ELISA
One hundred and ninety one sera 
provided by 47 renal allograft recipients 
and 7 renal donors were tested for HCMV- 
IgG by Labsystems ELISA. The HCMV-IgG 
level in each serum is denoted by a symbol 
unique to a particular batch of the ELISA 
(°r • , A / A / ♦ / v , T and ■
respectively). The variation in the level 
of HCMV-IgG within each serum tested in 2 
batches of the ELISA is represented by a 
solid vertical line.
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4.7.2 Correlation between HCMV-IgG levels measured bv 
Labsystems ELISA and HSV and VZV CF antibody titres
An investigation was made into the possibility of HSV 
and VZV antibodies being detected by the Labsystems HCMV- 
IgG ELISA. Sera obtained immediately pretransplant from 
each of 47 renal allograft recipients and 26 renal donors 
were tested in parallel for HSV and VZV CF antibodies as 
described in Section 4.6.1. Titres were correlated with 
HCMV-IgG levels measured by Labsystems ELISA and the 
results are shown in Figure 47. No correlation was 
observed between HCMV-IgG levels and HSV or VZV CF antibody 
titres.
4.7.3 Correlation between HCMV-IgG levels measured bv 
Labsystems ELISA and HCMV CF antibody titres
The sera described in Section 4.7.2 were also tested 
in parallel for HCMV CF antibody and the results correlated 
with the HCMV-IgG level (Figure 48).
There was a wide scatter in HCMV-IgG levels amongst
sera with equivalent HCMV CF antibody titres of > 1:8.
However, HCMV-IgG levels measured by Labsystems ELISA and 
HCMV CF antibody titres correlated significantly overall, 
the Spearman rank correlation being 0.891 (p < 0.01).
All 38 sera with an HCMV CF antibody titre of less
than 1:2 were negative for HCMV-IgG on the first occasion
of testing. Of the 22 sera which were reanalysed, 18 were 
confirmed to be negative for HCMV-IgG while 4 others had an 
HCMV-IgG level ranging from 10.3 to 11.9 EIU. However,
16
Figure 4 7 Correlation between HCMV-IgG levels 
measured bv Labsystems ELISA and HSV and 
VZV CF antibody titres
Seventy three sera provided by 2 6 renal 
donors and 47 renal allograft recipients 
immediately pretransplant were tested in 
parallel for HSV and VZV CF antibody. 
All reagents were identical with the 
exception of the respective CF antigen. 
Results are correlated with the level of 
HCMV-IgG measured in various batches of 
the Labsystems ELISA (O • A a  O  ♦  v ▼ 
and ■ respectively).
HCMV-IgG EIU Spearman rank correlation 
with
HSV CF antibody
titre 0.289 (p > 0.01)
VZV CF antibody
titre 0.135 (p > 0.01)
Spearman rank correlations were kindly 
provided by Dr G.D. Murray, Medical 
Statistics Unit, Western Infirmary, 
Glasgow.
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Figure 48 Correlation between the level of HCMV-IgG 
measured bv Labsystems ELISA and the 
respective HCMV CF antibody titre
Sera provided by each of 2 6 renal 
donors and 47 renal allograft recipients 
immediately pretransplant were tested in 
parallel for HCMV CF antibody. Titres 
were correlated with the respective level 
of HCMV-IgG measured by Labsystems ELISA. 
The HCMV-IgG level in each serum is 
denoted by a symbol unique to a particular 
batch of the ELISA (O, •,  A ,  * , < > , ♦ ,  
v , ▼ and ■ respectively) . Fifty
four sera were each tested in 2 batches of 
the ELISA and the variation in the level 
of HCMV-IgG is represented by a solid 
vertical line. A further 19 sera were 
tested for HCMV-IgG on only 1 occasion. 
Spearman rank correlation = 0.891 (p < 
0.01).
The Spearman rank correlation 
was kindly provided by Dr G.D. Murray, 
Medical Statistics Unit, Western 
Infirmary, Glasgow.
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when these 4 sera were retested for a third time all were 
found to be negative for HCMV-IgG.
A total of 35 sera, one each of which was provided by
10 renal donors and 25 renal allograft recipients
immediately pretransplant, were confirmed to have HCMV CF 
antibody titres ranging from 1:4 to greater than or equal 
to 1:1024. Of these, 31 sera were positive and 4 equivocal 
when first tested for HCMV-IgG by Labsystems ELISA. 
Reanalysis confirmed 29 sera to be positive for HCMV-IgG 
while 5 had levels ranging from 13.2 to 15.8 EIU and 1
serum was negative for HCMV-IgG. Two of the 5 sera 
regarded as equivocal for HCMV-IgG were also equivocal on 
the first occasion of testing and subsequent analysis. A 
third serum .from a renal donor who provided a kidney for 
patient (s) had an HCMV CF antibody titre of 1:16 on 2
occasions of testing and was equivocal for HCMV-IgG in 2 
batches of the ELISA. Sera obtained from each of patients 
(y) and (ss) immediately before the transplant operation 
had reproducible HCMV CF antibody titres of 1:32 and were 
also positive for HCMV-IgG when first tested by ELISA. On 
the second occasion of testing, the HCMV-IgG level in the 
serum provided by patient (y) was 15.8 EIU and retesting 
confirmed it to be equivocal for HCMV-IgG. The 
pretransplant serum obtained from patient (ss) was retested 
for HCMV-IgG on 3 more occasions and was considered to be 
equivocal once and negative twice. A sixth serum sample 
with an HCMV CF antibody titre of 1:8 was initially
17
regarded as equivocal for HCMV-IgG but when retested the 
HCMV-IgG level was found to be 6.2 3 EIU.
4.7.4 Correlation between the HCMV-IcrG serostatus 
determined bv NBL ELISA and the HCMV CF antibody titre 
Seventy two of the 73 sera whose HCMV antibody levels 
were determined by CFT were also analyzed for HCMV-IgG by 
NBL ELISA. Sixty four sera were each tested in 2 different 
batches of the ELISA while 7 were examined only once. A 
serum obtained from patient (uu) immediately pretransplant 
was overlooked and not analysed by NBL ELISA.
Of those sera with an HCMV CF antibody titre of less 
than 1:2 which were provided by 16 renal donors and 22 
renal allograft recipients immediately before the 
transplant operation, all 38 were confirmed to be negative 
for HCMV-IgG by NBL ELISA.
Ten renal donors were consistently positive for HCMV 
CF antibody and 7 of these were also positive for HCMV-IgG 
in the NBL ELISA. Sera obtained from 3 other renal donors 
had reproducible HCMV CF antibody titres ranging from 1:8 
to 1:16 but were considered to be negative for HCMV-IgG 
when tested in 2 different batches of the NBL ELISA.
Sera provided by 24 renal allograft recipients 
immediately before the transplant operation were positive 
for HCMV CF antibody. Twenty two of these sera were 
confirmed positive and 2 negative for HCMV-IgG on 2 
occasions of testing in varied batches of the NBL ELISA.
18
4.7.5 Analysis of 7 sera with uncertain levels of HCMV
antibody
Of the 73 sera whose HCMV CF antibody titres were 
correlated with HCMV-IgG levels measured by Labsystems 
ELISA, 72 were also examined by the NBL HCMV-IgG ELISA. 
Concordant results were obtained for 65 sera, 27 being 
seropositive and 38 seronegative by each method of 
analysis. Discordant : results were found in 7 sera which 
are described in more detail below.
Three renal donors each provided sera which were 
positive for HCMV CF antibody but negative for HCMV-IgG 
when tested in 2 batches of the NBL ELISA. On reanalysis 
by Labsystems ELISA, 1 serum with an HCMV CF antibody titre 
of 1:16 was consistently positive for HCMV-IgG while 
another serum with an HCMV CF antibody titre of 1:8 had 
HCMV-IgG levels of 6.2 and 10.2 EIU on each occasion of 
testing. Both these sera were obtained from renal donors 
whose kidneys were transplanted into 2 recipients each of 
whom developed a primary HCMV infection post-operatively. 
Such findings are suggestive of both renal donors having 
prior exposure to the virus. Serum obtained from a third 
renal donor had an HCMV CF antibody titre of 1:16 but was 
equivocal for HCMV-IgG in each of 3 batches of the 
Labsystems ELISA. This renal donor provided a kidney for 
patient (s) whose pretransplantation HCMV serostatus is 
discussed below.
Four other sera, one each of which was provided by 
patients (1), (s), (y) and (ss) immediately prior to renal
19
transplantation, also had uncertain levels of HCMV-specific 
antibody. The sera obtained from patients (1) and (y) each 
had a reproducible HCMV CF antibody titre of 1:32 and were 
positive for HCMV-IgG when twice tested by NBL ELISA. 
Reanalysis by Labsystems ELISA found the serum from patient 
(1) to be equivocal for HCMV-IgG while the serum from 
patient (y) had an HCMV-IgG level of 14.9, 15.8 and 25.0
EIU on each occasion of testing. Patient (s) provided a 
serum with an HCMV CF antibody titre of 1:4 which was 
negative for HCMV-IgG in 2 batches of the NBL ELISA and 
equivocal on 3 occasions of testing by Labsystems HCMV-IgG 
ELISA. The pretransplant serum from patient (ss) had a 
reproducible HCMV CF antibody titre of 1:32 but was 
negative for HCMV-IgG when twice analysed by NBL ELISA. 
Reexamination in 4 batches of the Labsystems ELISA found 
the HCMV-IgG level to be 3.5, 7.2, 13.2 and 21.8 EIU on
each occasion of testing.
As discussed in Section 4.5.3(b), there was consistent 
inability to isolate HCMV from the urine of some renal 
allograft recipients who showed evidence of an HCMV- 
specif ic humoral response after the transplant operation. 
This group of renal transplant recipients, which includes 
patients (s) (y) and (ss), were generally considered to
have reinfection and/or reactivation of HCMV rather than 
primary infection. Indeed, the post transplantation HCMV- 
IgG response in each of patients (s) and (y) was typical of 
reinfection and/or reactivation of the virus with levels
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falling by the end of the first year after the transplant 
operation (Figure 59B). Patient (ss) would have been most 
unlikely to have developed a primary HCMV infection because 
the transplanted kidney was donated by an individual 
confirmed to be seronegative for HCMV. Furthermore, this 
patient's post transplantation HCMV-IgM response was 
negligible and atypical of primary infection (Figure 59B). 
In patient (1) , HCMV was isolated from only 1 urine sample 
and this together with the absence of rising levels of 
HCMV-IgM and IgG after the transplant operation were 
features consistent with reinfection and/or reactivation of 
virus (Figure 59B).
4.7.6 Kinetics of the post transplantation HCMV-IgG 
response
Ten renal allograft recipients (a,b,c,d,e,f,g,h,i,j) 
with primary HCMV infection each showed an increase in 
HCMV-IgG during the first year post transplantation while 
an HCMV-IgG response in patient (k) was first noted in a 
serum obtained at 69 weeks post transplantation (Figure 
49A) . Similarly, 18 (m,n,o,p,q,r,s,t,u,v,w,x,y,z,qq,rr,ss, 
uu) of the 20 renal allograft recipients with reinfection 
and/or reactivation of HCMV showed a significant increase 
in HCMV-IgG which peaked between 8 and 14 weeks after the 
transplant operation (Figure 49B).
Because of the large number of sera involved it was 
not possible to retest all sera from all patients. 
Therefore, confirmation of the post transplantation HCMV-
21
Figure 49A Post transplantation levels of HCMV-IgG
measured bv Labsystems ELISA: Primary
infection
The figure shows the levels of HCMV-IgG 
between 0 and 7 6 weeks post 
transplantation in each of 11 renal 
allograft recipients (a to k) with 
primary HCMV infection.
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Figure 49B Post transplantation levels of HCMV-IgG
measured bv Labsystems E L I S A :
Reinfection and/or reactivation
The figure shows the levels of HCMV-IgG 
between 0 and 77 weeks post 
transplantation in each of 20 renal 
allograft recipients (l,m,n,o,p,q,r,s,t, 
u,v,w,x,y,z ,qq,rr,s s ,t t ,uu) with
reinfection and/or reactivation of HCMV.
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IgG response in patients with primary and secondary HCMV 
infection was obtained by reanalysis of 2 sera taken from 
each patient, 1 between 6 and 14 weeks after the transplant 
operation and another obtained as near as possible to the 
fifty second week post transplantation. To reduce error 
attributable to inter-assay variation, sera were retested 
in parallel within the same batch of the HCMV-IgG ELISA. 
Whenever possible, levels of HCMV-IgG were compared with 
those previously recorded in another batch of the ELISA 
(Figures 50A, B and C).
(a) Primary HCMV infection
In 10 patients (a,b ,c ,d , e ,f ,g,h,i, j ) the level of 
HCMV-IgG between 8 and 14 weeks after the transplant 
operation was an average of 22.3 EIU (range 4.0 to 73.1) 
higher than observed immediately pretransplant. HCMV was 
isolated from all patients with the exception of 1 (j)
whose HCMV-IgG level had increased by an average of 32.2 
EIU (range 25.2 to 39.2) by the eleventh week post 
transplantation. Between 35 and 53 weeks after the 
transplant operation, sera were available from 9 patients 
(b,c,d,e,f,g,h,i,j). By this time post transplantation, 
levels of HCMV-IgG had risen above the pretransplant value 
by an average of 51.8 EIU (range 29.1 to 101.7) and in 
patient (j) by 94.9 EIU (range 88.1 to 101.7). In 8 (b,c, 
d /^,f,g,h,j) of the 9 patients for whom sufficient data are 
available, there was an average increase in HCMV-IgG of 
28.9 EIU (range - 3.2 to 62.7) from between 6 and 14 weeks
22
Figure 50A Change in post transplantation levels of
HCMV-IgG measured bv Labsystems ELISA
Between 8 and 14 weeks post
transplantation, a serum sample was taken 
from each of 10 renal allograft recipients 
(a,b,c,d,e,f,g,h,i,j) with primary HCMV 
infection while 20 patients
(l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,qq,rr,ss, 
tt,uu) with reinfection and/or 
reactivation provided a serum sample 
between 6 and 14 weeks after the
transplant operation. Serum was obtained
between 11 and 17 weeks post 
transplantation from each of 11 renal 
allograft recipients (bb,cc,dd,ee,ff,gg,
ii,jj,kk,mm,oo) with no evidence of active 
- HCMV infection. All sera were tested for 
HCMV-IgG by Labsystems ELISA. The 
magnitude of the HCMV-IgG response in each 
patient was then calculated by reference 
to the pretransplant HCMV-IgG level, a 
negative value indicating a fall in HCMV- 
IgG. Sera were initially tested in 1 of 9 
different batches of the Labsystems ELISA 
( • / O )  and whenever possible retested in 
parallel within a single batch of the 
ELISA ( ■ / □ ) .  The variation in the 
magnitude of the HCMV-IgG response when 
measured in 2 batches of the Labsystems 
ELISA is represented by a solid vertical 
line. ( • / ■ )  or ( O / □ ) differentiate 
sera obtained from those renal allograft 
recipients who shed or did not shed HCMV 
respectively. Within each group of 
patients ^ indicates the average change in 
the level of HCMV-IgG above that recorded 
immediately pretransplant. Five renal 
allograft recipients with no evidence of 
active HCMV infection and patient (k) who 
first showed serological evidence of HCMV 
infection at 59 weeks post transplantation 
were omitted from this correlation.
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Figure 50B Change in post transplantation levels of
HCMV-IaG measured bv Labsystems ELISA
Nine renal allograft recipients 
(b,c,d,e,f,g,h,i,j) with primary HCMV 
infection each provided a serum sample 
between 35 and 53 weeks after the 
transplant operation. A serum sample 
was also obtained between 21 and 60 
weeks post transplantation from all 20 
patients (l,m,n,o,p,q,r,s,t,u,v,w,x,y,z, 
qq,rr,ss,tt,uu) with reinfection and/or 
reactivation. Between 31 and 61 weeks 
post transplantation, serum was taken 
from 11 (bb,cc,dd,ee,ff,gg,ii,jj,kk,mm, 
oo) of the 16 renal allograft recipients 
with no evidence of active HCMV 
infection. The procedure for testing 
and reporting the HCMV-IgG level in each 
serum was as described in Figure 50A.
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Figure 50C Change in post transplantation levels of
HCMV-IgG measured bv Labsystems ELISA
Nine renal allograft recipients (b,c,d, 
e,f,g,h,i,j) with primary HCMV infection 
each provided 2 serum samples, 1 between 
8 and 14 weeks and another between 3 5 
and 53 weeks post transplantation. 
Similarly 2 sera, 1 taken between 6 and 
14 weeks and another between 21 and 60 
weeks after the transplant operation, 
were obtained from each of 2 0 patients 
(l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,qq,rr,ss, 
tt,uu) with reinfection and/or 
reactivation. The HCMV-IgG level in 
each serum was measured in 2 batches of 
the Labsystems ELISA and an average 
value calculated. Only that serum 
provided by patient (i) at 13 weeks post 
transplantation was tested in a single 
batch of the ELISA. The difference 
between the average HCMV-IgG level in 
the 2 sera taken from each patient is 
indicated by a solid line • and O
differentiate those renal allograft 
recipients from whom HCMV was isolated 
and not isolated respectively.
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up to the end of the first year after renal 
transplantation, a negative value indicating a fall in IgG.
Between 9 and 44 weeks after the transplant operation, 
patient (g) showed a progressive increase in HCMV-IgG from 
1.3 to 43.6 EIU, a level which was maintained with minimal 
fluctuation for at least 51 weeks post transplantation 
(Figure 59A). The HCMV-IgG response in patient (c) peaked 
at 78.7 EIU 8 weeks after the transplant operation and then 
declined to 25.8 EIU by 14 weeks post transplantation. 
Thereafter, the HCMV-IgG level did not change significantly 
until it increased to 72.2 EIU at 43 weeks after the 
transplant operation. The next recorded serum sample taken 
from this patient at 52 weeks post transplantation showed 
an HCMV-IgG level of 73.7 EIU. In patient (d), there was a 
gradual increase in the level of HCMV-IgG from 3.23 to 51.3 
EIU between 7 and 12 weeks post transplantation. The HCMV- 
IgG level then decreased to 37.5 EIU at 19 weeks after the 
transplant operation but did not fluctuate significantly 
thereafter. In patient (e), the level of HCMV-IgG increased 
by 22.7 EIU between 3 and 5 weeks post transplantation and 
did not alter significantly until 28 weeks after the 
transplant operation when the level of HCMV-IgG had 
increased by 23.2 EIU beyond that recorded in the preceding 
serum sample taken at 14 weeks post transplantation. 
Thereafter the HCMV-IgG response did not change 
significantly. HCMV-IgG in patient (j) gradually increased 
from 6.25 to 47.6 EIU between 4 and 13 weeks post
23
transplantation and did not fluctuate significantly until 
an HCMV-IgG level of 99.4 EIU was noted at 31 weeks after 
the transplant operation. The last recorded serum sample 
taken from this patient at 3 5 weeks post transplantation 
showed the HCMV-IgG level to be 108.0 EIU. In patients 
(a), (b) , (f) and (i) , there was a gap of 63,32,23 and 29
weeks respectively between 2 consecutive serum samples and 
therefore it was not possible to comment on the pattern of 
the HCMV-IgG response in these renal allograft recipients 
although in each patient the level of HCMV-IgG had 
increased during the period of observation.
(b) Reinfection and/or reactivation
Eighteen patients (m,n,o,p,q,r,s,t,u,v,w,x,y,z,qq,rr, 
ss, uu) showed a significant increase in HCMV-IgG with the 
highest levels being recorded in sera obtained between 6 
and 14 weeks after the transplant operation. By this time 
post transplantation, HCMV-IgG had increased by an average 
of 55.2 EIU (range -2.9 to 126.2). Between 21 and 60 weeks 
after the transplant operation, the HCMV-IgG level was an 
average of 24.2 EIU (range -19.3 to 72.5) higher than that 
observed immediately pretransplant although in 3 patients 
(l,tt,uu) HCMV-IgG had approximated pretransplant levels 
while in 2 others (o and v) HCMV-IgG showed an average fall 
of 14.5 and 19.3 EIU respectively below that recorded 
immediately pretransplant.
From between 6 and 14 weeks to between 21 and 60 weeks 
post transplantation, HCMV-IgG decreased by an average of 
31.0 EIU (range -6.6 to 66.2), 1 patient (ss) showing an
24
increase in HCMV-IgG of 6.6 EIU (range 3.6 to 9.6).
Change in HCMV-IgG levels post transplantation could 
not differentiate those renal allograft recipients who shed 
HCMV from those who did not. Within 6 to 14 weeks after 
the transplant operation the HCMV-IgG level had increased 
by an average of 58.7 EIU (range -8.3 to 137.1) in the 12 
patients (l,m,n,o,p,q,r,s,t,u,v,w) from whom the virus was 
isolated. During the same period, 8 patients (x,y,z ,qq,rr, 
ss, tt, uu) from whom HCMV was never isolated showed an 
average increase in HCMV-IgG of 49.6 EIU (range 10.8 to 
87.7) above that recorded immediately pretransplant. 
Between 21 and 60 weeks post transplantation, the HCMV-IgG 
level was an average of 22.5 EIU (range -21.5 to 79.7) or
26.5 EIU (range -4.5 to 49.2) above the pretransplant value 
in those renal allograft recipients who shed or did not 
shed HCMV respectively. In the 12 patients from whom virus 
was isolated, the level of HCMV-IgG decreased by an average 
of 3 6.4 EIU (range 0.85 to 66.2) from between 6 and 14 
weeks to between 21 and 60 weeks post transplantation. 
During the same period, the HCMV-IgG level decreased by an 
average of 22.9 EIU (range -6.6 to 39.5) in the 8 patients 
from whom HCMV was never isolated.
The HCMV serological status of the renal donors did 
not influence the HCMV-IgG response in those renal 
allograft recipients with reinfection and/or reactivation 
of the virus. Between 6 and 14 weeks after the transplant 
operation, the 8 patients (1,m,s,t ,x ,y ,u ,qq) who each
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received their kidney from donors known to be seropositive 
for HCMV showed an average increase in HCMV-IgG of 63.7 EIU 
(range -5.35 to 126.2) above that recorded immediately 
pretransplant. During the same period, HCMV-IgG had risen 
above the pretransplant level by an average of 49.1 EIU 
(range 11.7 to 77.2) in the 8 renal allograft recipients 
(n,p,r,v,z,rr,ss,tt) who were each transplanted with a 
kidney from an HCMV-seronegative donor. Between 21 and 60 
weeks post transplantation, the level of HCMV-IgG was an 
average of 35.1 EIU (range -2.7 to 72.5) or 22.6 EIU (range 
-19.3 to 44.5) higher than that observed immediately 
pretransplant in those patients who received their kidney 
from donors known to be seropositive or seronegative for 
HCMV respectively. Levels of HCMV-IgG decreased by an 
average of 29.0 EIU (range 0.85 to 55.2) from between 6 and 
14 weeks to between 21 and 60 weeks post transplantation in 
the 8 patients who were each transplanted with a kidney 
from an HCMV-seropositive donor while during the same 
period HCMV-IgG fell by an average of 2 6.2 EIU (range -6.6 
to 57.8) in the 8 renal allograft recipients who each 
received their kidney from donors known to be seronegative 
for HCMV. The donor serological status was not available 
for 4 other renal allograft recipients (o,q,w,uu) who 
showed evidence of reinfection and/or reactivation.
Figure 59B shows the post transplantation levels of 
HCMV-IgG in each of the 20 renal allograft recipients with 
reinfection and/or reactivation. Eighteen patients (m,n,o, 
p,q,r,s,t,u,v,w,x,y,z,qq,rr,ss,uu) developed a significant
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HCMV-IgG response the onset of which was first recorded up 
to 14 weeks after the transplant operation. A serum 
provided by patient (ss) at 4 weeks post transplantation 
was the first to show a significant increase in HCMV-IgG. 
Within 8 weeks of the transplant operation, the HCMV-IgG 
level had significantly increased in 10 other renal 
allograft recipients (m, n, p , s , t , v, w, y , qq, r r ) . By the 
twelfth week post transplantation, a further 6 patients 
(o, r , u , x , z , uu) had developed a significant increase in 
HCMV-IgG the precise onset of which is uncertain because of 
the time interval between consecutive serum samples. No 
serum was available from patient (q) until 14 weeks post 
transplantation when the HCMV-IgG level had increased by
35.6 EIU.
HCMV-IgG levels in patients (m,n,o,p,q,r,s,t,u,v,w,x, 
y /z ,q q ,rr,ss,uu) peaked between 6 and 14 weeks post 
transplantation and declined gradually thereafter. In 
patient (z) , the HCMV-IgG level decreased by 21.5 EIU below 
the pretransplant level before showing a significant 
increase at 9 weeks after the transplant operation. 
Pretransplant levels of HCMV-IgG were approximated at 25, 
23, 27, 26 and 32 weeks post transplantation in patients
(°)/ (q)/ (u), (v) and (uu) respectively. At 32 weeks after
the transplant operation, the HCMV-IgG level in patient (v) 
fell by 23.1 EIU below that recorded immediately 
pretransplant. However, sera taken from patients 
(m,n,p,r,s,t,w,x,y,z,qq, rr,ss) between 21 and 77 weeks
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post transplantation continued to show a significant 
increase in HCMV-IgG ranging from 21.5 to 79.7 EIU above 
the pretransplant level.
(c) No active HCMV infection
In the 11 renal allograft recipients (bb,cc,dd,ee,ff, 
gg,ii,jj,kk,mm,oo) for whom sufficient data are available, 
the level of HCMV-IgG in sera obtained between 11 and 17 
weeks post transplantation was an average of 3.89 EIU 
(range -14.1 to 22.7) lower than that recorded immediately 
pretransplant. By 31 to 61 weeks after the transplant 
operation, HCMV-IgG had fallen by an average of 4.75 EIU 
(range -14.7 to 32.6) below the pretransplant level. In 
patient (kk) who was seropositive for HCMV prior to renal 
transplantation, virus-specific IgG dropped below the 
pretransplant level by 20.6 and 32.6 EIU at 13 and 55 weeks 
respectively post transplantation. Patient (oo), who was 
also seropositive for HCMV pre-operatively, provided sera at 
16 and 51 weeks after the transplant operation when the 
HCMV-IgG level was noted to be 22.7 and 23.6 EIU 
respectively below that recorded immediately pretransplant.
4.8 Post transplantation levels of HCMV-IaM measured bv
Labsvstems ELISA
4.8.1 Specificity
HCMV-IgM levels in the sera of 14 renal donors and 47 
renal allograft recipients immediately pretransplant were 
compared with the respective HSV and VZV CF antibody titres 
measured in parallel as described in Section 4.6.1.
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Fourteen renal donors whose HCMV CF antibody titres were 
less than 1:2 were not tested for HCMV-IgM. Insufficient 
serum prevented the measurement of HCMV-IgM in 1 donor who 
was seropositive HCMV. One other donor was tested for 
HCMV-IgM and CF antibodies to HCMV and HSV but not VZV. 
The results are shown in Figure 51.
All of the 61 sera tested were negative for HCMV-IgM, 
the maximum recorded level being 19 EIU in a serum sample 
whose HSV and VZV CF antibody titres were 1:64 and 1:16 
respectively. No correlation was observed between the CF 
antibody titres and the respective HCMV-IgM level.
4.8.2 Cross reaction with heterophile agglutinins
In this study, pretransplant sera from 44 of the 47 
renal allograft recipients were tested for heterophile 
agglutinins and all were found to be negative . Of the 3 
patients whose pretransplant sera were not tested for 
heterophile antibodies, 1 (aa) remained seronegative for 
HCMV throughout the period of observation and 2 (a,j) had
evidence of primary HCMV infection.
An investigation was also made into the possibility 
that post transplantation levels of HCMV-IgM measured by 
Labsystems ELISA may be unduly elevated as a result of 
cross reaction with heterotypic antibodies. In each 
patient with a positive or equivocal HCMV-IgM response only 
1 serum, that with the highest HCMV-IgM level post 
transplantation, was tested and found to be negative for 
heterotypic antibody.
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Figure 51 Correlation between HCMV-IaM levels 
’ measured bv Labsvstems ELISA and the 
respective HSV and VZV CF antibody titres
Sixty sera provided by 13 renal donors 
and 47 renal allograft recipients 
immediately pretransplant were tested in 
parallel for HSV and VZV CF antibody. 
All reagents were identical with the 
exception of the respective CF antigen. 
Serum taken from another renal donor was 
tested for HSV but not VZV CF antibody. 
Results are correlated with the 
respective HCMV-IgM levels measured in 
various batches of the Labsystems ELISA 
(0 # a a 0 ^ v v b ).
HCMV-IgM EIU Spearman rank correlation
with
HSV CF antibody
titre 0.161 (p > 0.01)
VZV CF antibody
titre 0.147 (p > 0.01)
Spearman rank correlations were kindly 
provided by Dr G.D. Murray, Medical 
Statistics Unit, Western Infirmary, 
Glasgow.
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4.8.3 Correlation between HCMV-IcrM levels measured by
Labsvstems ELISA and IgM-RF titres 
In this study, 74 sera from 21 renal allograft 
recipients (a,c,d,e,f,h,i,j,n,q,r,s,v,w,x,y,z,qq,rr,tt,uu) 
were each tested for RF by latex-slide agglutination and 27 
(38%) from 7 patients (c,d,f,i ,j ,v,tt) were positive. A 
further 2 sera, one each from patients (i) and (z) , were 
equivocal for RF. Because this is a qualitative test and 
non-specific reactions can occur due to, for example, 
hyperlipidaemia, a quantitative assessment of IgM-RF levels 
was undertaken. The number of samples precluded the 
testing of IgM-RF in all HCMV-IgM positive sera and 
therefore only 44 of the 74 sera positive for HCMV-IgM were 
submitted for measurement of the IgM-RF level. The 44 sera 
were provided by 20 renal allograft recipients 
(a,c,d,e,f,h,i,j,n,q,r,s,v,w,x,y,z ,qq,tt,uu) and, whenever 
possible, samples showing the highest level of HCMV-IgM 
within each individual were chosen. Only 2 sera from 1 
patient (d) had levels of IgM-RF higher than the normal 
limit. Of the 43 sera tested for RF by latex-slide 
agglutination and IgM-RF by ELISA, 24 (54%) from 16
individuals (a,c ,e ,f ,h ,i ,n ,q , r ,s ,w , x ,y ,z ,qq,uu) were 
considered to be negative by both methods of analysis. A 
further 18 sera (37%) from 6 renal allograft recipients 
(c,d,i,j,v,tt) were found to be positive for RF by latex- 
slide agglutination but only 2 (4.6%) from patient (d) had 
levels of IgM-RF above the upper limit of normal. One 
serum from patient (i) which was equivocal for RF by latex-
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slide agglutination had an IgM-RF level of 175 U/ml.
The temporal relationship between changes in post 
transplantation levels of IgM-RF and HCMV-IgM was assessed 
in each of 8 patients, 3 (c,d,i) with primary HCMV
infection, 3 (r,t,qq) with reinfection and/or reactivation 
and 2 (cc,mm) who remained seronegative for HCMV throughout 
the post transplant period. All sera obtained from these 8 
renal allograft recipients were simultaneously tested for 
IgM-RF and HCMV-IgM thereby allowing inter- and intra­
patient comparisons to be made between antibody - levels. 
Furthermore, patients (c) and (t) were transplanted on the 
same day with a kidney obtained from the same renal donor. 
The same is also true for patients (i and qq) and (r and 
mm) .
In patients (c) and (d) , a significant increase in 
IgM-RF levels had occurred by the eighth week after the 
transplant operation, no such rise being evident in 
previous samples obtained up to 5 and 7 weeks respectively 
post transplantation (Figure 52). IgM-RF levels in 
patients (c) and (d) continued to increase until 11 and 10 
weeks respectively post transplantation after which they 
decreased, approximating pretransplant levels at 52 and 39 
weeks respectively after the transplant operation. Patient
(c) also showed rising levels of IgM-RF with a maximum 
titre of 310 U/ml being recorded in a serum provided at 8 
weeks post transplantation. By 10 weeks after the 
transplant operation IgM-RF had decreased to 175 U/ml, a
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Figure 52 Correlation between post transplantation
levels of" HCMV-IgM. HCMV-IgG and IgM-RF
The figure shows the post transplantation 
levels of HCMV-IgM ( □ ) and HCMV-IgG ( 0) 
in each of 8 renal allograft recipients, 
3 (c,d,i) with primary HCMV infection, 3
(r,t,qq) with reinfection and/or 
reactivation and 2 (cc,mm) with no 
evidence of active HCMV infection. 
Results are correlated with IgM-RF levels 
( ■ ). The following scales are used:-
D : 20 EIU of HCMV-IgM
0. : 20 EIU of HCMV-IgG
> I : 200U/ml of IgM-RF
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level which was maintained with minimal fluctuation for at 
least 24 weeks post transplantation.
Of the 3 patients with reinfection and/or reactivation 
of HCMV, patient (qq) showed a significant increase in IgM- 
RF from less than 80 U/ml immediately pretransplant to 2 05 
U/ml at 5 weeks after the transplant operation. Thereafter, 
an IgM-RF level of approximately 12 0 U/ml was maintained 
from 11 to 21 weeks post transplantation while sera 
obtained at 46 and 59 weeks after the transplant operation 
showed the IgM-RF level to be 350 and 275 U/ml 
respectively. In patient (t) , only minor fluctuations in 
post transplantation levels of IgM-RF were recorded while 
sera from patient (r) were unavailable between 2 and 12 
weeks after the transplant operation during which time a 
significant increase in the IgM-RF level may have occurred.
Neither of the 2 patients (cc,mm) who remained 
seronegative for HCMV showed any significant increase in 
IgM-RF throughout the post transplant period.
Synchronous changes in post transplantation levels of 
IgM-RF and HCMV-IgM were noted in each of patients (c), (d)
and (qq) but not in patient (r) whose IgM-RF levels did not 
alter significantly throughout the post transplant period 
while levels of HCMV-IgM had increased and subsequently 
declined. Between 6 and 10 weeks after the transplant 
operation, IgM-RF and HCMV-IgM levels in patient (i) were 
seen to increase and then decrease in parallel. 
Thereafter, no significant change in the HCMV-IgM level was 
noted until a decrease of 29.5 EIU was recorded in a serum
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taken at 24 weeks post transplantation. During the same 
period IgM-RF levels did not change significantly.
Post transplantation levels of IgM-RF and HCMV-IgM 
measured by ELISA did not correlate with those of HCMV-IgG. 
For example, throughout the post transplant period, patients 
(i) and (qq) had equivalent levels of IgM-RF but HCMV-IgM 
was consistently higher in patient (i) who had lower levels 
of HCMV-IgG than those found in patient (qq).
In order to establish whether IgM-RF was complexing 
with HCMV-IgG and producing false positive results in the 
HCMV-IgM ELISA, 13 6 sera provided by 3 3 renal allograft 
recipients were each analysed for IgM-RF and the results 
correlated with the respective HCMV-IgM level. The results 
are shown in Figure 53. No correlation was observed 
between levels of IgM-RF and those of HCMV-IgM. For 
example, in all sera whose IgM-RF titre fell between 100 
and 200U/ml, HCMV-IgM levels ranged from 3.5 to 75.4 EIU. 
Furthermore, in 4 sera considered to be negative for HCMV- 
IgM (range 7.66 to 12.2 EIU), IgM-RF levels ranged from 650 
to 1000 EIU.
In a further attempt to determine whether IgM-RF 
present in serum samples would produce false positive 
reactions in the HCMV-IgM ELISA, reconstruction experiments 
were performed in which a known number of units of 
polyclonal RF were added to aliquots of a serum whose IgM- 
RF, HCMV-IgM and HCMV-IgG levels were < 80 U/ml, 6.08 EIU 
and 61.0 EIU respectively. This serum was selected because
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Figure 53 Correlation between post transplantation
levels of HCMV-IgM and IcrM-RF
In each of 13 6 sera provided by 33 
renal allograft recipients the HCMV-IgM 
level measured by Labsystems ELISA was 
correlated with the respective IgM-RF 
titre. Whenever possible a minimum of 3 
sera were obtained from each renal 
allograft recipient, one immediately 
pretransplant, another containing the 
highest recorded level of HCMV-IgM and a 
third taken near the end of the first year 
after renal transplantation. All sera 
were positive for HCMV-IgG by Labsystems 
ELISA. HCMV-IgM levels were measured in 
any 1 of 9 different batches of the 
Labsystems ELISA (O, • , A , ▲ , O  , ♦  , 
V , ▼ and ■ respectively).
IgM-RF levels were kindly provided by 
Mrs J. Veitch and Professor K. Whaley, 
Immunopathology Department, University 
of Glasgow.
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it was the only one known to be positive for HCMV-IgG but 
negative for HCMV-IgM and had undetectable (<80 U/ml) 
levels of IgM-RF. All sera were negative for HCMV-IgM and 
there was no correlation between the concentration of the 
polyclonal RF and the level of HCMV-IgM (Figure 54) . For 
each serum tested the intra-assay reproducibility in the 
level of HCMV-IgM was very good, the average variation in 
antibody levels being 2.28 EIU (range 0 to 6.81).
4.8.4 Correlation betweem HCMV-IgM levels measured bv 
Labsystems ELISA and rubella-specific IaM levels 
measured bv Abbott ELISA
RF causing false positive reactions in the Labsystems 
indirect HCMV-IgM ELISA may also be expected to produce 
falsely elevated IgM levels to any other infectious agent 
when similarly tested by indirect ELISA.
No correlation was noted between the HCMV-IgM level 
measured by Labsystems ELISA and the corresponding level of 
rubella-IgM tested by Abbott ELISA (Figure 55) . Thirty 
seven (97.3%) of the sera assayed were clearly negative for 
rubella-IgM although the HCMV-IgM level ranged from 1.51 to
105.1 EIU. The remaining serum, that from patient (b) at 
13 weeks post transplantation, had a level of rubella-IgM 
equivalent to the low positive control while the HCMV-IgM 
level was 38.3 EIU and no RF was detected by latex-slide 
agglutination.
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Figure 54 HCMV-IoM levels in serum to which poly­
clonal RF had been added
A serum with an IgM-RF, HCMV-IgM and 
HCMV-IgG level of < 80 U/ml, 6.08 EIU and
61.0 EIU respectively was divided into 
aliquots. Three preparations of
polyclonal RF at a starting concentration 
of 15000 U/ml ( • ) , 4400 U/ml ( ▲ ) or
2600 U/ml ( ■ ) were added to separate 
aliquots so that the final concentration 
of RF ranged from 2000 to 31 U/ml, 800 to 
27 U/ml or 500 to 31 U/ml respectively. 
These ranges in the concentration were 
chosen because they reflected those found 
in sera provided by the renal transplant 
recipients. All reconstructed sera were 
tested in parallel and on 2 occasions 
within a single batch of the Labsystems 
HCMV-IgM ELISA. The intra-assay variation 
in the level of HCMV-IgM within each 
reconstructed serum is represented by a 
solid vertical line.
IgM-RF levels were kindly provided by 
Mrs J. Veitch and Professor K. Whaley, 
Immunopathology Department, University 
of Glasgow.
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Figure 55 Correlation between HCMV-IgM levels
measured bv Labsystems ELISA and rubella-
IaM levels tested by Abbott ELISA
A post transplantation serum sample 
was obtained from each of 38 renal
allograft recipients, 11 (a,b,c,d,
e, f , g, h, i , j , k) with primary HCMV
infection, 19 (l,m,n,o,p,q,r,s,t,u,v,w,x,
y ,z ,qq,rr,ss,uu) with reinfection and/or 
reactivation and 8 (bb,cc,dd,ee,ff,ii, 
kk,oo) with no active HCMV infection.
Whenever possible the serum showing the 
highest recorded level of HCMV-IgM 
within each patient was chosen. All
sera were tested on 1 occasion within a 
single batch of the Abbott indirect 
rubella-IgM ELISA and the results
correlated with HCMV-IgM levels measured 
in any 1 of 9 different batches of the 
Labsystems indirect ELISA (O, • , A ,
A , O  , ♦  , v , ▼ and ■
respectively).
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4.8.5 Kinetics of the post transplantation HCMV-IgM
response
(a) Primary HCMV infection (Figures 56A and 59A)
The earliest serum to show a significant increase in 
HCMV-IgM was taken from patient (e) at 5 weeks after the 
transplant operation. By 6 weeks post transplantation the 
HCMV-IgM level had risen significantly in 3 other renal
allograft recipients (a,f,j) while patients (c,d,i) showed 
a significant HCMV-IgM response which was first recorded at 
8 weeks after the transplant operation. The last renal 
allograft recipient (h) to show a significant increase in 
HCMV-IgM did so in a serum provided at 10 weeks post 
transplantation although no sera were available during the 
preceding 6 weeks. A significant HCMV-IgM response was 
never observed in patients (b) , (g) and (k) who first
showed serological evidence of primary HCMV infection in a 
serum obtained at 59 weeks post transplantation.
In patient (a), the HCMV-IgM level increased from 6.5 
EIU at 4 weeks post transplantation to 12 3 EIU by the sixth 
week after the transplant operation. The level of HCMV-IgM 
then decreased to 58.1 EIU at 12 weeks post transplantation 
while the next available serum taken 66 weeks later had an 
HCMV-IgM level of 12.4 EIU.
Patient (c) showed a significant HCMV-IgM response of
94.3 EIU in a serum provided at 8 weeks post
transplantation. By 21 weeks after the transplant 
operation, HCMV-IgM had dropped to a level of 43.4 EIU 
which was then maintained with minimal fluctuation until at
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Figure 56A Post transplantation levels of HCMV-IgM
measured bv Labsystems ELISA: Primary
infection
The figure shows the levels of HCMV-IgM 
between 0 and 7 6 weeks post 
transplantation in each of 11 renal 
allograft recipients (a to k) with 
primary HCMV infection.
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sera were obtained during the preceding 6 weeks. 
Thereafter, HCMV-IgM gradually decreased to a level of 12.1 
EIU by 24 weeks after the transplant operation.
Patient (i) first showed an HCMV-IgM response of 39.7 
EIU in a serum provided at 6 weeks post transplantation. 
Two weeks later HCMV-IgM had increased to a level of 64.6 
EIU which was maintained with minimal variation until 22 
weeks after the transplant operation. A serum taken at 2 4 
weeks post transplantation showed the HCMV-IgM level to be
39.2 EIU. The next available serum was obtained after an 
interval of 29 weeks when the HCMV-IgM level was 47.8 EIU.
In patient (j), HCMV-IgM increased from 3.86 EIU at 4 
weeks post transplantation to 61.5 EIU by the sixth week 
after the transplant operation. The HCMV-IgM response 
continued to rise, reaching a level of 77.5 EIU two weeks 
later. Thereafter, the HCMV-IgM level gradually decreased 
and was noted to be 18.5 EIU in the last serum obtained 
from this patient at 38 weeks post transplantation.
Two other patients (b,g) with primary HCMV infection 
never showed evidence of a significant HCMV-IgM response. 
In patient (b) , HCMV-IgM increased from 6.4 to 20.2 EIU 
between 4 and 6 weeks respectively post transplantation. 
By the seventh week after the transplant operation, HCMV- 
IgM had risen to a level of 29.8 EIU which was maintained 
with minimal fluctuation for at least a further 6 weeks. 
No other sera were available until 45 weeks post 
transplantation when the HCMV-IgM level was 29.6 EIU. A 
serum taken from patient (g) at 9 weeks after the
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transplant operation had an HCMV-IgM level of 4.3 4 EIU. 
The next serum was obtained 5 weeks later when the HCMV-IgM 
level had increased to 2 6.0 EIU. There was an interval of 
14 weeks until the next serum sample which showed the HCMV- 
IgM level to be 8.07 EIU. In all subsequent sera the HCMV- 
IgM level never exceeded 7.8 6 EIU.
(b) Reinfection and/or reactivation (Figures 56B and 
59B)
Thirteen renal allograft recipients (n,q,r,s,v,w,x,y, 
z ,qq,rr,tt,uu) developed a significant HCMV-IgM response 
after the transplant operation, while 7 (l,m,o,p,t,u,ss) 
did not. The earliest sera to be regarded as positive for 
HCMV-IgM were taken from patients (s) and (qq) at 5 weeks 
post transplantation. By the eighth week after the 
transplant operation 4 other patients (n,v,w,y) had 
evidence of a significant increase in HCMV-IgM while 
patients (r) , (x) , (z) , (rr) and (uu) became positive for
HCMV-IgM at 12, 9, 10, 10 and 11 weeks respectively post
transplantation. The last patients (q and tt) to show a 
significant HCMV-IgM response did so in sera provided at 14 
weeks after the transplant operation.
In patient (n), HCMV-IgM increased from 3.74 EIU at 3 
weeks post transplantation to 22.4 EIU at 5 weeks after the 
transplant operation. The HCMV-IgM response continued and 
reached a peak of 68.0 EIU at 13 weeks post 
transplantation. Thereafter, the HCMV-IgM level gradually 
decreased so that by 32 weeks after the transplant
38
Figure 56B Post transplantation levels of HCMV-IgM
measured by Labsvstems E L I S A :
Reinfection and/or reactivation
The figure shows the levels of HCMV-IgM 
between 0 and 77 weeks post 
transplantation in each of 20 renal 
allograft recipients (l/m,n,o/p /q /r,s,t, 
u,v,w,x,y,z,qq,rr,ss,tt,uu) with rein­
infection and/or reactivation of HCMV.
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operation it had fallen to 15.8 EIU. This level was 
maintained for at least a further 6 weeks while the next 
available serum taken at 60 weeks post transplantation 
showed an HCMV-IgM level of 13.6 EIU.
No sera were received from patient (q) until 14 weeks 
post transplantation when the HCMV-IgM level was 54.6 EIU, 
an increase of 3 5.6 EIU above that recorded immediately 
pretransplant. Eleven weeks later, HCMV-IgM had dropped to
24.0 EIU and it remained at this level in the 2 subsequent 
sera obtained at 3 0 and 37 weeks after the transplant 
operation.
Patient (r) first provided a post transplant serum 
sample 2 weeks after receiving the renal allograft. At 
this time the HCMV-IgM level was 4.22 EIU but it then 
increased being 71.1 EIU in the next available serum taken 
10 weeks later. The HCMV-IgM level then gradually 
decreased and was 32.7 EIU in the final serum to be 
obtained from this patient at 21 weeks post-operatively.
An HCMV-IgM response of 44.8 EIU was recorded in a 
serum provided by patient (s) at 5 weeks after the 
transplant operation. Thereafter the HCMV-IgM level did 
not change significantly in 5 other sera obtained up to 19 
weeks post transplantation. No serum was then available 
until 56 weeks after the transplant operation when the 
HCMV-IgM level was 45.2 EIU.
In patient (v) , HCMV-IgM increased from 11.1 EIU 
immediately pretransplant to 54.5 EIU at 8 weeks post- 
operatively. Thereafter, HCMV-IgM, gradually decreased to a
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level of 20.4 EIU at 21 weeks after the transplant 
operation. This level was then maintained until at least 
33 weeks post transplantation after which no other 
specimens were available for analysis.
Between 2 and 6 weeks post transplantation, the HCMV- 
IgM level in patient (w) increased from 8.02 to 71.7 EIU. 
The next serum was provided 6 weeks later when the HCMV-IgM 
level had decreased to 13.3 EIU. In all subsequent sera 
obtained up to 48 weeks post-operatively, the HCMV-IgM 
level never exceeded 8.75 EIU.
Patient (x) showed an HCMV-IgM level of 3.1 EIU in a 
serum taken 1 week after the transplant operation while 
sera obtained at 5 and 9 weeks post transplantation had an 
HCMV-IgM level of 14.3 and 47.6 EIU respectively. By 21 
weeks after the transplant operation, HCMV-IgM had fallen 
to a level of 22.8 EIU which did not change significantly 
in 5 subsequent sera taken up to 39 weeks post- 
operatively. An HCMV-IgM level of 22.8 EIU was observed in 
the next serum provided by this patient at 76 weeks after 
the transplant operation.
The HCMV-IgM response in patient (y) gradually 
increased from 4.35 EIU at 3 weeks post transplantation to
63.0 EIU at 8 weeks after the transplant operation. This 
level was then maintained with minimal variation until at 
least 16 weeks post-operatively. The next available serum 
taken 33 weeks later showed the HCMV-IgM level to be 33.3 
EIU.
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Between 3 and 10 weeks after the transplant operation, 
the HCMV-IgM level in patient (z) increased from 9.1 to
105.1 EIU. By 29 weeks post transplantation, HCMV-IgM had 
decreased to a level of 24.1 EIU which was equivalent to 
that observed in 4 other sera obtained up to 41 weeks after 
the transplant operation. There was an interval of 17 
weeks until the next serum sample which had an HCMV-IgM 
level of 48.6 EIU.
Patient (qq) first provided a post transplantation 
serum sample 5 weeks after receiving the renal allograft. 
At this time the HCMV-IgM level was 40.6 EIU. A serum 
taken 6 weeks later showed the HCMV-IgM level to be 34.3 
EIU. By 21 weeks post transplantation, HCMV-IgM had 
dropped to a level of 19.3 EIU which did not change 
significantly in the 2 subsequent sera obtained from this 
patient at 46 and 51 weeks after the transplant operation.
In patient (rr), the post transplantation HCMV-IgM 
response gradually increased and reached a maximum recorded 
level of 55.0 EIU at 10 weeks after the transplant 
operation. Thereafter, the HCMV-IgM level gradually 
decreased and was 24.0 EIU at 25 weeks post 
transplantation. Four weeks later the HCMV-IgM level was
24.8 EIU while the next recorded serum taken at 57 weeks 
after the transplant operation had an HCMV-IgM level of
24.2 EIU.
Between 5 and 10 weeks post transplantation, the HCMV- 
IgM level in patient (tt) had increased from 4.73 to 37.5 
EIU. A serum taken 4 weeks later showed the HCMV-IgM level
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to be 40.1 EIU. By 31 weeks after the transplant 
operation, the HCMV-IgM level had decreased to 13.2 EIU. 
In 5 subsequent sera obtained up to 54 weeks post- 
operatively, the HCMV-IgM level never exceeded 14.3 EIU.
An HCMV-IgM level of 5.38 EIU was recorded in a serum 
taken from patient (uu) at 2 weeks post transplantation. 
The next serum sample was obtained 11 weeks after the 
transplant operation when the HCMV-IgM level was 59.6 EIU. 
Twenty one weeks later, HCMV-IgM had dropped to a level of
14.0 EIU which was maintained with minimal variation in 3 
other sera provided at 38 , 42 and 57 weeks post-
operatively.
In patients (1), (p), (u) and (ss), the HCMV-IgM level
never exceeded 15.3, 18.9, 10.6 and 11.7 EIU respectively. 
The highest recorded level of HCMV-IgM in patient (m) was
37.8 EIU in a serum taken at 8 weeks after the transplant 
operation although no sera were available during the 
intervening period. Nine weeks later, HCMV-IgM had 
decreased to a level of 12.9 EIU which did not change 
significantly in the 6 subsequent sera obtained up to 66 
weeks post-operatively. Between 4 and 15 weeks after the 
transplant operation, only 3 sera were provided by patient
(o) , the highest HCMV-IgM level being 27.3 EIU in a serum 
taken at 9 weeks post transplantation. At 25 weeks after 
the transplant operation the HCMV-IgM level was 11.9 EIU. 
Five other sera obtained between 3 0 and 59 weeks post 
transplantation showed an average HCMV-IgM level of 10.5
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EIU (range 9.5 to 11.5). In patient (t) , the HCMV-IgM 
response gradually increased from 13.1 EIU at 4 weeks after 
the transplant operation to 38.4 EIU at 11 weeks post 
transplantation. No serum was then available until 8 weeks 
later when HCMV-IgM had decreased to a level of 29.5 EIU 
which was equivalent to that observed in 9 other sera 
obtained between 2 3 and 55 weeks post-operatively.
In conclusion therefore, no difference was observed 
between the pattern of the HCMV-IgM response in patients 
(l,m,n,o,p,q,r,s,t,u,v,w) who shed HCMV and those who did 
not (x,y,z ,q q ,rr,ss,tt,uu). Similarly, the HCMV-IgM 
response could not differentiate renal allograft recipients 
(l,m,s,t,x,y,u,qq) who each received their kidney from an 
HCMV-seropositive donor from those (n,p,r,v,z,rr,ss,tt) who 
were each transplanted with a kidney from an HCMV- 
seronegative donor. The donor serological status was not 
available for 4 other renal allograft recipients 
(o,q,w,uu).
4 3
4.8.6 Comparison between HCMV-IgM levels in primary
infection and reinfection and/or reactivation
Some authors have suggested that post transplantation 
HCMV-IgM levels may be significantly higher in patients 
with primary infection than in those with reinfection 
and/or reactivation of HCMV (Wreghitt et a l . , 1986) .
Therefore, a comparison was made between HCMV-IgM levels in 
both these groups of patients during the course of this 
project. To avoid inter-assay variation when comparing 
HCMV-IgM levels in sera obtained from different patients it 
is necessary to reanalyse such samples in parallel within 1 
batch of the ELISA. Because of the large number of sera 
involved it was impossible to retest all samples from all 
patients in this project. Therefore, the comparison between 
HCMV-IgM levels in patients with primary HCMV infection and 
those with reinfection and/or reactivation was based on the 
simultaneous testing of 2 sera from each individual, 1 
taken between 5 and 11 weeks and another between 9 and 18 
weeks post transplantation. Examination of the serological 
response has already shown that the HCMV-IgM levels in such 
sera would represent the highest recorded in 29 of the 3 0 
patients with HCMV infection during the first year after 
the transplant operation. Results were compared with those 
already obtained in another batch of the ELISA (Figure 57).
A comparison between HCMV-IgM levels in patients with 
primary HCMV infection and those with reinfection and/or 
reactivation of the virus found no obvious difference in 
samples obtained from these individuals between 5 and 11
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Figure 57 Comparison between HCMV-IgM levels in 
renal allograft recipients with primary 
HCMV infection, reinfection and/or 
reactivation or no active HCMV infection
Between 5 and 11 weeks after the 
transplant operation, a serum was 
obtained from each of 10 renal allograft 
recipients (a,b,c,d,e,f,g,h,i,j) with 
primary HCMV infection, 18
(l,m,n,o,p,s,t,u,v,w,x,y,z,qq,rr,ss,tt,uu) 
with reinfection and/of reactivation and 
8 (bb,cc,dd,ff,i i ,kk,mm,oo) with no 
evidence of active HCMV infection (Figure 
A ) . With the exception of patient (ss), 
a serum was also provided by each of the 
aforementioned renal allograft recipients 
between 12 and 18 weeks post 
transplantation (Figure B) . Patient (ee) 
who showed no evidence of active HCMV 
infection and patients (q) and (r) who 
developed reinfection and/or reactivation 
of HCMV after the transplant operation 
also provided a serum between 12 and 18 
weeks but not between 5 and 11 weeks post 
transplantation. Sera were initially 
tested in 1 of 9 different batches of the 
ELISA ( • / O) and were retested in 
parallel within a single batch of the 
ELISA ( ■ / □ ) . The variation in the 
magnitude of the HCMV-IgM response when 
measured in 2 batches of the Labsystems 
ELISA is represented by a solid vertical 
line. ( • / ■ )  or (O/n)  differentiate 
sera obtained from those renal allograft 
recipients who shed or did not shed HCMV 
respectively. Within each group of 
patients shows the average change in
the HCMV-IgM level above that recorded 
immediately pretransplant. Seven renal 
allograft recipients (aa,gg,hh,jj,11,nn, 
pp) with no evidence of active HCMV 
infection and patient (k) who first 
showed serological evidence of primary 
HCMV infection at 59 weeks post 
transplantation were omitted from this 
experiment.
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weeks or 12 and 18 weeks post renal transplantation. In 10 
patients (a,b,c,d,e,f,g,h,i,j) with primary HCMV infection, 
HCMV-IgM had risen above the pretransplant level by an 
average of 54.9 EIU (range 3.9 to 123.0) between 5 and 11 
weeks after the transplant operation. During the same 
period HCMV-IgM levels were an average of 41.7 EIU (range 
5.7 to 105.1) higher than the pretransplant level in 18 
patients (l,m,n,o,p,s,t,u,v,w,x,y,z,qq,rr,ss,tt,uu) with 
reinfection and/or reactivation of HCMV for whom sufficient 
data was available. Between 12 and 18 weeks post 
transplantation, HCMV had risen above the pretransplant 
level by an average of 47.8 EIU (range 20.6 to 86.3) and
33.8 EIU (range 8.5 to 71.1) in the 10 patients with 
primary HCMV infection and 19 (l,m,n,o,p,q,r,s,t,u,v,w,x,y, 
z ,qq,rr,tt,uu) with reinfection and/or reactivation of the 
virus respectively.
For each serum there was good reproducibility in the 
HCMV-IgM ELISA value. A serum sample obtained between 5 
and 11 weeks post transplantation from each of 9 patients 
(b,c,d,e,f,g,h,i,j) with primary HCMV infection was tested 
in 2 batches of the ELISA and HCMV-IgM levels found to vary 
by an average of 9.73 EIU (range 1.8 to 30.5). Similar 
examination of a serum obtained between 12 and 18 weeks 
after the transplant operation from each of 10 patients 
(a,b,c,d,e,f,g,h,i,j) with primary HCMV infection showed 
the HCMV-IgM level in any 1 sample to vary by an average of
7.08 EIU (range 0.4 to 15.9). With regard to those
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patients with reinfection and/or reactivation of HCMV, the 
average variation between HCMV-IgM levels measured in 2 
batches of the ELISA was 8.3 5 EIU (range 0.9 to 2 0.8) for 
18 sera or 7.51 EIU (range 0.4 to 21.1) for 19 sera, each 
obtained from a different renal allograft recipient.
Post transplantation HCMV-IgM levels did not 
differentiate those patients with reinfection and/or 
reactivation of HCMV who shed virus from those who did not. 
In 10 (l,m,n,o,p,s,t,u,v,w) of the 12 individuals (l,m,n,o, 
p,q,r,s,t,u,v,w) from whom HCMV was isolated and sufficient 
data available, the highest recorded HCMV-IgM level between 
5 and 11 weeks post transplantation ranged from 5.7 to 79.7 
EIU with an average of 37.2 EIU. During the same period 
the highest recorded HCMV-IgM level in 8 patients 
(x,y,z,qq,rr,ss,tt,uu) from whom HCMV was never isolated 
ranged from 11.7 to 105.1 EIU with an average of 47.2 EIU. 
Similarly, between 12 and 18 weeks after the transplant 
operation, the highest recorded HCMV-IgM level ranged from 
8.5 to 71.1 EIU (an average of 3 0.9 EIU) in the 12 patients 
(1 ,m,n,o,p,q,r, s,t,u,v,w) who shed HCMV and from 17.8 to
69.1 EIU (an average of 38.7 EIU) in 7 (x, y ,z ,qq,rr,tt,uu) 
of the 8 patients who did not shed HCMV after renal 
transplantation and for whom sufficient data was available.
Eight renal allograft recipients (l,m,s,t,u,x,y,qq) 
with reinfection and/or reactivation of HCMV each received 
their kidney from an HCMV-seropositive donor while 8 other 
patients (n,p,r,v,z,rr,ss,tt) who were each transplanted 
with a kidney from an HCMV-seronegative donor most likely
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experienced reactivation of endogenous virus. Both groups 
of patients could not be differentiated on the basis of the 
HCMV-IgM response, the highest recorded levels between 5 
and 11 weeks and between 12 and 18 weeks post 
transplantation being 33.3 EIU (range 8.1 to 60.9) and 29.9 
EIU (range 11.6 to 66.3) respectively in those renal 
allograft recipients who each received a kidney from an 
HCMV-seropositive donor while sera obtained from patients 
(n,p,v,z,rr,ss,tt) between 5 and 11 weeks after the 
transplant operation and from patients (n,p,r,v,z,rr,tt) 
between 12 and 18 weeks post transplantation showed an 
average HCMV-IgM level of 45.2 EIU (range 12.6 to 97.7) and
40.8 EIU (range 13.7 to 65.4) respectively.
4.9 Overall correlation between HCMV-specific IqM. IaG and 
CF antibody levels and the detection of HCMV bv tissue 
culture and RNA-DNA hybridization
4.9.1 Primary HCMV infection
HCMV was isolated from 9 (a,b,c,d,e,f,g,h,i) of the 11 
renal allograft recipients with primary HCMV infection all 
of whom showed a fourfold or greater rise in the HCMV CF 
antibody titre (Figure 58A). In patients (a), (b), (e) and
(i), this rise was recorded between 1 and 6 weeks prior to 
the onset of HCMV isolation while the virus was first 
isolated from patients (c) and (d) at 4 and 2 weeks 
respectively before a fourfold rise in HCMV CF antibody 
titre was observed. In patients (f), (g) and (h) , HCMV
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Figure 58A Correlation between the onset of HCMV 
isolation, the fourfold or greater rise in 
HCMV CF antibody titre and HCMV-IaM and IqG 
levels measured bv Labsvstems ELISA: 
Primary HCMV infection
In each of 9 renal allograft 
recipients (a,b ,c ,d ,e ,f ,g ,h ,i ) with 
primary HCMV infection who shed the 
virus post-operatively, the onset of 
HCMV isolation (Time 0) has been 
correlated with HCMV-IgM levels 
( — Q—  negative; — ®—
equivocal; — •—  positive) and
HCMV-IgG levels ( --q -
negative; — 3 —  equivocal;
— 9 —  positive) measured by
Labsystems ELISA. Results are 
correlated with the timing of the 
fourfold or greater rise in HCMV CF 
antibody titre (*) and the renal 
transplant operation ( Jr ) .
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isolation and the fourfold or greater rise in virus- 
specific CF antibody titre were coincident.
When the fourfold or greater rise in HCMV CF antibody 
titre was first detected, patients (a,c,d,e,h,i) were 
positive for HCMV-IgM while (b) and (g) were equivocal and
(f) negative. Four patients (c,d,e,h) were positive, 2 
(b,g) were equivocal and 2 (f,i) were negative for HCMV-IgG 
when the fourfold or greater rise in HCMV CF antibody titre 
was first recorded. The serum obtained from patient (a) 
which showed a fourfold rise in HCMV CF antibody titre was 
not tested for HCMV-IgG. Virus was never isolated from 2 
other renal allograft recipients (j and k) with primary 
HCMV infection. Patient (j) was positive and (k) equivocal 
for HCMV-IgM when the fourfold rise in CF antibody titre 
was first observed while both patients were seronegative 
for HCMV-IgG at this time. In no case were HCMV-IgM or IgG 
levels positive prior to the fourfold or greater rise in 
the virus-specific CF antibody titre.
Patients (a) , (e) and (i) were positive for HCMV-IgM
at 6, 5 and 3 weeks respectively prior to the onset of 
virus isolation. At the time of initial HCMV isolation, 3 
renal allograft recipients (a,h,i) were positive for HCMV- 
IgM while patients (b) , (e) and (g) were equivocal.
Patient (b) remained equivocal for HCMV-IgM until at least 
6 weeks after the onset of HCMV isolation. A serum taken 
from patient (g) at 14 weeks after initial HCMV isolation 
was negative for HCMV-IgM although no specimens were 
available during the intervening period. Patients (c), (d)
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and (f) who were negative for HCMV-IgM on the day of first 
HCMV isolation became positive between 1 and 4 weeks later.
Only 1 renal allograft recipient (e) was positive for 
HCMV-IgG prior to the onset of HCMV isolation while on the 
day of initial HCMV isolation 3 patients (a,e,h) were 
positive for HCMV-IgG. Patients (b) , (g) and (i) were
equivocal for HCMV-IgG when HCMV was" first isolated but 
patient (i) became positive 10 weeks later. Patient (b) 
remained equivocal for HCMV-IgG in sera taken up to 6 weeks 
after initial HCMV isolation while insufficient data are 
available to draw conclusions about the timing of 
seroconversion in patient (g) who was noted to be positive 
for HCMV-IgG 14 weeks after HCMV was first isolated. The 3 
renal allograft recipients (c,d,f) who were negative for 
HCMV-IgG at the onset of virus isolation became positive 
between 2 and 10 weeks later.
The following data is shown in Figure 59A.
When a fourfold or greater rise in HCMV CF antibody 
titre was first recorded, urine specimens submitted 
simultaneously by each of patients (c) , (e) and (h) were
positive by hybridot assay while those taken from patients
(b) and (g) were equivocal and those from patients (d), (f) 
and (i) were negative. Urine samples provided by patients
(c) and (g) were positive by RNA-DNA hybridization at 7 and 
9 weeks respectively prior to the fourfold or greater rise 
in HCMV CF antibody titre while in patients (b) , (d) and
(i) this rise preceded a positive result in the hybridot
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Figure 59A Post transplantation levels of HCMV-IgM
and IaG measured bv Labsvstems ELISA:
Primary infection
The figure shows the post transplantation
levels of HCMV-IgM ( 0 = 2 0  EIU) and
HCMV-IgG ( I = 2 0  EIU) measured by
Labsystems ELISA in each of 10 renal
allograft recipients (a,b,c,d,e,f,g,h,i,
j) with primary HCMV infection. The
timing of the fourfold or greater rise in
HCMV CF antibody titre is shown by *.
Urine samples and/or throat swabs which
did not yield HCMV in tissue culture are
indicated by —  . Symbols T and 1
differentiate those HCMV isolates
obtained from urine samples and throat
swabs respectively. Simultaneous
isolation of HCMV from a urine sample and
throat swab is indicated by X . The
results of the RNA-DNA hybridot assay
( O negative; 3 equivocal;
• positive) are also shown.
Patient (k) who showed serological
evidence of primary HCMV infection at 59
weeks post transplantation is omitted
from the diagram. Figures within
brackets indicate the number of weeks
post transplantation when that serum was
obtained.
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assay by 7, 39 and 13 weeks respectively. In patients (e) 
and (h) , the fourfold or greater rise in HCMV CF antibody 
titre and the first positive result by hybridot assay were 
coincident.
When an increase in HCMV-IgM of greater than 4 0 EIU 
was first recorded, urine specimens submitted by each of 
patients (c) , (e) and (h) were positive by hybridot assay
while those taken from patients (d) , (f) and (i) were
negative. Patient (c) became positive for HCMV-IgM at 8 
weeks post transplantation, 7 weeks after providing a urine 
sample which was the first to be classified as positive by 
RNA-DNA hybridization. Patients (d) and (i) showed a 
significant HCMV-IgM response 39 and 13 weeks respectively 
prior to the urine becoming positive by dot blot 
hybridization. The first recorded positive HCMV-IgM level 
and hybridot assay in each of patients (e) and (h) were 
coincident. No serum from patient (b) was ever positive 
for HCMV-IgM although 2 urines provided at 13 and 14 weeks 
after the transplant operation were positive by hybridot 
assay. The highest recorded level of HCMV-IgM in patient
(g) was 26.0 EIU in a serum taken at 14 weeks post 
transplantation, 9 weeks after providing a urine sample, 
the only one from this patient found positive by RNA-DNA 
hybridization.
Urine obtained from both patients (d) and (g) was 
negative while that provided by each of patients (c), (e),
(h) and (i) was positive by RNA-DNA hybridization when an 
HCMV-IgG level of greater than 2 0 EIU was first recorded.
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Patient (f) became positive for HCMV-IgG at 15 weeks after 
the transplant operation when a urine sample was equivocal 
by hybridot assay. A positive HCMV-IgG level was first
detected in patient (c) 7 weeks after a urine specimen had
been found positive by dot blot hybridization. A urine 
sample submitted by patient (g) 5 weeks after the
transplant operation was positive by hybridot assay while a 
serum taken simultaneously had an HCMV-IgG level of 0.2 
EIU. Consecutive sera taken at 8, 9 and 14 weeks post
transplantation showed the HCMV-IgG level to be 2.8, 1.3
and 14.3 EIU respectively. The only urine provided by 
patient (d) which was positive by RNA-DNA hybridization was 
taken 47 weeks after the transplant operation, 39 weeks 
after the onset of a significant HCMV-IgG response. The 
first urine specimen taken from patient (b) and shown to be 
positive by RNA-DNA hybridization was provided at 13 weeks 
post transplantation when the HCMV-IgG level was 15.5 EIU. 
The next available serum was obtained 32 weeks later when 
the HCMV-IgG level was 56.4 EIU but no urine specimen was 
available for analysis.
Only 2 urine samples obtained from patient (j), one at 
4 weeks and the other at 7 weeks after the transplant 
operation, were tested by dot blot hybridization and both 
were negative while a serum provided at 6 weeks post 
transplantation showed an eightfold increase in the HCMV CF 
antibody titre and a 57.6 EIU increase in the level of 
HCMV-IgM. Patient (j) became positive for HCMV-IgG 8 weeks
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after the transplant operation. Insufficient data is 
available for patient (a) to allow a correlation to be made 
between the results of the hybridot assay and the humoral 
immune response.
4.9.2 Reinfection and/or reactivation
Ten (l,m,n,o,p,q,r,s,t,u) of the 12 patients from whom 
HCMV was isolated showed a fourfold or greater rise in HCMV 
CF antibody titre (Figure 58B). In patients (n), (s) and
(u), this rise was recorded between 2 and 6 weeks prior to 
the onset of virus isolation while HCMV was first isolated 
from patients (1), (o) and (t) at 7, 6 and 5 weeks
respectively before a fourfold or greater rise in virus- 
specific CF antibody titre was observed. Patients (p) and 
(q) showed a fourfold or greater rise in HCMV CF antibody 
titre coincident with the onset of HCMV isolation while in 
patients (m) and (r) it was not possible to accurately 
relate initial virus isolation to the rise in CF antibody 
titre.
When the fourfold or greater rise in HCMV CF antibody 
titre was recorded, patients (n) , (q) , (r) and (s) were 
positive for HCMV-IgM while (m) and (t) were equivocal and 
(1) , (o) , (p) and (u) negative. No renal allograft
recipient was positive for HCMV-IgM prior to showing a 
fourfold or greater rise in HCMV CF antibody titre. Nine 
patients (m,n,o,p,q,r,s,t,u) had evidence of a fourfold or 
greater rise in HCMV CF antibody titre coincident with a 20 
EIU or greater increase in HCMV-IgG although in patients
52
Figure 58B Correlation between the onset of HCMV 
isolation, the fourfold or greater rise in 
HCMV CF antibody titre and HCMV-IgM and IqG 
levels measured bv Labsvstems ELISA: Re­
infection and/or reactivation of HCMV
In each of 12 renal allograft 
recipients (l,m,n,o,p,q,r,s,t,u,v,w) 
with reinfection and/or reactivation of 
HCMV who shed the virus post- 
operatively, the onset of HCMV isolation 
(Time 0) has been correlated with HCMV- 
IgM levels ( — Q—  negative;
— equivocal; — •—  positive) 
an increase in HCMV-IgG of 0 to 9 EIU 
( --g - ) , 10 to 19 EIU ( ) and 20
EIU or more ( — 9—  ) measured by
Labsystems ELISA. Results are
correlated with the timing of the 
fourfold or greater rise in HCMV CF 
antibody titre (*) and the renal 
transplant operation ( ^ ). Patient (1) 
received a renal allograft 18 weeks 
prior to the onset of HCMV isolation.
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(n) , (o) , (p) and (t) a significant increase in HCMV-IgG
was first recorded in a serum taken at 5, 6, 3 and 5 weeks 
respectively before the fourfold or greater rise in HCMV CF 
antibody titre was observed. In patient (1) , the highest 
recorded increase in HCMV-IgG was 11.4 EIU in a serum taken 
7 weeks before that showing the fourfold rise in HCMV CF 
antibody titre but no sera were submitted in the 
intervening period.
HCMV was never isolated from 8 other renal allograft 
recipients (x,y,z,qq,rr,ss,tt,uu) with reinfection and/or 
reactivation. Patients (y) and (qq) showed a significant 
increase in HCMV-IgM at 1 and 6 weeks respectively before 
the fourfold or greater rise in HCMV CF antibody titre was 
detected while patients (x, z,rr,tt,uu) first became 
positive for HCMV-IgM coincidentally with the fourfold or 
greater rise in virus-specific CF antibody titre. Patient 
(ss) remained negative for HCMV-IgM throughout the period 
of study. When the fourfold or greater rise in HCMV CF 
antibody titre was first recorded, patients (x) , (y) , (z),
(rr), (ss) and (uu) showed a 20 EIU or greater increase in 
HCMV-IgG. A significant HCMV-IgG response was noted in a 
serum taken from patient (qq) 6 weeks before a sixteenfold 
rise in HCMV CF antibody titre was detected. The highest 
recorded increase in HCMV-IgG in patient (tt) was 14.9 EIU 
in a serum provided 2 weeks after that showing a fourfold 
rise in virus-specific CF antibody titre.
Patients (n) and (s) were positive for HCMV-IgM at 4
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and 6 weeks respectively prior to the onset of virus 
isolation. At the time of initial HCMV isolation, 2 renal 
allograft recipients (q and s) were positive for HCMV-IgM, 
while (o) and (v) were equivocal and (1), (p), (u) and (w)
negative. Patients (v) and (w) became positive for HCMV-IgM 
at 3 and 4 weeks respectively after the onset of virus 
isolation while (1) , (p) and (u) remained negative
throughout. No serological data are available for patients 
(m) , (r) and (t) at the time of first HCMV isolation but
from subsequent results patient (t) must have been negative 
for HCMV-IgM at that time. Four renal allograft recipients 
(n,p,s,u) developed a 20 EIU or greater rise in HCMV-IgG 
between 2 and 7 weeks prior to the onset of HCMV isolation. 
On the day of first virus isolation, HCMV-IgG had increased 
by 20 EIU or more in patients (o) , (p) , (q) , (s) and (u) ,
between 10 and 19 EIU in patient (1) and between 0 and 9 
EIU in patients (v) and (w) . Patients (t) , (v) and (w)
showed a significant rise in HCMV-IgG at 3, 3 and 4 weeks 
respectively after the onset of first HCMV isolation while 
the HCMV-IgG level in patient (1) never increased by more 
than 11.4 EIU above that recorded immediately 
pretransplant.
The following data are shown in Figure 59B.
When a fourfold or greater rise in HCMV CF antibody 
titre was first recorded, urine specimens submitted 
simultaneously by each of patients (p) , (u) , (x) and (uu)
were positive by hybridot assay while those taken from 
patients (n) , (s) , (z) and (ss) were equivocal and those
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Figure 59B Post transplantation levels of HCMV-IgM
and IcrG measured bv Labsvstems ELISA:
Reinfection and/or reactivation
The figure shows the post transplantation
levels of HCMV-IgM ( 0. = 2 0  EIU) and
HCMV-IgG ( I = 2 0  EIU) measured by
Labsystems ELISA in each of 20 renal
allograft recipients(l,m,n,o,p,q,r,s,t,u,
v,w,x,y,z,qq,rr,ss,tt,uu) with reinfect-
tion and/or reactivation of HCMV. The
timing of the fourfold or greater rise in
HCMV CF antibody titre is shown by *.
Urine samples and/or throat swabs which
did not yield HCMV in tissue culture are
indicated by —  . Symbols t and ^
differentiate those HCMV isolates
obtained from urine samples and throat
swabs respectively. Simultaneous
isolation of HCMV from a urine sample and
throat swab is indicated by ^ . The
results of the RNA-DNA hybridot assay
( O negative; O equivocal;
• positive) are also shown.
Figures within brackets indicate the
number of weeks post transplantation when
that serum was obtained.
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from patients (1), (m) , (r) , (t) , (y) , (qq) , (rr) and (tt)
were negative. Urine obtained from each of patients (o) 
and (q) at the time of the fourfold or greater rise in HCMV 
CF antibody titre was insufficient for testing by RNA-DNA 
hybridization. Urine specimens provided by patients (m) , 
(P)/ (<3)/ (t)t (x), (tt) and (uu) were positive by dot blot
hybridization at 2,3,10,7,9,12 and 9 weeks respectively 
prior to the fourfold or greater rise in HCMV CF antibody 
titre while in patients (n), (z), (qq), (rr) and (ss) this
rise preceded a positive result in the hybridot assay by 5, 
13, 9, 15 and 3 weeks respectively. In patient (u) , the
fourfold or greater rise in HCMV CF antibody titre and 
first positive result by RNA-DNA hybridization were 
coincident. Five other renal allograft recipients (l,o,r, 
s,y) who showed a fourfold or greater rise in HCMV CF 
antibody titre never provided urine specimens that were 
positive by hybridot assay. Of the 2 renal allograft 
recipients who never showed a fourfold or greater rise in 
HCMV CF antibody titre, patient (v) submitted urine 
specimens which were positive by dot blot hybridization at 
5, 11 and 21 weeks post transplantation. No urine sample 
provided by patient (w) was positive by hybridot assay.
When an increase in HCMV-IgM of greater than 40 EIU 
was first recorded, urine specimens submitted by each of 
patients (x) and (uu) were positive by hybridot assay while 
those taken from patients (n) , (s) , (v) and (z) were
equivocal and those from patients (r), (w), (y), (qq), (rr)
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and (tt) were negative. Insufficient urine for testing by 
dot blot hybridization was provided by patient (q) at 14 
weeks post transplantation when a significant increase in 
HCMV-IgM was first noted. Transplant recipients (n), (z),
(qq) and (rr) showed a significant increase in HCMV-IgM at 
5, 13, 15 and 15 weeks respectively prior to providing a
urine sample that was positive by RNA-DNA hybridization 
while in patients (q) , (v) , (x) , (tt) and (uu) , a urine
sample was positive by hybridot assay at 10, 3, 9, 12 and 9 
weeks respectively prior to a significant increase in HCMV- 
IgM. No urine specimen submitted by patients (r), (s), (w) 
and (y) was ever positive by dot blot hybridization 
although post transplantation levels of HCMV-IgM exceeded 
40 EIU. HCMV-IgM levels in patients (m), (p), (t), (u) and
(ss) remained equivocal throughout although each renal 
allograft recipient provided at least 1 urine specimen that 
was positive by RNA-DNA hybridization. In patients (1) and 
(o), HCMV-IgM levels never exceeded 15.3 and 27.3 EIU 
respectively and all urine samples remained negative or 
equivocal by hybridot assay.
When a significant increase in HCMV-IgG was first
recorded, urine specimens provided by each of patients (p),
(t) , (u) , (x) and (uu) were positive by dot blot
hybridization while those obtained from patients (s) , (v) ,
(z) and (ss) were equivocal and those from patients (m) , 
(n) , (o), (r), (w) , (y) , (qq) and (rr) were negative.
Insufficient urine for testing by RNA-DNA hybridization was 
taken from patient (q) at 14 weeks post transplantation
5 6
when the HCMV-IgG level had increased by 55.0 EIU. 
Transplant recipients (n), (z), (qq), (rr) and (ss) showed
a significant increase in HCMV-IgG at 8 , 13, 15 , 19 and 3 
weeks respectively prior to providing a urine specimen 
which was positive by hybridot assay while in patients (m), 
(t) , (v) , (x) and (uu) the urine was positive by dot blot
hybridization at 2, 5, 3, 9 and 9 weeks respectively prior 
to a significant increase in HCMV-IgG. In each of patients 
(p) and (u) a significant increase in HCMV-IgG and first 
positive result by hybridot assay were coincident. No 
urine specimen submitted by patients (o), (r) , (s), (w) and
(y) was ever positive by RNA-DNA hybridization although 
significant increases in HCMV-IgG were observed. In 
patient (1), the highest recorded increase in HCMV-IgG was 
11.4 EIU and none of the 7 urines provided were positive by 
dot blot hybridization. No significant increase in HCMV- 
IgG was noted in any serum obtained from patient (tt) but 1 
urine sample, that taken at 2 weeks post transplantation, 
was positive by hybridot assay.
57
4.10 Blood donors
4.10.1 HCMV serostatus
The HCMV serostatus was determined in 127 individuals 
who donated blood subsequently transfused into 37 of the 47 
renal allograft recipients involved in this study. Forty 
eight (38%) of the blood donors were seropositive and 79 
(62%) seronegative for HCMV by the modified CFT. HCMV-IgM 
levels were determined in each of 33 HCMV-seropositive 
blood donations provided by 15 individuals and all were 
found to be negative.
4.10.2 Age groups
The majority of the blood donations were received from 
individuals aged between 20 and 29 years of age who 
provided 61 blood packs comprising 48% of the total (Figure 
60). With increasing age the number of donors gradually 
declined so that only 1 blood donation was received from 
each of 2 individuals aged between 60 and 69 years.
One of 12 blood donations provided by individuals aged 
18 or 19 years was seropositive for HCMV. Thereafter, the 
proportion of blood packs which was HCMV-seropositive 
increased from 15/61 (24%) of those obtained from people
aged betweeen 20 and 29 years to 17/29 (59%) of those
provided by donors aged 30 to 39 years. Of the 25 blood 
donations received from individuals aged 40 years and over, 
15 (60%) were HCMV-seropositive.
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Figure 60 Aae of blood donors
The 127 blood donors who provided blood 
for 37 renal allograft recipients are 
grouped according to age in years (18 and 
19, 20 to 29 , 30 to 39, up to and
including 60 to 69). The total number of 
blood donors in each age group is shown 
while the hatched area indicates that 
proportion of donors found to be 
seropositive for HCMV.
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4.10.3 Transmission of HCMV
Four patients (aa,ff,gg,hh) who were seronegative for 
HCMV immediately pretransplant and who each received a 
kidney from an HCMV-seronegative renal donor were each 
transfused with 1 unit of blood provided by individuals who 
were seropositive for HCMV. All blood had been stored at 
4°C for up to 3 weeks. In every case the serostatus was 
confirmed by CFT and Labsystems HCMV-IgG ELISA. Throughout 
the period of the study none of the 4 renal allograft 
recipients described above showed any evidence of primary 
HCMV infection.
4.11 HSV infections in renal allograft recipients
The CFT was used to determine the HSV serostatus of 
the 47 renal allograft recipients involved in this study 
and 35 (74%) were found to be seropositive immediately
before the transplant operation. There was evidence of 
post transplantation HSV infection in 24 patients (d,h,i,l, 
m,n,o,p,r,v,w,x,y, z,bb,cc, ff, j j ,kk,nn,qq,rr,ss,tt) all of 
whom were seropositive immediately pretransplant and must 
therefore have developed reinfection and/or reactivation of 
the virus. No renal allograft recipient sustained a 
primary HSV infection after the transplant operation.
4.11.1 Isolation of HSV
Three hundred and seventy two urine samples and 337 
throat swabs were obtained from the 35 transplant 
recipients who were seropositive for HSV immediately
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pretransplant. Six urine samples (2%) from 3 patients (y, 
jj/Ss) yielded HSV in tissue culture while the virus was 
isolated from 13 throat swabs (4%) provided by 9 renal 
allograft recipients (1,m,r,w,y,cc,ff,jj,nn).
Isolation of HSV from the urine was first recorded in 
a sample provided by patient (jj) at 2 weeks after the 
transplant operation (Figure 61) . Other urine specimens 
obtained from the same patient at 3,5 and 6 weeks post 
transplantation also yielded HSV in tissue culture while a 
urine sample provided at 4 weeks after the transplant 
operation was free of the virus. Patients (y) and (ss) 
also shed HSV in the urine, virus being isolated from 
specimens taken at 49 and 46 weeks respectively post 
transplantation.
The first throat swab to yield HSV in tissue culture 
was obtained from patient (ff) at 1 week after the 
transplant operation. By 13 weeks post transplantation, HSV 
had been isolated from 10 throat swabs, 1 from each of 
patients (1), (m) , (r) , (w) , (y) , (cc) , (ff) , (nn) and 2
from patient (jj) . A throat swab taken from each of 
patients (1) and (r) at 18 and 17 weeks respectively after 
renal transplantation also yielded HSV in tissue culture 
while the final HSV isolate was harvested from a throat 
swab provided by patient (m) at 38 weeks post 
transplantation.
Five patients (w,y,cc, ff ,nn) shed HSV from the throat 
on only 1 occasion while 4 other renal allograft recipients
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Figure 61 HSV shedding after renal transplantation
The figure shows urine samples 
( — □—  ) and throat swabs ( — n—  )
provided by 10 renal allograft 
recipients (l,m,r,w,y,cc,ff,jj,nn,ss) 
who shed HSV post-operatively. Urine 
samples and throat swabs which yielded 
HSV in tissue culture are differentiated 
by — ■—  and — g—  respectively.
CMun
I D
C D
C D
C D
C D
C D
C D
C D
C D
C D
C D
C D
C D
C D
C D
C D
Cl
C D
C D
C D
C D
C D
■  D
■  D
C D
C D
C
C D
C D
C D
C
C D
C
E3— E3— cd-
C D
C D
C D
C D
C D
D
CD
CDcm
£ 1
C D
Cl
C D
C D
C D
C D
C D
C
-CD-
C D
C D
C D
C D
C D
Ci
CD
C D
£1
C D
C D
CP
C D
C
c
c
Cl
-CD-
C l
C D
c
C D
C D
C D
C D
C D
C D
Cl
C
c
C D
D
Cl
C D
C D
D
Cl
oo■a*
■S’•3"
, O ■a*
, <oKN
.CMf
00 
' CM
a-
CM
O
CM
_  CM
siu9iiBd jenpTAipui
We
ek
s 
po
st
 
tr
an
sp
la
nt
at
io
n
(l,m,r,j) each provided 2 independent throat swabs from 
which the virus was isolated. HSV was harvested from 2 
consecutive throat swabs taken from patient (jj) at 2 and 3 
weeks respectively post transplantation. The pattern of 
HSV shedding from the throat of patients (1) , (m) and (r)
was intermittent with an interval of 12, 3 0 and 15 weeks
respectively between isolates, no virus being isolated from 
throat swabs provided within the intervening period.
HSV was isolated from both the urine and throat of 2
renal allograft recipients. In patient (y) , isolation of 
HSV from the throat preceded that from the urine by 3 6 
weeks while HSV was cultured from urine samples and throat 
swabs provided by patient (jj) at 2 and 3 weeks after the 
transplant operation.
Restriction enzyme analysis of HSV strains isolated 
from patients (1), (m), (y) and (jj) confirmed the urinary
isolates to be Type 2 while those cultured from throat 
swabs were Type 1 (Figures 62A and B). Both HSV-1 isolates 
shed from the throat of patient (m) at 8 and 38 weeks post 
transplantation had an identical DNA profile after 
digestion with restriction enzymes EcoRI and BamHI. 
Restriction enzyme analysis also showed the virus isolated 
from each of the throat swabs provided by patient (jj) at 
3, 5 and 6 weeks after the transplant operation to belong 
to the same strain of HSV-1. Furthermore, at 2 and 3 weeks 
post transplantation, patient (jj) also shed HSV-2 in the 
urine, both isolates having an identical DNA profile after 
digestion with restriction enzymes Xbal and BamHI.
61
Figure 62A Autoradiographs of BamHI digests of HSV
DNA labelled in vivo with
All isolates were obtained from patient
(jj) •
Weeks Post
Lane Source Transplantation
2 Throat swab 2
3 Urine 3
4 Throat swab 3
5 Urine 5
6 Urine 6
Lanes 1 and 7 show the DNA profiles of
HSV-1 17 syn+ and HSV-2 HG52 
respectively.
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Figure 62B Autoradiographs of BamHI digests of HSV
DNA labelled in vivo with  ^ P
Weeks Post
Lane Patient Source Transplantation
2 m Throat swab 8
3 m Throat swab 38
4 1 Throat swab 6
5 1 Throat swab 18
6 y Throat swab 13
7 y Urine - 49
Lanes 1 and 8 show the DNA profiles of 
HSV-1 17 syn+ and HSV-2 HG52 
respectively.
Lanes
4.11.2 Timing of the fourfold or greater rise in HSV CF
antibody titre post renal transplantation
Sixteen renal allograft recipients showed a fourfold 
or greater rise in the HSV CF antibody titre after renal 
transplantation (Figure 63). In patients (d), (o), (p) and
(z) , this rise occurred within the first 4 weeks after the 
transplant operation. By 12 weeks post transplantation, a 
further 10 renal allograft recipients (h,i,l,m,v,x,cc,kk,qq 
rr) had evidence of a fourfold or greater rise in the HSV 
CF antibody titre. Patient (n) had an eightfold rise in 
the HSV CF antibody titre between 8 and 13 weeks post- 
operatively while in patient (tt) the fourfold rise in HSV 
CF antibody titre occurred between the tenth and fourteenth 
week after the transplant operation. The last renal 
allograft recipient (bb) to show a fourfold rise in HSV CF 
antibody titre did so in a serum taken at 3 6 weeks post 
transplantation, the CF titre in the preceding serum taken 
at 20 weeks being the same as that immediately 
pretransplant.
Three renal allograft recipients shed HSV and had a 
significant increase in the HSV CF antibody titre. 
Patients (1) and (m) showed an eightfold rise in the HSV CF 
antibody titre between 8 and 12 weeks and between 8 and 10 
weeks respectively after the transplant operation while 
patient (cc) had a sixteenfold increase in the HSV CF 
antibody titre between the fourth and eleventh week post 
transplantation.
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Timing of the fourfold or greater rise in 
HSV CF antibody titre after renal 
transplantation
The figure shows the timing of the 
fourfold or greater rise in HSV CF 
antibody titre in each of 17 renal 
allograft recipients (d,h,i,l,m,n,o,p,v,x, 
z ,bb,cc,kk,qq,rr,tt) with reinfection 
and/or reactivation of HSV after the 
transplant operation. Each bar identifies 
the time interval between 2 consecutive 
serum samples the last of which showed the 
fourfold or greater rise in HSV CF 
antibody titre. ■ and □ differentiate 
patients from whom virus was isolated and 
not isolated respectively.
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Thirteen renal allograft recipients demonstrated a 
fourfold or greater rise in CF antibody titre to both HSV 
and HCMV. In 6 patients (d, 1, o,p, z, rr) , the rise in HSV CF 
antibody titre preceded that of HCMV while in 3 other renal 
transplant recipients (i, m,n) the fourfold or greater rise 
in HCMV CF antibody titre preceded that of HSV. Sera taken 
from each of patients (h) , (x), (qq) and (tt) at 10, 9, 11
and 14 weeks respectively post transplantation showed a 
fourfold or greater rise in CF antibody titre to both HSV 
and HCMV.
4.11.3 Correlation between HSV isolation and the fourfold or 
greater rise in HSV CF antibody titre 
HSV was isolated from throat swabs provided by 3 renal 
allograft recipients (l,m,cc) who were known to have a 
fourfold or greater rise in HSV CF antibody titre. On the 
day of first HSV isolation none of these 3 patients showed 
a significant increase in the HSV CF antibody titre above 
that recorded immediately pretransplant (Figure 64) . In 
patient (1) , there was a fourfold rise in HSV CF antibody 
titre between 2 and 6 weeks after the onset of HSV 
isolation while patient (cc) had evidence of a sixteenfold 
increase in the HSV CF antibody titre which must have 
occurred between 1 and 8 weeks after HSV was first 
isolated. Patient (m) showed a fourfold rise in HSV CF 
antibody titre which was recorded in a serum provided at 2 
weeks after initial isolation of HSV from a throat swab.
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4.11.4 Transmission of HSV bv renal donors
An investigation was made into the possibility that 
neurones in parasympathetic ganglia within the transplanted 
kidneys may have harboured latent HSV which subsequently 
reactivated and infected the renal allograft recipients. 
The HSV serostatus immediately pretransplant was known for 
34 transplant recipients and their respective 2 6 renal 
donors, 6 of whom provided both their kidneys. Of the 19 
HSV-seropositive patients who each received their kidney 
from an HSV-seropositive donor, 16 (d,i,m,n,r,v,x,y,z,ff,
jj,kk,qq,rr,ss,tt) developed HSV infection after renal 
transplantation while 3 (p,bb,cc) of the 6 (c,p,t,aa,bb,cc) 
HSV-seropositive recipients of a kidney from an HSV- 
seronegative donor had evidence of post transplantation HSV 
infection which was most likely due to reactivation of the 
virus. None of the 9 renal allograft recipients who were 
seronegative for HSV immediately pretransplant subsequently 
developed HSV infection though 5 of them (k,s,gg,ii,mm) had 
each been transplanted with a kidney whose donor was 
seropositive for HSV.
4.12 Clinical details
4.12.1 Source of HCMV infection
Many studies have shown the renal allograft to be one 
source of post transplantation HCMV infection and these 
observations have been confirmed during the course of this 
project. The HCMV serostatus was available for 31 donors
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who provided kidneys for 37 renal allograft recipients, 12 
kidneys being received from 6 cadaveric donors. Sera from 
28 of the renal donors were tested for antibody to HCMV by 
the modified CFT while the HCMV serostatus of the other 3 
donors was determined in the donating hospital by FAT or 
RIA.
Post transplantation HCMV infection developed in all 8 
HCMV-seronegative renal allograft recipients (a,b,c,d,f,i,j 
k) whose kidney donors were seropositive for HCMV. By 
contrast, no evidence of HCMV infection was ever found in 
the 9 HCMV-seronegative patients (aa,cc,ff,gg,hh,ii,jj,mm, 
pp) who each received a kidney from a donor known to be 
seronegative for HCMV. The 8 individuals (l,m,s,t,u,x,y, 
qq) who were seropositive for HCMV immediately 
pretransplant and whose kidney donors were also HCMV- 
seropositive all showed evidence of HCMV infection after 
the transplant operation. Of the 12 patients (n,p,r,v,z, 
bb,dd,kk,11,rr,ss,tt) who were also seropositive for HCMV 
prior to renal transplantation but who each received a 
kidney from an HCMV-seronegative donor, 8 (n,p,r,v,z,rr,ss, 
tt) developed HCMV infection which was assumed to be 
reactivation of latent virus.
Maintenance of the renal allograft was shown to be 
unnecessary for the development of post transplantation 
HCMV and HSV infection. One patient suffered acute 
rejection and underwent nephrectomy 8 days after the 
transplant operation. Although no post transplantation 
urine samples or throat swabs were submitted for tissue
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culture, serum specimens (taken between 4 and 9 weeks after 
the transplant operation), showed a fourfold rise in HCMV 
and HSV CF antibody titres, no such increases being 
observed in a preceding serum obtained at 2 weeks post 
transplantation.
4.12.2 Symptoms
Table 6 summarizes the frequency of symptoms in 
patients with primary HCMV infection, reinfection and/or 
reactivation or no evidence of active HCMV infection. Only 
1 (9.1%) of the 11 renal allograft recipients with primary 
HCMV infection remained asymptomatic while 5 (25%) of the
20 patients with reinfection and/or reactivation were free 
of symptoms. Of the 16 transplant recipients who showed no 
evidence of active HCMV infection, 9 (56%) were
symptomatic. Symptoms developed in 3 of the 6 renal 
allograft recipients with secondary HSV infection in the 
absence of HCMV infection. Not all patients developed all 
symptoms and within each group of patients the timing of 
the onset and duration of symptoms was variable (Figure 
65) . However, a clustering of symptoms was evident within 
the first few months after the transplant operation and 
again at the onset of the second year post-operatively.
(a) Primary HCMV infection (Figure 65A)
Inpatients (a), (c) , (d) , (e) , (g) , (h) , (i) and (j)
there was a close temporal relationship between the timing 
of the fourfold or greater rise in HCMV CF antibody titre
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Table 6 The incidence of clinical findings
The frequency of leucopenia, 
thrombocytopenia, acute and chronic 
rejection, nephrectomy, pyrexial illness and 
abnormal liver function tests is shown in 
each of 11 renal allograft recipients with 
primary HCMV infection, 20 with reinfection 
and/or reactivation and 16 with no evidence 
of active HCMV infection. Also included in 
the Table is the frequency of symptoms in 6 
patients in whom evidence of active HSV but 
not HCMV infection was found.
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Figure 65A Clinical findings: Primary HCMV infection
The figure shows the timing of symptoms 
in each of 11 renal allograft recipients 
(a to k) with primary HCMV infection. 
The following symbols are used:-
H :  leucopenia
thrombocytopenia
pyrexial illness
acute rejection
chronic rejection
[ j: abnormal liver function tests.
In those cases where only 1 or 
2 liver enzymes are significantly 
increased these are identified 
by the appropriate abbreviation.
Fn : nephrectomy at n weeks post 
transplantation
L
t :
I :
t '
onset of azathioprine therapy
HCMV isolated from a urine sample
HCMV isolated from a throat swab
simultaneous isolation of HCMV from 
a urine sample and a throat swab
- : no viral isolates.
A solid line below the line of the 
patient indicates the time interval 
between consecutive sera, the last of 
which showed a fourfold or greater rise 
in HCMV CF antibody titre.
In
di
vi
du
al
 
pa
ti
en
ts
(k)-
V/777777//7/77/7/ /, T2//'H///////77//////77/;/7\ F64
I S G O T / S G P T
(h)-
(f>
(e>
Y///77///2/.//777/7T77/777777 /7777/77.Z/77Z/7/Z/7/ \^  4 6(d>
^/77777777//////7///7777777l F50
( C ) .
A s y m p t o m a t i c
(a>
We e k s  po st t r a n s p l a n t a t i o n
and the onset of symptoms. The time interval between
consecutive serum samples from each patient often precluded
immune response and the onset of symptoms but in patient 
(d) an episode of leucopenia and in patient (g) a pyrexial 
illness clearly preceded the fourfold or greater rise in 
HCMV CF antibody titre by at least 1 week.
Urine samples and/or throat swabs obtained from 
patients (a), (e) , (g) , (h) and (j) at the onset of
symptoms failed to yield HCMV in culture while in patient 
(d) an episode of leucopenia and first isolation of HCMV 
were coincident. In 5 renal allograft recipients 
(a,e,g,h,i), the onset of symptoms preceded first isolation 
of HCMV by between 5 and 11 weeks. Patients (e) , (g) and
(i) continued to shed HCMV from the urine and/or throat 14 
to 38 weeks after all symptoms had resolved. Throughout 
the period of observation patient (b) remained asymptomatic 
although HCMV was consistently isolated from urine
specimens provided between 7 and 14 weeks after the 
transplant operation. Symptoms were initially noted in 
patient (k) at 56 weeks post transplantation but
insufficient data are available to allow an accurate 
temporal correlation to be made either with virus isolation 
or the humoral immune response. Of the 6 renal allograft 
recipients who received azathioprine, 4 (f,h,i,k) developed 
symptoms which were first recorded between 0 and 12 weeks 
after the onset of therapy.
an accurate correlation
frorn^being made
between the humoral
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Acute graft rejection was noted in 6 renal transplant 
recipients (c,d,e,h,j,k). Urine obtained from patients 
(d), (h) and (j) at the time of acute renal failure did not
yield HCMV in culture. Patients (c) and (d) both shed HCMV 
in urine taken 1 and 2 weeks prior to the onset of acute 
rejection which in patient (c) proceeded to chronic 
rejection and nephrectomy at 3 0 weeks post transplantation. 
The onset of HCMV shedding in the urine of patients (e) and 
(h) followed an episode of acute rejection by 6 weeks but 
no specimens were submitted for culture during the 
intervening period. Chronic rejection was first observed 
in patients (c), (d) , (f) and (h) at 2, 24, 64 and 12 weeks
respectively after initial HCMV isolation. During the
period of chronic rejection, 5 of the 7 urine specimens 
submitted by patient (c) and all 6 of those provided by 
patient (h) yielded HCMV in culture while virus was
isolated from only 1 of 6 urine samples obtained from 
patient (d) . No specimens were provided by patient (f)
during the episode of chronic rejection. Nephrectomy was 
undertaken in patients (c), (d), (h) and (j) at 30, 146, 64
and 8 weeks respectively after the transplant operation.
(b) Reinfection and/or reactivation (Figures 65B and C) 
Of those patients who shed HCMV post-operatively, (1),
(n) , (o) , (p) , (q) , (r) , (s) and (t) remained asymptomatic
when a fourfold or greater rise in HCMV CF antibody titre 
was detected. A close temporal relationship was observed 
between a thirty two fold increase in HCMV CF antibody
68
Figure 65B Clinical findings: Reinfection and/or
reactivation of HCMV
The figure shows the timing of symptoms 
in each of 12 renal allograft recipients 
(l,m,n,o,p,q,r,s,t,u,v,w) with
reinfection and/or reactivation of HCMV 
and from whom the virus was isolated. 
The following symbols are used:-
leucopenia
thrombocytopenia
pyrexial illness
acute rejection
chronic rejection
I Is abnormal liver function tests.
In those cases where only 1 or 
2 liver enzymes are significantly 
increased these are identified 
by the appropriate abbreviation.
Fn : nephrectomy at n weeks post 
transplantation
i:
t :  
I :
onset of azathioprine therapy
HCMV isolated from a urine sample
HCMV isolated from a throat swab
simultaneous isolation of HCMV from 
a urine sample and a throat swab
— : no viral isolates.
A solid line below the line of the 
patient indicates the time interval 
between consecutive sera, the last of 
which showed a fourfold or greater rise 
in HCMV CF antibody titre.
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Figure 65C Clinical findings: Reinfection and/or
reactivation of HCMV
The figure shows the timing of symptoms 
in each of 8 renal allograft recipients 
(x,y,z,qq,rr,ss,tt,uu) with reinfection 
and/or reactivation of HCMV but from whom 
the virus was never isolated. The 
following symbols are used:-
leucopenia
thrombocytopenia
pyrexial illness
acute rejection
: chronic rejection
| |: abnormal liver function tests.
In those cases where only 1 or 
2 liver enzymes are significantly 
increased these are identified 
by the appropriate abbreviation.
Fn : nephrectomy at n weeks post 
transplantation
A : onset of azathioprine therapy
t : HCMV isolated from a urine sample
^ : HCMV isolated from a throat swab
X simultaneous isolation of HCMV from a urine sample and a throat swab
— : no viral isolates.
A solid line below the line of the 
patient indicates the time interval 
between consecutive sera, the last of 
which showed a fourfold or greater rise 
in HCMV CF antibody titre.
Weeks post transplantation
titre and acute rejection in patient (m) while in patients 
(o) , (p) and (t) acute rejection clearly preceded the
fourfold or greater rise in the HCMV CF antibody titre by
at least 2 to 5 weeks. Patient (u) showed a fourfold rise
in HCMV CF antibody titre in a serum provided at 8 and 4 
weeks after the onset of leucopenia and thrombocytopenia 
respectively. Of the 2 renal allograft recipients in whom 
a fourfold or greater rise in HCMV CF antibody titre was 
never detected, patient (w) remained asymptomatic 
throughout while patient (v) had episodes of acute 
rejection, leucopenia and abnormal liver function tests 
during the first 10 weeks after the transplant operation.
Patients (1), (n), (q), (r), (s) and (w) remained free
of symptoms during the first year post transplantation 
although HCMV was frequently isolated from urine samples 
and/or throat swabs. In patient (u) , leucopenia and 
thrombocytopenia were first recorded at 10 and 6 weeks 
respectively prior to the onset of HCMV isolation while a 
raised level of serum ^ G T  was observed between 16 and 20 
weeks after first virus isolation. Patient (v), from whose 
urine HCMV was isolated on 8 occasions between 5 and 31 
weeks post transplantation, was symptomatic as described in 
the previous paragraph. Of the 4 transplant recipients who 
received azathioprine, 3 (l,m,n) developed abnormal liver
function tests between 2 and 3 weeks after the onset of
therapy. In patient (n) , a pyrexial illness was noted 1 
week after commencing azathioprine while in patient (1) 
acute rejection progressing to chronic rejection was
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reported 16 weeks after starting azathioprine.
Five renal allograft recipients (m,o,p,t,v) 
experienced 1 or more episodes of acute rejection during 
the first year after the transplant operation and these 
were all recorded within the first 8 weeks post 
transplantation. Urine taken from patients (o) and (t) at 
the onset of acute rejection failed to yield HCMV in tissue 
culture while virus was isolated from urine provided by 4 
renal allograft recipients (m,o,p,v) between 3 and 7 weeks 
after the onset of acute rejection. In patient (t) , the 
only urine to yield HCMV in culture was taken 1 week before 
an episode of acute rejection. After acute rejection had 
resolved, patients (m) , (p) and (t) remained asymptomatic
while patient (o) proceeded to chronic rejection and graft 
failure at 53 weeks post transplantation. During this 
episode of chronic rejection, HCMV was isolated from 2 of 
the 8 urine samples provided. Nephrectomy was undertaken 
in 2 of this group of recipients (o and u ) at 53 and 47 
weeks respectively after the transplant operation.
Of the 8 patients (x,y,z,qq,rr,ss,tt,uu) with 
reinfection and/or reactivation of HCMV but from whom the 
virus was never isolated, 1 (ss) remained asymptomatic 
throughout the period of observation. Five renal allograft 
recipients (x,y,z,rr,uu) had abnormal liver function tests. 
Patient (rr) showed a raised serum ^GT level from the 
onset of renal transplantation while in patient (y) 
abnormal liver function tests were first observed at least
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6 weeks prior to the fourfold rise in the HCMV CF antibody 
titre. In patients (z) and (uu) , there was a close 
temporal relationship between the fourfold or greater rise 
in HCMV CF antibody titre and the onset of abnormal liver 
function tests. A raised level of serum ^  GT in patient 
(x) which was initially observed at 60 weeks post 
transplantation persisted up to 3 years after the 
transplant operation. The onset of leucopenia in each of 
patients (z) , (qq) and (tt) clearly preceded the fourfold 
or greater rise in the HCMV CF antibody titre by a minimum 
of 3, 4 and 7 weeks respectively. Neither of the 2 renal 
allograft recipients (y and z) who received azathioprine 
developed symptoms after receiving therapy. Acute 
rejection was noted in patients (x) and (z) 1 week after
the transplant operation and at least 4 and 3 weeks 
respectively before the fourfold or greater rise in the 
HCMV CF antibody titre. In patient (uu), there was an 
episode of acute rejection 9 weeks after the transplant 
operation but it was not possible to accurately relate this 
to the timing of the fourfold rise in the HCMV CF antibody 
titre. None of the patients in this group experienced 
chronic rejection or underwent nephrectomy.
Clinical virologic correlations were also unable to 
distinguish the 8 renal allograft recipients (l,m,s,t,u,x, 
who each received a kidney from an HCMV-seropositive 
donor and at risk of reinfection by a donor strain of virus 
from the 8 patients (n,p,r,v,z,rr,ss,tt) who each received 
their kidney from an HCMV-seronegative donor and most
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likely experienced reactivation of endogenous virus.
(c) No active HCMV infection (Figure 65D)
Of the 16 renal allograft recipients in whom there was 
no evidence of active HCMV infection, 8 (aa,cc,ff,hh,ii,kk, 
mm,pp) developed symptoms. A pyrexial illness was noted in 
patient (ff) at 1 week post transplantation while 
leucopenia of 1 week duration was first recorded in patient
(ii) at 21 weeks after the transplant operation. Abnormal 
liver function tests were observed in 4 renal allograft
recipients (hh, ii, kk, pp) . In patients (hh) and (ii) , 
abnormal liver function tests were initially recorded at 1 
and 7 weeks respectively post transplantation. Abnormal 
liver function tests in patient (kk) were first noted at 52 
weeks after the transplant operation coincident with the 
onset of azathioprine therapy while in patient (pp) 
abnormal liver function tests were observed from 69 weeks
post transplantation. Two (ii, kk) of the 4 renal
transplant recipients who received azathioprine developed 
symptoms very soon after receiving therapy. Episodes of 
acute rejection occurring at intervals of 1 to 53 weeks
after the transplant operation were recorded in 5 renal 
allograft recipients (aa,cc,ff,ii,mm). In 2 patients (aa 
and ii), acute rejection proceeded to chronic rejection and 
nephrectomy at 3 3 and 20 weeks respectively post 
transplantation. Sixty seven weeks after receiving a renal 
allograft, patient (cc) suffered graft failure and 
subsequent nephrectomy on account of CsA toxicity.
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Figure 65D Clinical findings: No active HCMV
infection
The figure shows the timing of symptoms 
in each of 8 renal allograft recipients 
(aa,cc,ff,hh,ii,kk,mm,pp) with no
evidence of active HCMV infection. The
following symbols are used:-
leucopenia
: thrombocytopenia
: pyrexial illness
: acute rejection
\//\'* chronic rejection
| |: abnormal liver function tests.
In those cases where only 1 or 
2 liver enzymes are significantly 
increased these are identified 
by the appropriate abbreviation.
Fn : nephrectomy at n weeks post 
transplantation
I
t
4
t
onset of azathioprine therapy
HCMV isolated from a urine sample
HCMV isolated from a throat swab
simultaneous isolation of HCMV from 
a urine sample and a throat swab
- : no viral isolates.
A solid line below the line of the 
patient indicates the time interval 
between consecutive sera, the last of 
which showed a fourfold or greater rise 
in HCMV CF antibody titre.
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DISCUSSION
5.1 Incidence of HCMV infection
In this study 31 (66%) of the 47 renal allograft
recipients developed HCMV infection on the basis of 
serology and/or virus isolation. Eleven (35%) were primary 
HCMV infections while 20 (65%) were secondary, either
reinfection and/or reactivation. This incidence is in 
accord with previous studies which have shown that between 
43% and 92% of renal transplant patients develop HCMV 
infection post-operatively (Glenn, 1981).
5.2 HCMV isolation
Only 6 (1.2%) of the 490 urine samples and none of the 
449 throat swabs submitted for tissue culture had to be 
reinoculated on to a newly prepared monolayer of Flow 2 002 
cells after the original culture had become contaminated. 
This low frequency of contamination is accounted for by the 
filtration of all specimens prior to inoculation of the 
cell monolayer. Specimen filtration may also have depleted 
the number of epithelial cells containing infectious virus. 
The isolation data reported in this study may therefore 
underestimate the frequency of HCMV shedding. However, a 
pilot study using unfiltered specimens resulted in an 
unacceptably high level of culture contamination.
In cultures showing a cpe, plaques developed an 
average of 26 days (range 7 to 54) after inoculation of the 
cell monolayer. Many investigators dispose of apparently 
uninfected cultures after 3 to 4 weeks of incubation (Lui 
et al.. 1987). However, this study shows that 38 (40.8%) of
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the 93 cpes identified as HCMV were first observed more 
than 4 weeks after specimen inoculation. This has 
important implications when considering the effect of 
antiviral therapy since premature disposal of cultures may 
underestimate HCMV shedding. The data shown here confirm 
that incubation may need to be continued for at least up to 
8 weeks after specimen inoculation before any clinical 
sample can be reported as negative for HCMV (Sorbello et 
al. , 1988) . However, a laboratory dealing with large
numbers of specimens for the routine screening of HCMV has 
to maintain a balance between achieving the best possible 
sensitivity at the most effective cost both in monetary and 
labour terms.
Twenty two specimens yielded a cpe that progressed 
slowly and could only be identified as HCMV on the basis of 
plaque morphology. Such plaques were isolated from both 
urine samples and throat swabs obtained at intervals 
throughout the period of study and from patients with 
primary HCMV infection or reinfection and/or reactivation. 
Specimens taken from any one individual also varied in the 
time taken to show a cpe. Renal allograft recipients with 
primary infection usually only shed 1 strain of HCMV 
(Wertheim et al.. 1983). Therefore, the inability of some 
plaques to progress in tissue culture cannot always be 
explained on the basis of inter-strain variation. Some 
urine samples may have been toxic to the cell monolayer and 
inhibited HCMV replication. Alternatively, the condition
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of some cell monolayers may not have favoured HCMV 
infection. Indeed, embryonic lung fibroblasts may vary by 
as much as tenfold in their susceptibility to HCMV 
infection (Stirk and Griffiths, 1987). When dealing with 
large numbers of specimens it is not always possible to 
maintain subconfluent monolayers of cells which may 
occasionally have overgrown and therefore provided sub- 
optimal conditions for viral replication (Tanaka et al., 
1985). Rapid diagnostic tests such as the hybridot assay 
do not require virus replication and should theoretically 
detect HCMV irrespective of its ability to grow in culture. 
Furthermore, highly specific probes are available that do 
not cross react with contaminating bacterial DNA. DEAFF 
can detect HCMV after 6 hr of incubation in tissue culture 
but does not rely on a cpe to become apparent. This method 
should theoretically also detect infectious virus prior to 
the cell monolayer being overgrown with bacterial or fungal 
contaminants.
The usefulness of new procedures in detecting HCMV in 
clinical specimens is commonly assessed by reference to 
virus isolation and some assays have been shown to be 
highly specific and sensitive. The study reported here 
shows that some patients with serological evidence of 
active HCMV infection provided urine samples that failed to 
yield HCMV in tissue culture. These specimens may 
nevertheless have contained HCMV that could not be detected 
by conventional techniques. Whether new rapid diagnostic 
procedures can detect such virus particles remains unclear.
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However, a prospective study correlating the HCMV-specific 
immune response and virus isolation with DEAFF or hybridot 
assay may permit a more accurate assessment of the 
sensitivity of these new techniques. In all reported 
studies to date isolation of HCMV has been, albeit 
sometimes slightly, more sensitive, than other methods of 
virus detection. However, positive results by DEAFF or 
hybridot assay in the absence of HCMV isolation should not 
simply be disregarded as spurious reactions without taking 
into account other parameters of infection such as serology 
or symptoms.
HCMV was isolated more frequently from urine specimens 
provided by patients with primary HCMV infection than those 
with reinfection and/or reactivation. Of the 108 urine 
samples obtained from 11 renal allograft recipients with 
primary HCMV infection, 44 (40.7%) yielded the virus in
tissue culture. However, HCMV was cultured from only 39 
(17.5%) of the 222 urine specimens taken from 20 patients 
with reinfection and/or reactivation. Pre-existing humoral 
and cellular immunity in HCMV-seropositive transplant 
recipients most likely limited viral dissemination. 
However, the immune response could not entirely contain 
replication and spread of the virus since HCMV was isolated 
from urine samples obtained up to 47 or 39 weeks post 
transplantation in patients with primary HCMV infection or 
reinfection and/or reactivation respectively. Furthermore, 
there was no obvious difference in the time interval
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between transplantation and first detection of HCMV 
shedding in allograft recipients who were HCMV-seronegative 
or -seropositive immediately pretransplant. HCMV is highly 
cell associated and therefore may escape circulating 
antibodies while cell-mediated immunity is compromised by 
immunosuppressive therapy (Tamura et al., 1980).
HCMV was isolated regularly but not always 
consistently from 9 of the 10 patients with primary 
infection who showed an HCMV-specific humoral response 
during the first year after renal transplantation. The 
pattern of HCMV isolation in renal allograft recipients 
with reinfection and/or reactivation was more varied: 
urine samples provided by 1 patient consistently yielded 
HCMV in tissue culture while specimens taken from others 
did so intermittently or not at all. This may be related 
to non- homogenous distribution of the virus in specimens. 
From the variable nature of HCMV isolation it is clear that 
serial urine samples must be submitted for tissue culture 
and that a single negative culture does not exclude active 
HCMV infection.
The pattern of HCMV isolation may reflect the ability 
of the immune system to contain the infection. However, 
virus isolation could not be correlated with 
immunosuppressive therapy. CsA is excreted primarily 
unchanged in the urine but HCMV isolation could not be 
related to deterioration in renal function when increased 
blood levels of CsA and further immunosuppression may 
favour virus dissemination. In any event, blood levels of
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CsA are monitored regularly and maintained within the
therapeutic range. HCMV is known to remain latent in the
host after primary infection but not all individuals may
harbour HCMV in a form that can be reactivated. HCMV-
seropositive renal transplant recipients who receive a 
kidney from an HCMV-seropositive donor may be reinfected 
with HCMV of donor origin. In this project, restriction 
endonuclease analysis of HCMV isolates was not undertaken 
but the pattern of virus isolation could not be related to 
donor HCMV serostatus. Indeed, of the 8 renal allograft 
recipients with reinfection and/or reactivation of HCMV who 
each received a kidney from an HCMV-seropositive donor, 3 
provided urine samples from which virus was never isolated.
coats HCMV particles present in clinical samples and 
assists in the binding of the virus to receptors present on 
the target cell (McKeating et al.. 1987). Based on a
limited analysis of a single urine specimen taken from each 
of 40 renal transplant patients, only 3 had a level
below the limit of normal. No correlation was noted 
between the concentration of /32m anc* virus isolation.
Of the 3 06 throat swabs submitted for tissue culture 
by all patients with serological evidence of active HCMV 
infection, only 10 (3.2%) yielded HCMV in culture.
Isolation of HCMV from throat swabs was coincident with or 
followed but in no case preceded isolation of the virus 
from the urine. HCMV was isolated from the throat but not 
the urine obtained from 2 renal transplant patients, 1 with
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primary infection and the other with reinfection and/or 
reactivation. Therefore, in most cases adequate information 
on HCMV shedding following renal transplantation can be 
gained by culturing urine samples alone. In only 
exceptional cases (e.g. anuria) would additional diagnostic 
information become available from throat swabs.
5.3 Serology
5.3.1 CFT
The CFT used in this project for the detection of 
antibodies to HCMV was specific and did not cross react 
with HSV or VZV. The modified CFT proved to be more 
sensitive than the standard test. One patient, who 
immediately pretransplant had an HCMV antibody titre of 1:4 
in the modified CFT, must have been seropositive for HCMV 
but would have been regarded as seronegative by the 
standard assay. In 17 of the 18 renal allograft recipients 
who showed a fourfold or greater rise in the HCMV CF 
antibody titre, this rise was first recorded between 3 and 
16 weeks post transplantation. The final patient to show a 
fourfold rise in HCMV CF antibody titre did so between 18 
and 25 weeks after the transplant operation. In all 18 
renal allograft recipients, the rise in HCMV CF antibody 
titre was maintained with minimal fluctuation until at 
least between 35 and 53 weeks post-operatively. This is in 
part attributable to the use of glycine-extracted antigen 
which is known to improve the reproducibility of the CFT 
for HCMV antibody (Pereira et al., 1982a). The results
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also show that in most patients, paired sera submitted for 
CFT beyond the first 4 months post transplantation are 
unlikely to yield clinically useful data. Indeed, by this 
time after the transplant operation the HCMV CF antibody 
titre may have reached a plateau and any preceding rise in 
titre may go undetected. Early detection of a fourfold or 
greater rise in HCMV CF antibody titre is facilitated by 
the provision of a serum immediately pretransplant which 
can be tested in parallel with sera obtained at intervals 
throughout the first year after the transplant operation. 
The timing of the fourfold or greater rise in HCMV CF 
antibody titre could not distinguish between patients with 
primary HCMV infection and those with reinfection and/or 
reactivation nor could it distinguish patients from whom 
virus was or was not isolated. However, this may be 
attributed to the frequency of sampling. Sera obtained at 
weekly intervals may have been more useful in this respect.
Many studies have reported on the insensitivity of the 
CFT (Booth et al.. 1982). However in this project, all 11 
renal allograft recipients with primary HCMV infection and 
18 of the 20 patients with reinfection and/or reactivation 
showed a fourfold or greater rise in the HCMV CF antibody 
titre. This rise was first recorded prior to or coincident 
with the onset of HCMV isolation in 7 of the 9 transplant 
recipients with primary infection and 5 of the 8 patients 
with reinfection and/or reactivation who shed the virus 
post-operatively and for whom sufficient data are 
available. Furthermore, a fourfold or greater rise in the
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HCMV CF antibody titre was detected in 1 patient with 
primary HCMV infection when a significant increase in HCMV- 
IgM but not IgG was noted. The results of this project 
also show that in a small proportion of renal allograft 
recipients (3/31 [9.6%] in this study) a fourfold or
greater rise in HCMV CF antibody titre may also be detected 
when changes in HCMV-IgM and IgG levels are negative or 
equivocal. Therefore, the CFT may be a useful adjunct to 
the battery of investigations in the diagnosis of HCMV 
infection in renal allograft recipients particularly in 
those with primary infection. However, the data also shows 
that 2 patients with reinfection and/or reactivation of 
HCMV who shed the virus post-operatively did not show a 
fourfold or greater rise in HCMV CF antibody titre. This 
may be related to strain heterogeneity described by Faix 
(1985). Therefore, the inability to detect a significant 
increase in HCMV CF antibody levels in some renal 
transplant recipients does not exclude active infection. 
Indeed, some authors have reported significant increases in 
HCMV-IgM levels prior to a fourfold or greater rise in the 
HCMV CF antibody titre (Tardy et al.. 1987).
The CFT also proved to be more reliable than HCMV-I^G 
ELISA in determining the HCMV serostatus of renal donors 
and recipients immediately pretransplant. Of 73 sera 
tested by both methods, concordant results were obtained in 
67 (91.7%). By retrospective analysis of the pattern of
HCMV isolation, the clinical findings and careful
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examination of donor/recipient pairings, it was considered 
that the HCMV CF antibody titre more accurately reflected 
the HCMV serostatus in 7 sera with uncertain HCMV-IgG 
levels. Although measurement of HCMV-IgG levels by ELISA 
may be a practical solution to quickly determining donor 
and recipient HCMV serostatus immediately pretransplant, 
the results of this project show that all sera should be 
retested by CFT at the earliest opportunity. The CFT is 
itself impractical as a rapid diagnostic test on account of 
the overnight incubation step. Recently, a latex method for 
the rapid detection of HCMV antibody has been shown to be 
useful in determining donor and recipient serostatus 
immediately pretransplant (Wreghitt, 1988). However, time 
did not permit an assessment to be made of the usefulness 
of the latex test in determining the HCMV serostatus in 
those sera with uncertain HCMV-IgG levels.
5.3.2 HCMV-IaG
Labsystems ELISA was routinely used to determine HCMV- 
IgG levels in all sera. The ELISA was specific and did not 
cross react with antibodies to HSV and VZV. However, 
considerable variation was noted in the HCMV-IgG level in 
some sera when tested in different batches of the ELISA. 
This is probably attributable to batch to batch variation 
in reagents and the amount of antigen bound to wells of the 
ELISA. Operator error in, for example, pipetting may also 
contribute. The variability in estimated levels of HCMV- 
IgG emphasizes the need to retest all sera within a single
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batch of the ELISA when comparing antibody levels in a 
number of sera taken from 1 or more individuals.
Although there was good overall correlation between 
HCMV-IgG levels and HCMV CF antibody titres, there was 
considerable variation between HCMV-IgG levels in sera with 
the same titre of HCMV CF antibody. This confirms the 
findings of other investigators (Nielsen et al. , 1986).
Different serological assays most likely measure different 
antibodies. Indeed, IgG subclasses fix complement in the 
order IgG3 > IgGl > IgG2 > IgG4 but all may be equally 
detected by ELISA. Furthermore, renal allograft recipients 
may vary in the subtype and epitope specificity of 
antibodies produced.
HCMV-IgG ELISAs produced by different manufacturers 
may also give conflicting data. In this project, 6 (8.3%) 
of 72 sera tested by both Labsystems and NBL ELISA yielded 
disconcordant results. This may reflect differences 
between assays in the antigens, reagents, serum dilutions 
and incubation times used. Unfortunately, reference sera 
against which the sensitivity and specificity of an ELISA 
can be compared are as yet unavailable. All disconcordant 
results in this study were from sera subsequently found to 
be positive for HCMV by CFT and of these 2 were provided by 
renal donors. Confusion as to the HCMV serostatus of 
kidney donors and recipients may result in an HCMV- 
seronegative transplant patient receiving a kidney from a 
donor thought to be seronegative for HCMV but who is in 
fact seropositive. Allograft recipients in this category
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may not be considered as being at high risk of developing 
HCMV infection and prophylactic therapy may not be 
instigated.
Early diagnosis of HCMV infection by measuring virus- 
specific IgG proved disappointing in the 11 renal 
transplant patients with primary infection. A significant 
increase in HCMV-IgG was noted in 3 patients on or before 
the onset of virus isolation and in 4 transplant recipients 
prior to or coincident with a fourfold or greater rise in 
the HCMV CF antibody titre. However, in patients with 
reinfection and/or reactivation measurement of HCMV-IgG 
levels by ELISA proved useful. Of 10 renal allograft 
recipients who shed HCMV post-operatively and from whom 
sufficient data are available, 6 showed a significant 
increase in HCMV-IgG on or before the onset of virus 
isolation. Seven of the 20 patients with serological 
evidence of reinfection and/or reactivation had evidence of 
a significant increase in HCMV-IgG prior to a fourfold or 
greater rise in the HCMV CF antibody titre while in 10 
other patients the fourfold or greater rise in HCMV CF 
antibody titre and significant increase in HCMV-IgG were 
coincident. Furthermore, 2 renal transplant recipients with 
reinfection and/or reactivation of HCMV showed a 
significant increase in HCMV-IgG but not CF antibody post- 
operatively. These data clearly show the usefulness of the 
HCMV-IgG ELISA in the early detection of HCMV infection in 
renal allograft recipients with reinfection and/or
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reactivation. This probably reflects the ability of this 
group of patients to mount an early anamnestic response by 
clonal expansion of circulating memory lymphocytes which 
are absent in HCMV-seronegative recipients. CF antibody 
may appear later in the course of HCMV infection than IgG 
of a subclass which mediates other in vivo functions 
including neutralization or ADCC and which is not detected 
by CFT. The magnitude of the HCMV-IgG response in 
transplant recipients with reinfection and/or reactivation 
could not distinguish patients from whom HCMV was or was 
not isolated. However, the immune response is influenced by 
a variety of factors including the host's age and HLA type. 
Therefore, unless large numbers of individuals are studied, 
it may be difficult to correlate antibody levels with other 
parameters of HCMV infection. The magnitude of the HCMV- 
IgG response was also unable to distinguish HCMV- 
seropositive individuals who received their kidney from 
HCMV-seronegative donors and most likely to experience 
reactivation of endogenous virus from those who received 
their kidney from HCMV-seropositive donors and also at risk 
of reinfection by donor virus. However, not all renal 
allografts transmit HCMV post-operatively.
In patients with primary infection, HCMV-IgG levels 
gradually increased between 6 and 14 weeks to the end of 
the first year post transplantation while during the same 
period HCMV-IgG levels decreased in 19 of the 20 patients 
with reinfection and/or reactivation. In the absence of a
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serum taken immediately pretransplant the pattern of the 
HCMV-IgG response may be helpful in distinguishing renal 
allograft recipients with primary HCMV infection from those 
with reinfection and/or reactivation. Patients with 
reinfection and/or reactivation of HCMV who provide paired 
sera beyond the first 3 months post transplantation may 
show static or falling levels of HCMV-IgG. This could be 
interpreted as resolution of infection. However, the 
isolation data reported here shows that virus shedding may 
persist and antiviral therapy should not be discontinued. 
These findings provide further evidence as to the inability 
of the humoral immune response to contain HCMV infection in 
some renal transplant recipients.
5.3.3 HCMV-IgM
Labsystems ELISA was routinely used for the 
determination of HCMV-IgM levels in all sera. In some 
studies, macroglobulins specific for HCMV have been shown 
to cross react with other herpesvirus antigens (Hanshaw et 
al.. 1972). The findings in this study are consistent with 
those of other investigators (Rasmussen et al. . 1982) who
found no cross reaction between HCMV-IgM and HSV or VZV 
antigens.
Heterotypic IgM antibody responses have been reported 
in as many as 3 0% of patients with IMN and polyclonal 
stimulation of B lymphocytes by EBV seems to be the most 
likely explanation (Schmitz, 1982). In this project, none 
of the 44 patients examined had evidence of heterophile
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antibodies immediately pretransplant. Time did not permit 
the testing for heterophile agglutinins in all sera from 
all patients. However, in each renal allograft recipient 
with an HCMV-IgM response that serum showing the highest 
recorded level of HCMV-IgM was negative for heterotypic 
antibody.
HCMV-IgM may be falsely positive in the presence of 
IgM-RF which is an IgM antibody to IgG circulating in the 
blood of patients with certain collagen vascular disorders. 
IgM-RF may complex with HCMV-specific IgG and adsorb to the 
specific antigen of the ELISA. It may then cross react 
with conjugated anti-IgM and produce false-positive 
results. The data reported here show that in renal 
allograft recipients with increasing levels of IgM-RF 
during the first few months post-operatively, there was a 
close temporal relationship between the HCMV-IgM and IgM-RF 
response. This probably reflects the on-going interaction 
between HCMV and the immune system. Many investigators 
pretreat all sera to remove IgM-RF prior to testing for 
HCMV-IgM (Stagno et al. , 1985). However, the results of
this project show that there was no obvious correlation 
between levels of IgM-RF and HCMV-IgM in 13 6 sera submitted 
by 33 patients. Furthermore, only 4 of these sera had an 
IgM-RF level above the upper limit of normal. If IgM-RF 
caused false-positive reactions in sera tested by 
Labsystems ELISA it may also be expected to yield falsely 
elevated IgM levels to any other virus when tested by
87
indirect ELISA. However, sera with equivocal or positive 
levels of HCMV-IgM were clearly negative when tested for 
rubella-IgM. In reconstruction experiments, IgM-RF added 
to an HCMV-IgG positive but HCMV-IgM and IgM-RF negative 
serum did not raise the level of HCMV-IgM when tested by 
Labsystems indirect ELISA. These data clearly show that 
IgM-RF does not interact with the Labsystems ELISA and 
create falsely elevated HCMV-IgM levels. Salonen et al. 
(1980) have reported similar findings using another HCMV- 
IgM ELISA. It may be that the use of a sensitive assay 
allows the virus-specific IgM to be diluted beyond the 
concentration of IgM-RF thus eliminating the potential for 
interference. Indeed, attempts to remove IgM-RF may also 
deplete HCMV-IgM and produce false negative results. Some 
studies have used a latex-slide agglutination method to 
identify RF positive sera (Rasmussen et a l ., 1982).
However, this is a qualitative test and non-specific 
reactions may occur due to, for example, hyperlipidaemia 
(Hechemy and Michaelson, 1984). In this project the 
specificity of the RF latex assay was 40% in comparison to 
measurement of IgM-RF by ELISA. Therefore, testing by 
latex-slide agglutination alone vastly overestimates the 
number of IgM-RF positive sera.
Considerable effort has gone into developing a 
reliable assay for HCMV-specific IgM antibodies and 
numerous immunoassays have been reported. Although such 
methods may be of use in the diagnosis of acute HCMV 
infection, particularly in immunosuppressed patients who
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are at considerable risk of HCMV-induced disease, little is 
known about the temporal relationship between the onset of 
HCMV isolation and HCMV-IgM levels. An HCMV-IgM response 
may be detected prior to virus isolation (Tardy et al., 
1987) . In this project, of the 9 patients with primary 
HCMV infection from whom the virus was isolated, 4 showed 
evidence of an HCMV-IgM response at or before the onset of 
HCMV isolation. Only 3 of 12 renal allograft recipients 
with reinfection and/or reactivation had elevated HCMV-IgM 
levels at or before virus isolation. Similar findings have 
been reported by Sutherland and Briggs (1983) who used a 
MACRIA assay and showed HCMV isolation from 2 renal 
transplant recipients at 13 and 23 days prior to a 
significant increase in HCMV-IgM. The results of this 
project also show that some patients have a transient 
increase in HCMV-IgM and therefore the inability to detect 
this antibody does not exclude active HCMV infection. This 
confirms the findings of Kangro et al. (1982). Some renal
allograft recipients have been noted to maintain high 
levels of HCMV-IgM throughout the first year post 
transplantation both in this study and in others (Pass et 
al., 1983). Therefore, a significantly increased HCMV-IgM 
level is not necessarily diagnostic of acute infection.
The results of this project confirm other reports that 
renal allograft recipients with reinfection and/or 
reactivation are able to mount an HCMV-IgM response post 
transplantation (Kangro et al.. 1982). Some investigators
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have reported significantly higher levels of HCMV-IgM in 
renal transplant patients with primary HCMV infection than 
in those with reinfection and/or reactivation (Wreghitt et 
al. . 1986a). However, the results of this project do not
concur with these findings. Inter-assay variation may 
account for this discrepancy. Furthermore, unless sera 
from a number of individuals are tested within a single 
batch of any serological assay, as in this project, it may 
be difficult to compare HCMV-IgM levels between groups of 
patients. Some authors may also have pretreated certain 
sera to remove RF and inadvertently reduced the 
concentration of HCMV-IgM. Sutherland and Briggs (1983) 
have proposed that an HCMV-IgM response in renal allograft 
recipients with reinfection and/or reactivation of HCMV is 
due to reinfection by a new HCMV strain, presumably from 
the donated kidney. In this project, the highest recorded 
levels of HCMV-IgM in HCMV-seropositive patients who 
received a kidney from an HCMV-seronegative donor were not 
obviously different from those in HCMV-seropositive 
recipients of a kidney from an HCMV-seropositive donor. 
However, restriction endonuclease analysis of HCMV isolates 
was not undertaken and the number of patients studied was 
small.
In conclusion therefore, the results of this project 
show that measurement of HCMV-specif ic CF, IgM and IgG 
antibodies in each individual patient is required to 
establish the presence of an active infection at the 
earliest opportunity. In a number of cases HCMV isolation
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precedes a detectable host humoral response. This temporal 
advantage may be lost because the cpe evolves slowly. 
Therefore, rapid diagnostic methods such as DEAFF have an 
important role in the early diagnosis of HCMV infection. 
The usefulness of nucleic acid probes in this respect 
remains to be determined.
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5.4 Dot blot hybridization
5.4.1 M13 probes
Although M13 probes have been successfully employed in 
the selection of complementary clones from within a shotgun 
sequencing bank (Hu and Messing, 1982), the M13 
hybridization system described here proved to be 
disappointing. The sensitivity of the assay did not extend 
beyond the ng range although nick-translated (Spector et 
al. , 1984b) and RNA (Schuster et al. , 1986) probes have
been reported to detect pg quantities of cDNA. This may 
have been attributable to the low concentration (50ng) of 
M13 DNA in 8 ml of hybridization solution. Background 
noise also proved to be a problem. There was marked 
variation in the concentration of [a-32P] dATP from within 
different batches of the radionucleotide, a problem which 
could not be resolved after discussion with the 
manufacturers. The newly synthesized radiolabelled DNA 
strand remained attached to the M13 template but did not 
extend beyond a few hundred bp. This could not be 
explained on the basis of insufficient substrate. Second 
strand M13 synthesis was theoretically limited to within a 
few bp of cloned viral sequences by restricting [a- P] 
dATP to 33pmol per 50ng of template DNA. However, 
increasing [a-32P] dATP to 66pmol per 50ng of template DNA 
did not achieve radiolabelled M13 second strands of higher 
MWt. Consequently, most of the M13 template remained 
single stranded and able to hybridize with cDNA other than 
cloned viral-specific sequences. Replacing [a- ^P] dATP by
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biotinylated dATP was also unsuccessful in efficiently 
labelling M13 DNA possibly due to a steric hindrance effect 
of the biotin molecule attached to the nucleotide. 
However, many authors have successfully used biotinylated 
probes to detect cDNA (Leary et al.. 1983).
5.4.2 Riboprobe p GHBI
The BamHI subclone of the Hindlll E region of HCMV 
AD169 was successfully cloned in the transcription plasmid 
pGEM2 which contains promoters for both T7 and SP6 
polymerase. In all experiments T7 polymerase was used, the 
resultant transcripts having the same sense as mRNA 
originating from the same fragment of the HCMV genome. The 
magnitude of any specific hybrid signal is then 
proportional to the amount of cDNA bound to the 
nitrocellulose filter and to the number of HCMV particles 
from which the DNA was extracted. After urea-polyacrylamide 
gel electrophoresis, radiolabelled transcription products 
of predicted MWt 1400 bp were observed in addition to a 
number of transcripts of lower MWt. These latter 
transcription products may represent incompletely 
synthesized cRNA or breakdown products of full length 
radiolabelled transcripts.
In the hybridot assay, radiolabelled cRNA transcripts 
routinely detected 8 and/or 80pg of vector pGHBI DNA and 10 
and/or lOOpg of vector pEHBI DNA after 24 hr of 
autoradiography. This level of sensitivity is in accord
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with the findings of Melton et al. (1984) although Church
and Gilbert (1984) have been able to detect fg quantities 
of cDNA using a single stranded RNA probe. Background 
noise was negligible probably reflecting the reduced 
tendency of single stranded RNA to bind to nitrocellulose 
paper. The hybrid signals observed at each dilution of 
target pGHBI DNA from 800ng to 80pg increased as the 
hybridization temperature was raised from 4 0 to 60°C. This 
phenomenon probably reflects increased diffusion of 
available cRNA probe to filter bound sequences with 
increasing hybridization temperature. At 70°C the 
nitrocellulose filter became too fragile to manipulate. 
Nylon filters which are stable at 70°C were tested in the 
hybridot assay but background noise was unacceptably high 
and time did not permit reappraisal of hybridization 
conditions. When the period of hybridization was extended 
from 14 to 62 hr, the hybrid signal detected at each 
dilution of the target DNA diminished and the lower limit 
of detection was reduced by 1 log1Q. This is probably 
accounted for by sequences leaching off the filter and 
gradual degradation of the radiolabelled probe. Hybrid 
signals obtained after hybridization for 38 hr compared to 
14 hr were only marginally reduced. The sensitivity of the 
hybridot assay was not evaluated at hybridization periods 
of less than 14 hr since it was convenient if all 
hybridization reactions were allowed to proceed overnight 
(approximately 14 hr).
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The specificity of the hybridot assay was established. 
There was no cross reactivity with lOjixg of human DNA thus 
confirming the findings of Ruger et al. (1984) . 10/xg each
of HSV-1 and E.coli DNA were also negative by dot blot 
hybridization but 10/xg of HSV-2 HG52 DNA showed a hybrid 
signal equivalent to that obtained with 8pg of vector pGHBI 
DNA. However, it was not considered necessary to increase 
the stringency of the hybridot assay since HSV-2 in 
clinical samples can be readily detected by culture in 
BHK21/C13 cells. Furthermore, it would be most unlikely to 
extract microgram amounts of HSV-2 DNA from the urine of a 
renal transplant recipient as this would require the virus 
to be present in excess of 109 particles/ml. Contrary to 
other findings that RNA transcripts may react non- 
specifically with ribosomal RNA (Cova et al. . 1988), the
cRNA probe used in this project did not detect 10fig of 
ribosomal RNA. This could be attributed to the preparative 
procedure involving denaturation by sodium hydroxide which 
would degrade RNA (Anderson and Young, 1985) . The 
radiolabelled cRNA transcripts also hybridized to vector 
pGEM2 DNA, lOng of this plasmid DNA giving a hybrid signal 
equivalent to that observed with 8pg of vector pGHBI DNA. 
This cross hybridization was probably attributable to 
identical leader sequences present in both vectors. 
However, it was considered unlikely that vector pGEM2, 
recently constructed for in vitro use, would be found in 
any urine specimen.
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The sensitivity of the hybridot assay was also 
established. Radiolabelled cRNA transcripts consistently 
detected between 4.3 x 104 to 3.9 x 105 particles taken 
from any one of 3 stocks of HCMV AD169 and added to 7.2 ml 
of urine. These findings are in accord with those of Chou 
and Merigan (1983). Dot blot hybridization was more 
sensitive than electron microscopy in the detection of 
HCMV. One stock of HCMV AD169 in which no virus particles 
were observed by electron microscopy had a titre of 1.3 x 
102 pfu/ml and was also positive by hybridot assay. 
Furthermore, electron microscopy cannot distinguish between 
members of the herpesvirus group whilst the cRNA probe did 
not cross react with HSV-1 or VZV. One other advantage of 
the hybridot assay was the ability to detect non-infectious 
particles which presumably contained a DNA core that 
provided a target for the radiolabelled cRNA transcripts. 
Other diagnostic procedures such as DEAFF only detect HCMV 
which can replicate in a cell monolayer and express viral 
antigens.
Compared with HCMV isolation, the results of the 
hybridot assay were disappointing with a specificity of 67% 
and a sensitivity of 25% when 445 urine specimens were 
tested for HCMV DNA. Sixty eight urine specimens could not 
be clearly identified as either positive or negative by 
RNA-DNA hybridization. Therefore, the RNA-DNA hybridot 
assay described here was clearly less sensitive and 
specific than that described by other authors whose 
radiolabelled cRNA transcripts originated from the Hindlll
96
L fragment of HCMV AD169 (Schuster et a l . , 1986) . This
poor performance cannot be explained on the basis of 
genetic heterogeneity between viral isolates since the cRNA 
probe detected HCMV strains AD169 and Davis in addition to 
65 other independent isolates cultured from urine samples 
or throat swabs provided by 18 patients. Restriction 
endonuclease analysis of HCMV isolates was not undertaken 
but it is unlikely that any 2 individuals would shed 
identical HCMV strains. However, the cRNA probe was 
generated from the major IE gene of HCMV which does show 
heterogeneity between isolates (Chandler and McDougall, 
1986). Urinary DNase activity was observed and noted to 
reduce the sensitivity of the hybridot assay by 2 logs10 in 
reconstruction experiments. However, most viral DNA in 
clinical specimens is likely to be encapsidated. When HCMV 
particles were incubated overnight at 37°C the sensitivity 
of the hybridot assay was also reduced by 2 logs1 Q . 
Urinary proteases may have degraded the viral capsid 
protein and exposed HCMV nucleic acid to DNase. The lower 
limit of detection of cDNA was also reduced when HCMV DNA 
was added to 10/xg of either human or E.coli DNA prior to 
binding to the nitrocellulose filter. Therefore, DNA 
extracted from human epithelial cells or bacteria present 
in urine samples may also compete for available space on 
the nitrocellulose filter whose binding capacity was 8/xg of 
DNA. Smaller DNA molecules bind more efficiently to 
nitrocellulose paper than those of a higher MWt and
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therefore it is difficult to explain why human DNA reduced 
the sensitivity of the hybridot assay more effectively than 
E.coli DNA. It is possible that human DNA was fragmented 
during the preparative procedure. The poor performance of 
the hybridot assay may also be explained on the basis that 
all urine specimens had been stored at -70°C for up to 3 
years prior to testing by RNA-DNA hybridization. Long 
periods of storage in urine may have degraded the virus 
particles and/or DNA although Gibson et al. (1985) have
been able to detect polyomavirus DNA in urine specimens 
which had been stored at 4°C for up to 7 years. Attempts 
to increase the sensitivity of the hybridot assay by using 
PEG 6000 to aid precipitation of HCMV, by using alternative 
autoradiography film and by reducing the stringency of the 
procedure for washing the nitrocellulose filters after 
hybridization all proved to be unsuccessful.
Most reports investigating the usefulness of dot blot 
hybridization in the rapid diagnosis of HCMV infections 
have involved testing 1 or a few urine specimens taken from 
individuals with a variety of clinical conditions. No 
group has yet prospectively followed a cohort of renal 
allograft recipients and correlated the results of virus 
isolation and the HCMV-specific humoral response with the 
results of a hybridot assay. The study reported here shows 
virus isolation to be more sensitive than RNA-DNA 
hybridization in detecting urinary HCMV shedding post renal 
transplantation. Nine (45%) of the 20 renal allograft 
recipients from whom HCMV was isolated submitted urine
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samples found to be positive by hybridot assay on or
before the day of first HCMV isolation. Only 13 (43%) of
the 30 patients who showed an HCMV-specific humoral
response provided urine specimens which were positive by
dot blot hybridization on or before the day when a
significant increase in either HCMV-IgM, IgG or CF antibody
was first recorded. However, the significance of a positive
result in the hybridot assay is unclear since 10 patients
who remained HCMV-seronegative throughout the period of
study provided 17 urine samples which were clearly
positive by RNA-DNA hybridization. Such hybrid signals
must have been false-positives and may be attributed to
cross reaction with DNA of another virus, possibly 
human polyomavirus (e.g. BK virus)
which is shed in high titre in the urine of
some renal allograft recipients post-operatively (Gardner
et a l .. 1984). With few exceptions however, positive
results in the hybridot assay were spurious and atypical of
any pattern of virus shedding. Nevertheless,it is possible
to rehybridize the filters with a probe specific for
another virus. Radiolabelled cRNA may have been trapped on
the nitrocellulose filter by impurities originating from
the urine specimens, but the latter were routinely phenol
extracted and ethanol precipitated. Finally, false
positive signals may have resulted from incomplete
digestion of the DNA template after RNA transcription
(Melton et al.. 1984). False positive hybrid signals may be
reduced by incorporating RNase into the washing solution.
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This enzyme would digest cRNA probe not wholly 
complementary to the target DNA but time did not permit a 
detailed assessment of this approach.
Some studies correlate the sensitivity of HCMV- 
specific probes with virus isolation from urine submitted 
by individuals who usually shed HCMV in high titre e.g. 
congenitally infected neonates. However,it is important to 
take account of the population whose specimens have been 
tested by dot blot hybridization. Renal allograft 
recipients are less heavily immunosuppressed than some 
other transplant patients and experience less severe HCMV 
infection. This is probably attributable to a more 
effective immune response and increased clearing of 
circulating virus. Therefore, the majority of renal 
allograft recipients may not shed HCMV in an amount which 
exceeds the lower limit of sensitivity of the hybridot 
assay. Recently, Schuster et al. (1986) have described an
RNA-DNA hybridot assay which has a sensitivity of 83% when 
used to detect HCMV shedding by patients, including renal 
allograft recipients, with a variety of clinical disorders. 
The sensitivity of the RNA-DNA hybridot assay described in 
this project may be improved by increasing the volume of 
urine submitted for testing but this may create 
difficulties in terms of storage and processing. 
Furthermore, renal allograft recipients whose kidney 
function is already compromised may not be able to provide 
large quantities of urine especially within the first few 
months after the transplant operation when the risk of HCMV
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infection is at its greatest. An alternative approach 
would be to use PCR to amplify DNA sequences from a small 
volume of urine.
5.5 Source of HCMV infection
The results of this project clearly show that the 
donor kidney most likely transmitted HCMV infection in 
renal allograft recipients and confirms the findings of 
others (Chou, 1986). All 8 HCMV-seronegative recipients of 
a kidney from an HCMV-seropositive donor developed primary 
HCMV infection while no evidence of infection was ever 
found in any of the 9 HCMV-seronegative recipients of a 
kidney from an HCMV-seronegative donor. Some studies have 
reported on the inability of some kidneys from HCMV- 
seropositive donors to transmit the infection even to HCMV- 
seronegative recipients (Chou and Norman, 1988). However, 
this may simply reflect the inability to detect active HCMV 
infection in some patients. Restriction endonuclease 
analysis of HCMV isolates was not undertaken and therefore 
it is not possible to comment on the frequency of HCMV 
reinfection in HCMV-seropositive recipients of a kidney 
from an HCMV-seropositive donor.
In this study there was no evidence of HCMV 
transmission by blood products but the number of patients 
studied was small. The risk of HCMV infection via blood 
products increases with the number of units transfused. 
However, few renal allograft recipients in this project
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received large numbers of transfusions. Furthermore, all 
blood products had been stored at 4°C for up to 3 weeks 
thus decreasing the risk of HCMV transmission even further. 
Finally, the majority of blood donors were aged between 19 
and 29 years and, as expected, were mostly seronegative for 
HCMV.
5.6 HSV infections
Twenty four (51%) of the 47 renal allograft recipients 
had evidence of post transplantation HSV infection all of 
which were reinfection and/or reactivation. These data 
confirm the findings of Ho (1977) who has reported that 
most HSV infections in renal allograft recipients are due 
to reactivation of latent virus.
Isolation of HSV was less frequent than that of HCMV 
with only 6 (1.2%) of 490 urine samples and 13 (2.8%) of
449 throat swabs yielding the virus in tissue culture. 
Unlike HCMV, HSV can establish latent infection in the 
trigeminal ganglia. Therefore, it is not surprising that 
HSV was more commonly isolated from throat swabs than urine 
samples. Isolation of HSV from urine was only attained in 
female transplant recipients and most likely represents 
contamination of these specimens by virus shed from the 
genital tract. HSV isolation was more common during the 
first 3 months post-operatively when immunosuppressive 
therapy is maximal. However in some renal allograft 
recipients, HSV was first isolated many months after the 
transplant operation and may represent random shedding
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which occurs in healthy individuals in response to a
variety of stimuli. Unlike most cases of HCMV infection,
isolation of HSV was transient and probably reflects the
ability of the immune response to contain HSV infection.
Restriction endonuclease analysis of virus isolates showed
that only HSV-1 was ever isolated from throat swabs while
only HSV-2 was shed in the urine. This contrasts with the
findings in HCMV infection when 1 strain is commonly
isolated from many sites (Grundy et al. , 1987) . In this
project there was no evidence of reinfection by exogenous
either
strains of HSV, all viruses isolated frompurine samples or 
throat swabs of any 1 individual having the same 
restriction enzyme profile. Transmission of HSV by the 
renal allograft has recently been reported by some workers 
(Koneru et al. , 1988) but these findings could not be
confirmed here. However, not all renal allografts may 
harbour HSV in a form that can be readily reactivated as in 
the case of HCMV.
Of the 16 renal transplant recipients with serological 
evidence of active HSV infection, only 3 submitted 
specimens from which the virus was isolated. While this 
may be explained on the basis of efficient clearing of HSV 
by the immune response it is also possible that infrequent 
sampling may have overlooked transient or intermittent 
shedding. However, it is interesting to note that a 
fourfold or greater rise in HSV CF antibody titre was never 
observed in sera taken from 7 patients who shed the virus
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post-operatively. In 3 other renal allograft recipients, a 
fourfold or greater rise in HSV CF antibody titre was first 
recorded in sera provided some weeks after initial HSV 
isolation. These data provide further evidence on the 
importance of virus isolation in the early diagnosis of 
infection and underline the insensitivity of the CFT in 
some cases.
5.7 Clinical findings
Unfortunately, the small number of patients in this 
study precluded any statistical correlations to be made 
between HCMV infection and clinical findings. However, 
symptoms were more common in those patients with HCMV 
infection and, with the exception of abnormal liver 
function tests, symptoms occurred more frequently in renal 
allograft recipients with primary HCMV infection. This 
confirms the findings of others and provides further 
evidence as to the ability of the immune response to 
abrogate the effects of HCMV infection (Ho et al. , 1975) .
Not all patients developed all symptoms. This may be
attributable to genetic susceptibility to HCMV infection 
and disease but the small number of patients in this study 
did not permit a correlation to be made with HLA status. 
Furthermore, some strains of HCMV may be more pathogenic 
than others.
In this study the onset of symptoms was often 
associated with a humoral immune response thus confirming 
the findings of Kangro et a l . (1982). However, this
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temporal association cannot be taken as evidence that HCMV 
infection is responsible for the clinical findings. In 
some patients the onset of symptoms often preceded by a 
number of weeks first detection of HCMV infection by 
serology and/or virus isolation. Similar findings have 
been reported by Pass et al. (1983) . Such data suggest
that symptoms suggestive of HCMV infection should be 
treated with the appropriate antiviral therapy even in the 
absence of laboratory evidence of active infection. By 
contrast, some renal allograft recipients showed evidence 
of active HCMV infection many weeks prior to the onset of 
symptoms while in others HCMV shedding continued after all 
symptoms had resolved. In such cases, symptoms may be
entirely related to infection by another virus. 
Alternatively, symptoms may only develop when HCMV 
infection occurs concomitantly with another factor(s) such 
as high doses of immunosuppressive therapy which promotes 
HCMV dissemination. Some renal allograft recipients with 
HCMV infection remained asymptomatic throughout. The 
ability to identify this group of patients immediately 
pretransplant would permit prophylactic therapy to be 
targeted at those transplant recipients at highest risk of 
HCMV-induced disease.
As in previous reports, graft rejection and 
nephrectomy were more common in patients with primary HCMV 
infection but a cause and effect relationship is difficult 
to establish. Indeed, some renal allograft recipients who
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remained seronegative for HCMV throughout the period of 
study showed episodes of acute rejection within the first 
few months post transplantation.
Recent reports have suggested that post 
transplantation HCMV-IgM levels are prognostic of clinical 
outcome (Wreghitt et al. , 1986) . In this project only 1
patient with primary HCMV infection remained asymptomatic. 
Interesting HCMV-IgM levels were equivocal by Labsystems 
ELISA. However, HCMV-IgM levels varied irrespective of 
clinical findings in patients with reinfection and/or 
reactivation when pre-existing immunity may have abrogated 
the effects of HCMV infection.
Renal transplant recipients at the Western Infirmary, 
Glasgow routinely have their immunosuppressive therapy 
changed from CsA to azathioprine at the end of the first 
year post transplantation. CsA is nephrotoxic. Indeed, in 
one renal allograft recipient CsA adversely affected renal 
function and nephrectomy was undertaken. Azathioprine was 
well tolerated although some patients developed abnormal 
liver function tests. However, these data cannot be 
compared with those from other centres which use 
azathioprine as the primary immunosuppressive agent from 
the onset of the transplant operation. One patient with 
primary HCMV infection developed symptoms shortly after the 
onset of azathioprine therapy. Unfortunately, virus 
isolation data was unavailable and the time interval 
between consecutive sera did not permit the timing of the 
humoral immune response to be determined precisely.
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Nevertheless, it is interesting to speculate that the 
immunosuppressive effect of azathioprine but not CsA 
induced HCMV reactivation. If this is indeed the case some 
transplant recipients may not benefit from azathioprine 
therapy.
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Future Prospects
This project has provided information concerning the 
temporal correlation between the onset of HCMV infection 
and the humoral immune response in renal transplant 
recipients during the first year post-operatively. 
However, a study confined to the first few months post 
transplantation may yield more detailed information 
concerning how frequently and for how long HCMV isolation 
precedes the host humoral immune response. Such an 
investigation could also incorporate a study of the cell- 
mediated immune system.
A number of sera have been collected during the course 
of this project from patients whose virus isolation data 
and clinical features are now known. Such sera provide a 
good opportunity to assess the sensitivity and specificity 
of new serological assays. The host humoral immune 
response to specific HCMV antigens could also be assessed 
and the results correlated with early diagnosis of and 
recovery from HCMV infection.
Restriction enzyme analysis of HCMV isolates obtained 
during the course of this project was not undertaken. 
However, it would be interesting to study the DNA profiles 
of viruses isolated from individual patients throughout the 
first year post transplantation and to establish if only 1 
HCMV strain is ever shed by 1 renal allograft recipient. 
The clinical details could possibly also be correlated with
the restriction enzyme profiles to establish if some HCMV 
isolates are potentially more pathogenic than others.
Further work requires to be done on the detection of 
HCMV in clinical specimens by dot blot hybridization. The 
sensitivity of the hybridot assay when using fresh rather 
than stored specimens needs to be assessed. The use of PCR 
to increase the concentration of HCMV-specific sequences in 
clinical specimens may also improve the sensitivity of the 
hybridization technique. The origin of the false-positive 
hybrid signals in the RNA-DNA hybridot assay also needs 
further investigation. Re-hybridization of the
nitrocellulose filters with a specific probe may yield 
information concerning which virus, if any, contained 
sequences which cross-hybridized with those of the cRNA 
probe used in this project. However, if the false-positive 
hybrid signals were solely attributable to non-specific 
binding then an alternative HCMV cRNA probe and/or improved 
washing procedures may be requisite.
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